96_CD
GlaxoSmithKline_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
1_CD
Presentation_NOMZ
of_PIN
the_DT
Financial_NN
statements_NOMZ
Additional_JJ
information_NOMZ
in_PIN
accordance_NN
with_PIN
the_DT
requirements_NOMZ
of_PIN
US_FPP1
generally_RB
accepted_VBD [PRIV]
accounting_GER
principles_NN
US_FPP1
GAAP_NN
is_VPRT [PASS]
included_VBN
Description_NOMZ
of_PIN
business_NOMZ
in_PIN
the_DT
Notes_NN
to_PIN
the_DT
Financial_NN
statements_NOMZ
._.
In_PIN
Note_NN
37_CD
a_DT
statement_NOMZ
GlaxoSmithKline_NN
is_VPRT [BEMA]
a_DT
major_JJ
global_JJ
healthcare_NN
group_NN
which_WDT [WHSUB]
is_VPRT [BEMA]
of_PIN
differences_NN
,_,
and_ANDC
reconciliations_NOMZ
of_PIN
net_JJ
income_NN
and_PHC
shareholders_NN
engaged_VBN [WZPAST]
in_PIN
the_DT
creation_NOMZ
and_PHC
discovery_NN
,_,
development_NOMZ
,_,
manufacture_NN
equity_NOMZ
,_,
between_PIN
UK_NN
and_PHC
US_FPP1
GAAP_NN
are_VPRT [PASS]
provided_VBN
._.
and_ANDC
marketing_GER
of_PIN
pharmaceutical_JJ
products_NN
,_,
including_VBG
vaccines_NN
,_,
over-the-counter_JJ
OTC_NN
medicines_NN
and_CC
health-related_JJ
consumer_NN
Presentation_NOMZ
of_PIN
statement_NOMZ
of_PIN
profit_NN
and_PHC
loss_NN
products_NN
._.
GlaxoSmithKlines_NN
principal_JJ
pharmaceutical_JJ
products_NN
During_PIN
the_DT
years_NN
2000_CD
to_PIN
2003_CD
,_,
a_DT
columnar_NN
presentation_NOMZ
was_VBD
include_VPRT
medicines_NN
in_PIN
the_DT
following_VBG
therapeutic_JJ
areas_NN
:_:
adopted_VBN [PASTP]
in_PIN
the_DT
statement_NOMZ
of_PIN
profit_NN
and_PHC
loss_NN
in_PIN
order_NN
to_TO
illustrate_VB
central_JJ
nervous_JJ
system_NN
,_,
respiratory_JJ
,_,
anti-virals_NN
,_,
anti-bacterials_NN
,_,
underlying_VBG
business_NOMZ
performance_NN
,_,
as_IN
this_DEMP
was_VBD [BEMA]
the_DT
primary_JJ
measure_NN
vaccines_NN
,_,
oncology_NN
and_PHC
emesis_NN
,_,
metabolic_JJ
,_,
cardiovascular_JJ
and_CC
used_VBN
by_PIN
management_NOMZ
._.
For_PIN
this_DEMO
purpose_NN
certain_JJ
items_NN
were_VBD [BEMA]
urogenital_PRED
._.
identied_JJ
separately_RB
and_CC
excluded_VBN
from_PIN
business_NOMZ
performance_NN
._.
These_DEMP
comprised_VBN
:_:
merger_NN
and_PHC
integration_NOMZ
items_NN
,_,
including_VBG
product_NN
Financial_JJ
period_NN
divestments_NOMZ
:_:
costs_NN
relating_VBG [WZPRES]
to_TO [SPIN]
previously_TIME
announced_VBN [PUBV]
manufacturing_GER
These_DEMO
Financial_NN
statements_NOMZ
cover_VPRT
the_DT
financial_JJ
year_NN
from_PIN
and_CC
other_JJ
restructuring_GER
,_,
and_ANDC
the_DT
effect_NN
of_PIN
disposals_NN
of_PIN
subsidiaries_NN
._.
1st_CD
January_NN
to_TO
31st_VB
December_NN
2004_CD
,_,
with_PIN
comparative_JJ
gures_NN
for_PIN
Management_NOMZ
believes_VPRT [PRIV]
that_THVC
exclusion_NN
of_PIN
these_DEMO
items_NN
provided_VBD
a_DT
the_DT
financial_JJ
years_NN
from_PIN
1st_CD
January_NN
to_TO
31st_VB
December_NN
2003_CD
and_CC
better_JJ
reection_NOMZ
for_PIN
those_DEMO
years_NN
of_PIN
the_DT
way_NN
in_PIN
which_WDT [PIRE]
the_DT
business_NOMZ
from_PIN
1st_CD
January_NN
to_TO
31st_VB
December_NN
2002_CD
._.
was_VBD [PASS]
managed_VBN
and_PHC
gives_VPRT
an_DT
indication_NOMZ
of_PIN
the_DT
performance_NN
of_PIN
the_DT
Group_NN
in_PIN
terms_NN
of_PIN
those_DEMO
elements_NOMZ
of_PIN
revenue_NN
and_PHC
expenditure_NN
Composition_NOMZ
of_PIN
the_DT
Group_NN
which_WDT [WHOBJ]
local_JJ
management_NOMZ
is_VPRT [BEMA]
able_PRED
to_PIN
inuence_NN
._.
A_DT
list_NN
of_PIN
the_DT
subsidiary_NN
and_CC
associated_VBN
undertakings_GER
which_WDT [WHOBJ]
,_,
in_PIN
the_DT
opinion_NN
of_PIN
the_DT
Directors_NN
,_,
principally_RB
affected_VBD
the_DT
amount_NN
of_PIN
profit_NN
For_PIN
2004_CD
,_,
with_PIN
the_DT
completion_NOMZ
of_PIN
these_DEMO
programs_NN
,_,
the_DT
Group_NN
or_CC
the_DT
net_JJ
assets_NN
of_PIN
the_DT
Group_NN
is_VPRT [PASS]
given_VBN
in_PIN
Principal_NN
Group_NN
is_VPRT
reporting_VBG [PUBV]
results_NN
on_PIN
a_DT
statutory_JJ
basis_NN
only_DWNT
._.
Growth_NN
rates_NN
are_VPRT
companies_NN
,_,
Note_VB [PRIV]
38_CD
._.
presented_VBN
comparing_VBG
2004_CD
results_NN
both_DT
with_PIN
2003_CD
business_NOMZ
performance_NN
results_NN
and_CC
2003_CD
statutory_JJ
results_NN
._.
Management_NOMZ
Composition_NOMZ
of_PIN
financial_JJ
statements_NOMZ
considers_VPRT [PRIV]
that_THVC
the_DT
comparison_NN
of_PIN
2004_CD
statutory_JJ
results_NN
with_PIN
2003_CD
The_DT
consolidated_JJ
Financial_NN
statements_NOMZ
are_VPRT [PASS]
drawn_VBN
up_RP
in_PIN
accordance_NN
business_NOMZ
performance_NN
results_NN
gives_VPRT
the_DT
most_EMPH
appropriate_JJ
indication_NOMZ
with_PIN
UK_NN
generally_RB
accepted_VBD [PRIV]
accounting_GER
principles_NN
UK_NN
GAAP_NN
and_CC
of_PIN
the_DT
Groups_NN
performance_NN
for_PIN
that_DEMO
period_NN
._.
Trading_GER
profit_NN
reects_VPRT
turnover_NN
less_RB
:_:
cost_NN
of_PIN
sales_NN
,_,
comprising_VBG [PRESP]
The_DT
Financial_NN
statements_NOMZ
comprise_VPRT
:_:
costs_NN
of_PIN
manufacture_NN
and_CC
external_JJ
royalties_NN
:_:
selling_GER
,_,
general_JJ
and_PHC
administrative_JJ
expenditure_NN
,_,
comprising_VBG [PRESP]
the_DT
costs_NN
of_PIN
selling_GER
,_,
Consolidated_NN
statement_NOMZ
of_PIN
profit_NN
and_PHC
loss_NN
distribution_NOMZ
and_CC
medical_JJ
support_NN
of_PIN
currently_RB
marketed_VBN
products_NN
Consolidated_NN
statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
and_CC
the_DT
costs_NN
of_PIN
administration_NOMZ
:_:
and_ANDC
the_DT
costs_NN
of_PIN
research_NN
and_PHC
Consolidated_NN
statement_NOMZ
of_PIN
cash_NN
ow_NN
development_NOMZ
to_TO
create_VB
future_JJ
products_NN
for_PIN
sale_NN
._.
Consolidated_NN
balance_NN
sheet_NN
Reconciliation_NOMZ
of_PIN
movements_NOMZ
in_PIN
consolidated_JJ
equity_NOMZ
Accounting_GER
convention_NOMZ
shareholders_NN
funds_NN
The_DT
Financial_NN
statements_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
using_VBG
the_DT
historical_JJ
Company_NN
balance_NN
sheet_NN
cost_NN
convention_NOMZ
._.
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
._.
As_IN
permitted_VBN
by_PIN
Section_NOMZ
230_CD
of_PIN
the_DT
Companies_NN
Act_NN
1985_CD
,_,
the_DT
Accounting_GER
standards_NN
profit_NN
and_PHC
loss_NN
account_NN
of_PIN
the_DT
company_NN
is_VPRT [PASS]
not_XX0
presented_VBN
._.
The_DT
Financial_NN
statements_NOMZ
comply_VPRT
with_PIN
applicable_JJ
UK_NN
accounting_GER
standards_NN
._.
The_DT
consolidated_JJ
statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
includes_VPRT
:_:
Accounting_GER
principles_NN
and_PHC
policies_NN
the_DT
realized_VBN [PRIV]
profit_NN
attributable_JJ
to_PIN
shareholders_NN
as_IN
reected_VBN
The_DT
preparation_NOMZ
of_PIN
the_DT
Financial_NN
statements_NOMZ
in_PIN
conformity_NOMZ
with_PIN
in_PIN
the_DT
consolidated_JJ
statement_NOMZ
of_PIN
profit_NN
and_PHC
loss_NN
generally_RB
accepted_VBD [PRIV]
accounting_GER
principles_NN
requires_VPRT [SUAV]
management_NOMZ
the_DT
unrealised_JJ
gain_NN
or_CC
loss_NN
in_PIN
the_DT
value_NN
of_PIN
the_DT
Groups_NN
to_TO
make_VB
estimates_NN
and_PHC
assumptions_NOMZ
that_TSUB
affect_VPRT
the_DT
reported_VBN [PUBV]
overseas_PLACE
net_JJ
assets_NN
,_,
less_JJ
related_JJ
foreign_JJ
currency_NN
borrowings_GER
,_,
amounts_NN
of_PIN
assets_NN
and_PHC
liabilities_NOMZ
and_PHC
disclosure_NN
of_PIN
contingent_JJ
attributable_JJ
to_PIN
currency_NN
movements_NOMZ
over_IN
the_DT
period_NN
assets_NN
and_PHC
liabilities_NOMZ
at_PIN
the_DT
date_NN
of_PIN
the_DT
Financial_NN
statements_NOMZ
and_PHC
tax_NN
on_PIN
the_DT
above_PLACE
items_NN
._.
the_DT
reported_JJ
amounts_NN
of_PIN
revenues_NN
and_PHC
expenses_NN
during_PIN
the_DT
reporting_GER
period_NN
._.
Actual_JJ
results_NN
could_POMD
differ_VB
from_PIN
those_DEMO
estimates_NN
._.
The_DT
reconciliation_NOMZ
of_PIN
movements_NOMZ
in_PIN
equity_NOMZ
shareholders_NN
funds_NN
comprises_VPRT
the_DT
items_NN
contributing_VBG [WZPRES]
to_PIN
the_DT
increase_NN
or_CC
decrease_NN
The_DT
Financial_NN
statements_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
in_PIN
accordance_NN
with_PIN
over_IN
the_DT
period_NN
in_PIN
shareholders_NN
funds_NN
._.
Such_JJ
items_NN
include_VPRT
:_:
the_DT
companys_NN
accounting_VBG [WZPRES]
policies_NN
approved_VBN [WZPAST]
by_PIN
the_DT
Board_NN
and_CC
described_VBN
in_PIN
Note_NN
2_CD
._.
the_DT
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
for_PIN
the_DT
period_NN
dividends_NN
paid_VBN
and_PHC
proposed_VBN [SUAV]
the_DT
proceeds_NN
of_PIN
shares_NN
issued_VBN [WZPAST]
during_PIN
the_DT
period_NN
the_DT
cost_NN
of_PIN
shares_NN
purchased_VBN
as_IN
Treasury_NN
shares_NN
or_CC
for_PIN
cancellation_NOMZ
under_IN
the_DT
share_NN
buy-back_NN
program_NN
changes_NN
to_PIN
goodwill_NN
,_,
arising_VBG [PRESP]
on_PIN
acquisitions_NOMZ
prior_RB
to_PIN
1st_CD
January_NN
1998_CD
,_,
which_WDT [SERE]
has_VPRT [PEAS]
been_VBN [PASS]
set_VBN
directly_RB
against_PIN
reserves_NN
._.
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
GlaxoSmithKline_NN
97_CD
2_CD
Accounting_GER
policies_NN
Foreign_JJ
currency_NN
transactions_NOMZ
Foreign_JJ
currency_NN
transactions_NOMZ
by_PIN
Group_NN
companies_NN
are_VPRT [PASS]
booked_VBN
Consolidation_NOMZ
in_PIN
local_JJ
currency_NN
at_PIN
the_DT
exchange_NN
rate_NN
ruling_NN
on_PIN
the_DT
date_NN
of_PIN
The_DT
consolidated_JJ
Financial_NN
statements_NOMZ
include_VPRT
:_:
transaction_NOMZ
,_,
or_CC
at_PIN
the_DT
forward_JJ
rate_NN
if_COND
hedged_VBN
by_PIN
a_DT
forward_RB
the_DT
assets_NN
and_PHC
liabilities_NOMZ
,_,
and_ANDC
the_DT
results_NN
and_PHC
cash_NN
ow_NN
,_,
of_PIN
the_DT
exchange_NN
contract_NN
._.
Foreign_JJ
currency_NN
assets_NN
and_PHC
liabilities_NOMZ
are_VPRT
company_NN
and_CC
its_PIT
subsidiary_NN
undertakings_GER
,_,
including_VBG
Employee_NN
translated_VBN [WZPAST]
into_PIN
local_JJ
currency_NN
at_PIN
rates_NN
of_PIN
exchange_NN
ruling_NN
at_PIN
the_DT
Share_NN
Ownership_NN
Plan_NN
ESOP_NN
Trusts_NN
balance_NN
sheet_NN
date_NN
,_,
or_CC
at_PIN
the_DT
forward_JJ
rate_NN
._.
Exchange_NN
differences_NN
the_DT
Groups_NN
share_NN
of_PIN
the_DT
net_JJ
assets_NN
and_PHC
results_NN
of_PIN
joint_JJ
ventures_NN
are_VPRT [PASS]
included_VBN
in_PIN
trading_GER
profit_NN
._.
Revenue_NN
The_DT
Financial_NN
statements_NOMZ
of_PIN
undertakings_GER
consolidated_VBN [WZPAST]
are_VPRT [PASS]
made_VBN
Revenue_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
when_RB
goods_NN
up_IN
to_PIN
31st_CD
December_NN
._.
are_VPRT [PASS]
supplied_VBN
or_CC
made_VBN
available_JJ
to_PIN
external_JJ
customers_NN
against_PIN
orders_NN
Undertakings_GER
in_PIN
which_WDT [PIRE]
the_DT
Group_NN
has_VPRT
a_DT
material_NN
interest_NN
are_VPRT [PASS]
received_VBN
and_ANDC
when_RB
title_NN
and_PHC
risk_NN
of_PIN
loss_NN
passes_VPRT
to_PIN
the_DT
customer_NN
._.
accounted_VBD
for_PIN
as_IN
subsidiaries_NN
where_RB
the_DT
Group_NN
exercises_VPRT
dominant_JJ
Turnover_NN
represents_VPRT
net_JJ
invoice_NN
value_NN
after_IN
the_DT
deduction_NOMZ
of_PIN
inuence_NN
,_,
as_IN
joint_JJ
ventures_NN
where_RB
the_DT
Group_NN
exercises_VPRT
joint_JJ
control_NN
discounts_NN
given_VBN [WZPAST]
at_PIN
the_DT
point_NN
of_PIN
sale_NN
,_,
and_ANDC
accruals_NN
for_PIN
estimated_VBN [PRIV]
and_CC
as_IN
associates_NN
where_RB
the_DT
Group_NN
can_POMD
exercise_VB
significant_JJ
future_JJ
rebates_NN
and_PHC
returns_NN
._.
The_DT
methodology_NN
and_PHC
assumptions_NOMZ
inuence_NN
._.
used_VBN
to_TO
estimate_VB [PRIV]
rebates_NN
and_PHC
returns_NN
are_VPRT [PASS]
monitored_VBN
and_PHC
adjusted_VBN
regularly_RB
in_PIN
the_DT
light_NN
of_PIN
contractual_JJ
and_PHC
historical_JJ
information_NOMZ
and_PHC
Interests_NN
acquired_VBN [WZPAST]
in_PIN
undertakings_GER
are_VPRT [PASS]
consolidated_VBN
from_PIN
the_DT
past_JJ
experience_NN
._.
Turnover_NN
also_RB
includes_VPRT
co-promotion_JJ
income_NN
effective_JJ
date_NN
of_PIN
acquisition_NOMZ
and_PHC
interests_NN
sold_VBN [WZPAST]
are_VPRT [BEMA]
consolidated_PRED
where_RB
the_DT
Group_NN
records_NN
its_PIT
share_NN
of_PIN
the_DT
revenue_NN
but_CC
with_PIN
no_DT
up_RB
to_PIN
the_DT
date_NN
of_PIN
disposal_NN
._.
Value_NN
added_VBD [PUBV]
tax_NN
and_CC
other_JJ
sales_NN
taxes_NN
are_VPRT
Transactions_NOMZ
and_PHC
balances_NN
between_PIN
subsidiary_NN
undertakings_GER
are_VPRT [PASS]
excluded_VBN
from_PIN
revenue_NN
._.
eliminated_VBN
:_:
no_SYNE
profit_NN
is_VPRT [PASS]
taken_VBN
on_PIN
sales_NN
between_PIN
subsidiary_NN
undertakings_GER
or_CC
sales_NN
to_PIN
joint_JJ
ventures_NN
and_CC
associated_VBN
undertakings_GER
Expenditure_NN
until_IN
the_DT
products_NN
are_VPRT [PASS]
sold_VBN
to_PIN
customers_NN
outside_PLACE
the_DT
Group_NN
._.
Expenditure_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
respect_NN
of_PIN
goods_NN
and_PHC
services_NN
received_VBN
when_RB
supplied_VBN
in_PIN
accordance_NN
with_PIN
contractual_JJ
terms_NN
._.
Provision_NN
is_VPRT
Goodwill_NN
arising_VBG [WZPRES]
on_PIN
the_DT
acquisition_NOMZ
of_PIN
interests_NN
in_PIN
subsidiary_NN
made_VBN
when_RB
an_DT
obligation_NOMZ
exists_VPRT
for_PIN
a_DT
future_JJ
liability_NOMZ
in_PIN
respect_NN
of_PIN
a_DT
undertakings_GER
,_,
joint_JJ
ventures_NN
and_CC
associated_VBN
undertakings_GER
,_,
past_JJ
event_NN
and_ANDC
where_RB
the_DT
amount_NN
of_PIN
the_DT
obligation_NOMZ
can_POMD
be_VB [SPAU]
reliably_RB
representing_VBG
the_DT
excess_NN
of_PIN
the_DT
purchase_NN
consideration_NOMZ
over_IN
the_DT
estimated_VBN [PRIV]
._.
Advertising_GER
and_PHC
promotion_NOMZ
expenditure_NN
is_VPRT [PASS]
charged_VBN
to_PIN
Groups_NN
share_NN
of_PIN
the_DT
separable_JJ
net_JJ
assets_NN
acquired_VBN
,_,
is_VPRT [PASS]
capitalized_VBN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
as_IN
incurred_VBN
._.
Shipment_NOMZ
costs_NN
on_PIN
interas_NN
a_DT
separate_JJ
item_NN
in_PIN
the_DT
case_NN
of_PIN
subsidiary_NN
undertakings_GER
and_CC
as_IN
company_NN
transfers_NN
are_VPRT [PASS]
charged_VBN
to_PIN
cost_NN
of_PIN
sales_NN
:_:
distribution_NOMZ
costs_NN
part_NN
of_PIN
the_DT
cost_NN
of_PIN
investment_NOMZ
in_PIN
the_DT
case_NN
of_PIN
joint_JJ
ventures_NN
and_CC
on_PIN
sales_NN
to_PIN
customers_NN
are_VPRT [PASS]
included_VBN
in_PIN
selling_GER
,_,
general_JJ
and_CC
associated_VBN
undertakings_GER
._.
Goodwill_NN
is_VPRT [PASS]
denominated_VBN
in_PIN
the_DT
currency_NN
administrative_JJ
expenditure_NN
._.
Restructuring_GER
costs_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
in_PIN
which_WDT [PIRE]
the_DT
acquisition_NOMZ
is_VPRT [PASS]
made_VBN
and_PHC
nanced_VBN
._.
In_PIN
the_DT
case_NN
of_PIN
respect_NN
of_PIN
the_DT
direct_JJ
expenditures_NN
of_PIN
a_DT
business_NOMZ
reorganisation_NOMZ
acquisitions_NOMZ
prior_RB
to_PIN
1998_CD
,_,
goodwill_NN
was_VBD [PASS]
written_VBN [PUBV]
off_PIN
against_PIN
where_RB
the_DT
plans_NN
are_VPRT [SPAU] [PASS]
sufciently_RB
detailed_VBN
and_CC
well_RB
advanced_VBD
,_,
and_ANDC
reserves_NN
:_:
on_PIN
a_DT
subsequent_JJ
disposal_NN
of_PIN
assets_NN
from_PIN
such_JJ
acquisitions_NOMZ
,_,
where_RB
appropriate_JJ
communication_NOMZ
to_PIN
those_DEMP
affected_VBN
has_VPRT [PEAS]
been_VBN [BEMA]
any_QUAN
related_JJ
goodwill_NN
is_VPRT [PASS]
removed_VBN
from_PIN
consolidated_JJ
reserves_NN
and_CC
undertaken_VBN
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
._.
charged_VBN [PASTP]
to_PIN
the_DT
consolidated_JJ
profit_NN
and_PHC
loss_NN
account_NN
._.
The_DT
Groups_NN
interests_NN
in_PIN
its_PIT
joint_JJ
ventures_NN
are_VPRT [PASS]
accounted_VBN
for_PIN
using_VBG
Research_NN
and_PHC
development_NOMZ
the_DT
gross_JJ
equity_NOMZ
method_NN
._.
The_DT
Groups_NN
interests_NN
in_PIN
its_PIT
associated_VBN
Research_NN
and_PHC
development_NOMZ
expenditure_NN
is_VPRT [PASS]
charged_VBN
to_PIN
the_DT
profit_NN
undertakings_GER
are_VPRT [PASS]
accounted_VBN
for_PIN
using_VBG
the_DT
equity_NOMZ
method_NN
._.
and_ANDC
loss_NN
account_NN
in_PIN
the_DT
period_NN
in_PIN
which_WDT [PIRE]
it_PIT
is_VPRT [PASS]
incurred_VBN
._.
Tangible_JJ
xed_JJ
assets_NN
used_VBN [WZPAST]
for_PIN
research_NN
and_PHC
development_NOMZ
are_VPRT [PASS]
depreciated_VBN
Deferred_JJ
taxation_NOMZ
relief_NN
on_PIN
unrealised_JJ
intra-Group_JJ
profit_NN
is_VPRT [BEMA]
in_PIN
accordance_NN
with_PIN
the_DT
Groups_NN
policy_NN
._.
accounted_VBD
for_PIN
only_DWNT
to_PIN
the_DT
extent_NN
that_TOBJ
it_PIT
is_VPRT [PASS]
considered_VBN [PRIV]
recoverable_JJ
._.
Assets_NN
and_PHC
liabilities_NOMZ
of_PIN
overseas_PLACE
subsidiary_NN
and_CC
associated_VBN
Environmental_JJ
expenditure_NN
undertakings_GER
and_CC
joint_JJ
ventures_NN
including_VBG [WZPRES]
related_JJ
goodwill_NN
,_,
are_VPRT [BEMA]
Environmental_JJ
expenditure_NN
related_VBN
to_TO
existing_VBG
conditions_NOMZ
resulting_VBG [WZPRES]
translated_VBN
into_PIN
sterling_GER
at_PIN
rates_NN
of_PIN
exchange_NN
ruling_NN
at_PIN
the_DT
balance_NN
from_PIN
past_JJ
or_CC
current_JJ
operations_NOMZ
and_CC
from_PIN
which_WDT [PIRE]
no_SYNE
current_JJ
or_CC
sheet_NN
date_NN
._.
The_DT
results_NN
and_PHC
cash_NN
ows_NN
of_PIN
overseas_PLACE
subsidiary_NN
and_CC
future_JJ
benefit_NN
is_VPRT [BEMA]
discernible_PRED
is_VPRT [PASS]
charged_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
associated_VBN
undertakings_GER
and_CC
joint_JJ
ventures_NN
are_VPRT [PASS]
translated_VBN
into_PIN
account_NN
._.
The_DT
Group_NN
determines_VPRT [SUAV] [PRIV]
its_PIT
liability_NOMZ
on_PIN
a_DT
site-by-site_JJ
basis_NN
sterling_GER
using_VBG [WZPRES]
average_JJ
rates_NN
of_PIN
exchange_NN
._.
Exchange_NN
adjustments_NOMZ
and_PHC
records_NN
a_DT
liability_NOMZ
at_PIN
the_DT
time_NN
when_RB
it_PIT
is_VPRT [BEMA]
probable_PRED
and_CC
can_POMD
be_VB
arising_VBG
when_RB
the_DT
opening_GER
net_JJ
assets_NN
and_CC
the_DT
profits_NN
for_PIN
the_DT
year_NN
reasonably_RB
estimated_VBN [PRIV]
._.
This_DEMO
liability_NOMZ
includes_VPRT
the_DT
Groups_NN
own_VPRT
retained_VBN
by_PIN
overseas_PLACE
subsidiary_NN
and_CC
associated_VBN
undertakings_GER
and_PHC
portion_NOMZ
of_PIN
the_DT
costs_NN
and_CC
also_RB
a_DT
portion_NOMZ
of_PIN
other_JJ
potentially_RB
joint_JJ
ventures_NN
are_VPRT [PASS]
translated_VBN
into_PIN
sterling_GER
,_,
less_JJ
exchange_NN
differences_NN
responsible_JJ
parties_NN
costs_NN
when_RB
it_PIT
is_VPRT [BEMA]
probable_PRED
that_THAC
they_TPP3
will_PRMD
not_XX0
be_VB
arising_VBG
on_PIN
related_VBN
foreign_JJ
currency_NN
borrowings_GER
,_,
are_VPRT [PASS]
taken_VBN
directly_RB
able_JJ
to_TO
satisfy_VB
their_TPP3
respective_JJ
shares_NN
of_PIN
the_DT
clean-up_JJ
obligation_NOMZ
._.
to_PIN
reserves_NN
and_CC
reported_VBN [PUBV]
in_PIN
the_DT
statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
When_RB [WHCL]
recoveries_NN
of_PIN
reimbursements_NOMZ
are_VPRT [BEMA]
virtually_RB
certain_PRED
they_TPP3
are_VPRT
gains_NN
and_PHC
losses_NN
._.
In_PIN
translating_VBG
into_PIN
sterling_JJ
assets_NN
,_,
liabilities_NOMZ
,_,
results_NN
and_PHC
cash_NN
ows_VPRT
Pensions_NN
and_CC
post-retirement_JJ
benets_NN
of_PIN
overseas_PLACE
subsidiary_NN
and_CC
associated_VBN
undertakings_GER
and_CC
joint_JJ
The_DT
cost_NN
of_PIN
providing_VBG
pensions_NN
and_CC
other_JJ
employee_NN
post-retirement_JJ
ventures_NN
reported_VBN [PUBV] [WZPAST]
in_PIN
currencies_NN
of_PIN
hyper-inationary_JJ
economies_NN
,_,
benets_NN
is_VPRT [PASS]
charged_VBN
to_PIN
the_DT
consolidated_JJ
profit_NN
and_PHC
loss_NN
account_NN
on_PIN
a_DT
adjustments_NOMZ
are_VPRT [PASS]
made_VBN
to_TO
reect_VB
current_JJ
price_NN
levels_NN
._.
Any_QUAN
loss_NN
on_PIN
systematic_JJ
and_PHC
rational_JJ
basis_NN
,_,
based_VBN [PASTP]
on_PIN
actuarial_JJ
assumptions_NOMZ
,_,
over_IN
net_JJ
monetary_JJ
assets_NN
is_VPRT [PASS]
charged_VBN
to_PIN
the_DT
consolidated_JJ
profit_NN
and_PHC
loss_NN
the_DT
period_NN
during_PIN
which_WDT [PIRE]
benefit_NN
is_VPRT [PASS]
derived_VBN
from_PIN
employees_NN
services_NN
._.
Any_QUAN
difference_NN
between_PIN
this_DEMO
charge_NN
and_CC
the_DT
contributions_NOMZ
paid_VBN [WZPAST]
is_VPRT [PASS]
included_VBN
as_IN
an_DT
asset_NN
or_CC
liability_NOMZ
in_PIN
the_DT
consolidated_JJ
balance_NN
sheet_NN
._.
98_CD
GlaxoSmithKline_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
2_CD
Accounting_GER
policies_NN
continued_VBD
Brands_NN
are_VPRT [PASS]
valued_VBN
independently_RB
as_IN
part_NN
of_PIN
the_DT
fair_JJ
value_NN
of_PIN
businesses_NOMZ
acquired_VBN [WZPAST]
from_PIN
third_JJ
parties_NN
where_RB
the_DT
brand_NN
has_VPRT
a_DT
Legal_JJ
and_PHC
other_JJ
disputes_NN
value_NN
which_WDT [WHSUB]
is_VPRT [BEMA]
substantial_PRED
and_PHC
long-term_PRED
and_ANDC
where_RB
the_DT
brands_NN
Provision_NN
is_VPRT [PASS]
made_VBN
for_PIN
anticipated_JJ
settlement_NOMZ
costs_NN
where_RB
a_DT
can_POMD
be_VB [PASS]
sold_VBN
separately_RB
from_PIN
the_DT
rest_NN
of_PIN
the_DT
businesses_NOMZ
acquired_VBN
._.
reasonable_JJ
estimate_NN
can_POMD
be_VB [PASS]
made_VBN
of_PIN
the_DT
likely_JJ
outcome_NN
of_PIN
legal_JJ
or_CC
Brands_NN
are_VPRT [PASS]
amortised_VBN
over_IN
the_DT
estimated_VBN [PRIV]
useful_JJ
lives_NN
but_CC
no_SYNE
longer_JJ
other_JJ
disputes_NN
against_PIN
the_DT
Group_NN
._.
In_CONJ
addition_NULL
provision_NN
is_VPRT [PASS]
made_VBN
for_PIN
than_PIN
20_CD
years_NN
,_,
except_PIN
where_RB
the_DT
end_NN
of_PIN
the_DT
useful_JJ
economic_JJ
life_NN
legal_JJ
and_PHC
other_JJ
expenses_NN
arising_VBG [WZPRES]
from_PIN
claims_NN
received_VBN
or_CC
other_JJ
of_PIN
the_DT
brand_NN
can_POMD
not_XX0
be_VB [PASS]
foreseen_VBN
._.
In_PIN
respect_NN
of_PIN
product_NN
liability_NOMZ
claims_NN
related_VBN [WZPAST]
to_PIN
products_NN
where_RB
there_EX
is_VPRT
sufficient_JJ
history_NN
of_PIN
claims_NN
made_VBN
and_CC
settlements_NOMZ
,_,
an_DT
Prior_RB
to_PIN
1998_CD
,_,
acquired_VBN
minor_JJ
brands_NN
and_CC
similar_JJ
intangibles_NN
were_VBD [PASS]
incurred_VBN
but_CC
not_XX0
reported_VBD [PUBV]
IBNR_NN
actuarial_JJ
technique_NN
is_VPRT [PASS]
used_VBN
to_TO
eliminated_VBN
in_PIN
the_DT
Group_NN
balance_NN
sheet_NN
against_PIN
reserves_NN
in_PIN
the_DT
year_NN
determine_VB [SUAV] [PRIV]
a_DT
reasonable_JJ
estimate_NN
of_PIN
the_DT
Groups_NN
exposure_NN
to_PIN
of_PIN
acquisition_NOMZ
._.
unasserted_JJ
claims_NN
for_PIN
those_DEMO
products_NN
and_CC
a_DT
provision_NN
is_VPRT [PASS]
made_VBN
on_PIN
that_DEMP
basis_NN
._.
No_SYNE
provision_NN
is_VPRT [PASS]
made_VBN
for_PIN
other_JJ
unasserted_JJ
claims_NN
or_CC
Tangible_JJ
xed_JJ
assets_NN
where_RB
an_DT
obligation_NOMZ
exists_VPRT
under_IN
a_DT
dispute_NN
but_CC
it_PIT
is_VPRT [BEMA]
not_XX0
possible_PRED
to_PIN
Tangible_JJ
xed_JJ
assets_NN
are_VPRT [PASS]
stated_VBN [PUBV]
at_PIN
cost_NN
less_JJ
provisions_NN
for_PIN
make_VPRT
a_DT
reasonable_JJ
estimate_NN
._.
Costs_NN
associated_VBN [WZPAST]
with_PIN
claims_NN
made_VBN [WZPAST]
by_PIN
depreciation_NOMZ
or_CC
impairment_NOMZ
._.
The_DT
costs_NN
of_PIN
acquiring_VBG
and_PHC
developing_VBG
the_DT
Group_NN
against_PIN
third_JJ
parties_NN
are_VPRT [PASS]
charged_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
computer_NN
software_NN
for_PIN
internal_JJ
use_NN
and_PHC
internet_NN
sites_NN
for_PIN
external_JJ
account_NN
as_IN
they_TPP3
are_VPRT [PASS]
incurred_VBN
._.
use_NN
are_VPRT [PASS]
capitalized_VBN
as_IN
a_DT
tangible_JJ
xed_JJ
asset_NN
where_RB
the_DT
software_NN
or_CC
site_NN
supports_VPRT
a_DT
significant_JJ
business_NOMZ
system_NN
and_CC
the_DT
expenditure_NN
Employee_NN
share_NN
plans_VPRT
leads_NN
to_PIN
the_DT
creation_NOMZ
of_PIN
a_DT
durable_JJ
asset_NN
._.
Incentives_NN
in_PIN
the_DT
form_NN
of_PIN
shares_NN
are_VPRT [PASS]
provided_VBN
to_PIN
employees_NN
under_IN
Depreciation_NOMZ
is_VPRT [PASS]
calculated_VBN [PRIV]
to_TO
write_VB [PUBV]
off_PIN
the_DT
cost_NN
of_PIN
tangible_JJ
xed_JJ
share_NN
option_NOMZ
and_PHC
share_NN
award_NN
schemes_NN
._.
In_PIN
respect_NN
of_PIN
certain_JJ
award_NN
assets_NN
,_,
excluding_VBG
freehold_JJ
land_NN
,_,
in_PIN
equal_JJ
annual_JJ
instalments_NOMZ
over_IN
schemes_NN
and_PHC
share_NN
option_NOMZ
grants_NN
,_,
the_DT
company_NN
provides_VPRT
finance_NN
to_PIN
their_TPP3
expected_VBN [PRIV]
useful_JJ
lives_NN
._.
The_DT
normal_JJ
expected_VBN [PRIV]
useful_JJ
lives_NN
of_PIN
the_DT
ESOP_NN
Trusts_NN
to_TO
purchase_VB
company_NN
shares_NN
on_PIN
the_DT
open_JJ
market_NN
to_PIN
major_JJ
categories_NN
of_PIN
tangible_JJ
xed_JJ
assets_NN
are_VPRT [PASS]
reviewed_VBN
annually_RB
meet_VB
the_DT
companys_NN
obligation_NOMZ
to_TO
provide_VB
shares_NN
when_RB
employees_NN
and_CC
are_VPRT
:_:
exercise_VB
their_TPP3
option_NOMZ
or_CC
award_NN
._.
Any_QUAN
excess_NN
of_PIN
the_DT
fair_JJ
value_NN
of_PIN
the_DT
shares_NN
at_PIN
the_DT
date_NN
of_PIN
the_DT
award_NN
over_IN
the_DT
exercise_NN
price_NN
of_PIN
the_DT
Freehold_NN
buildings_GER
20_CD
to_PIN
50_CD
years_NN
options_NOMZ
or_CC
awards_NN
is_VPRT [PASS]
charged_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
over_IN
Leasehold_NN
land_NN
and_CC
The_DT
shorter_JJ
of_PIN
lease_NN
term_NN
and_CC
50_CD
the_DT
periods_NN
of_PIN
service_NN
in_PIN
respect_NN
of_PIN
which_WDT [PIRE]
the_DT
options_NOMZ
and_PHC
awards_NN
buildings_GER
years_NN
are_VPRT [PASS]
granted_VBN [SUAV]
._.
In_PIN
respect_NN
of_PIN
other_JJ
share_NN
option_NOMZ
grants_NN
,_,
share_NN
options_NOMZ
Plant_NN
and_PHC
machinery_NN
10_CD
to_PIN
20_CD
years_NN
when_RB
exercised_VBN
are_VPRT [PASS]
accounted_VBN
for_PIN
as_IN
share_NN
issues_NN
at_PIN
exercise_NN
price_NN
._.
Fixtures_NN
and_PHC
equipment_NOMZ
3_CD
to_PIN
10_CD
years_NN
Additional_JJ
employer_NN
costs_NN
in_PIN
respect_NN
of_PIN
options_NOMZ
and_PHC
awards_NN
are_VPRT
ERP_NN
systems_NN
software_NN
7_CD
years_NN
charged_VBN [WZPAST]
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
over_IN
the_DT
periods_NN
of_PIN
service_NN
._.
Other_JJ
computer_NN
software_NN
3_CD
to_PIN
5_CD
years_NN
Assets_NN
and_PHC
liabilities_NOMZ
of_PIN
the_DT
ESOP_NN
Trusts_NN
are_VPRT [PASS]
included_VBN
in_PIN
the_DT
Group_NN
Enterprise_NN
Resource_NN
Planning_GER
ERP_NN
systems_NN
software_NN
generally_RB
balance_NN
sheet_NN
._.
Costs_NN
of_PIN
running_VBG
the_DT
Trusts_NN
are_VPRT [PASS]
charged_VBN
to_PIN
the_DT
profit_NN
involves_VPRT
significant_JJ
customisation_NOMZ
prior_RB
to_PIN
implementation_NOMZ
and_CC
is_VPRT
and_CC
loss_NN
account_NN
._.
Company_NN
shares_NN
held_VBN [PRIV] [WZPAST]
by_PIN
the_DT
Trusts_NN
are_VPRT [PASS]
deducted_VBN
expected_VBN [PRIV]
to_TO
have_VB
a_DT
useful_JJ
economic_JJ
life_NN
of_PIN
seven_CD
years_NN
,_,
rather_CONJ
than_PIN
from_PIN
other_JJ
reserves_NN
and_CC
held_VBN [PRIV]
at_PIN
a_DT
value_NN
which_WDT [WHSUB]
recognizes_VPRT [PRIV]
any_QUAN
the_DT
maximum_NN
five_CD
years_NN
of_PIN
other_JJ
computer_NN
software_NN
._.
On_PIN
disposal_NN
shortfall_NN
in_PIN
the_DT
proceeds_NN
receivable_NN
from_PIN
employees_NN
on_PIN
exercise_NN
._.
of_PIN
a_DT
tangible_JJ
xed_JJ
asset_NN
,_,
the_DT
cost_NN
and_CC
related_JJ
accumulated_VBN
If_COND
there_EX
is_VPRT [PASS]
deemed_VBN [PRIV]
to_TO
be_VB [BEMA]
a_DT
further_JJ
permanent_JJ
impairment_NOMZ
in_PIN
value_NN
depreciation_NOMZ
are_VPRT [PASS]
removed_VBN
from_PIN
the_DT
financial_JJ
statements_NOMZ
and_CC
the_DT
this_DEMP
is_VPRT [BYPA]
reected_VBN
by_PIN
a_DT
transfer_NN
to_PIN
profit_NN
and_PHC
loss_NN
account_NN
reserve_NN
._.
net_JJ
amount_NN
,_,
less_JJ
any_QUAN
proceeds_NN
,_,
is_VPRT [PASS]
taken_VBN
to_PIN
the_DT
consolidated_JJ
profit_NN
and_PHC
loss_NN
account_NN
._.
Goodwill_NN
Goodwill_NN
is_VPRT [PASS]
stated_VBN [PUBV]
at_PIN
cost_NN
less_JJ
a_DT
provision_NN
for_PIN
amortisation_NOMZ
._.
Leases_NN
Amortisation_NOMZ
is_VPRT [PASS]
calculated_VBN [PRIV]
to_TO
write_VB [PUBV]
off_PIN
the_DT
cost_NN
in_PIN
equal_JJ
annual_JJ
Leasing_GER
agreements_NOMZ
which_WDT [WHSUB]
transfer_VPRT
to_PIN
the_DT
Group_NN
substantially_RB
all_QUAN
instalments_NOMZ
over_IN
its_PIT
expected_VBN [PRIV]
useful_JJ
life_NN
._.
The_DT
useful_JJ
life_NN
is_VPRT [BEMA]
not_XX0
the_DT
benets_NN
and_PHC
risks_NN
of_PIN
ownership_NN
of_PIN
an_DT
asset_NN
are_VPRT [PASS]
treated_VBN
as_IN
normally_RB
expected_VBN [PRIV]
to_TO
exceed_VB
20_CD
years_NN
._.
finance_NN
leases_NN
,_,
as_IN
if_COND
the_DT
asset_NN
had_VBD [PEAS]
been_VBN [PASS]
purchased_VBN
outright_RB
._.
The_DT
assets_NN
are_VPRT [PASS]
included_VBN
in_PIN
tangible_JJ
xed_JJ
assets_NN
and_CC
the_DT
capital_NN
element_NOMZ
Intangible_NN
xed_VBD
assets_NN
of_PIN
the_DT
leasing_GER
commitments_NOMZ
is_VPRT [PASS]
shown_VBN [PRIV]
as_IN
obligations_NOMZ
under_IN
finance_NN
Intangible_JJ
assets_NN
are_VPRT [PASS]
stated_VBN [PUBV]
at_PIN
cost_NN
less_JJ
a_DT
provision_NN
for_PIN
amortisation_NOMZ
._.
Assets_NN
held_VBN [PRIV]
under_IN
finance_NN
leases_NN
are_VPRT [PASS]
depreciated_VBN
over_IN
the_DT
Acquired_VBN
licences_NN
,_,
patents_NN
,_,
know-how_NN
and_PHC
marketing_GER
rights_NN
are_VPRT [BEMA]
shorter_PRED
of_PIN
the_DT
lease_NN
terms_NN
and_CC
the_DT
useful_JJ
lives_NN
of_PIN
the_DT
assets_NN
._.
The_DT
amortised_VBN
over_IN
their_TPP3
estimated_VBN [PRIV]
useful_JJ
lives_NN
in_PIN
equal_JJ
instalments_NOMZ
,_,
interest_NN
element_NOMZ
of_PIN
the_DT
lease_NN
rental_NN
is_VPRT [PASS]
charged_VBN
against_PIN
profit_NN
._.
Items_NN
capitalized_VBN [WZPAST]
are_VPRT [PASS]
restricted_VBN
to_PIN
All_QUAN
other_JJ
leases_NN
are_VPRT
operating_VBG
leases_NN
and_CC
the_DT
annual_JJ
rentals_NN
are_VPRT [BEMA]
those_DEMP
related_VBN
to_PIN
specic_JJ
compounds_NN
or_CC
products_NN
which_WDT [WHSUB]
are_VPRT
being_VBG [PASS]
charged_VBN
against_PIN
profit_NN
on_PIN
a_DT
straight-line_JJ
basis_NN
over_IN
the_DT
lease_NN
term_NN
._.
The_DT
estimated_VBN [PRIV]
useful_JJ
lives_NN
for_PIN
determining_VBG [SUAV] [PRIV]
the_DT
amortisation_NOMZ
charge_NN
are_VPRT [PASS]
reviewed_VBN
annually_RB
,_,
Impairment_NOMZ
of_PIN
xed_JJ
assets_NN
and_CC
take_VB
into_PIN
account_NN
the_DT
estimated_VBN [PRIV]
time_NN
it_PIT
takes_VPRT
to_TO
bring_VB
the_DT
The_DT
carrying_VBG
values_NN
of_PIN
xed_JJ
assets_NN
are_VPRT [PASS]
reviewed_VBN
for_PIN
impairment_NOMZ
compounds_NN
or_CC
products_NN
to_PIN
market_NN
as_IN
marketable_JJ
products_NN
._.
when_RB
there_EX
is_VPRT
an_DT
indication_NOMZ
that_TOBJ
the_DT
assets_NN
might_POMD
be_VB [PASS]
impaired_VBN
._.
Any_QUAN
development_NOMZ
costs_NN
which_WDT [WHSUB]
are_VPRT [BYPA]
incurred_VBN
by_PIN
the_DT
Group_NN
and_CC
Any_QUAN
provision_NN
for_PIN
impairment_NOMZ
is_VPRT [PASS]
charged_VBN
against_PIN
profit_NN
in_PIN
the_DT
year_NN
are_VPRT [PASS]
associated_VBN
with_PIN
an_DT
acquired_VBN
licence_NN
,_,
patent_NN
,_,
know-how_NN
or_CC
concerned_VBN
._.
First_JJ
year_NN
impairment_NOMZ
reviews_NN
are_VPRT [PASS]
conducted_VBN
for_PIN
marketing_GER
rights_NN
are_VPRT [PASS]
written_VBN [PUBV]
off_PIN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
acquired_VBD
goodwill_NN
and_CC
intangible_JJ
assets_NN
._.
Certain_JJ
intangibles_NN
are_VPRT
when_RB
incurred_VBN
._.
considered_VBN [PRIV]
to_TO
have_VB
an_DT
indefinite_JJ
life_NN
and_CC
are_VPRT [PASS]
therefore_CONJ
not_XX0
amortised_VBN
._.
Such_JJ
intangibles_NN
are_VPRT [BEMA]
subject_PRED
to_PIN
annual_JJ
impairment_NOMZ
tests_NN
._.
Impairment_NOMZ
is_VPRT [BYPA]
determined_VBN [SUAV] [PRIV]
by_PIN
reference_NN
to_PIN
the_DT
higher_JJ
of_PIN
net_JJ
realisable_JJ
value_NN
and_PHC
value_NN
in_PIN
use_NN
,_,
which_WDT [SERE]
is_VPRT [BYPA]
measured_VBN
by_PIN
reference_NN
to_PIN
discounted_JJ
future_JJ
cash_NN
ows_NN
._.
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
GlaxoSmithKline_NN
99_CD
2_CD
Accounting_GER
policies_NN
continued_VBD
Gains_NN
and_PHC
losses_NN
on_PIN
foreign_JJ
exchange_NN
contracts_NN
designated_VBN
as_IN
hedges_NN
of_PIN
forecast_NN
foreign_JJ
exchange_NN
transactions_NOMZ
are_VPRT [PASS]
deferred_VBN
Investments_NOMZ
in_PIN
joint_JJ
ventures_NN
and_PHC
associates_NN
and_CC
included_VBN
in_PIN
the_DT
measurement_NOMZ
of_PIN
the_DT
related_VBN
foreign_JJ
currency_NN
Investments_NOMZ
in_PIN
joint_JJ
ventures_NN
and_CC
associated_VBN
undertakings_GER
are_VPRT
transactions_NOMZ
in_PIN
the_DT
period_NN
they_TPP3
occur_VPRT
._.
Gains_NN
and_PHC
losses_NN
on_PIN
balance_NN
carried_VBD
in_PIN
the_DT
consolidated_JJ
balance_NN
sheet_NN
at_PIN
the_DT
Groups_NN
share_VPRT
sheet_NN
hedges_NN
are_VPRT [PASS]
accrued_VBN
and_PHC
are_VPRT [PASS]
taken_VBN
directly_RB
to_PIN
reserves_NN
,_,
except_PIN
of_PIN
their_TPP3
net_JJ
assets_NN
at_PIN
date_NN
of_PIN
acquisition_NOMZ
and_CC
of_PIN
their_TPP3
postthat_NN
forward_RB
premiums_NN
discounts_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
as_IN
interest_NN
over_IN
acquisition_NOMZ
retained_VBD
profits_NN
or_CC
losses_NN
together_RB
with_PIN
any_QUAN
goodwill_NN
the_DT
life_NN
of_PIN
the_DT
contracts_NN
._.
arising_VBG [PRESP]
on_PIN
the_DT
acquisition_NOMZ
,_,
net_NN
of_PIN
amortisation_NOMZ
._.
Interest_NN
differentials_NN
under_IN
interest_NN
swap_NN
agreements_NOMZ
are_VPRT [PASS]
recognized_VBN [PRIV]
Stocks_NN
in_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
by_PIN
adjustment_NOMZ
of_PIN
interest_NN
expense_NN
Stocks_NN
are_VPRT [PASS]
included_VBN
in_PIN
the_DT
financial_JJ
statements_NOMZ
at_PIN
the_DT
lower_JJ
of_PIN
over_IN
the_DT
life_NN
of_PIN
the_DT
agreement_NOMZ
._.
cost_NN
including_VBG [WZPRES]
manufacturing_GER
overheads_NN
,_,
where_RB
appropriate_JJ
and_PHC
net_JJ
realisable_JJ
value_NN
._.
Cost_NN
is_VPRT [SPAU] [PASS]
generally_RB
determined_VBN [SUAV] [PRIV]
on_PIN
a_DT
first_JJ
in_PIN [STPR]
,_,
Debt_NN
instruments_NOMZ
first_RB
out_PIN
basis_NN
._.
Debt_NN
instruments_NOMZ
are_VPRT [PASS]
stated_VBN [PUBV]
at_PIN
the_DT
amount_NN
of_PIN
net_JJ
proceeds_NN
adjusted_VBN
to_TO
amortise_VB
the_DT
issue_NN
cost_NN
of_PIN
debt_NN
evenly_RB
over_IN
the_DT
Taxation_NOMZ
term_NN
of_PIN
the_DT
debt_NN
._.
The_DT
Group_NN
accounts_NN
for_PIN
taxation_NOMZ
which_WDT [WHSUB]
is_VPRT [PASS]
deferred_VBN
or_CC
accelerated_VBN
by_PIN
reason_NN
of_PIN
timing_NN
differences_NN
which_WDT [WHSUB]
have_VPRT [PEAS]
originated_VBN
but_CC
not_XX0
3_CD
New_JJ
accounting_GER
policies_NN
and_CC
future_JJ
requirements_NOMZ
reversed_VBN [WZPAST]
by_PIN
the_DT
balance_NN
sheet_NN
date_NN
._.
Deferred_JJ
tax_NN
assets_NN
are_VPRT [BEMA]
only_DWNT
In_PIN
December_NN
2003_CD
,_,
the_DT
Urgent_NN
Issues_NN
Task_NN
Force_NN
issued_VBD
Abstract_NN
recognized_VBD [PRIV]
to_PIN
the_DT
extent_NN
that_TOBJ
they_TPP3
are_VPRT [PASS]
considered_VBN [PRIV]
recoverable_JJ
38_CD
and_CC
amended_VBN
Abstract_NN
17_CD
,_,
relating_VBG [PRESP]
to_PIN
the_DT
accounting_GER
for_PIN
and_CC
against_PIN
future_JJ
taxable_JJ
profits_NN
._.
Deferred_JJ
tax_NN
on_PIN
the_DT
retained_VBN
presentation_NOMZ
of_PIN
ESOP_NN
Trusts_NN
and_PHC
share_NN
options_NOMZ
and_PHC
awards_NN
granted_VBN [SUAV]
earnings_GER
of_PIN
overseas_PLACE
subsidiaries_NN
is_VPRT [SPAU] [PASS]
only_DWNT
provided_VBN
when_RB
there_EX
is_VPRT
a_DT
to_PIN
employees_NN
._.
These_DEMO
requirements_NOMZ
became_VBD
mandatory_JJ
for_PIN
2004_CD
binding_JJ
commitment_NOMZ
to_TO
distribute_VB
past_JJ
earnings_GER
in_PIN
future_NN
periods_NN
._.
reporting_VBG [PUBV]
and_PHC
require_VB [SUAV] [THATD]
the_DT
shares_NN
held_VBN [PRIV] [WZPAST]
by_PIN
the_DT
ESOP_NN
Trusts_NN
to_TO
be_VB [PASS]
Deferred_VBN
tax_NN
is_VPRT [PASS]
measured_VBN
at_PIN
the_DT
average_JJ
tax_NN
rates_NN
that_TSUB
are_VPRT [PASS]
expected_VBN [PRIV]
shown_VBN [PRIV]
as_IN
a_DT
deduction_NOMZ
in_PIN
arriving_VBG
at_PIN
shareholders_NN
funds_NN
._.
The_DT
to_TO
apply_VB
in_PIN
the_DT
periods_NN
in_PIN
which_WDT [PIRE]
the_DT
timing_NN
differences_NN
are_VPRT
charge_NN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
for_PIN
employee_NN
share_NN
options_NOMZ
expected_VBN [PRIV]
to_TO
reverse_VB
._.
Deferred_JJ
tax_NN
liabilities_NOMZ
and_PHC
assets_NN
are_VPRT
not_XX0
is_VPRT [PASS]
restricted_VBN
to_PIN
the_DT
intrinsic_JJ
loss_NN
,_,
the_DT
difference_NN
between_PIN
the_DT
market_NN
discounted_VBD
._.
price_NN
and_PHC
exercise_NN
price_NN
,_,
at_PIN
the_DT
date_NN
of_PIN
grant_NN
._.
Comparative_JJ
data_NN
for_PIN
prior_JJ
periods_NN
has_VPRT [PEAS]
been_VBN [PASS]
restated_VBN
for_PIN
comparability_NOMZ
._.
Trading_GER
profit_NN
Current_JJ
asset_NN
investments_NOMZ
and_PHC
profit_NN
before_IN
tax_NN
in_PIN
2003_CD
have_VPRT [PEAS]
been_VBN [BYPA]
reduced_VBN
by_PIN
16_CD
million_CD
Current_JJ
asset_NN
investments_NOMZ
are_VPRT [PASS]
stated_VBN [PUBV]
at_PIN
the_DT
lower_JJ
of_PIN
cost_NN
and_PHC
net_NN
and_CC
net_JJ
assets_NN
at_PIN
31st_CD
December_NN
2003_CD
by_PIN
2,661_CD
million_CD
._.
It_PIT
is_VPRT [BEMA]
not_XX0
realisable_JJ
value_NN
._.
practicable_JJ
to_TO
quantify_VB
the_DT
effect_NN
on_PIN
2004_CD
because_CAUS
of_PIN
the_DT
different_JJ
measurement_NOMZ
basis_NN
adopted_VBN
._.
In_PIN
the_DT
case_NN
of_PIN
securities_NOMZ
acquired_VBN [WZPAST]
at_PIN
a_DT
significant_JJ
premium_NN
or_CC
discount_NN
to_PIN
maturity_NOMZ
value_NN
,_,
and_ANDC
intended_VBN [SUAV]
to_TO
be_VB [PASS]
held_VBN [PRIV]
to_PIN
redemption_NOMZ
,_,
In_PIN
June_NN
2002_CD
,_,
the_DT
Council_NN
of_PIN
the_DT
European_NN
Union_NN
adopted_VBD
a_DT
cost_NN
is_VPRT [PASS]
adjusted_VBN
to_TO
amortise_VB
the_DT
premium_NN
or_CC
discount_NN
over_IN
the_DT
life_NN
Regulation_NOMZ
requiring_VBG [SUAV] [WZPRES]
listed_VBN
companies_NN
in_PIN
its_PIT
Member_NN
States_NN
to_TO
to_PIN
maturity_NOMZ
of_PIN
the_DT
security_NOMZ
._.
Floating_VBG
rate_NN
bonds_NN
are_VPRT [PASS]
stated_VBN [PUBV]
at_PIN
cost_NN
._.
prepare_VB
their_TPP3
consolidated_JJ
financial_JJ
statements_NOMZ
in_PIN
accordance_NN
Interest_NN
income_NN
is_VPRT [PASS]
taken_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
on_PIN
a_DT
with_PIN
International_NN
Financial_NN
Reporting_GER
Standards_NN
IFRS_NN
from_PIN
2005_CD
._.
receivable_JJ
basis_NN
._.
GlaxoSmithKline_NN
has_VPRT [PEAS]
completed_VBN
its_PIT
conversion_NN
project_NN
,_,
subject_JJ
to_PIN
any_QUAN
changes_NN
in_PIN
standards_NN
and_PHC
pronouncements_NOMZ
,_,
and_ANDC
unaudited_JJ
Equity_NOMZ
investments_NOMZ
are_VPRT [PASS]
included_VBN
as_IN
current_JJ
assets_NN
when_RB
regarded_VBN
information_NOMZ
for_PIN
2004_CD
and_CC
2003_CD
restated_VBN
onto_PIN
an_DT
IFRS_NN
basis_NN
,_,
is_VPRT
as_IN
available_JJ
for_PIN
sale_NN
._.
Derivative_JJ
financial_JJ
instruments_NOMZ
4_CD
Exchange_NN
rates_NN
The_DT
Group_NN
does_VPRT
not_XX0
hold_VB [PRIV]
or_CC
issue_VB
derivative_JJ
financial_JJ
instruments_NOMZ
for_PIN
trading_GER
purposes_NN
._.
The_DT
Group_NN
uses_VPRT
the_DT
average_NN
of_PIN
exchange_NN
rates_NN
prevailing_VBG [WZPRES]
during_PIN
the_DT
period_NN
to_TO
translate_VB
the_DT
results_NN
and_PHC
cash_NN
ows_NN
of_PIN
overseas_PLACE
Derivative_JJ
financial_JJ
instruments_NOMZ
are_VPRT [PASS]
used_VBN
to_TO
manage_VB
exposure_NN
to_PIN
subsidiaries_NN
,_,
joint_JJ
ventures_NN
and_CC
associated_VBN
undertakings_GER
into_PIN
market_NN
risks_NN
from_PIN
treasury_NN
operations_NOMZ
._.
The_DT
principal_JJ
derivative_JJ
sterling_GER
and_PHC
period_NN
end_NN
rates_NN
to_TO
translate_VB
the_DT
net_JJ
assets_NN
of_PIN
those_DEMO
instruments_NOMZ
are_VPRT
currency_NN
swaps_NN
,_,
forward_RB
exchange_NN
contracts_NN
and_PHC
undertakings_GER
._.
The_DT
currencies_NN
which_WDT
most_EMPH
inuence_JJ
these_DEMO
interest_NN
rate_NN
swaps_NN
._.
The_DT
derivative_JJ
contracts_NN
are_VPRT [PASS]
treated_VBN
from_PIN
translations_NOMZ
,_,
and_ANDC
the_DT
relevant_JJ
exchange_NN
rates_NN
,_,
were_VBD
:_:
inception_NOMZ
as_IN
an_DT
economic_JJ
hedge_NN
of_PIN
the_DT
underlying_VBG
financial_JJ
2004 2003 2002_CD
instrument_NOMZ
,_,
with_PIN
matching_JJ
accounting_GER
treatment_NOMZ
and_PHC
cash_NN
ows_NN
._.
The_DT
derivative_JJ
contracts_NN
have_VPRT
high_JJ
correlation_NOMZ
with_PIN
the_DT
specic_JJ
Average_JJ
rates_NN
:_:
financial_JJ
instrument_NOMZ
being_VBG [WZPRES] [PASS]
hedged_VBN
both_DT
at_PIN
inception_NOMZ
and_CC
US$_$
1.83_CD
1.64_CD
1.50_CD
throughout_PIN
the_DT
hedge_JJ
period_NN
._.
Derivative_JJ
instruments_NOMZ
no_RB
longer_RB
Euro_NN
1.47_CD
1.45_CD
1.59_CD
designated_VBN
as_IN
hedges_NN
are_VPRT [PASS]
restated_VBN
at_PIN
market_NN
value_NN
and_CC
any_QUAN
future_JJ
Yen_NN
197.00_CD
191.00_CD
188.00_CD
changes_NN
in_PIN
value_NN
are_VPRT [PASS]
taken_VBN
directly_RB
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
._.
Period_NN
end_NN
rates_NN
:_:
US$_$
1.92_CD
1.79_CD
1.61_CD
Currency_NN
swaps_NN
and_CC
forward_RB
exchange_NN
contracts_NN
used_VBN
to_TO
x_SYM
the_DT
Euro_NN
1.41_CD
1.42_CD
1.54_CD
value_NN
of_PIN
the_DT
related_JJ
asset_NN
or_CC
liability_NOMZ
in_PIN
the_DT
contract_NN
currency_NN
and_PHC
Yen_NN
197.00_CD
192.00_CD
192.00_CD
at_PIN
the_DT
contract_NN
rate_NN
are_VPRT [PASS]
accrued_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
over_IN
the_DT
life_NN
of_PIN
the_DT
contract_NN
._.
100_CD
GlaxoSmithKline_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
5_CD
Merger_NN
of_PIN
Glaxo_NN
Wellcome_NN
and_PHC
SmithKline_NN
Beecham_NN
The_NN
combination_NOMZ
of_PIN
Glaxo_NN
Wellcome_NN
plc_NN
and_PHC
SmithKline_NN
Beecham_NN
plc_NN
was_VBD [PASS]
treated_VBN
as_IN
a_DT
merger_NN
at_PIN
27th_JJ
December_NN
2000_CD
under_IN
UK_NN
GAAP_NN
._.
Under_IN
the_DT
merger_NN
relief_NN
provisions_NN
of_PIN
the_DT
Companies_NN
Act_NN
1985_CD
,_,
the_DT
shares_NN
issued_VBN [WZPAST]
by_PIN
GlaxoSmithKline_NN
plc_NN
to_TO
acquire_VB
Glaxo_NN
Wellcome_NN
and_PHC
SmithKline_NN
Beecham_NN
were_VBD [PASS]
accounted_VBN
for_PIN
at_PIN
par_NN
and_CC
no_SYNE
share_NN
premium_NN
arose_VBD
:_:
the_DT
shares_NN
acquired_VBN [WZPAST]
by_PIN
GlaxoSmithKline_NN
in_PIN
Glaxo_NN
Wellcome_NN
and_PHC
SmithKline_NN
Beecham_NN
were_VBD [SPAU] [PASS]
similarly_CONJ
accounted_VBN
for_PIN
at_PIN
the_DT
nominal_JJ
value_NN
of_PIN
the_DT
shares_NN
issued_VBN
._.
In_PIN
the_DT
consolidated_JJ
Financial_NN
statements_NOMZ
of_PIN
GlaxoSmithKline_NN
,_,
the_DT
results_NN
and_CC
net_JJ
assets_NN
of_PIN
Glaxo_NN
Wellcome_NN
and_PHC
SmithKline_NN
Beecham_NN
were_VBD [PASS]
combined_VBN
at_PIN
their_TPP3
book_NN
amounts_NN
,_,
subject_JJ
to_TO
alignment_VB
adjustments_NOMZ
._.
6_CD
Segment_NOMZ
information_NOMZ
An_DT
analysis_NN
of_PIN
turnover_NN
,_,
profit_NN
before_IN
taxation_NOMZ
,_,
total_JJ
assets_NN
and_CC
net_JJ
assets_NN
by_PIN
business_NOMZ
and_CC
geographical_JJ
sector_NN
,_,
tangible_JJ
xed_JJ
assets_NN
by_PIN
geographical_JJ
sector_NN
and_PHC
turnover_NN
by_PIN
location_NOMZ
of_PIN
customer_NN
are_VPRT [PASS]
set_VBN
out_PIN
below_PLACE
._.
The_DT
business_NOMZ
sectors_NN
consist_VPRT
of_PIN
Pharmaceuticals_NN
prescription_NOMZ
pharmaceuticals_NN
and_PHC
vaccines_NN
and_PHC
Consumer_NN
Healthcare_NN
oral_JJ
care_NN
,_,
OTC_NN
medicines_NN
and_CC
nutritional_JJ
healthcare_NN
._.
Assets_NN
by_PIN
business_NOMZ
sector_NN
in_PIN
2003_CD
have_VPRT [PEAS]
been_VBN [PASS]
adjusted_VBN
to_TO
ensure_VB [SUAV] [PRIV]
consistency_NN
with_PIN
2004_CD
._.
The_DT
geographical_JJ
sectors_NN
reect_VPRT
the_DT
Groups_NN
most_EMPH
significant_JJ
regional_JJ
markets_NN
and_CC
are_VPRT [BEMA]
consistent_PRED
with_PIN
the_DT
Groups_NN
regional_JJ
market_NN
management_NOMZ
reporting_VBG [PUBV] [WZPRES]
structure_NN
._.
Business_NOMZ
sector_NN
data_NN
includes_VPRT
an_DT
allocation_NOMZ
of_PIN
corporate_JJ
costs_NN
to_PIN
each_QUAN
sector_NN
._.
There_EX
are_VPRT
no_SYNE
sales_NN
between_PIN
business_NOMZ
sectors_NN
._.
The_DT
Groups_NN
activities_NOMZ
are_VPRT [PASS]
organised_VBN
on_PIN
a_DT
global_JJ
basis_NN
._.
The_DT
geographical_JJ
sector_NN
gures_NN
are_VPRT [SPAU] [BYPA]
therefore_CONJ
inuenced_VBN
by_PIN
the_DT
location_NOMZ
of_PIN
the_DT
Groups_NN
operating_VBG [WZPRES]
resources_NN
,_,
in_CONJ
particular_NULL
manufacturing_GER
and_PHC
research_NN
,_,
and_ANDC
by_PIN
variations_NOMZ
over_IN
time_NN
in_PIN
intra-Group_JJ
trading_GER
and_PHC
funding_GER
arrangements_NOMZ
._.
Where_RB
the_DT
Group_NN
co-promotes_NN
a_DT
product_NN
and_CC
the_DT
third_JJ
party_NN
records_NN
the_DT
sale_NN
,_,
the_DT
Group_NN
records_NN
its_PIT
share_NN
of_PIN
revenue_NN
as_IN
co-promotion_JJ
income_NN
within_PIN
turnover_NN
._.
The_DT
nature_NN
of_PIN
co-promotion_NOMZ
activities_NOMZ
is_VPRT [BEMA]
such_OSUB
that_NULL
the_DT
Group_NN
records_NN
no_SYNE
costs_NN
of_PIN
sales_NN
._.
Pharmaceutical_NN
turnover_NN
includes_VPRT
co-promotion_JJ
income_NN
of_PIN
65_CD
million_CD
2003_CD
35_CD
million_CD
,_,
2002_CD
nil_NN
._.
2003 2002 2004_CD
restated_VBN
restated_VBN
Turnover_NN
by_PIN
business_NOMZ
sector_NN
m_NN
m_FW
m_FW
Pharmaceuticals_NN
17,146_CD
18,181_CD
17,995_CD
Consumer_NN
Healthcare_NN
3,213_CD
3,260_CD
3,217_CD
External_NN
turnover_NN
20,359_CD
21,441_CD
21,212_CD
Statutory_JJ
profit_NN
before_IN
tax_NN
by_PIN
business_NOMZ
sector_NN
Pharmaceuticals_NN
5,428_CD
5,785_CD
5,085_CD
Consumer_NN
Healthcare_NN
662 591 484_CD
Operating_GER
profit_NN
6,090_CD
6,376_CD
5,569_CD
Share_NN
of_PIN
profits_NN
of_PIN
joint_JJ
ventures_NN
and_CC
associated_VBN
undertakings_GER
95_CD
93_CD
75_CD
profit_NN
on_PIN
disposal_NN
of_PIN
interest_NN
in_PIN
associate_JJ
138_CD
Loss_NN
profit_NN
on_PIN
disposal_NN
of_PIN
businesses_NOMZ
1_CD
5_CD
10_CD
Product_NN
divestments_VPRT
11_CD
Net_JJ
interest_NN
payable_JJ
203 161 141_CD
profit_NN
before_IN
taxation_NOMZ
6,119_CD
6,313_CD
5,524_CD
profit_NN
before_IN
taxation_NOMZ
6,119_CD
6,313_CD
5,524_CD
Taxation_NOMZ
1,701_CD
1,729_CD
1,464_CD
Minority_NOMZ
interests_NN
114_CD
94_CD
110_CD
Preference_NN
share_NN
dividends_NN
2_CD
12_CD
20_CD
Statutory_JJ
earnings_GER
4,302_CD
4,478_CD
3,930_CD
Total_JJ
assets_NN
by_PIN
business_NOMZ
sector_NN
Pharmaceuticals_NN
18,875_CD
17,384_CD
Consumer_NN
Healthcare_NN
3,703_CD
3,816_CD
Total_JJ
assets_NN
22,578_CD
21,200_CD
Net_JJ
assets_NN
by_PIN
business_NOMZ
sector_NN
Pharmaceuticals_NN
3,698_CD
3,316_CD
Consumer_NN
Healthcare_NN
2,504_CD
2,488_CD
Net_JJ
assets_NN
6,202_CD
5,804_CD
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
GlaxoSmithKline_NN
101_CD
6_CD
Segment_NOMZ
information_NOMZ
continued_VBD
2003 2002 2004_CD
restated_VBN
restated_VBN
Turnover_NN
by_PIN
location_NOMZ
of_PIN
subsidiary_NN
undertaking_GER
m_NN
m_FW
m_FW
USA_NN
9,524_CD
10,569_CD
11,096_CD
Europe_NN
11,431_CD
11,798_CD
10,423_CD
International_NN
7,847_CD
7,945_CD
6,824_CD
Turnover_NN
including_VBG [WZPRES]
inter-segment_JJ
turnover_NN
28,802_CD
30,312_CD
28,343_CD
USA_NN
289 219 168_CD
Europe_NN
4,278_CD
4,690_CD
3,873_CD
International_NN
3,876_CD
3,962_CD
3,090_CD
Inter-segment_NOMZ
turnover_NN
8,443_CD
8,871_CD
7,131_CD
USA_NN
9,235_CD
10,350_CD
10,928_CD
Europe_NN
7,153_CD
7,108_CD
6,550_CD
International_NN
3,971_CD
3,983_CD
3,734_CD
External_NN
turnover_NN
20,359_CD
21,441_CD
21,212_CD
Statutory_JJ
profit_NN
before_IN
tax_NN
by_PIN
location_NOMZ
of_PIN
subsidiary_NN
undertaking_GER
USA_NN
1,266_CD
1,983_CD
2,117_CD
Europe_NN
2,739_CD
3,045_CD
2,508_CD
International_NN
2,085_CD
1,348_CD
944_CD
Operating_GER
profit_NN
6,090_CD
6,376_CD
5,569_CD
Share_NN
of_PIN
profits_NN
of_PIN
joint_JJ
ventures_NN
and_CC
associated_VBN
undertakings_GER
95_CD
93_CD
75_CD
profit_NN
on_PIN
disposal_NN
of_PIN
interest_NN
in_PIN
associate_JJ
138_CD
profit_NN
on_PIN
disposal_NN
of_PIN
businesses_NOMZ
1_CD
5_CD
10_CD
Product_NN
divestments_VPRT
11_CD
Net_JJ
interest_NN
payable_JJ
203 161 141_CD
profit_NN
before_IN
taxation_NOMZ
6,119_CD
6,313_CD
5,524_CD
profit_NN
before_IN
taxation_NOMZ
6,119_CD
6,313_CD
5,524_CD
Taxation_NOMZ
1,701_CD
1,729_CD
1,464_CD
Minority_NOMZ
interests_NN
114_CD
94_CD
110_CD
Preference_NN
share_NN
dividends_NN
2_CD
12_CD
20_CD
Statutory_JJ
earnings_GER
4,302_CD
4,478_CD
3,930_CD
Total_JJ
assets_NN
by_PIN
location_NOMZ
of_PIN
subsidiary_NN
undertaking_GER
USA_NN
4,351_CD
4,385_CD
Europe_NN
11,374_CD
10,362_CD
International_NN
2,874_CD
2,998_CD
Total_JJ
operating_VBG
assets_NN
18,599_CD
17,745_CD
Cash_NN
at_PIN
bank_NN
and_CC
liquid_JJ
investments_NOMZ
3,979_CD
3,455_CD
Total_JJ
assets_NN
22,578_CD
21,200_CD
Net_JJ
assets_NN
by_PIN
location_NOMZ
of_PIN
subsidiary_NN
undertaking_GER
USA_NN
233_CD
484_CD
Europe_NN
5,973_CD
4,922_CD
International_NN
1,980_CD
2,046_CD
Net_NN
operating_VBG [WZPRES]
assets_NN
8,186_CD
7,452_CD
Net_JJ
debt_NN
1,984_CD
1,648_CD
Net_JJ
assets_NN
6,202_CD
5,804_CD
102_CD
GlaxoSmithKline_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
6_CD
Segment_NOMZ
information_NOMZ
continued_VBD
2004_CD
2003_CD
Plant_NN
,_,
Land_NN
and_PHC
equipment_NOMZ
Computer_NN
Assets_NN
in_PIN
buildings_GER
and_PHC
vehicles_NN
software_NN
construction_NOMZ
Total_JJ
Total_JJ
Tangible_JJ
xed_JJ
assets_NN
by_PIN
location_NOMZ
of_PIN
subsidiary_NN
undertaking_GER
m_NN
m_FW
m_FW
m_FW
m_FW
m_FW
USA_NN
662_CD
399_CD
40_CD
157_CD
1,258_CD
1,295_CD
Europe_NN
1,591_CD
2,023_CD
159_CD
500_CD
4,273_CD
4,184_CD
International_NN
503_CD
357_CD
11 69 940 962_CD
Total_JJ
2,756_CD
2,779_CD
210_CD
726_CD
6,471_CD
6,441_CD
2004 2003 2002_CD
Turnover_NN
by_PIN
location_NOMZ
of_PIN
customer_NN
m_NN
mm_NN
USA_NN
9,243_CD
10,333_CD
10,807_CD
Europe_NN
6,658_CD
6,611_CD
6,064_CD
International_NN
4,458_CD
4,497_CD
4,341_CD
External_NN
turnover_NN
20,359_CD
21,441_CD
21,212_CD
UK_NN
segment_NOMZ
Information_NOMZ
is_VPRT [PASS]
given_VBN
separately_RB
in_PIN
respect_NN
of_PIN
the_DT
UK_NN
,_,
which_WDT [SERE]
,_,
although_CONC
included_VBN
in_PIN
the_DT
Groups_NN
Europe_NN
market_NN
region_NN
,_,
is_VPRT [PASS]
considered_VBN [PRIV]
the_DT
Groups_NN
home_NN
segment_NOMZ
for_PIN
the_DT
purposes_NN
of_PIN
segmental_JJ
reporting_GER
._.
2003 2002 2004_CD
restated_VBN
restated_VBN
m_FW
m_FW
m_FW
Turnover_NN
by_PIN
location_NOMZ
of_PIN
customer_NN
1,461_CD
1,404_CD
1,366_CD
Turnover_NN
including_VBG [WZPRES]
inter-segment_JJ
turnover_NN
4,467_CD
4,678_CD
4,945_CD
Inter-segment_NOMZ
turnover_NN
2,709_CD
2,883_CD
3,230_CD
Turnover_NN
by_PIN
location_NOMZ
of_PIN
subsidiary_NN
1,758_CD
1,795_CD
1,715_CD
Operating_GER
profit_NN
1,403_CD
1,519_CD
1,294_CD
Total_JJ
assets_NN
7,578_CD
7,145_CD
Net_NN
operating_VBG [WZPRES]
assets_NN
2,635_CD
2,023_CD
7_CD
Merger_NN
items_NN
,_,
restructuring_VBG
costs_NN
and_CC
divested_JJ
businesses_NOMZ
Manufacturing_GER
and_CC
other_JJ
restructuring_GER
costs_NN
were_VBD [BYPA]
incurred_VBN
by_PIN
GlaxoSmithKline_NN
during_PIN
2003_CD
and_CC
2002_CD
in_PIN
the_DT
implementation_NOMZ
of_PIN
previously_TIME
announced_VBN [PUBV]
plans_NN
for_PIN
the_DT
restructuring_GER
of_PIN
manufacturing_GER
and_CC
other_JJ
activities_NOMZ
._.
Merger_NN
integration_NOMZ
costs_NN
relate_VPRT
to_PIN
the_DT
integration_NOMZ
of_PIN
Glaxo_NN
Wellcome_NN
and_PHC
SmithKline_NN
Beecham_NN
into_PIN
a_DT
unied_JJ
GlaxoSmithKline_NN
business_NOMZ
._.
These_DEMO
costs_NN
include_VPRT
consultancy_NN
fees_NN
in_PIN
respect_NN
of_PIN
integration_NOMZ
planning_GER
,_,
severance_NN
costs_NN
,_,
asset_NN
write-offs_NN
,_,
costs_NN
related_VBN [WZPAST]
to_PIN
the_DT
early_TIME
vesting_GER
or_CC
lapse_NN
of_PIN
performance_NN
conditions_NOMZ
on_PIN
share_NN
options_NOMZ
and_PHC
share_NN
incentive_NN
awards_NN
and_PHC
costs_NN
of_PIN
the_DT
program_NN
to_TO
encourage_VB
staff_NN
to_TO
convert_VB
Glaxo_NN
Wellcome_NN
and_PHC
SmithKline_NN
Beecham_NN
share_NN
options_NOMZ
into_PIN
GlaxoSmithKline_NN
share_NN
options_NOMZ
._.
Integration_NOMZ
costs_NN
were_VBD [PASS]
incurred_VBN
in_PIN
2003_CD
and_CC
2002_CD
relating_VBG
to_PIN
the_DT
integration_NOMZ
of_PIN
the_DT
Block_NN
Drug_NN
businesses_NOMZ
._.
These_DEMO
costs_NN
include_VPRT
professional_JJ
fees_NN
,_,
severance_NN
costs_NN
and_PHC
asset_NN
write-offs_NN
._.
Product_NN
divestment_NOMZ
income_NN
arising_VBG [WZPRES]
in_PIN
2002_CD
related_VBN
to_PIN
the_DT
nalisation_NOMZ
of_PIN
the_DT
disposals_NN
of_PIN
Famvir_NN
,_,
Kytril_NN
and_CC
other_JJ
products_NN
required_VBN [SUAV] [WZPAST]
in_PIN
2000_CD
in_PIN
order_NN
to_TO
obtain_VB
regulatory_JJ
approval_NN
for_PIN
the_DT
merger_NN
._.
The_DT
disposal_NN
of_PIN
businesses_NOMZ
in_PIN
2003_CD
and_CC
2002_CD
related_VBN
to_PIN
the_DT
nalisation_NOMZ
of_PIN
the_DT
disposals_NN
of_PIN
Clinical_JJ
Laboratories_NN
and_PHC
Healthcare_NN
Services_NN
in_PIN
1999_CD
._.
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
GlaxoSmithKline_NN
103_CD
7_CD
Merger_NN
items_NN
,_,
restructuring_VBG
costs_NN
and_CC
divested_JJ
businesses_NOMZ
continued_VBD
Disposal_NN
of_PIN
Merger_NN
Restructuring_GER
Block_NN
Drug_NN
subsidiaries_NN
Total_JJ
2003_CD
m_FW
m_FW
m_FW
m_FW
m_FW
Manufacturing_GER
and_CC
other_JJ
restructuring_GER
83_CD
83_CD
Merger_NN
integration_NOMZ
costs_NN
286_CD
286_CD
Block_NN
Drug_NN
integration_NOMZ
costs_NN
26_CD
26_CD
Effect_NN
on_PIN
operating_GER
profit_NN
286_CD
83_CD
26_CD
395_CD
profit_NN
on_PIN
disposal_NN
of_PIN
businesses_NOMZ
5_CD
5_CD
Effect_NN
on_PIN
profit_NN
before_IN
tax_NN
286_CD
83_CD
26_CD
5_CD
390_CD
Effect_NN
on_PIN
taxation_NOMZ
operating_GER
items_NN
98_CD
Effect_NN
on_PIN
taxation_NOMZ
non-operating_JJ
items_NN
11_CD
Effect_NN
on_PIN
taxation_NOMZ
109_CD
Effect_NN
on_PIN
earnings_GER
281_CD
Disposal_NN
of_PIN
Merger_NN
Restructuring_GER
Block_NN
Drug_NN
subsidiaries_NN
Total_JJ
2002_CD
m_FW
m_FW
m_FW
m_FW
m_FW
Manufacturing_GER
and_CC
other_JJ
restructuring_GER
121_CD
121_CD
Merger_NN
integration_NOMZ
costs_NN
851_CD
851_CD
Block_NN
Drug_NN
integration_NOMZ
costs_NN
60_CD
60_CD
Effect_NN
on_PIN
operating_GER
profit_NN
851_CD
121_CD
60_CD
1,032_CD
Product_NN
divestments_VPRT
11_CD
11_CD
profit_NN
on_PIN
disposal_NN
of_PIN
businesses_NOMZ
10_CD
10_CD
Effect_NN
on_PIN
profit_NN
before_IN
tax_NN
840_CD
121_CD
60_CD
10_CD
1,011_CD
Effect_NN
on_PIN
taxation_NOMZ
operating_GER
items_NN
266_CD
Effect_NN
on_PIN
taxation_NOMZ
non-operating_JJ
items_NN
33_CD
Effect_NN
on_PIN
taxation_NOMZ
299_CD
Effect_NN
on_PIN
earnings_GER
712_CD
8_CD
Other_JJ
operating_GER
income_NN
expense_NN
2004 2003 2002_CD
m_FW
m_FW
m_FW
Royalties_NN
and_CC
other_JJ
income_NN
96_CD
75_CD
75_CD
Other_JJ
operating_GER
expense_NN
296 436 209 200_CD
361_CD
134_CD
Income_NN
from_PIN
equity_NOMZ
investments_NOMZ
and_CC
other_JJ
disposals_NN
140_CD
228_CD
23 60 133 111_CD
Royalties_NN
and_CC
other_JJ
income_NN
is_VPRT [BEMA]
principally_RB
a_DT
core_NN
of_PIN
recurring_VBG
income_NN
in_PIN
the_DT
form_NN
of_PIN
royalties_NN
from_PIN
the_DT
out-licensing_GER
of_PIN
intellectual_JJ
property_NN
._.
Other_JJ
operating_GER
expense_NN
includes_VPRT
litigation_NOMZ
costs_NN
and_PHC
provisions_NN
relating_VBG [WZPRES]
to_PIN
legal_JJ
claims_NN
on_PIN
withdrawn_VBN
products_NN
,_,
product_NN
withdrawals_NN
,_,
anti-trust_JJ
matters_NN
and_PHC
claims_NN
with_PIN
respect_NN
to_PIN
sales_NN
,_,
marketing_GER
and_PHC
reimbursement_NOMZ
._.
Income_NN
from_PIN
equity_NOMZ
investments_NOMZ
and_CC
other_JJ
disposals_NN
includes_VPRT
equity_NOMZ
investment_NOMZ
carrying_VBG [WZPRES]
value_NN
adjustments_NOMZ
arising_VBG [WZPRES]
from_PIN
stock_NN
market_NN
changes_NN
,_,
product_NN
disposals_NN
and_PHC
equity_NOMZ
investment_NOMZ
sales_NN
._.
104_CD
GlaxoSmithKline_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
9_CD
Operating_GER
profit_NN
2003 2002 2004_CD
restated_VBN
restated_VBN
m_FW
m_FW
m_FW [BEMA]
The_DT
following_JJ
items_NN
have_VPRT [PEAS]
been_VBN [PASS]
charged_VBN
in_PIN
operating_GER
profit_NN
:_:
Employee_NN
costs_NN
Note_VPRT [PRIV]
35_CD
4,704_CD
5,074_CD
4,922_CD
Advertising_GER
599 615 688_CD
Distribution_NOMZ
costs_NN
271 284 281_CD
Depreciation_NOMZ
of_PIN
tangible_JJ
xed_JJ
assets_NN
:_:
Owned_JJ
assets_NN
780 771 760_CD
Leased_JJ
assets_NN
5_CD
24_CD
Amortisation_NOMZ
of_PIN
goodwill_NN
12_CD
13_CD
12_CD
Amortisation_NOMZ
of_PIN
intangible_JJ
xed_JJ
assets_NN
94_CD
74_CD
60_CD
Exchange_NN
losses_NN
on_PIN
foreign_JJ
currency_NN
deposits_NN
loans_NN
1_CD
Operating_GER
lease_NN
rentals_NN
:_:
Plant_NN
56_CD
90_CD
50_CD
Land_NN
and_PHC
buildings_GER
63_CD
62_CD
61_CD
Audit_NN
fees_NN
7.2_CD
6.9_CD
6.1_CD
Fees_NN
to_PIN
auditors_NN
for_PIN
other_JJ
work_NN
:_:
Auditors_NN
UK_NN
rm_VBD
2.6_CD
1.7_CD
5.2_CD
Auditors_NN
overseas_PLACE
rms_VPRT
4.7_CD
5.9_CD
9.6_CD
Analysis_NN
of_PIN
fees_NN
to_PIN
auditors_NN
for_PIN
other_JJ
work_NN
:_:
Further_JJ
assurance_NN
audit-related_JJ
services_NN
3.4_CD
2.6_CD
1.8_CD
Tax_NN
services_NN
3.0_CD
4.6_CD
4.9_CD
Merger_NN
of_PIN
Glaxo_NN
Wellcome_NN
and_PHC
SmithKline_NN
Beecham_NN
6.0_CD
Other_JJ
services_NN
0.9_CD
0.4_CD
2.1_CD
Included_VBN
within_PIN
audit_NN
fees_NN
above_PLACE
is_VPRT [BEMA]
a_DT
fee_NN
of_PIN
10,000_CD
2003_CD
10,000_CD
,_,
2002_CD
10,000_CD
relating_VBG
to_PIN
the_DT
company_NN
audit_NN
of_PIN
GlaxoSmithKline_NN
plc._NN
._.
Included_VBN [PASTP]
in_PIN
further_JJ
assurance_NN
services_NN
in_PIN
2004_CD
and_CC
2003_CD
are_VPRT [PASS]
amounts_NN
related_VBN [WZPAST]
to_PIN
the_DT
Groups_NN
preparation_NOMZ
for_PIN
the_DT
adoption_NOMZ
of_PIN
International_NN
Financial_NN
Reporting_GER
Standards_NN
and_PHC
preparation_NOMZ
for_PIN
section_NOMZ
404_CD
of_PIN
the_DT
Sarbanes-Oxley_NN
Act_NN
2002_CD
._.
Tax_NN
services_NN
relates_VPRT
to_PIN
fees_NN
paid_VBN [WZPAST]
for_PIN
corporate_JJ
tax_NN
compliance_NN
,_,
tax_NN
planning_GER
and_PHC
advice_NN
._.
Other_JJ
services_NN
include_VPRT
human_JJ
resources_NN
advisory_JJ
,_,
compliance_NN
and_PHC
treasury_NN
related_VBN
services_NN
._.
Included_VBN [PASTP]
within_PIN
fees_NN
to_PIN
auditors_NN
for_PIN
other_JJ
work_NN
in_PIN
2002_CD
is_VPRT [BEMA]
6.0_CD
million_CD
paid_VBN
to_PIN
the_DT
auditors_NN
management_NOMZ
consulting_GER
practice_NN
,_,
which_WDT [SERE]
was_VBD [BYPA]
sold_VBN
by_PIN
them_TPP3
in_PIN
2002_CD
._.
In_PIN
2004_CD
and_CC
2003_CD
,_,
the_DT
Group_NN
applied_VBD
discounting_VBG
to_PIN
certain_JJ
long-term_JJ
assets_NN
and_PHC
liabilities_NOMZ
,_,
using_VBG
risk-free_JJ
rates_NN
of_PIN
return_NN
._.
10_CD
Joint_NN
ventures_NN
and_CC
associated_VBN
undertakings_GER
2004 2003 2002_CD
m_FW
m_FW
m_FW
Associated_NN
undertakings_GER
:_:
Share_NN
of_PIN
profits_NN
of_PIN
Quest_NN
Diagnostics_NN
Inc._NN
100_CD
102_CD
94_CD
Share_NN
of_PIN
losses_NN
of_PIN
other_JJ
associated_VBN
undertakings_GER
1_CD
3_CD
Amortisation_NOMZ
of_PIN
goodwill_NN
5_CD
6_CD
6_CD
94_CD
93_CD
88_CD
Share_NN
of_PIN
profits_NN
losses_NN
of_PIN
joint_JJ
ventures_NN
1_CD
13_CD
95_CD
93_CD
75_CD
Share_NN
of_PIN
turnover_NN
of_PIN
joint_JJ
ventures_NN
31_CD
31_CD
29_CD
Sales_NN
to_PIN
joint_JJ
ventures_NN
and_CC
associated_VBN
undertakings_GER
50_CD
51_CD
49_CD
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
GlaxoSmithKline_NN
105_CD
11_CD
Net_JJ
interest_NN
payable_JJ
2004 2003 2002_CD
m_NN
mm_NN
Interest_NN
payable_JJ
On_PIN
bank_NN
loans_NN
and_PHC
overdrafts_NN
6_CD
6_CD
6_CD
On_PIN
other_JJ
loans_NN
273 186 198_CD
In_PIN
respect_NN
of_PIN
finance_NN
leases_NN
2_CD
2_CD
2_CD
Realised_JJ
losses_NN
1_CD
Unwinding_GER
of_PIN
discount_NN
on_PIN
provisions_NN
16 20 298 214_CD
206_CD
Share_NN
of_PIN
interest_NN
payable_JJ
of_PIN
associate_JJ
7_CD
8_CD
8_CD
305 222 214_CD
Investment_NOMZ
income_NN
Interest_NN
income_NN
99_CD
58_CD
71_CD
Realised_VBN [PRIV]
gains_NN
2_CD
Unwinding_GER
of_PIN
discount_NN
on_PIN
assets_NN
3_CD
3_CD
102 6173 203 161_CD
141_CD
12_CD
Taxation_NOMZ
2003 2002 2004_CD
restated_VBN
restated_VBN
Taxation_NOMZ
charge_NN
based_VBN [WZPAST]
on_PIN
profits_NN
for_PIN
the_DT
period_NN
m_NN
m_FW
m_FW
UK_NN
corporation_NOMZ
tax_NN
at_PIN
the_DT
UK_NN
statutory_JJ
rate_NN
429 673479_CD
Less_RB
double_JJ
taxation_NOMZ
relief_NN
156 290 117 273_CD
383_CD
362_CD
Overseas_PLACE
taxation_NOMZ
1,394_CD
1,578_CD
1,036_CD
Deferred_JJ
taxation_NOMZ
6_CD
272_CD
32_CD
1,661_CD
1,689_CD
1,430_CD
Share_NN
of_PIN
taxation_NOMZ
charge_NN
of_PIN
associates_NN
40_CD
40_CD
34_CD
1,701_CD
1,729_CD
1,464_CD
2003 2002 2004_CD
restated_VBN
restated_VBN
Reconciliation_NOMZ
of_PIN
the_DT
current_JJ
taxation_NOMZ
rate_NN
on_PIN
Group_NN
profits_NN
%_NN
%_NN
%_NN
UK_NN
statutory_JJ
rate_NN
of_PIN
taxation_NOMZ
30.0_CD
30.0_CD
30.0_CD
Overseas_PLACE
taxes_NN
1.2_CD
0.1_CD
0.1_CD
Average_NN
Group_NN
tax_NN
rate_NN
31.2_CD
30.1_CD
30.1_CD
Effect_NN
of_PIN
special_JJ
tax_NN
status_NN
in_PIN
manufacturing_VBG
locations_NOMZ
3.6_CD
3.9_CD
3.9_CD
Share_NN
option_NOMZ
deductions_NOMZ
0.2_CD
0.1_CD
0.2_CD
Merger_NN
and_CC
restructuring_VBG
costs_NN
0.1_CD
0.7_CD
R&D_NN
credits_NN
1.5_CD
1.1_CD
1.2_CD
Other_JJ
permanent_JJ
differences_NN
2.1_CD
1.1_CD
0.8_CD
Capital_NN
allowances_NN
in_PIN
excess_NN
of_PIN
depreciation_NOMZ
0.3_CD
0.3_CD
0.5_CD
Intra-Group_NN
profit_NN
0.3_CD
0.1_CD
1.3_CD
Reversing_VBG
timing_NN
differences_NN
on_PIN
tax_NN
losses_NN
1.6_CD
Other_JJ
timing_NN
differences_NN
0.7_CD
4.0_CD
2.2_CD
Prior_RB
year_NN
items_NN
1.0_CD
1.5_CD
2.4_CD
Current_JJ
tax_NN
rate_NN
on_PIN
ordinary_JJ
activities_NOMZ
27.3_CD
31.1_CD
25.3_CD
Capital_NN
allowances_NN
in_PIN
excess_NN
of_PIN
depreciation_NOMZ
0.3_CD
0.3_CD
0.5_CD
Intra-Group_NN
profit_NN
0.3_CD
0.1_CD
1.3_CD
Reversing_VBG
timing_NN
differences_NN
on_PIN
tax_NN
losses_NN
1.6_CD
Other_JJ
timing_NN
differences_NN
0.7_CD
4.0_CD
2.2_CD
Share_NN
of_PIN
taxation_NOMZ
charge_NN
of_PIN
associates_NN
0.6_CD
0.6_CD
0.6_CD
Prior_RB
year_NN
items_NN
1.8_CD
0.6_CD
3.6_CD
UITF_NN
17_CD
restatement_NOMZ
0.1_CD
Tax_NN
rate_NN
on_PIN
ordinary_JJ
activities_NOMZ
27.8_CD
27.4_CD
26.5_CD
The_DT
Group_NN
operates_VPRT
in_PIN
countries_NN
where_RB
the_DT
tax_NN
rate_NN
differs_VPRT
from_PIN
the_DT
UK_NN
tax_NN
rate_NN
._.
The_DT
average_JJ
Group_NN
tax_NN
rate_NN
has_VPRT [PEAS]
been_VBN [BYPA]
determined_VBN [SUAV] [PRIV]
by_PIN
aggregating_VBG
the_DT
local_JJ
standard_JJ
tax_NN
rates_NN
and_PHC
weighting_GER
these_DEMO
in_PIN
proportion_NOMZ
to_TO
accounting_VBG
profits_NN
._.
profits_NN
arising_VBG [WZPRES]
from_PIN
manufacturing_VBG
operations_NOMZ
in_PIN
Singapore_NN
,_,
Puerto_NN
Rico_NN
and_PHC
Ireland_NN
are_VPRT [PASS]
taxed_VBN
at_PIN
reduced_JJ
rates_NN
._.
The_DT
effect_NN
of_PIN
this_DEMO
reduction_NOMZ
in_PIN
the_DT
taxation_NOMZ
charge_NN
increased_VBD
earnings_GER
per_PIN
share_NN
by_PIN
3.8_CD
p_NN
in_PIN
2004_CD
,_,
4.2_CD
p_NN
in_PIN
2003_CD
and_CC
3.7_CD
p_NN
in_PIN
2002_CD
._.
106_CD
GlaxoSmithKline_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
12_CD
Taxation_NOMZ
continued_VBD
The_DT
integrated_VBN
nature_NN
of_PIN
the_DT
Groups_NN
worldwide_JJ
operations_NOMZ
,_,
involving_VBG
significant_JJ
investment_NOMZ
in_PIN
research_NN
and_CC
strategic_JJ
manufacture_NN
at_PIN
a_DT
limited_JJ
number_NN
of_PIN
locations_NOMZ
,_,
with_PIN
consequential_JJ
cross-border_JJ
supply_NN
routes_NN
into_PIN
numerous_JJ
end-markets_NN
,_,
gives_VPRT
rise_NN
to_PIN
complexity_NOMZ
and_PHC
delay_NN
in_PIN
negotiations_NOMZ
with_PIN
revenue_NN
authorities_NOMZ
as_IN
to_PIN
the_DT
profits_NN
on_PIN
which_WDT [PIRE]
individual_JJ
Group_NN
companies_NN
are_VPRT [BEMA]
liable_PRED
to_PIN
tax_NN
._.
Disagreements_NOMZ
with_PIN [STPR]
,_,
and_ANDC
between_PIN [STPR]
,_,
revenue_NN
authorities_NOMZ
as_IN
to_PIN
intra-Group_JJ
transactions_NOMZ
,_,
in_CONJ
particular_NULL
the_DT
price_NN
at_PIN
which_WDT [PIRE]
goods_NN
should_NEMD
be_VB [PASS]
transferred_VBN
between_PIN
Group_NN
companies_NN
in_PIN
different_JJ
tax_NN
jurisdictions_NOMZ
,_,
can_POMD
produce_VB
conicting_VBG
claims_NN
from_PIN
revenue_NN
authorities_NOMZ
as_IN
to_PIN
the_DT
profits_NN
to_TO
be_VB [PASS]
taxed_VBN
in_PIN
individual_JJ
territories_NN
._.
Resolution_NOMZ
of_PIN
such_JJ
issues_NN
is_VPRT [BEMA]
a_DT
continuing_VBG
fact_NN
of_PIN
life_NN
for_PIN
GlaxoSmithKline_NN
._.
The_DT
Group_NN
has_VPRT
open_JJ
issues_NN
with_PIN
the_DT
revenue_NN
authorities_NOMZ
in_PIN
the_DT
USA_NN
,_,
UK_NN
,_,
Japan_NN
and_PHC
Canada_NN
._.
By_PIN
far_PLACE
the_DT
largest_JJ
relates_VPRT
to_PIN
Glaxo_NN
heritage_NN
products_NN
,_,
in_PIN
respect_NN
of_PIN
which_WDT [PIRE]
the_DT
US_FPP1
Internal_NN
Revenue_NN
Service_NN
IRS_NN
and_PHC
UK_NN
Inland_NN
Revenue_NN
have_VPRT [PEAS]
made_VBN
competing_VBG
and_CC
contradictory_JJ
claims_NN
._.
GlaxoSmithKline_NN
has_VPRT [PEAS]
attempted_VBN
to_TO
settle_VB
the_DT
US_FPP1
dispute_NN
,_,
first_RB
through_PIN
direct_JJ
discussion_NN
with_PIN
the_DT
IRS_NN
and_CC
subsequently_TIME
through_PIN
discussions_NN
between_PIN
the_DT
US_FPP1
and_PHC
UK_NN
authorities_NOMZ
under_IN
the_DT
terms_NN
of_PIN
the_DT
double_JJ
tax_NN
convention_NOMZ
between_PIN
the_DT
two_CD
countries_NN
and_PHC
discussions_NN
were_VBD [PASS]
terminated_VBN
in_PIN
July_NN
2003_CD
._.
On_PIN
6th_JJ
January_NN
2004_CD
,_,
the_DT
IRS_NN
issued_VBD
a_DT
Notice_NN
of_PIN
deficiency_NN
for_PIN
the_DT
years_NN
1989-1996_CD
claiming_VBG [PUBV]
additional_JJ
taxes_NN
of_PIN
$_$
2.7_CD
billion_CD
._.
On_PIN
2nd_JJ
April_NN
2004_CD
the_DT
Group_NN
led_VBD
a_DT
petition_NOMZ
in_PIN
the_DT
US_FPP1
Tax_NN
Court_NN
disputing_VBG [WZPRES]
the_DT
IRS_NN
claim_NN
and_CC
seeking_VBG
a_DT
refund_NN
of_PIN
$_$
1_CD
billion_CD
in_PIN
taxes_NN
._.
On_PIN
25th_JJ
January_NN
2005_CD
the_DT
IRS_NN
issued_VBD
a_DT
further_JJ
Notice_NN
of_PIN
deficiency_NN
for_PIN
the_DT
years_NN
1997-2000_CD
claiming_VBG [PUBV]
additional_JJ
taxes_NN
of_PIN
$_$
1.9_CD
billion_CD
._.
If_COND
the_DT
IRS_NN
claims_NN
for_PIN
the_DT
years_NN
1989-2000_CD
were_VBD [PASS]
upheld_VBN
,_,
the_DT
Group_NN
would_PRMD [SPAU]
additionally_RB
be_VB [BEMA]
liable_PRED
for_PIN
interest_NN
on_PIN
late_TIME
payment_NOMZ
,_,
estimated_VBN [PRIV]
to_TO
amount_VB
to_TO
$_$
3.0_CD
billion_CD
net_NN
of_PIN
federal_JJ
tax_NN
relief_NN
at_PIN
31st_CD
December_NN
2004_CD
,_,
giving_VBG [PRESP]
a_DT
total_NN
of_PIN
$_$
7.6_CD
billion_CD
for_PIN
the_DT
years_NN
1989-2000_CD
._.
The_DT
Group_NN
expects_VPRT [PRIV]
to_TO
le_FW
a_DT
petition_NOMZ
against_PIN
the_DT
tax_NN
claims_NN
for_PIN
1997-2000_CD
in_PIN
April_NN
2005_CD
,_,
including_VBG [PRESP]
a_DT
further_JJ
claim_NN
for_PIN
refund_NN
of_PIN
taxes_NN
,_,
and_ANDC
will_PRMD
ask_VB [SUAV]
the_DT
Tax_NN
Court_NN
to_TO
consolidate_VB
the_DT
IRS_NN
claims_NN
for_PIN
all_QUAN
the_DT
years_NN
1989-2000_CD
into_PIN
a_DT
single_JJ
trial_NN
._.
A_DT
provisional_JJ
trial_NN
date_NN
for_PIN
the_DT
1989-1996_CD
claims_NN
has_VPRT [PEAS]
been_VBN [PASS]
set_VBN
for_PIN
October_NN
2006_CD
._.
As_IN
similar_JJ
tax_NN
issues_NN
remain_VPRT
open_JJ
for_PIN
2001_CD
to_PIN
date_NN
,_,
GlaxoSmithKline_NN
expects_VPRT [PRIV]
to_TO
receive_VB
further_JJ
substantial_JJ
claims_NN
by_PIN
the_DT
IRS_NN
for_PIN
these_DEMO
years_NN
._.
GlaxoSmithKline_NN
continues_VPRT
to_TO
believe_VB [PRIV]
that_THVC
the_DT
profits_NN
reported_VBN [PUBV] [WZPAST]
by_PIN
its_PIT
US_FPP1
subsidiaries_NN
for_PIN
the_DT
period_NN
1989_CD
to_PIN
date_NN
,_,
on_PIN
which_WDT [PIRE]
it_PIT
has_VPRT [PEAS]
paid_VBN
taxes_NN
in_PIN
the_DT
USA_NN
,_,
are_VPRT [BEMA]
more_EMPH
than_PIN
sufficient_JJ
to_TO
reect_VB
the_DT
activities_NOMZ
of_PIN
its_PIT
US_FPP1
operations_NOMZ
._.
GlaxoSmithKline_NN
is_VPRT [BEMA]
in_PIN
continuing_VBG
discussions_NN
with_PIN
the_DT
Inland_NN
Revenue_NN
in_PIN
respect_NN
of_PIN
UK_NN
transfer_NN
pricing_GER
disputes_NN
._.
GlaxoSmithKline_NN
uses_VPRT
the_DT
best_JJ
advice_NN
in_PIN
determining_VBG [SUAV] [PRIV]
its_PIT
transfer_NN
pricing_GER
methodology_NN
and_CC
in_PIN
seeking_VBG
to_TO
manage_VB
transfer_NN
pricing_GER
issues_NN
to_PIN
a_DT
satisfactory_JJ
conclusion_NN
and_CC
,_,
on_PIN
the_DT
basis_NN
of_PIN
external_JJ
professional_JJ
advice_NN
,_,
continues_VPRT
to_TO
believe_VB [PRIV]
that_THVC
it_PIT
has_VPRT [PEAS]
made_VBN
adequate_JJ
provision_NN
for_PIN
the_DT
liabilities_NOMZ
likely_JJ
to_TO
arise_VB
from_PIN
open_JJ
assessments_NOMZ
._.
However_CONJ
,_,
there_EX
continues_VPRT
to_TO
be_VB [BEMA]
a_DT
wide_JJ
difference_NN
of_PIN
views_NN
between_PIN
the_DT
Group_NN
,_,
the_DT
IRS_NN
,_,
the_DT
Inland_NN
Revenue_NN
and_CC
other_JJ
relevant_JJ
taxation_NOMZ
authorities_NOMZ
where_RB
open_JJ
issues_NN
exist_VPRT
._.
The_DT
ultimate_JJ
liability_NOMZ
for_PIN
such_JJ
matters_NN
may_POMD
vary_VB
from_PIN
amounts_NN
provided_VBN
and_PHC
is_VPRT [BEMA]
dependent_PRED
upon_PIN
the_DT
outcome_NN
of_PIN
litigation_NOMZ
proceedings_GER
and_PHC
negotiations_NOMZ
with_PIN
the_DT
relevant_JJ
tax_NN
authorities_NOMZ
._.
Except_PIN
as_IN
shown_VBN [PRIV]
in_PIN
this_DEMO
Annual_JJ
Report_NN
,_,
no_SYNE
provision_NN
has_VPRT [PEAS]
been_VBN [PASS]
made_VBN
for_PIN
taxation_NOMZ
which_WDT [WHSUB]
would_PRMD
arise_VB
on_PIN
the_DT
distribution_NOMZ
of_PIN
profits_NN
retained_VBN [WZPAST]
by_PIN
overseas_PLACE
subsidiary_NN
and_CC
associated_VBN
undertakings_GER
,_,
on_PIN
the_DT
grounds_NN
that_TOBJ
no_SYNE
remittance_NN
of_PIN
profit_NN
retained_VBN [WZPAST]
at_PIN
31st_CD
December_NN
2004_CD
is_VPRT [PASS]
required_VBN [SUAV]
in_PIN
such_EMPH
a_NULL
way_NN
that_TOBJ
incremental_JJ
tax_NN
will_PRMD
arise_VB
._.
At_PIN
31st_CD
December_NN
2004_CD
,_,
the_DT
Group_NN
had_VBD
income_NN
tax_NN
losses_NN
of_PIN
approximately_RB
385_CD
million_CD
2003_CD
225_CD
million_CD
and_CC
capital_NN
losses_NN
estimated_VBN [PRIV]
to_TO
be_VB [BEMA]
in_PIN
excess_NN
of_PIN
10_CD
billion_CD
2003_CD
in_PIN
excess_NN
of_PIN
10_CD
billion_CD
on_PIN
which_WDT [PIRE]
the_DT
related_JJ
deferred_JJ
tax_NN
assets_NN
are_VPRT [PASS]
not_XX0
recognized_VBN [PRIV]
because_CAUS
there_EX
is_VPRT
insufficient_JJ
evidence_NN
that_TOBJ
these_DEMO
losses_NN
will_PRMD
be_VB [PASS]
used_VBN
._.
Current_JJ
Deferred_NN
Deferred_NN
tax_NN
creditor_NN
tax_NN
debtor_NN
tax_NN
provision_NN
Tax_NN
balances_NN
m_VPRT
m_FW
m_FW [BEMA]
At_PIN
1st_CD
January_NN
2004_CD
1,458_CD
1,441_CD
618_CD
Exchange_NN
adjustments_NOMZ
67_CD
52_CD
Charge_NN
to_TO
profit_VB
and_CC
loss_NN
account_NN
1,667_CD
148_CD
142_CD
Cash_NN
paid_VBN
1,583_CD
Other_JJ
movements_NOMZ
123_CD
50_CD
At_PIN
31st_CD
December_NN
2004_CD
1,598_CD
1,537_CD
710 2003 2004_CD
restated_VBN
Deferred_JJ
taxation_NOMZ
asset_NN
liability_NOMZ
m_NN [PASS]
m_NN [PASS]
Accelerated_VBD
capital_NN
allowances_NN
664_CD
689_CD
Stock_NN
valuation_NOMZ
adjustment_NOMZ
51_CD
52_CD
Intra-Group_NN
profit_NN
594_CD
485_CD
Product_NN
and_PHC
business_NOMZ
disposals_NN
31_CD
59_CD
Pensions_NN
and_CC
other_JJ
post-retirement_JJ
benets_NN
38_CD
113_CD
Tax_NN
losses_NN
20_CD
94_CD
Legal_NN
and_CC
other_JJ
disputes_NN
157_CD
167_CD
Merger_NN
integration_NOMZ
and_PHC
manufacturing_GER
restructuring_GER
89_CD
157_CD
Other_JJ
net_JJ
timing_NN
differences_NN
675 607 827 823_CD
Deferred_JJ
taxation_NOMZ
provided_VBN [WZPAST]
on_PIN
stock_NN
valuation_NOMZ
adjustments_NOMZ
,_,
intra-Group_JJ
profit_NN
and_CC
other_JJ
timing_NN
differences_NN
shown_VBN [PRIV]
above_PLACE
are_VPRT [BEMA]
current_PRED
._.
All_QUAN
deferred_VBN
taxation_NOMZ
movements_NOMZ
arise_VPRT
from_PIN
the_DT
origination_NOMZ
and_PHC
reversal_NN
of_PIN
timing_NN
differences_NN
._.
Other_JJ
net_JJ
timing_NN
differences_NN
include_VPRT
accrued_VBN
expenses_NN
and_CC
other_JJ
provisions_NN
._.
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
GlaxoSmithKline_NN
107_CD
13_CD
Earnings_GER
per_PIN
share_NN
2003 2002 2004_CD
restated_VBN
restated_VBN
p_FW
p_FW
p_FW
Basic_JJ
earnings_GER
per_PIN
share_NN
75.0_CD
77.1_CD
66.5_CD
Adjustment_NOMZ
for_PIN
merger_NN
items_NN
,_,
restructuring_VBG
costs_NN
and_PHC
disposal_NN
of_PIN
subsidiaries_NN
:_:
Merger_NN
integration_NOMZ
and_PHC
transaction_NOMZ
costs_NN
3.8_CD
10.8_CD
Restructuring_GER
costs_NN
1.0_CD
1.5_CD
Block_NN
Drug_NN
integration_NOMZ
costs_VPRT
0.3_CD
0.7_CD
Disposal_NN
of_PIN
businesses_NOMZ
0.2_CD
0.9_CD
Adjusted_VBN
earnings_GER
per_PIN
share_NN
75.0_CD
82.0_CD
78.6_CD
Diluted_VBN
earnings_GER
per_PIN
share_NN
74.8_CD
76.9_CD
66.3_CD
Basic_JJ
and_PHC
adjusted_JJ
earnings_GER
per_PIN
share_NN
have_VPRT [PEAS]
been_VBN [BYPA]
calculated_VBN [PRIV]
by_PIN
dividing_VBG
the_DT
profit_NN
attributable_JJ
to_PIN
shareholders_NN
by_PIN
the_DT
weighted_JJ
average_JJ
number_NN
of_PIN
shares_NN
in_PIN
issue_NN
during_PIN
the_DT
period_NN
._.
The_DT
numbers_NN
used_VBN [WZPAST]
in_PIN
calculating_VBG [PRIV]
basic_JJ
and_PHC
diluted_JJ
earnings_GER
per_PIN
share_NN
are_VPRT [PASS]
reconciled_VBN
below_PLACE
._.
Adjusted_VBN
earnings_GER
per_PIN
share_NN
is_VPRT [PASS]
calculated_VBN [PRIV]
using_VBG
business_NOMZ
performance_NN
earnings_GER
._.
During_PIN
the_DT
years_NN
2000_CD
to_PIN
2003_CD
,_,
business_NOMZ
performance_NN
was_VBD [BEMA]
the_DT
primary_JJ
performance_NN
measure_NN
used_VBN [WZPAST]
by_PIN
management_NOMZ
and_CC
was_VBD [PASS]
presented_VBN
after_IN
excluding_VBG
merger_NN
items_NN
,_,
integration_NOMZ
and_PHC
restructuring_GER
costs_NN
and_PHC
disposals_NN
of_PIN
businesses_NOMZ
,_,
as_IN
management_NOMZ
believed_VBD [PRIV]
that_THVC
exclusion_NN
of_PIN
these_DEMO
items_NN
provided_VBD
a_DT
better_JJ
comparison_NN
of_PIN
business_NOMZ
performance_NN
for_PIN
the_DT
periods_NN
presented_VBN
._.
For_PIN
2004_CD
,_,
with_PIN
the_DT
completion_NOMZ
of_PIN
these_DEMO
programs_NN
,_,
the_DT
Group_NN
is_VPRT
reporting_VBG [PUBV]
results_NN
on_PIN
a_DT
statutory_JJ
basis_NN
only_DWNT
._.
This_DEMO
information_NOMZ
,_,
which_WDT [SERE]
is_VPRT [PASS]
provided_VBN
in_CONJ
addition_NULL
to_PIN
the_DT
statutory_JJ
results_NN
prepared_VBN
under_IN
UK_NN
GAAP_NN
,_,
is_VPRT [PASS]
given_VBN
to_TO
assist_VB
shareholders_NN
to_TO
gain_VB
a_DT
clearer_JJ
understanding_GER
of_PIN
the_DT
underlying_VBG
performance_NN
of_PIN
the_DT
business_NOMZ
and_CC
to_TO
increase_VB
comparability_NOMZ
for_PIN
the_DT
periods_NN
presented_VBN
._.
Net_JJ
profit_NN
for_PIN
the_DT
period_NN
attributable_JJ
to_PIN
shareholders_NN
m_VPRT
mm_NN
Earnings_GER
basic_JJ
and_PHC
diluted_JJ
4,302_CD
4,478_CD
3,930_CD
Adjustments_NOMZ
for_PIN
merger_NN
items_NN
,_,
restructuring_VBG
costs_NN
and_PHC
disposal_NN
of_PIN
subsidiaries_NN
281_CD
712_CD
Adjusted_VBN
earnings_GER
4,302_CD
4,759_CD
4,642_CD
Weighted_VBN
average_JJ
number_NN
of_PIN
shares_NN
in_PIN
issue_NN
millions_NN
millions_NN
millions_NN
Basic_JJ
and_PHC
adjusted_JJ
5,736_CD
5,806_CD
5,912_CD
Dilution_NOMZ
for_PIN
share_NN
options_NOMZ
12_CD
18_CD
22_CD
Diluted_NN
5,748_CD
5,824_CD
5,934_CD
Shares_NN
held_VBN [PRIV] [WZPAST]
by_PIN
the_DT
ESOP_NN
Trusts_NN
are_VPRT [PASS]
excluded_VBN
._.
The_DT
trustees_NN
have_VPRT [PEAS]
waived_VBN
their_TPP3
rights_NN
to_PIN
dividends_NN
on_PIN
the_DT
shares_NN
held_VBN [PRIV] [WZPAST]
by_PIN
the_DT
ESOP_NN
Trusts_NN
._.
14_CD
Dividends_NN
2004 2003 2002_CD
m_FW
m_FW
m_FW
First_NN
interim_JJ
575 524 535_CD
Second_JJ
interim_JJ
573 522 530_CD
Third_JJ
interim_JJ
571 520 527_CD
Fourth_JJ
interim_JJ
683 808 754_CD
2,402_CD
2,374_CD
2,346_CD
2004 2003 2002_CD
Dividends_NN
per_PIN
share_NN
p_NN
pp_NN
First_NN
interim_JJ
10_CD
99_CD
Second_JJ
interim_JJ
10_CD
9_CD
9_CD
Third_NN
interim_JJ
10_CD
99_CD
Fourth_JJ
interim_JJ
12_CD
14_CD
13_CD
42_CD
41_CD
40_CD
108_CD
GlaxoSmithKline_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
15_CD
Goodwill_NN
Total_NN
m_VBD
Cost_NN
at_PIN
1st_CD
January_NN
2004_CD
195_CD
Exchange_NN
adjustments_NOMZ
13_CD
Asset_NN
written_VBN [PUBV] [WZPAST]
off_PIN
2_CD
Cost_NN
at_PIN
31st_CD
December_NN
2004_CD
206_CD
Amortisation_NOMZ
at_PIN
1st_CD
January_NN
2004_CD
52_CD
Exchange_NN
adjustments_NOMZ
4_CD
Provision_NN
for_PIN
the_DT
year_NN
12_CD
Asset_NN
written_VBN [PUBV] [WZPAST]
off_PIN
1_CD
Amortisation_NOMZ
at_PIN
31st_CD
December_NN
2004_CD
67_CD
Net_JJ
book_NN
value_NN
at_PIN
1st_CD
January_NN
2004_CD
143_CD
Net_JJ
book_NN
value_NN
at_PIN
31st_CD
December_NN
2004_CD
139_CD
Licences_NN
,_,
16_CD
Other_JJ
intangible_JJ
assets_NN
patents_NN
,_,
etc._FW
._.
Brands_NN
Total_NN
m_FW
m_FW
m_FW
Cost_NN
at_PIN
1st_CD
January_NN
2004_CD
838_CD
1,169_CD
2,007_CD
Exchange_NN
adjustments_NOMZ
24_CD
25_CD
49_CD
Additions_NOMZ
462_CD
462_CD
Disposals_NN
1_CD
1_CD
2_CD
Assets_NN
written_VBN [PUBV] [WZPAST]
off_PIN
19_CD
19_CD
Cost_NN
at_PIN
31st_CD
December_NN
2004_CD
1,256_CD
1,143_CD
2,399_CD
Amortisation_NOMZ
at_PIN
1st_CD
January_NN
2004 229 229_CD
Exchange_NN
adjustments_NOMZ
7_CD
7_CD
Provision_NN
for_PIN
the_DT
year_NN
94_CD
94_CD
Disposals_NN
1_CD
1_CD
Assets_NN
written_VBN [PUBV] [WZPAST]
off_PIN
1_CD
1_CD
Amortisation_NOMZ
at_PIN
31st_CD
December_NN
2004 314 314_CD
Impairment_NOMZ
at_PIN
1st_CD
January_NN
2004_CD
58_CD
23_CD
81_CD
Exchange_NN
adjustments_NOMZ
1_CD
1_CD
2_CD
Impairment_NOMZ
loss_NN
4_CD
4_CD
Disposals_NN
1_CD
1_CD
Impairment_NOMZ
at_PIN
31st_CD
December_NN
2004_CD
61_CD
21_CD
82_CD
Total_JJ
amortisation_NOMZ
and_PHC
impairment_NOMZ
at_PIN
31st_CD
December_NN
2004_CD
375_CD
21_CD
396_CD
Net_JJ
book_NN
value_NN
at_PIN
1st_CD
January_NN
2004_CD
551_CD
1,146_CD
1,697_CD
Net_JJ
book_NN
value_NN
at_PIN
31st_CD
December_NN
2004_CD
881_CD
1,122_CD
2,003_CD
The_DT
additions_NOMZ
to_PIN
licences_NN
and_PHC
patents_NN
in_PIN
the_DT
year_NN
relate_VPRT
to_PIN
the_DT
purchases_NN
of_PIN
Fraxiparine_NN
and_PHC
Arixtra_NN
product_NN
rights_NN
from_PIN
Sano-Synthelabo_NN
,_,
the_DT
OTC_NN
marketing_GER
rights_NN
for_PIN
orlistat_NN
from_PIN
Roche_NN
and_CC
various_JJ
other_JJ
compound_NN
rights_NN
see_VPRT [PRIV]
Note_NN
26_CD
._.
Brands_NN
largely_RB
comprise_VPRT
a_DT
portfolio_NN
of_PIN
products_NN
acquired_VBN [WZPAST]
with_PIN
the_DT
acquisition_NOMZ
of_PIN
Sterling_GER
Winthrop_NN
Inc._NN
in_PIN
1994_CD
,_,
such_JJ
as_IN
Panadol_NN
,_,
Solpadeine_NN
and_PHC
Hedex_NN
,_,
and_ANDC
the_DT
products_NN
acquired_VBN [WZPAST]
with_PIN
the_DT
acquisition_NOMZ
of_PIN
The_DT
Block_NN
Drug_NN
Company_NN
in_PIN
2001_CD
,_,
such_JJ
as_IN
Sensodyne_NN
,_,
Polident_NN
and_PHC
Poligrip_NN
._.
Each_QUAN
of_PIN
these_DEMP
is_VPRT [PASS]
considered_VBN [PRIV]
to_TO
have_VB
an_DT
indefinite_JJ
life_NN
given_VBN
the_DT
strength_NN
and_PHC
durability_NOMZ
of_PIN
the_DT
brand_NN
and_CC
the_DT
level_NN
of_PIN
marketing_GER
support_NN
._.
Accordingly_RB
,_,
they_TPP3
are_VPRT [PASS]
not_XX0
amortised_VBN
._.
The_DT
valuation_NOMZ
of_PIN
each_QUAN
Sterling_GER
brand_NN
is_VPRT [PASS]
reviewed_VBN
annually_RB
using_VBG
a_DT
10_CD
year_NN
cash_NN
ow_NN
forecast_NN
as_IN
this_DEMP
was_VBD [BEMA]
the_DT
basis_NN
for_PIN
the_DT
original_JJ
independent_JJ
assessment_NOMZ
when_RB
they_TPP3
were_VBD [PASS]
acquired_VBN
in_PIN
1994_CD
and_CC
a_DT
post-tax_JJ
discount_NN
rate_NN
of_PIN
eight_CD
per_PIN
cent_NN
._.
The_DT
valuation_NOMZ
of_PIN
each_QUAN
Block_NN
Drug_NN
brand_NN
is_VPRT [SPAU] [PASS]
also_RB
reviewed_VBN
annually_RB
using_VBG
a_DT
five_CD
year_NN
cash_NN
ow_NN
forecast_NN
and_CC
a_DT
post-tax_JJ
discount_NN
rate_NN
of_PIN
eight_CD
per_PIN
cent_NN
._.
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
GlaxoSmithKline_NN
109_CD
Plant_NN
,_,
Land_NN
and_PHC
equipment_NOMZ
Computer_NN
Assets_NN
in_PIN
17_CD
Tangible_JJ
xed_JJ
assets_NN
buildings_GER
and_PHC
vehicles_NN
software_NN
construction_NOMZ
Total_JJ
m_NN
m_FW
m_FW
m_FW
m_FW
Cost_NN
at_PIN
1st_CD
January_NN
2004_CD
3,999_CD
7,206_CD
431_CD
768_CD
12,404_CD
Exchange_NN
adjustments_NOMZ
78_CD
91_CD
6_CD
3_CD
178_CD
Additions_NOMZ
91_CD
363_CD
8_CD
531_CD
993_CD
Disposals_NN
61_CD
270_CD
13_CD
6_CD
350_CD
Reclassications_NOMZ
113 291 133 537_CD
Cost_NN
at_PIN
31st_CD
December_NN
2004_CD
4,064_CD
7,499_CD
553_CD
753_CD
12,869_CD
Depreciation_NOMZ
at_PIN
1st_CD
January_NN
2004_CD
1,112_CD
4,276_CD
239_CD
5,627_CD
Exchange_NN
adjustments_NOMZ
25_CD
63_CD
4_CD
92_CD
Provision_NN
for_PIN
the_DT
year_NN
122_CD
569_CD
94_CD
785_CD
Disposals_NN
29_CD
215_CD
12_CD
256_CD
Reclassications_NOMZ
8_CD
6_CD
2_CD
Depreciation_NOMZ
at_PIN
31st_CD
December_NN
2004_CD
1,172_CD
4,573_CD
319_CD
6,064_CD
Impairment_NOMZ
at_PIN
1st_CD
January_NN
2004 129 157_CD
22_CD
28_CD
336_CD
Exchange_NN
adjustments_NOMZ
42_CD
6_CD
Impairment_NOMZ
loss_NN
17_CD
9_CD
2_CD
28_CD
Disposals_NN
617_CD
1_CD
24_CD
Impairment_NOMZ
at_PIN
31st_CD
December_NN
2004 136 147_CD
24_CD
27_CD
334_CD
Total_JJ
depreciation_NOMZ
and_PHC
impairment_NOMZ
at_PIN
31st_CD
December_NN
2004_CD
1,308_CD
4,720_CD
343_CD
27_CD
6,398_CD
Net_JJ
book_NN
value_NN
at_PIN
1st_CD
January_NN
2004_CD
2,758_CD
2,773_CD
170_CD
740_CD
6,441_CD
Net_JJ
book_NN
value_NN
at_PIN
31st_CD
December_NN
2004_CD
2,756_CD
2,779_CD
210_CD
726_CD
6,471_CD
The_DT
net_JJ
book_NN
value_NN
at_PIN
31st_CD
December_NN
2004_CD
of_PIN
the_DT
Groups_NN
land_NN
and_PHC
buildings_GER
comprises_VPRT
freehold_NN
properties_NN
2,557_CD
million_CD
at_PIN
1st_CD
January_NN
2004_CD
2,532_CD
million_CD
,_,
properties_NN
with_PIN
leases_NN
of_PIN
50_CD
years_NN
or_CC
more_EMPH
143_CD
million_CD
at_PIN
1st_CD
January_NN
2004_CD
182_CD
million_CD
and_CC
properties_NN
with_PIN
leases_NN
of_PIN
less_JJ
than_PIN
50_CD
years_NN
56_CD
million_CD
at_PIN
1st_CD
January_NN
2004_CD
44_CD
million_CD
._.
Included_VBN [PASTP]
in_PIN
plant_NN
,_,
equipment_NOMZ
and_PHC
vehicles_NN
at_PIN
31st_CD
December_NN
2004_CD
are_VPRT [PASS]
leased_VBN
assets_NN
with_PIN
a_DT
cost_NN
of_PIN
93_CD
million_CD
at_PIN
1st_CD
January_NN
2004_CD
3_CD
million_CD
,_,
accumulated_VBN
depreciation_NOMZ
of_PIN
25_CD
million_CD
at_PIN
1st_CD
January_NN
2004_CD
2_CD
million_CD
and_CC
a_DT
net_JJ
book_NN
value_NN
of_PIN
68_CD
million_CD
at_PIN
1st_CD
January_NN
2004_CD
1_CD
million_CD
._.
The_DT
impairment_NOMZ
loss_NN
principally_RB
arises_VPRT
from_PIN
decisions_NN
to_TO
rationalise_VB
facilities_NOMZ
and_CC
is_VPRT [PASS]
calculated_VBN [PRIV]
based_VBN
on_PIN
either_DT
net_JJ
realisable_JJ
value_NN
or_CC
value_NN
in_PIN
use_NN
,_,
typically_RB
using_VBG
a_DT
discount_NN
rate_NN
of_PIN
eight_CD
per_PIN
cent_NN
._.
Joint_NN
Associated_NN
Equity_NOMZ
18_CD
Fixed_JJ
asset_NN
investments_NOMZ
ventures_NN
undertakings_GER
investments_NOMZ
Total_JJ
m_NN
m_FW
m_FW
m_FW [BEMA]
At_PIN
1st_CD
January_NN
2004_CD
13_CD
183_CD
98_CD
294_CD
Exchange_NN
adjustments_NOMZ
14_CD
5_CD
19_CD
Additions_NOMZ
2_CD
84_CD
86_CD
Impairment_NOMZ
20_CD
20_CD
Transfers_NN
1_CD
4_CD
5_CD
Disposals_NN
31_CD
8_CD
39_CD
Retained_VBN
profit_NN
for_PIN
the_DT
year_NN
1_CD
41_CD
40_CD
Goodwill_NN
amortisation_NOMZ
5_CD
5_CD
At_PIN
31st_CD
December_NN
2004 12 175 145_CD
332_CD
Investments_NOMZ
in_PIN
joint_JJ
ventures_NN
comprise_VPRT
14_CD
million_CD
share_NN
of_PIN
gross_JJ
assets_NN
2003_CD
15_CD
million_CD
and_CC
2_CD
million_CD
share_NN
of_PIN
gross_JJ
liabilities_NOMZ
2003_CD
2_CD
million_CD
._.
The_DT
principal_NN
associated_VBN
undertaking_GER
is_VPRT
Quest_NN
Diagnostics_NN
Inc._NN
a_DT
US_FPP1
clinical_JJ
laboratory_NN
business_NOMZ
listed_VBN [WZPAST]
on_PIN
the_DT
New_NN
York_NN
Stock_NN
Exchange_NN
._.
The_DT
investment_NOMZ
has_VPRT
a_DT
book_NN
value_NN
at_PIN
31st_CD
December_NN
2004_CD
of_PIN
153_CD
million_CD
2003_CD
158_CD
million_CD
and_CC
a_DT
market_NN
value_NN
of_PIN
908_CD
million_CD
2003_CD
904_CD
million_CD
._.
At_PIN
31st_CD
December_NN
2004_CD
,_,
the_DT
Group_NN
owned_VBD
18.6_CD
per_PIN
cent_NN
of_PIN
Quest_NN
2003_CD
21_CD
per_PIN
cent_NN
._.
The_DT
book_NN
value_NN
includes_VPRT
goodwill_NN
which_WDT [WHSUB]
is_VPRT
being_VBG [PASS]
amortised_VBN
over_IN
20_CD
years_NN
:_:
the_DT
amortisation_NOMZ
charge_NN
for_PIN
2004_CD
was_VBD [BEMA]
5_CD
million_CD
2003_CD
-_:
6_CD
million_CD
._.
The_DT
goodwill_NN
at_PIN
31st_CD
December_NN
2004_CD
amounts_NN
to_PIN
61_CD
million_CD
2003_CD
85_CD
million_CD
._.
Goodwill_NN
of_PIN
80_CD
million_CD
which_WDT
relates_VPRT
to_PIN
the_DT
continuing_VBG
Group_NN
interest_NN
in_PIN
Clinical_NN
Laboratories_NN
assets_NN
attributed_VBD
to_PIN
Quest_NN
,_,
remains_VPRT
eliminated_VBN
against_PIN
Group_NN
reserves_NN
._.
Equity_NOMZ
investments_NOMZ
comprise_VPRT
listed_VBN
investments_NOMZ
of_PIN
91_CD
million_CD
2003_CD
7_CD
million_CD
and_CC
unlisted_JJ
investments_NOMZ
of_PIN
54_CD
million_CD
2003_CD
91_CD
million_CD
._.
The_DT
market_NN
value_NN
of_PIN
listed_VBN
investments_NOMZ
at_PIN
31st_CD
December_NN
2004_CD
was_VBD [BEMA]
98_CD
million_CD
2003_CD
9_CD
million_CD
._.
110_CD
GlaxoSmithKline_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
19_CD
Equity_NOMZ
investments_NOMZ
Total_JJ
m_NN [BEMA]
At_PIN
1st_CD
January_NN
2004_CD
164_CD
Exchange_NN
adjustments_NOMZ
6_CD
Additions_NOMZ
19_CD
Impairments_NOMZ
5_CD
Transfers_NN
5_CD
Disposals_NN
24_CD
At_PIN
31st_CD
December_NN
2004_CD
153_CD
Equity_NOMZ
investments_NOMZ
include_VPRT
listed_VBN
investments_NOMZ
of_PIN
127_CD
million_CD
2003_CD
111_CD
million_CD
._.
The_DT
market_NN
value_NN
of_PIN
listed_VBN
investments_NOMZ
was_VBD [BEMA]
172_CD
million_CD
2003_CD
184_CD
million_CD
._.
20_CD
Stocks_NN
2004_CD
2003_CD
m_NN
m_NN
Raw_NN
materials_NN
and_PHC
consumables_NN
629_CD
636_CD
Work_NN
in_PIN
progress_NN
644_CD
474_CD
Finished_VBN
goods_NN
919_CD
999_CD
2,192_CD
2,109_CD
21_CD
Debtors_NN
2004_CD
2003_CD
m_NN
m_NN
Amounts_NN
due_JJ
within_PIN
one_CD
year_NN
Trade_NN
debtors_NN
3,786_CD
3,715_CD
Other_JJ
debtors_NN
374_CD
532_CD
Prepaid_JJ
pension_NN
contributions_NOMZ
733_CD
440_CD
Other_JJ
prepayments_NOMZ
and_CC
accrued_VBN
income_NN
282_CD
247_CD
Amounts_NN
due_JJ
after_IN
one_CD
year_NN
Other_JJ
debtors_NN
596_CD
512_CD
Prepayments_NOMZ
and_CC
accrued_VBN
income_NN
1_CD
10_CD
Deferred_VBN
taxation_NOMZ
Note_NN
12_CD
1,537_CD
1,441_CD
7,309_CD
6,897_CD
Debtors_NN
include_VPRT
trading_GER
balances_NN
of_PIN
7_CD
million_CD
2003_CD
1_CD
million_CD
due_JJ
from_PIN
joint_JJ
ventures_NN
and_CC
associated_VBN
undertakings_GER
._.
Other_JJ
debtors_NN
due_RB
after_IN
one_CD
year_NN
include_VPRT
insurance_NN
recovery_NN
receivables_NN
which_WDT [WHSUB]
have_VPRT [PEAS]
been_VBN [PASS]
discounted_VBN
using_VBG
a_DT
risk-free_JJ
rate_NN
of_PIN
return_NN
._.
22_CD
Other_JJ
creditors_NN
2003_CD
2004_CD
restated_VBN
m_NN
m_NN
Amounts_NN
due_JJ
within_PIN
one_CD
year_NN
Trade_NN
creditors_NN
707_CD
686_CD
Taxation_NOMZ
Note_NN
12_CD
1,598_CD
1,458_CD
Social_NN
security_NOMZ
114_CD
108_CD
Other_JJ
creditors_NN
351_CD
313_CD
Accruals_NN
and_CC
deferred_VBN
income_NN
3,110_CD
3,121_CD
Dividends_NN
payable_JJ
1,260_CD
1,333_CD
7,140_CD
7,019_CD
Amounts_NN
due_JJ
after_IN
one_CD
year_NN
Other_JJ
creditors_NN
178_CD
130_CD
Accruals_NN
and_CC
deferred_VBN
income_NN
66_CD
102_CD
._.
244_CD
232_CD
Accruals_NN
include_VPRT
obligations_NOMZ
for_PIN
wages_NN
and_PHC
salaries_NN
of_PIN
639_CD
million_CD
2003_CD
689_CD
million_CD
._.
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
GlaxoSmithKline_NN
111_CD
23_CD
Provisions_NN
for_PIN
Pensions_NN
and_CC
other_JJ
Legal_JJ
liabilities_NOMZ
and_PHC
charges_NN
post-retirement_JJ
Manufacturing_GER
Merger_NN
and_CC
other_JJ
Deferred_NN
Other_JJ
benets_NN
restructuring_VBG [WZPRES]
integration_NOMZ
disputes_NN
taxation_NOMZ
provisions_NN
Total_JJ
m_NN
m_FW
m_FW
m_FW
m_FW
m_FW
m_FW [BEMA]
At_PIN
1st_CD
January_NN
2004_CD
807_CD
99_CD
305_CD
1,007_CD
618_CD
206_CD
3,042_CD
Exchange_NN
adjustments_NOMZ
40_CD
2_CD
5_CD
59_CD
4_CD
110_CD
Charge_NN
for_PIN
the_DT
year_NN
145 25 660 142_CD
24_CD
946_CD
Unwinding_GER
of_PIN
discount_NN
4_CD
11_CD
1_CD
16_CD
Applied_NN
208_CD
25 80 545 122_CD
980_CD
Reclassications_NOMZ
and_CC
other_JJ
movements_NOMZ
81_CD
1_CD
50_CD
85_CD
115_CD
At_PIN
31st_CD
December_NN
2004_CD
785_CD
46_CD
224_CD
1,074_CD
710_CD
190_CD
3,029_CD
During_PIN
2004_CD
,_,
the_DT
Group_NN
made_VBD
special_JJ
cash_NN
contributions_NOMZ
totalling_VBG [WZPRES]
256_CD
million_CD
2003_CD
368_CD
million_CD
into_PIN
the_DT
UK_NN
and_PHC
US_FPP1
pension_NN
schemes_NN
._.
The_DT
contribution_NOMZ
relating_VBG [WZPRES]
to_PIN
the_DT
US_FPP1
pension_NN
scheme_NN
is_VPRT [PASS]
included_VBN
within_PIN
the_DT
amounts_NN
applied_VBD
to_PIN
the_DT
provision_NN
above_PLACE
:_:
the_DT
contributions_NOMZ
relating_VBG [WZPRES]
to_PIN
the_DT
UK_NN
pension_NN
scheme_NN
have_VPRT [PEAS]
increased_VBN
the_DT
pension_NN
prepayment_NOMZ
amount_NN
shown_VBN [PRIV]
under_IN
debtors_NN
in_PIN
Note_NN
21_CD
._.
The_DT
Group_NN
has_VPRT [PEAS]
recognized_VBN [PRIV]
costs_NN
in_PIN
previous_JJ
years_NN
in_PIN
respect_NN
of_PIN
plans_NN
for_PIN
manufacturing_VBG
the_DT
other_JJ
restructuring_GER
initiated_VBN [WZPAST]
in_PIN
1998_CD
,_,
1999_CD
and_CC
in_PIN
2001_CD
following_VBG
the_DT
merger_NN
of_PIN
Glaxo_NN
Wellcome_NN
and_PHC
SmithKline_NN
Beecham_NN
and_CC
the_DT
acquisition_NOMZ
of_PIN
Block_NN
Drug_NN
._.
These_DEMO
plans_NN
are_VPRT [SPAU] [PASS]
largely_RB
completed_VBN
._.
Costs_NN
recognized_VBD [PRIV]
as_IN
a_DT
provision_NN
,_,
principally_RB
in_PIN
respect_NN
of_PIN
identied_JJ
severances_NN
at_PIN
sites_NN
where_RB
it_PIT
has_VPRT [PEAS]
been_VBN [PASS]
announced_VBN [PUBV] [THATD]
that_DEMP
manufacturing_VBG
activities_NOMZ
will_PRMD
cease_VB
,_,
are_VPRT [PASS]
expected_VBN [PRIV]
to_TO
be_VB [PASS]
incurred_VBN
mainly_RB
in_PIN
2005_CD
and_CC
2006_CD
._.
Costs_NN
of_PIN
asset_NN
write-downs_NN
have_VPRT [PEAS]
been_VBN [PASS]
recognized_VBN [PRIV]
as_IN
impairments_NOMZ
of_PIN
xed_JJ
assets_NN
._.
The_DT
Group_NN
has_VPRT [PEAS]
recognized_VBN [PRIV]
costs_NN
in_PIN
previous_JJ
years_NN
in_PIN
respect_NN
of_PIN
plans_NN
for_PIN
the_DT
integration_NOMZ
of_PIN
the_DT
Glaxo_NN
Wellcome_NN
and_PHC
SmithKline_NN
Beecham_NN
businesses_NOMZ
._.
Implementation_NOMZ
of_PIN
the_DT
integration_NOMZ
following_VBG [WZPRES]
the_DT
merger_NN
is_VPRT [BEMA]
substantially_RB
complete_PRED
._.
Costs_NN
recognized_VBD [PRIV]
as_IN
a_DT
provision_NN
in_PIN
respect_NN
of_PIN
identied_JJ
severances_NN
are_VPRT [PASS]
expected_VBN [PRIV]
to_TO
be_VB [PASS]
incurred_VBN
in_PIN
2005_CD
and_CC
in_PIN
respect_NN
of_PIN
the_DT
program_NN
to_TO
encourage_VB
staff_NN
to_TO
convert_VB
Glaxo_NN
Wellcome_NN
or_CC
SmithKline_NN
Beecham_NN
share_NN
options_NOMZ
into_PIN
GlaxoSmithKline_NN
share_NN
options_NOMZ
when_RB
employees_NN
exercise_VPRT
these_DEMO
options_NOMZ
up_IN
to_PIN
2010_CD
._.
This_DEMO
latter_JJ
provision_NN
was_VBD [BYPA]
discounted_VBN
by_PIN
21_CD
million_CD
in_PIN
2004_CD
2003_CD
28_CD
million_CD
using_VBG
risk-free_JJ
rates_NN
of_PIN
return_NN
._.
GlaxoSmithKline_NN
is_VPRT [PASS]
involved_VBN
in_PIN
a_DT
number_NN
of_PIN
legal_JJ
and_PHC
other_JJ
disputes_NN
,_,
including_VBG
notication_NOMZ
of_PIN
possible_JJ
claims_NN
._.
Provisions_NN
for_PIN
legal_JJ
and_PHC
other_JJ
disputes_NN
include_VPRT
amounts_NN
relating_VBG [WZPRES]
to_PIN
US_FPP1
anti-trust_NN
,_,
product_NN
liability_NOMZ
,_,
contract_NN
terminations_NOMZ
,_,
self-insurance_NN
,_,
environmental_JJ
clean-up_JJ
and_CC
property_NN
rental_NN
._.
The_DT
companys_NN
Directors_NN
,_,
having_VBG [PEAS]
taken_VBN
legal_JJ
advice_NN
,_,
have_VPRT [PEAS]
established_VBN [PRIV]
provisions_NN
after_IN
taking_VBG
into_PIN
account_NN
insurance_NN
and_CC
other_JJ
agreements_NOMZ
and_CC
having_VBG
regard_NN
to_PIN
the_DT
relevant_JJ
facts_NN
and_PHC
circumstances_NN
of_PIN
each_QUAN
matter_NN
and_CC
in_PIN
accordance_NN
with_PIN
accounting_GER
requirements_NOMZ
._.
These_DEMO
provisions_NN
were_VBD [BYPA]
discounted_VBN
by_PIN
11_CD
million_CD
in_PIN
2004_CD
2003_CD
25_CD
million_CD
using_VBG
risk-free_JJ
rates_NN
of_PIN
return_NN
._.
GlaxoSmithKline_NN
has_VPRT [PEAS]
undertaken_VBN
a_DT
review_NN
of_PIN
its_PIT
product_NN
liability_NOMZ
claims_NN
and_CC
assessed_VBN
that_DEMO
a_DT
number_NN
of_PIN
products_NN
now_TIME
have_VPRT
a_DT
history_NN
of_PIN
claims_NN
made_VBN
and_CC
settlements_NOMZ
which_WDT [WHSUB]
makes_VPRT
it_PIT
possible_JJ
to_TO
use_VB
an_DT
IBNR_NN
incurred_VBN
but_CC
not_XX0
reported_VBD [PUBV]
actuarial_JJ
technique_NN
to_TO
determine_VB [SUAV] [PRIV]
a_DT
reasonable_JJ
estimate_NN
of_PIN
the_DT
Groups_NN
exposure_NN
for_PIN
unasserted_JJ
claims_NN
in_PIN
relation_NOMZ
to_PIN
those_DEMO
products_NN
._.
Apart_RB
from_PIN
the_DT
IBNR_NN
provision_NN
,_,
no_SYNE
provisions_NN
have_VPRT [PEAS]
been_VBN [PASS]
made_VBN
for_PIN
unasserted_JJ
claims_NN
._.
The_DT
ultimate_JJ
liability_NOMZ
for_PIN
such_JJ
matters_NN
may_POMD
vary_VB
from_PIN
the_DT
amounts_NN
provided_VBN
and_PHC
is_VPRT [BEMA]
dependent_PRED
upon_PIN
the_DT
outcome_NN
of_PIN
litigation_NOMZ
proceedings_GER
,_,
investigations_NOMZ
and_CC
possible_JJ
settlement_NOMZ
negotiations_NOMZ
._.
It_PIT
is_VPRT [BEMA]
in_PIN
the_DT
nature_NN
of_PIN
the_DT
Groups_NN
business_NOMZ
that_TOBJ
a_DT
number_NN
of_PIN
these_DEMO
matters_NN
,_,
including_VBG [PRESP]
those_DEMP
provided_VBN
using_VBG
the_DT
IBNR_NN
actuarial_JJ
technique_NN
,_,
may_POMD
be_VB [BEMA]
the_DT
subject_NN
of_PIN
negotiation_NOMZ
and_PHC
litigation_NOMZ
over_IN
several_QUAN
years_NN
._.
The_DT
largest_JJ
individual_JJ
amounts_NN
provided_VBN [WZPAST]
are_VPRT [PASS]
expected_VBN [PRIV]
to_TO
be_VB [PASS]
settled_VBN
within_PIN
three_CD
years_NN
._.
For_PIN
a_DT
discussion_NN
of_PIN
legal_JJ
issues_NN
,_,
refer_VPRT
to_TO
Note_VB [PRIV]
30_CD
,_,
Legal_NN
proceedings_GER
._.
24_CD
Contingent_JJ
liabilities_NOMZ
At_PIN
31st_CD
December_NN
2004_CD
contingent_JJ
liabilities_NOMZ
,_,
comprising_VBG
guarantees_NN
,_,
discounted_VBD
bills_NN
and_CC
other_JJ
items_NN
arising_VBG [WZPRES]
in_PIN
the_DT
normal_JJ
course_NN
of_PIN
business_NOMZ
,_,
amounted_VBD
to_PIN
207_CD
million_CD
2003_CD
236_CD
million_CD
._.
For_PIN
a_DT
discussion_NN
of_PIN
tax_NN
issues_NN
,_,
refer_VPRT
to_TO
Note_VB [PRIV]
12_CD
,_,
Taxation_NOMZ
and_CC
of_PIN
legal_JJ
issues_NN
,_,
refer_VPRT
to_TO
Note_VB [PRIV]
30_CD
,_,
Legal_NN
proceedings_GER
._.
112_CD
GlaxoSmithKline_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
25_CD
Net_JJ
debt_NN
2004_CD
2003_CD
m_NN
m_NN
Liquid_NN
investments_NOMZ
2,818_CD
2,493_CD
Cash_NN
at_PIN
bank_NN
1,161_CD
962_CD
3,979_CD
3,455_CD
Loans_NN
and_PHC
overdrafts_NN
due_JJ
within_PIN
one_CD
year_NN
:_:
7.375_CD
per_PIN
cent_NN
US$_$
US_FPP1
Medium_NN
Term_NN
Note_VB [PRIV]
2005_CD
52_CD
8.75_CD
per_PIN
cent_NN
sterling_GER
Euro_NN
Bond_NN
2005_CD
500_CD
Floating_VBG
rate_NN
US$_$
European_JJ
Medium_NN
Term_NN
Notes_NN
277_CD
2.0_CD
per_PIN
cent_NN
CHF_NN
Bond_NN
2004_CD
106_CD
Commercial_JJ
paper_NN
830_CD
836_CD
Bank_NN
loans_NN
and_PHC
overdrafts_NN
163_CD
230_CD
Other_JJ
loans_NN
2_CD
2_CD
Obligations_NOMZ
under_IN
finance_NN
leases_NN
35_CD
1_CD
1,582_CD
1,452_CD
Loans_NN
due_JJ
after_IN
one_CD
year_NN
:_:
7.375_CD
per_PIN
cent_NN
US$_$
Medium_NN
Term_NN
Note_VB [PRIV]
2005_CD
56_CD
8.75_CD
per_PIN
cent_NN
sterling_GER
Euro_NN
Bond_NN
2005_CD
499_CD
6.125_CD
per_PIN
cent_NN
US$_$
Notes_NN
2006 260 279_CD
2.375_CD
per_PIN
cent_NN
US$_$
US_FPP1
Medium_NN
Term_NN
Note_VB [PRIV]
2007_CD
260_CD
3.375_CD
per_PIN
cent_NN
euro_NN
European_JJ
Medium_NN
Term_NN
Note_VB [PRIV]
2008 705 699_CD
4.875_CD
per_PIN
cent_NN
sterling_GER
European_JJ
Medium_NN
Term_NN
Note_VB [PRIV]
2008 498 498_CD
3.25_CD
per_PIN
cent_NN
euro_NN
European_JJ
Medium_NN
Term_NN
Note_VB [PRIV]
2009 348 357_CD
4.375_CD
per_PIN
cent_NN
US$_$
US_FPP1
Medium_NN
Term_NN
Note_VB [PRIV]
2014_CD
772_CD
5.25_CD
per_PIN
cent_NN
sterling_GER
European_JJ
Medium_NN
Term_NN
Note_VB [PRIV]
2033 975 974_CD
5.375_CD
per_PIN
cent_NN
US$_$
US_FPP1
Medium_NN
Term_NN
Note_VB [PRIV]
2034_CD
258_CD
Loan_NN
Stock_NN
12_CD
13_CD
Bank_NN
loans_NN
4_CD
4_CD
Other_JJ
loans_NN
and_CC
private_JJ
nancing_GER
231_CD
260_CD
Obligations_NOMZ
under_IN
finance_NN
leases_NN
58_CD
12_CD
4,381_CD
3,651_CD
Net_JJ
debt_NN
1,984_CD
1,648_CD
At_PIN
the_DT
balance_NN
sheet_NN
date_NN
the_DT
Groups_NN
liquid_JJ
investments_NOMZ
had_VBD
an_DT
aggregate_JJ
market_NN
value_NN
of_PIN
2,820_CD
million_CD
2003_CD
2,509_CD
million_CD
._.
Liquid_NN
investments_NOMZ
include_VPRT
redeemable_JJ
preference_NN
shares_NN
,_,
which_WDT [SERE]
are_VPRT [SPAU] [PASS]
fully_AMP
collateralised_VBN
with_PIN
highly_AMP
rated_VBN
bonds_NN
,_,
of_PIN
1_CD
billion_CD
2003_CD
1_CD
billion_CD
._.
Loans_NN
and_PHC
overdrafts_NN
due_JJ
within_PIN
one_CD
year_NN
Commercial_JJ
paper_NN
comprises_VPRT
a_DT
US$_$
10_CD
billion_CD
program_NN
,_,
of_PIN
which_WDT [PIRE]
$_$
1,593_CD
million_CD
830_CD
million_CD
was_VBD [BEMA]
in_PIN
issue_NN
at_PIN
31st_CD
December_NN
2004_CD
2003_CD
$_$
1,497_CD
million_CD
836_CD
million_CD
,_,
backed_VBD
up_RP
by_PIN
committed_JJ
facilities_NOMZ
of_PIN
364_CD
days_NN
duration_NOMZ
of_PIN
$_$
900_CD
million_CD
469_CD
million_CD
2003_CD
$_$
1,404_CD
million_CD
784_CD
million_CD
renewable_JJ
annually_RB
,_,
and_ANDC
liquid_JJ
investments_NOMZ
as_IN
shown_VBN [PRIV]
in_PIN
the_DT
table_NN
above_PLACE
._.
The_DT
weighted_JJ
average_JJ
interest_NN
rate_NN
on_PIN
commercial_JJ
paper_NN
borrowings_GER
at_PIN
31st_CD
December_NN
2004_CD
was_VBD [BEMA]
2.35_CD
per_PIN
cent_NN
2003_CD
1.1_CD
per_PIN
cent_NN
._.
The_DT
weighted_JJ
average_JJ
interest_NN
rate_NN
on_PIN
bank_NN
loans_NN
and_PHC
overdrafts_NN
due_JJ
within_PIN
one_CD
year_NN
at_PIN
31st_CD
December_NN
2004_CD
was_VBD [BEMA]
3.0_CD
per_PIN
cent_NN
._.
Loans_NN
due_JJ
after_IN
one_CD
year_NN
In_PIN
2004_CD
,_,
three_CD
bonds_NN
were_VBD [PASS]
issued_VBN
under_IN
the_DT
US_FPP1
Medium_NN
Term_NN
Note_NN
program_NN
:_:
a_DT
US$_$
500_CD
million_CD
,_,
2.375_CD
per_PIN
cent_NN
coupon_NN
bond_NN
,_,
a_DT
US$_$
1.5_CD
billion_CD
,_,
4.375_CD
per_PIN
cent_NN
coupon_NN
bond_NN
and_CC
a_DT
US$_$
500_CD
million_CD
,_,
5.375_CD
per_PIN
cent_NN
coupon_NN
bond_NN
._.
Loans_NN
due_JJ
after_IN
one_CD
year_NN
are_VPRT [BEMA]
repayable_PRED
over_IN
various_JJ
periods_NN
as_IN
follows_VPRT
:_:
2004_CD
2003_CD
m_NN
m_NN [BEMA]
Between_PIN
one_CD
and_CC
two_CD
years_NN
289_CD
562_CD
Between_PIN
two_CD
and_CC
three_CD
years_NN
279_CD
281_CD
Between_PIN
three_CD
and_CC
four_CD
years_NN
1,210_CD
2_CD
Between_PIN
four_CD
and_CC
five_CD
years_NN
352_CD
1,199_CD
After_IN
five_CD
years_NN
2,251_CD
1,607_CD
4,381_CD
3,651_CD
The_DT
loans_NN
repayable_JJ
after_IN
five_CD
years_NN
carry_VPRT
interest_NN
at_PIN
effective_JJ
rates_NN
between_PIN
4.4_CD
per_PIN
cent_NN
and_CC
5.4_CD
per_PIN
cent_NN
._.
The_DT
repayment_NOMZ
dates_NN
range_VPRT
from_PIN
2010_CD
to_PIN
2034_CD
._.
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
GlaxoSmithKline_NN
113_CD
25_CD
Net_JJ
debt_NN
continued_VBD
Secured_JJ
loans_NN
Loans_NN
amounting_VBG [WZPRES]
to_PIN
11_CD
million_CD
2003_CD
13_CD
million_CD
are_VPRT [BYPA]
secured_VBN
by_PIN
charges_NN
on_PIN
xed_VBN
and_CC
current_JJ
assets_NN
._.
2004_CD
2003_CD
Finance_NN
lease_NN
obligations_NOMZ
m_VPRT
m_FW [BEMA]
Rental_JJ
payments_NOMZ
due_JJ
within_PIN
one_CD
year_NN
36_CD
1_CD
Rental_JJ
payments_NOMZ
due_JJ
between_PIN
one_CD
and_CC
two_CD
years_NN
28_CD
2_CD
Rental_JJ
payments_NOMZ
due_JJ
between_PIN
two_CD
and_CC
three_CD
years_NN
17_CD
1_CD
Rental_JJ
payments_NOMZ
due_JJ
between_PIN
three_CD
and_CC
four_CD
years_NN
5_CD
1_CD
Rental_JJ
payments_NOMZ
due_JJ
between_PIN
four_CD
and_CC
five_CD
years_NN
3_CD
2_CD
Rental_JJ
payments_NOMZ
due_JJ
after_IN
five_CD
years_NN
7_CD
6_CD
Total_JJ
future_JJ
rental_JJ
payments_NOMZ
96_CD
13_CD
Future_NN
finance_NN
charges_NN
3_CD
Total_JJ
finance_NN
lease_NN
obligations_NOMZ
93_CD
13_CD
Financial_NN
instruments_NOMZ
Further_JJ
information_NOMZ
is_VPRT [PASS]
given_VBN
in_PIN
Note_NN
34_CD
._.
26_CD
Commitments_NOMZ
2004_CD
2003_CD
Capital_NN
commitments_NOMZ
m_VPRT
m_FW [PASS]
Contracted_VBN
for_PIN
but_CC
not_XX0
provided_VBN
in_PIN
the_DT
financial_JJ
statements_NOMZ
:_:
Intangible_JJ
xed_JJ
assets_NN
1,256_CD
1,412_CD
Tangible_JJ
xed_JJ
assets_NN
235_CD
171_CD
1,491_CD
1,583_CD
A_DT
number_NN
of_PIN
commitments_NOMZ
were_VBD [PASS]
made_VBN
in_PIN
2004_CD
under_IN
licensing_GER
and_CC
other_JJ
agreements_NOMZ
,_,
principally_RB
with_PIN
Theravance_NN
Inc._NN
._.
Exelixis_NN
Inc._NN
._.
Tanabe_NN
Seiyaku_NN
Co._NN
._.
Ltd._NN
and_PHC
Human_NN
Genome_NN
Sciences_NN
,_,
Inc._NN
._.
The_DT
Group_NN
also_RB
has_VPRT
other_JJ
commitments_NOMZ
of_PIN
85_CD
million_CD
2003_CD
144_CD
million_CD
relating_VBG
to_PIN
revenue_NN
payments_NOMZ
to_TO
be_VB [PASS]
made_VBN
under_IN
licences_NN
and_CC
other_JJ
alliances_NN
,_,
principally_RB
to_PIN
Exelixis_NN
Inc._NN
2004_CD
2003_CD
Commitments_NOMZ
under_IN
operating_VBG
leases_NN
to_TO
pay_VB
rentals_NN
for_PIN
the_DT
next_JJ
year_NN
m_FW
m_FW
Operating_GER
leases_NN
on_PIN
land_NN
and_PHC
buildings_GER
which_WDT [WHSUB]
expire_VPRT
:_:
In_PIN
one_CD
year_NN
or_CC
less_JJ
4_CD
6_CD
Between_PIN
one_CD
and_CC
five_CD
years_NN
16_CD
19_CD
After_IN
five_CD
years_NN
30_CD
35_CD
50_CD
60_CD
Operating_GER
leases_NN
on_PIN
plant_NN
,_,
equipment_NOMZ
and_PHC
vehicles_NN
which_WDT [WHSUB]
expire_VPRT
:_:
In_PIN
one_CD
year_NN
or_CC
less_JJ
10_CD
8_CD
Between_PIN
one_CD
and_CC
five_CD
years_NN
23_CD
50_CD
After_IN
five_CD
years_NN
2_CD
33_CD
60_CD
Commitments_NOMZ
under_IN
operating_VBG
leases_NN
to_TO
pay_VB
rentals_NN
in_PIN
future_JJ
years_NN
2005_CD
83_CD
94_CD
2006_CD
73_CD
78_CD
2007_CD
54_CD
54_CD
2008_CD
42_CD
43_CD
2009_CD
36_CD
36_CD
2010_CD
and_CC
thereafter_RB
119 122 407 427_CD
114_CD
GlaxoSmithKline_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
Share_NN
premium_NN
Ordinary_NN
Shares_NN
of_PIN
25p_JJ
each_QUAN
27_CD
Share_NN
capital_NN
and_PHC
share_NN
premium_NN
account_NN
account_NN
Number_NN
m_FW
m_FW
Share_NN
capital_NN
authorised_VBN [WZPAST]
At_PIN
31st_CD
December_NN
2002_CD
10,000,000,000_CD
2,500_CD
At_PIN
31st_CD
December_NN
2003_CD
10,000,000,000_CD
2,500_CD
At_PIN
31st_CD
December_NN
2004_CD
10,000,000,000_CD
2,500_CD
Share_NN
capital_NN
issued_VBN
and_CC
fully_AMP
paid_VBN
At_PIN
1st_CD
January_NN
2002_CD
6,172,965,989_CD
1,543_CD
170_CD
Share_NN
capital_NN
issued_VBN
under_IN
share_NN
option_NOMZ
schemes_NN
7,049,394_CD
2_CD
54_CD
Share_NN
capital_NN
purchased_VBN
and_PHC
canceled_VBN
155,749,038_CD
39_CD
At_PIN
31st_CD
December_NN
2002_CD
6,024,266,345_CD
1,506_CD
224_CD
Share_NN
capital_NN
issued_VBN
under_IN
share_NN
option_NOMZ
schemes_NN
6,041,283_CD
1_CD
40_CD
Share_NN
capital_NN
purchased_VBN
and_PHC
canceled_VBN
80,844,000_CD
20_CD
At_PIN
31st_CD
December_NN
2003_CD
5,949,463,628_CD
1,487_CD
264_CD
Share_NN
capital_NN
issued_VBN
under_IN
share_NN
option_NOMZ
schemes_NN
6,300,203_CD
2_CD
40_CD
Share_NN
capital_NN
purchased_VBN
and_PHC
canceled_VBN
18,075,000_CD
5_CD
At_PIN
31st_CD
December_NN
2004_CD
5,937,688,831_CD
1,484_CD
304_CD
31st_CD
December_NN
31st_CD
December_NN
31st_CD
December_NN
2004 2003 2002_CD
Number_NN
000_CD
of_PIN
shares_NN
issuable_JJ
under_IN
outstanding_JJ
options_NOMZ
Note_VPRT [PRIV]
36_CD
276,954_CD
259,990_CD
217,953_CD
Number_NN
000_CD
of_PIN
unissued_JJ
shares_NN
not_XX0
under_IN
option_NOMZ
3,785,358_CD
3,790,546_CD
3,757,781_CD
At_PIN
31st_CD
December_NN
2004_CD
,_,
of_PIN
the_DT
issued_VBN
share_NN
capital_NN
,_,
174,527,097_CD
shares_NN
were_VBD [PASS]
held_VBN [PRIV]
in_PIN
the_DT
ESOP_NN
Trust_NN
,_,
69,948,000_CD
shares_NN
were_VBD [PASS]
held_VBN [PRIV]
in_PIN
Treasury_NN
and_CC
5,693,213,734_CD
shares_NN
were_VBD [BEMA]
in_PIN
free_JJ
issue_NN
._.
In_PIN
October_NN
2002_CD
,_,
GlaxoSmithKline_NN
commenced_VBD
a_DT
new_JJ
4_CD
billion_CD
share_NN
buy-back_JJ
program_NN
._.
This_DEMP
followed_VBD
the_DT
completion_NOMZ
of_PIN
the_DT
4_CD
billion_CD
buy-back_NN
program_NN
announced_VBN [PUBV] [WZPAST]
in_PIN
2001_CD
._.
A_DT
total_NN
of_PIN
2.2_CD
billion_CD
has_VPRT [PEAS]
been_VBN [PASS]
spent_VBN
on_PIN
the_DT
new_JJ
share_NN
buy-back_NN
program_NN
,_,
of_PIN
which_WDT [PIRE]
1_CD
billion_CD
was_VBD [PASS]
spent_VBN
in_PIN
2004_CD
._.
The_DT
exact_JJ
amount_NN
and_PHC
timing_NN
of_PIN
future_JJ
purchases_NN
,_,
and_ANDC
whether_IN
some_QUAN
repurchased_VBN
shares_NN
will_PRMD
be_VB [PASS]
held_VBN [PRIV]
as_IN
Treasury_NN
shares_NN
or_CC
be_VB [PASS]
canceled_VBN
,_,
will_PRMD
be_VB [BYPA]
determined_VBN [SUAV] [PRIV]
by_PIN
the_DT
company_NN
and_CC
is_VPRT [BEMA]
dependent_PRED
on_PIN
market_NN
conditions_NOMZ
and_CC
other_JJ
factors_NN
._.
No_SYNE
shares_NN
were_VBD [PASS]
purchased_VBN
in_PIN
the_DT
period_NN
1st_CD
January_NN
2005_CD
to_PIN
10th_JJ
February_NN
2005_CD
._.
In_PIN
the_DT
period_NN
11th_JJ
February_NN
2005_CD
to_PIN
25th_JJ
February_NN
2005_CD
a_DT
further_JJ
5.55_CD
million_CD
shares_NN
have_VPRT [PEAS]
been_VBN [PASS]
purchased_VBN
at_PIN
a_DT
cost_NN
of_PIN
70_CD
million_CD
._.
All_QUAN
purchases_NN
were_VBD [BEMA]
through_PIN
the_DT
publicly_RB
announced_VBN [PUBV]
buy-back_JJ
program_NN
._.
The_DT
table_NN
below_PLACE
sets_NN
out_PIN
the_DT
monthly_JJ
purchases_NN
under_IN
the_DT
current_JJ
share_NN
buy-back_NN
program_NN
:_:
Average_JJ
share_NN
price_NN
excluding_VBG [WZPRES]
Number_NN
of_PIN
shares_NN
commisson_NN
and_CC
stamp_VB
duty_NN
Month_NN
000_CD
January_NN
2004_CD
Nil_NN
February_NN
2004_CD
4,950_CD
11.09_CD
March_NN
2004_CD
20,545_CD
10.81_CD
April_NN
2004_CD
1,010_CD
11.85_CD
May_POMD
2004_CD
7,832_CD
11.73_CD
June_NN
2004_CD
10,156_CD
11.43_CD
July_NN
2004_CD
1,800_CD
11.06_CD
August_NN
2004_CD
11,850_CD
10.88_CD
September_NN
2004_CD
8,485_CD
11.72_CD
October_NN
2004_CD
Nil_NN
November_NN
2004_CD
10,305_CD
11.60_CD
December_NN
2004_CD
11,090_CD
11.64_CD
Total_JJ
88,023_CD
11.29_CD
For_PIN
details_NN
of_PIN
substantial_JJ
shareholdings_GER
refer_VPRT
to_PIN
Substantial_NN
shareholdings_GER
on_PIN
page_NN
177_CD
._.
28_CD
Non-equity_JJ
minority_NOMZ
interests_NN
At_PIN
1st_CD
January_NN
2004_CD
SmithKline_NN
Beecham_NN
Holdings_GER
Corporation_NOMZ
SBH_NN
Corp_NN
,_,
a_DT
subsidiary_NN
incorporated_VBN [WZPAST]
in_PIN
Delaware_NN
,_,
USA_NN
,_,
had_VBD
in_PIN
issue_NN
$_$
500_CD
million_CD
of_PIN
Flexible_NN
Auction_NOMZ
Market_NN
Preferred_NN
Stock_NN
Flex_NN
AMPS_NN
,_,
comprising_VBG [PRESP]
5,000_CD
shares_NN
of_PIN
$_$
100,000_CD
each_QUAN
,_,
issued_VBN [PASTP]
in_PIN
six_CD
series_NN
._.
SBH_NN
Corp_NN
also_RB
had_VBD
in_PIN
issue_NN
$_$
400_CD
million_CD
of_PIN
Auction_NOMZ
Rate_NN
Preference_NN
Stock_NN
ARPS_NN
,_,
comprising_VBG [PRESP]
4,000_CD
shares_NN
of_PIN
$_$
100,000_CD
each_QUAN
issued_VBN
in_PIN
five_CD
series_NN
._.
The_DT
ARPS_NN
and_CC
the_DT
Flex_NN
AMPS_NN
together_RB
constituted_VBD
the_DT
preference_NN
shares_NN
,_,
which_WDT [SERE]
represented_VBD
the_DT
non-equity_JJ
minority_NOMZ
interests_NN
._.
These_DEMP
were_VBD [PASS]
redeemed_VBN
in_PIN
March_NN
and_PHC
April_NN
2004_CD
._.
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
GlaxoSmithKline_NN
115_CD
Other_JJ
profit_NN
and_CC
29_CD
Reserves_NN
reserves_NN
loss_NN
account_NN
Total_JJ
restated_VBN
restated_VBN
restated_VBN
m_FW
m_FW
m_FW [BEMA]
At_PIN
31st_CD
December_NN
2001_CD
as_IN
previously_TIME
reported_VBN [PUBV]
1,866_CD
3,811_CD
5,677_CD
Prior_RB
year_NN
adjustment_NOMZ
implementation_NOMZ
of_PIN
UITF_NN
17_CD
revised_VBN
and_CC
UITF_NN
38_CD
2,970_CD
63_CD
2,907_CD
At_PIN
31st_CD
December_NN
2001_CD
as_IN
restated_VBN
1,104_CD
3,874_CD
2,770_CD
Exchange_NN
movements_NOMZ
82_CD
82_CD
UK_NN
tax_NN
on_PIN
exchange_NN
movements_NOMZ
65_CD
65_CD
Ordinary_NN
shares_NN
purchased_VBD
and_PHC
canceled_VBD
39_CD
2,220_CD
2,181_CD
Investment_NOMZ
in_PIN
ESOP_NN
shares_NN
144_CD
67_CD
77_CD
profit_NN
attributable_JJ
to_PIN
shareholders_NN
3,930_CD
3,930_CD
Dividends_NN
2,346_CD
2,346_CD
Unrealised_JJ
profit_NN
on_PIN
disposal_NN
of_PIN
intellectual_JJ
property_NN
7_CD
7_CD
At_PIN
31st_CD
December_NN
2002_CD
921_CD
3,031_CD
2,110_CD
Exchange_NN
movements_NOMZ
113_CD
113_CD
Tax_NN
on_PIN
exchange_NN
movements_NOMZ
and_CC
unrealised_JJ
profits_NN
92_CD
92_CD
Ordinary_NN
shares_NN
purchased_VBD
and_PHC
canceled_VBD
20 980 960_CD
Investment_NOMZ
in_PIN
ESOP_NN
shares_NN
97_CD
64_CD
33_CD
profit_NN
attributable_JJ
to_PIN
shareholders_NN
4,478_CD
4,478_CD
Dividends_NN
2,374_CD
2,374_CD
Unrealised_JJ
profit_NN
on_PIN
disposal_NN
of_PIN
intellectual_JJ
property_NN
7_CD
7_CD
Revaluation_NOMZ
of_PIN
goodwill_NN
due_JJ
to_TO
exchange_VB
7_CD
7_CD
At_PIN
31st_CD
December_NN
2003_CD
804_CD
4,112_CD
3,308_CD
Goodwill_NN
written_VBN [PUBV] [WZPAST]
back_RB
20_CD
20_CD
Exchange_NN
movements_NOMZ
54_CD
54_CD
Tax_NN
on_PIN
exchange_NN
movements_NOMZ
and_CC
unrealised_JJ
profits_NN
73_CD
73_CD
Ordinary_NN
shares_NN
purchased_VBD
and_PHC
canceled_VBD
5_CD
201_CD
196_CD
Ordinary_JJ
shares_NN
purchased_VBN
and_PHC
held_VBN [PRIV]
as_IN
Treasury_NN
shares_NN
799_CD
799_CD
Investment_NOMZ
in_PIN
ESOP_NN
shares_NN
155_CD
129_CD
26_CD
profit_NN
attributable_JJ
to_PIN
shareholders_NN
4,302_CD
4,302_CD
Dividends_NN
2,402_CD
2,402_CD
Unrealised_JJ
loss_NN
on_PIN
disposal_NN
of_PIN
intellectual_JJ
property_NN
1_CD
1_CD
Revaluation_NOMZ
of_PIN
goodwill_NN
due_JJ
to_TO
exchange_VB
6_CD
6_CD
At_PIN
31st_CD
December_NN
2004_CD
644_CD
4,781_CD
4,137_CD
Goodwill_NN
arising_VBG [WZPRES]
on_PIN
acquisitions_NOMZ
before_IN
1st_CD
January_NN
1998_CD
which_WDT
has_VPRT [PEAS]
been_VBN [PASS]
written_VBN [PUBV]
off_PIN
against_PIN
profit_NN
and_PHC
loss_NN
account_NN
reserves_NN
amounts_VPRT
to_PIN
6,180_CD
million_CD
,_,
including_VBG
goodwill_NN
of_PIN
4,840_CD
million_CD
previously_TIME
held_VBN [PRIV]
as_IN
a_DT
goodwill_NN
reserve_NN
which_WDT [WHSUB]
was_VBD [PASS]
offset_VBN
against_PIN
profit_NN
and_PHC
loss_NN
account_NN
reserves_NN
in_PIN
2000_CD
._.
The_DT
goodwill_NN
written_VBN [PUBV] [WZPAST]
back_RB
in_PIN
2004_CD
relates_VPRT
to_PIN
the_DT
disposal_NN
of_PIN
part_NN
of_PIN
the_DT
Groups_NN
holding_VBG [PRIV] [WZPRES]
in_PIN
Quest_NN
Diagnostics_NN
Inc._NN
and_CC
the_DT
disposal_NN
of_PIN
the_DT
Groups_NN
holding_VBG [PRIV] [WZPRES]
in_PIN
GlaxoSmithKline_NN
Pharmaceuticals_NN
Chongqing_GER
Limited_NN
._.
Goodwill_NN
denominated_VBD
in_PIN
local_JJ
currencies_NN
which_WDT [WHSUB]
is_VPRT [BEMA]
subject_PRED
to_PIN
revaluation_NOMZ
amounted_VBD
to_PIN
294_CD
million_CD
at_PIN
31st_CD
December_NN
2004_CD
._.
Goodwill_NN
on_PIN
acquisitions_NOMZ
after_IN
1st_CD
January_NN
1998_CD
has_VPRT [PEAS]
been_VBN [PASS]
capitalized_VBN
,_,
in_PIN
accordance_NN
with_PIN
the_DT
accounting_GER
policy_NN
set_VBN [WZPAST]
out_PIN
in_PIN
Note_NN
2_CD
._.
Exchange_NN
movements_NOMZ
taken_VBN [WZPAST]
to_PIN
reserves_NN
in_PIN
2004_CD
include_VPRT
losses_NN
of_PIN
86_CD
million_CD
2003_CD
losses_NN
27_CD
million_CD
,_,
2002_CD
losses_NN
1,179_CD
million_CD
on_PIN
foreign_JJ
currency_NN
loans_NN
less_RB
deposits_NN
,_,
gains_NN
of_PIN
38_CD
million_CD
2003_CD
gains_NN
133_CD
million_CD
,_,
2002_CD
gains_NN
1,097_CD
million_CD
on_PIN
the_DT
retranslation_NOMZ
of_PIN
net_JJ
assets_NN
and_CC
6_CD
million_CD
2003_CD
7_CD
million_CD
,_,
2002_CD
nil_NN
on_PIN
goodwill_NN
eliminated_VBN [WZPAST]
against_PIN
reserves_NN
._.
The_DT
tax_NN
on_PIN
exchange_NN
movements_NOMZ
and_CC
unrealised_JJ
profits_NN
in_PIN
2004_CD
of_PIN
73_CD
million_CD
2003_CD
92_CD
million_CD
,_,
2002_CD
65_CD
million_CD
relates_VPRT
to_PIN
the_DT
taxable_JJ
element_NOMZ
of_PIN
the_DT
foreign_JJ
currency_NN
loans_NN
less_RB
deposits_NN
and_CC
unrealised_JJ
profits_NN
taken_VBN [WZPAST]
to_PIN
reserves_NN
._.
Exchange_NN
adjustments_NOMZ
debited_VBD
to_PIN
reserves_NN
cumulatively_RB
amount_VB
to_PIN
1,291_CD
million_CD
2003_CD
1,243_CD
million_CD
,_,
2002_CD
1,356_CD
million_CD
._.
Other_JJ
reserves_NN
include_VPRT
the_DT
merger_NN
reserve_NN
created_VBN [WZPAST]
on_PIN
the_DT
merger_NN
of_PIN
Glaxo_NN
Wellcome_NN
and_PHC
SmithKline_NN
Beecham_NN
amounting_VBG [WZPRES]
to_PIN
1,561_CD
million_CD
at_PIN
31st_CD
December_NN
2004_CD
2003_CD
1,561_CD
million_CD
:_:
2002_CD
1,561_CD
million_CD
._.
Other_JJ
reserves_NN
also_RB
include_VPRT
the_DT
capital_NN
redemption_NOMZ
reserve_NN
created_VBN
as_CONJ
a_NULL
result_NULL
of_PIN
the_DT
share_NN
buy-back_JJ
program_NN
amounting_GER
to_PIN
81_CD
million_CD
at_PIN
31st_CD
December_NN
2004_CD
2003_CD
76_CD
million_CD
,_,
2002_CD
56_CD
million_CD
._.
Following_VBG [PRESP]
the_DT
implementation_NOMZ
of_PIN
UITF_NN
38_CD
,_,
investments_NOMZ
in_PIN
own_JJ
shares_NN
held_VBN [PRIV] [WZPAST]
by_PIN
the_DT
ESOP_NN
Trusts_NN
amounting_VBG [WZPRES]
to_PIN
2,574_CD
million_CD
at_PIN
31st_CD
December_NN
2004_CD
2003_CD
2,729_CD
million_CD
,_,
2002_CD
2,826_CD
million_CD
are_VPRT [SPAU] [PASS]
now_TIME
shown_VBN [PRIV]
as_IN
a_DT
deduction_NOMZ
from_PIN
other_JJ
reserves_NN
._.
Total_JJ
reserves_NN
amounted_VBD
to_PIN
4,137_CD
million_CD
at_PIN
31st_CD
December_NN
2004_CD
2003_CD
3,308_CD
million_CD
,_,
2002_CD
2,110_CD
million_CD
,_,
of_PIN
which_WDT [PIRE]
8,303_CD
million_CD
2003_CD
8,981_CD
million_CD
:_:
2002_CD
10,879_CD
million_CD
relates_VPRT
to_PIN
the_DT
company_NN
and_CC
97_CD
million_CD
2003_CD
86_CD
million_CD
,_,
2002_CD
76_CD
million_CD
relates_VPRT
to_PIN
joint_JJ
ventures_NN
and_CC
associated_VBN
undertakings_GER
._.
The_DT
profit_NN
of_PIN
GlaxoSmithKline_NN
plc_NN
for_PIN
the_DT
year_NN
was_VBD [BEMA]
2,719_CD
million_CD
2003_CD
1,436_CD
million_CD
,_,
2002_CD
10,598_CD
million_CD
,_,
which_WDT [SERE]
after_IN
dividends_NN
of_PIN
2,402_CD
million_CD
2003_CD
2,374_CD
million_CD
,_,
2002_CD
2,352_CD
million_CD
,_,
gave_VBD
a_DT
retained_VBN
profit_NN
of_PIN
317_CD
million_CD
2003_CD
loss_NN
938_CD
million_CD
,_,
2002_CD
profit_NN
8,246_CD
million_CD
._.
After_IN
the_DT
cost_NN
of_PIN
shares_NN
purchased_VBN
and_PHC
canceled_VBN
of_PIN
201_CD
million_CD
2003_CD
980_CD
million_CD
,_,
2002_CD
2,220_CD
million_CD
,_,
shares_NN
purchased_VBD
and_PHC
held_VBD [PRIV]
as_IN
Treasury_NN
shares_NN
of_PIN
799_CD
million_CD
2003_CD
nil_NN
,_,
2002_CD
nil_NN
and_CC
an_DT
unrealised_JJ
profit_NN
on_PIN
capital_NN
reduction_NOMZ
by_PIN
subsidiary_NN
of_PIN
nil_NN
2003_CD
nil_NN
,_,
2002_CD
4,096_CD
million_CD
,_,
the_DT
profit_NN
and_PHC
loss_NN
account_NN
reserve_NN
at_PIN
31st_CD
December_NN
2004_CD
stood_VBD
at_PIN
8,222_CD
million_CD
2003_CD
8,905_CD
million_CD
,_,
2002_CD
10,823_CD
million_CD
,_,
of_PIN
which_WDT [PIRE]
4,096_CD
million_CD
is_VPRT [BEMA]
unrealised_PRED
2003_CD
4,096_CD
million_CD
,_,
2002_CD
4,096_CD
million_CD
._.
116_CD
GlaxoSmithKline_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
30_CD
Legal_JJ
proceedings_GER
In_PIN
July_NN
1998_CD
,_,
GlaxoSmithKline_NN
led_VBD
an_DT
action_NOMZ
against_PIN
Apotex_NN
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
Northern_NN
District_NN
of_PIN
Illinois_NN
for_PIN
The_NN
Group_NN
is_VPRT [PASS]
involved_VBN
in_PIN
various_JJ
legal_JJ
and_PHC
administrative_JJ
infringement_NOMZ
of_PIN
the_DT
Groups_NN
patent_NN
for_PIN
paroxetine_JJ
hydrochloride_NN
proceedings_GER
,_,
principally_RB
product_NN
liability_NOMZ
,_,
intellectual_JJ
property_NN
,_,
tax_NN
,_,
hemihydrate_NN
._.
Apotex_NN
had_VBD [PEAS]
led_VBN
an_DT
Abbreviated_NN
New_NN
Drug_NN
anti-trust_JJ
and_PHC
governmental_JJ
investigations_NOMZ
and_CC
related_JJ
private_JJ
Application_NOMZ
ANDA_NN
with_PIN
the_DT
US_FPP1
Food_NN
and_PHC
Drug_NN
Administration_NOMZ
litigation_NOMZ
._.
The_DT
Group_NN
makes_VPRT
provision_NN
for_PIN
these_DEMO
proceedings_GER
on_PIN
a_DT
FDA_NN
seeking_VBG [WZPRES]
approval_NN
to_TO
introduce_VB
a_DT
generic_JJ
form_NN
of_PIN
Paxil_NN
._.
regular_JJ
basis_NN
as_IN
summarised_VBN
in_PIN
Notes_NN
2_CD
and_CC
23_CD
._.
The_DT
Group_NN
may_POMD
Following_VBG
a_DT
trial_NN
in_PIN
February_NN
2003_CD
the_DT
judge_NN
ruled_VBD [SUAV]
make_VB
additional_JJ
significant_JJ
provisions_NN
for_PIN
such_JJ
legal_JJ
proceedings_GER
,_,
GlaxoSmithKlines_NN
patent_NN
valid_JJ
but_CC
not_XX0
infringed_VBN
by_PIN
Apotexs_NN
as_IN
required_VBN [SUAV]
in_PIN
the_DT
event_NN
of_PIN
further_JJ
developments_NOMZ
in_PIN
these_DEMO
matters_NN
,_,
product_NN
._.
On_PIN
the_DT
Groups_NN
appeal_NN
of_PIN
the_DT
ruling_NN
of_PIN
non-infringement_JJ
,_,
consistent_JJ
with_PIN
generally_RB
accepted_VBN [PRIV]
accounting_GER
principles_NN
._.
Litigation_NOMZ
,_,
the_DT
US_FPP1
Court_NN
of_PIN
Appeals_NN
for_PIN
the_DT
Federal_NN
Circuit_NN
CAFC_NN
,_,
which_WDT [SERE]
particularly_RB
in_PIN
the_DT
USA_NN
,_,
is_VPRT [BEMA]
inherently_RB
unpredictable_PRED
and_PHC
excessive_PRED
hears_VPRT [PRIV]
all_QUAN
appeals_NN
from_PIN
US_FPP1
District_NN
Courts_NN
on_PIN
patent_NN
matters_NN
,_,
ruled_VBD [SUAV]
awards_NN
that_TSUB
may_POMD
not_XX0
be_VB [BYPA]
justied_VBN
by_PIN
the_DT
evidence_NN
may_POMD
occur_VB
._.
The_DT
that_DEMO
the_DT
Groups_NN
patent_NN
was_VBD [PASS]
infringed_VBN
but_CC
invalid_JJ
based_VBN
upon_PIN
Group_NN
could_POMD
in_PIN
the_DT
future_NN
incur_VPRT
judgments_NOMZ
or_CC
enter_VPRT
into_PIN
public_JJ
use_NN
in_PIN
clinical_JJ
trials_NN
prior_RB
to_PIN
the_DT
ling_NN
date_NN
settlements_NOMZ
of_PIN
claims_NN
that_TSUB
could_POMD
result_VB
in_PIN
payments_NOMZ
that_TSUB
exceed_VPRT
in_PIN
the_DT
USA_NN
._.
The_DT
Group_NN
led_VBD
a_DT
petition_NOMZ
to_PIN
the_DT
CAFC_NN
for_PIN
rehearing_GER
its_PIT
current_JJ
provisions_NN
by_PIN
an_DT
amount_NN
that_TSUB
would_PRMD
have_VB
a_DT
material_NN
of_PIN
its_PIT
appeal_NN
by_PIN
the_DT
full_JJ
court_NN
but_CC
as_IN
of_PIN
the_DT
date_NN
of_PIN
this_DEMO
report_NN
adverse_JJ
effect_NN
on_PIN
the_DT
Groups_NN
financial_JJ
condition_NOMZ
and_PHC
results_NN
no_SYNE
decision_NN
on_PIN
that_DEMO
petition_NOMZ
has_VPRT [SPAU] [PEAS]
yet_RB
been_VBN [PASS]
announced_VBN [PUBV]
._.
In_PIN
June_NN
1999_CD
,_,
GlaxoSmithKline_NN
led_VBD
an_DT
action_NOMZ
against_PIN
Geneva_NN
Intellectual_NN
property_NN
claims_NN
include_VPRT
challenges_NN
to_PIN
the_DT
validity_NOMZ
of_PIN
the_DT
Pharmaceuticals_NN
,_,
a_DT
subsidiary_NN
of_PIN
Novartis_NN
Pharmaceuticals_NN
,_,
in_PIN
the_DT
Groups_NN
patents_NN
on_PIN
various_JJ
products_NN
or_CC
processes_NN
and_PHC
assertions_NOMZ
of_PIN
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
Eastern_NN
District_NN
of_PIN
Pennsylvania_NN
for_PIN
non-infringement_NOMZ
of_PIN
those_DEMO
patents_NN
._.
A_DT
loss_NN
in_PIN
any_QUAN
of_PIN
these_DEMO
cases_NN
infringement_NOMZ
of_PIN
the_DT
Groups_NN
patents_NN
for_PIN
paroxetine_JJ
hydrochloride_NN
could_POMD
result_VB
in_PIN
loss_NN
of_PIN
patent_NN
protection_NOMZ
for_PIN
the_DT
product_NN
at_PIN
issue_NN
._.
following_VBG
notice_NN
of_PIN
Genevas_NN
ANDA_NN
ling_NN
._.
That_DEMO
case_NN
has_VPRT [PEAS]
been_VBN [BEMA]
The_DT
consequence_NN
of_PIN
any_QUAN
such_JJ
loss_NN
could_POMD
be_VB [BEMA]
a_DT
significant_JJ
decrease_NN
consolidated_VBN [WZPAST]
with_PIN
similar_JJ
infringement_NOMZ
actions_NOMZ
against_PIN
other_JJ
in_PIN
sales_NN
of_PIN
that_DEMO
product_NN
and_CC
could_POMD [SPAU]
materially_RB
affect_VB
future_JJ
results_NN
generic_JJ
companies_NN
that_TSUB
subsequently_TIME
led_VBD
ANDAs_NN
._.
Additional_JJ
of_PIN
operations_NOMZ
for_PIN
the_DT
Group_NN
._.
infringement_NOMZ
actions_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
brought_VBN
based_VBN
on_PIN
patents_NN
issued_VBN
Legal_JJ
expenses_NN
incurred_VBN
,_,
relating_VBG [PRESP]
to_PIN
the_DT
defense_NN
of_PIN
the_DT
Groups_NN
subsequent_JJ
to_PIN
the_DT
original_JJ
ling_NN
against_PIN
Apotex_NN
in_PIN
the_DT
Northern_NN
intellectual_JJ
property_NN
,_,
and_ANDC
litigation_NOMZ
costs_NN
and_PHC
provisions_NN
related_VBN [WZPAST]
to_PIN
District_NN
of_PIN
Illinois_NN
._.
The_DT
Group_NN
also_RB
led_VBD
an_DT
action_NOMZ
against_PIN
Apotex_NN
product_NN
liability_NOMZ
claims_NN
on_PIN
existing_VBG
products_NN
,_,
are_VPRT [PASS]
charged_VBN
to_TO
selling_VBG
,_,
relating_VBG [PRESP]
to_PIN
those_DEMO
new_JJ
patents_NN
in_PIN
the_DT
Eastern_NN
District_NN
of_PIN
general_JJ
and_CC
administration_NOMZ
costs_NN
._.
Litigation_NOMZ
costs_NN
and_PHC
provisions_NN
Pennsylvania_NN
._.
In_PIN
December_NN
2002_CD
the_DT
judge_NN
granted_VBN [SUAV] [WZPAST]
in_PIN
part_NN
and_CC
relating_VBG
to_PIN
legal_JJ
claims_NN
on_PIN
withdrawn_VBN
products_NN
,_,
anti-trust_JJ
and_CC
denied_VBD [PUBV]
in_PIN
part_NN
summary_NN
judgement_NOMZ
motions_NOMZ
led_VBN [WZPAST]
by_PIN
Apotex_NN
with_PIN
pricing_GER
matters_NN
are_VPRT [PASS]
charged_VBN
to_PIN
other_JJ
operating_GER
income_NN
expense_NN
._.
the_DT
result_NN
that_TOBJ
issues_NN
of_PIN
validity_NOMZ
and_PHC
infringement_NOMZ
of_PIN
three_CD
of_PIN
the_DT
Provisions_NN
are_VPRT [PASS]
made_VBN
,_,
after_IN
taking_VBG
appropriate_JJ
legal_JJ
advice_NN
,_,
when_RB
four_CD
new_JJ
patents_NN
remain_VPRT
for_PIN
trial_NN
._.
The_DT
Group_NN
has_VPRT [PEAS]
petitioned_VBN
the_DT
a_DT
reasonable_JJ
estimate_NN
can_POMD
be_VB [PASS]
made_VBN
of_PIN
the_DT
likely_JJ
outcome_NN
of_PIN
the_DT
District_NN
Court_NN
to_TO
permit_VB
an_DT
interim_JJ
appeal_NN
to_PIN
the_DT
CAFC_NN
of_PIN
summary_NN
dispute_NN
._.
In_PIN
2004_CD
the_DT
Group_NN
established_VBD [PRIV]
an_DT
actuarially_RB
determined_VBN [SUAV] [PRIV]
rulings_GER
that_TOBJ
one_CD
of_PIN
the_DT
four_CD
new_JJ
patents_NN
and_CC
certain_JJ
claims_NN
of_PIN
provision_NN
for_PIN
product_NN
liability_NOMZ
claims_NN
incurred_VBN
but_CC
not_XX0
yet_RB
reported_VBN [PUBV]
the_DT
other_JJ
three_CD
are_VPRT [BEMA]
invalid_PRED
._.
In_PIN
June_NN
2003_CD
the_DT
Group_NN
requested_VBD [SUAV]
the_DT
as_RB
described_VBN
in_PIN
Note_NN
23_CD
._.
At_PIN
31st_CD
December_NN
2004_CD
the_DT
Groups_NN
FDA_NN
to_TO
remove_VB
three_CD
patents_NN
related_VBN [WZPAST]
to_PIN
Paxil_NN
from_PIN
the_DT
register_NN
of_PIN
aggregate_JJ
provision_NN
for_PIN
legal_JJ
and_PHC
other_JJ
disputes_NN
not_XX0
including_VBG
tax_NN
pharmaceutical_JJ
patents_NN
maintained_VBN [PUBV] [WZPAST]
by_PIN
the_DT
FDA_NN
the_DT
Orange_NN
Book_NN
._.
matters_NN
described_VBN
under_IN
Taxation_NOMZ
in_PIN
Note_NN
12_CD
was_VBD
just_EMPH
over_IN
The_DT
delisting_GER
did_VBD
not_XX0
affect_VB
the_DT
validity_NOMZ
of_PIN
these_DEMO
patents_NN
or_CC
the_DT
1_CD
billion_CD
._.
The_DT
ultimate_JJ
liability_NOMZ
for_PIN
legal_JJ
claims_NN
may_POMD
vary_VB
from_PIN
the_DT
related_JJ
patent_NN
litigation_NOMZ
._.
Following_VBG
FDA_NN
approval_NN
of_PIN
its_PIT
ANDA_NN
,_,
amounts_VPRT
provided_VBN
and_PHC
is_VPRT [BEMA]
dependent_PRED
upon_PIN
the_DT
outcome_NN
of_PIN
litigation_NOMZ
Apotex_NN
subsequently_TIME
launched_VBD
a_DT
generic_JJ
version_NN
of_PIN
Paxil_NN
proceedings_GER
,_,
investigations_NOMZ
and_CC
possible_JJ
settlement_NOMZ
negotiations_NOMZ
._.
The_DT
most_EMPH
significant_JJ
of_PIN
those_DEMO
matters_NN
are_VPRT [PASS]
described_VBN
below_PLACE
._.
The_DT
Group_NN
continues_VPRT
to_TO
pursue_VB
patent_NN
infringement_NOMZ
claims_NN
in_PIN
litigation_NOMZ
in_PIN
the_DT
Eastern_NN
District_NN
of_PIN
Pennsylvania_NN
against_PIN
Apotex_NN
,_,
Intellectual_NN
property_NN
Geneva_NN
,_,
Alphapharm_NN
,_,
Andrx_NN
,_,
Teva_NN
Pharmaceuticals_NN
and_PHC
Zenith_NN
,_,
USA_NN
and_CC
bulk_JJ
suppliers_NN
BASF_NN
and_PHC
Sumika_NN
Fine_NN
Chemicals_NN
._.
Apotex_NN
,_,
Alphapharm_NN
,_,
BASF_NN
and_PHC
Sumika_NN
have_VPRT [PEAS]
led_VBN
counterclaims_NN
in_PIN
these_DEMO
Paxil_NN
actions_NOMZ
alleging_VBG [PUBV] [WZPRES]
that_THVC
the_DT
Group_NN
has_VPRT [PEAS]
violated_VBN
anti-trust_JJ
or_CC
unfair_JJ
In_PIN
the_DT
USA_NN
a_DT
number_NN
of_PIN
distributors_NN
of_PIN
generic_JJ
drugs_NN
led_VBD
competition_NOMZ
laws_NN
._.
In_PIN
February_NN
2003_CD
the_DT
CAFC_NN
heard_VBD [PRIV]
Apotexs_NN
applications_NOMZ
with_PIN
the_DT
FDA_NN
to_TO
market_VB
generic_JJ
versions_NN
of_PIN
appeal_NN
from_PIN
a_DT
decision_NN
by_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
District_NN
Paxil_NN
Seroxat_NN
paroxetine_JJ
hydrochloride_NN
prior_RB
to_PIN
the_DT
expiration_NOMZ
of_PIN
Columbia_NN
denying_VBG [PUBV] [WZPRES]
Apotexs_NN
request_NN
that_TOBJ
the_DT
FDA_NN
be_VB [PASS]
required_VBN [SUAV]
in_PIN
2006_CD
of_PIN
the_DT
Groups_NN
patent_NN
on_PIN
paroxetine_JJ
hydrochloride_NN
to_TO
delist_VB
certain_JJ
of_PIN
the_DT
Groups_NN
patents_NN
for_PIN
Paxil_NN
from_PIN
the_DT
Orange_NN
hemihydrate_NN
._.
Apotex_NN
launched_VBD
its_PIT
generic_JJ
version_NN
of_PIN
Paxil_NN
in_PIN
Book_NN
._.
In_PIN
October_NN
2003_CD
the_DT
CAFC_NN
afrmed_VBD
the_DT
district_NN
court_NN
September_NN
2003_CD
._.
Other_JJ
distributors_NN
sought_VBD
to_TO
bring_VB
to_PIN
market_NN
decision_NN
and_CC
dismissed_VBD
the_DT
case_NN
._.
Certain_JJ
but_CC
not_XX0
all_QUAN
of_PIN
the_DT
claims_NN
anhydrate_VPRT
or_CC
other_JJ
versions_NN
of_PIN
paroxetine_JJ
hydrochloride_NN
and_CC
in_PIN
and_CC
counterclaims_NN
with_PIN
respect_NN
to_PIN
Geneva_NN
,_,
Alphapharm_NN
,_,
BASF_NN
one_CD
case_NN
paroxetine_JJ
mesylate_NN
._.
In_PIN
response_NN
the_DT
Group_NN
led_VBD
actions_NOMZ
and_PHC
Sumika_NN
have_VPRT [SPAU] [PEAS]
now_TIME
been_VBN [PASS]
settled_VBN
._.
against_PIN
all_QUAN
those_DEMO
distributors_NN
for_PIN
infringement_NOMZ
of_PIN
various_JJ
of_PIN
the_DT
Groups_NN
patents_NN
on_PIN
the_DT
basis_NN
that_TOBJ
the_DT
generic_JJ
anhydrate_NN
and_CC
In_PIN
March_NN
2000_CD
,_,
GlaxoSmithKline_NN
led_VBD
an_DT
action_NOMZ
against_PIN
Pentech_NN
other_JJ
versions_NN
infringe_VPRT
because_CAUS
they_TPP3
contain_VPRT
and_CC
or_CC
convert_VB
to_PIN
Pharmaceuticals_NN
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
Northern_NN
District_NN
the_DT
hemihydrate_JJ
form_NN
and_CC
or_CC
infringe_VB
other_JJ
Group_NN
patents_NN
._.
of_PIN
Illinois_NN
for_PIN
infringement_NOMZ
of_PIN
the_DT
Groups_NN
patents_NN
for_PIN
paroxetine_JJ
hydrochloride_NN
._.
Pentech_NN
led_VBD
an_DT
ANDA_NN
for_PIN
a_DT
capsule_NN
version_NN
of_PIN
Paxil_NN
,_,
asserting_VBG [PUBV]
that_THVC
its_PIT
compound_NN
and_PHC
presentation_NOMZ
do_VPRT
not_XX0
infringe_VB
the_DT
Groups_NN
patents_NN
or_CC
that_THVC
the_DT
patents_NN
are_VPRT [BEMA]
invalid_PRED
._.
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
GlaxoSmithKline_NN
117_CD
30_CD
Legal_NN
proceedings_GER
continued_VBD
In_PIN
June_NN
2003_CD
,_,
the_DT
Group_NN
commenced_VBD
an_DT
action_NOMZ
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
District_NN
of_PIN
New_NN
Jersey_NN
against_PIN
the_DT
Faulding_GER
In_PIN
April_NN
2003_CD
,_,
the_DT
Group_NN
reached_VBD
a_DT
settlement_NOMZ
with_PIN
Pentech_NN
and_PHC
Pharmaceutical_NN
Company_NN
alleging_VBG [PUBV] [WZPRES]
infringement_NOMZ
of_PIN
the_DT
two_CD
method_NN
Par_NN
Pharmaceuticals_NN
to_PIN
which_WDT [PIRE]
Pentech_NN
had_VBD [PEAS]
granted_VBN [SUAV]
rights_NN
under_IN
of_PIN
use_NN
patents_NN
for_PIN
ondansetron_NN
._.
Faulding_GER
did_VBD
not_XX0
challenge_VB
the_DT
Pentechs_NN
ANDA_NN
for_PIN
paroxetine_JJ
hydrochloride_NN
capsules_NN
._.
That_DEMO
case_NN
,_,
as_IN
of_PIN
the_DT
date_NN
of_PIN
this_DEMO
report_NN
,_,
has_VPRT
The_DT
settlement_NOMZ
allowed_VBD [SUAV]
Par_NN
to_TO
distribute_VB
in_PIN
Puerto_NN
Rico_NN
been_VBN [PASS]
stayed_VBN
pending_VBG
decisions_NN
in_PIN
the_DT
Teva_NN
,_,
Reddy_NN
and_PHC
Kali_NN
cases_NN
._.
substitutable_JJ
generic_JJ
paroxetine_JJ
hydrochloride_NN
immediate_JJ
release_NN
In_PIN
August_NN
2004_CD
,_,
the_DT
Group_NN
commenced_VBD
an_DT
action_NOMZ
in_PIN
the_DT
US_FPP1
tablets_NN
supplied_VBD
and_PHC
licensed_VBD
from_PIN
the_DT
Group_NN
for_PIN
a_DT
royalty_NN
payable_JJ
District_NN
Court_NN
for_PIN
the_DT
District_NN
of_PIN
New_NN
Jersey_NN
against_PIN
Pliva_NN
alleging_VBG [PUBV] [WZPRES]
to_PIN
the_DT
Group_NN
._.
Par_NN
became_VBD
entitled_VBN
to_TO
distribute_VB
the_DT
same_JJ
product_NN
infringement_NOMZ
of_PIN
the_DT
Groups_NN
patent_NN
for_PIN
a_DT
reduced_VBN
crystal_NN
size_NN
of_PIN
in_PIN
the_DT
US_FPP1
market_NN
once_TIME
Apotexs_NN
generic_JJ
version_NN
of_PIN
Paxil_NN
became_VBD
ondansetron_NN
,_,
which_WDT [SERE]
expires_VPRT
in_PIN
March_NN
2012_CD
taking_VBG
into_PIN
account_NN
available_JJ
there_EX
in_PIN
September_NN
2003_CD
._.
In_PIN
the_DT
settlement_NOMZ
Par_NN
and_CC
the_DT
extension_NN
for_PIN
paediatric_JJ
exclusivity_NOMZ
._.
Pliva_NN
did_VBD
not_XX0
challenge_VB
the_DT
Pentech_NN
acknowledge_VPRT [PUBV]
that_THVC
the_DT
GlaxoSmithKline_NN
patent_NN
covering_VBG [WZPRES]
compound_NN
patent_NN
or_CC
the_DT
emesis_NN
use_NN
patents_NN
._.
The_DT
case_NN
is_VPRT [BEMA]
in_PIN
its_PIT
the_DT
hemihydrate_JJ
form_NN
of_PIN
paroxetine_JJ
hydrochloride_NN
is_VPRT [BEMA]
valid_PRED
and_PHC
preliminary_PRED
stages_NN
._.
enforceable_JJ
and_CC
would_PRMD
be_VB [BYPA]
infringed_VBN
by_PIN
Pentechs_NN
proposed_VBD [SUAV]
capsule_JJ
product_NN
._.
The_DT
Bureau_NN
of_PIN
Competition_NOMZ
of_PIN
the_DT
US_FPP1
Federal_NN
Trade_NN
In_PIN
January_NN
2005_CD
,_,
the_DT
Group_NN
commenced_VBD
two_CD
additional_JJ
actions_NOMZ
,_,
Commission_NN
reviewed_VBD
the_DT
settlement_NOMZ
._.
The_DT
review_NN
was_VBD [BEMA]
voluntary_PRED
both_DT
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
District_NN
of_PIN
New_NN
Jersey_NN
,_,
for_PIN
and_CC
was_VBD [PASS]
conducted_VBN
at_PIN
the_DT
request_NN
of_PIN
the_DT
Group_NN
,_,
Par_NN
and_PHC
Pentech_NN
._.
the_DT
same_JJ
reduced_VBN
crystal_NN
size_NN
patent_NN
against_PIN
Kali_NN
and_PHC
Apotex_NN
._.
In_PIN
Pentechs_NN
former_JJ
supplier_NN
Asahi_NN
Glass_NN
Co._NN
led_VBD
claims_NN
alleging_VBG [PUBV] [WZPRES]
that_THVC
contrast_NN
to_PIN
its_PIT
previous_JJ
ANDA_NN
for_PIN
orally_RB
disintegrating_VBG
tablets_NN
,_,
the_DT
settlement_NOMZ
violated_VBD
the_DT
anti-trust_JJ
laws_NN
._.
Those_DEMO
claims_NN
have_VPRT [PEAS]
been_VBN [PASS]
Kali_NN
did_VBD
not_XX0
challenge_VB
the_DT
emesis_NN
use_NN
patents_NN
in_PIN
its_PIT
recent_JJ
ANDA_NN
dismissed_VBN [WZPAST]
by_PIN
the_DT
court_NN
._.
Similar_JJ
claims_NN
brought_VBN [WZPAST]
by_PIN
Apotex_NN
and_CC
for_PIN
oral_JJ
tablets_NN
nor_SYNE
did_VBD
it_PIT
challenge_VB
the_DT
compound_NN
patent_NN
._.
Apotex_NN
Sumika_NN
are_VPRT
pending_VBG
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
Eastern_NN
did_VBD
not_XX0
challenge_VB
either_DT
compound_NN
or_CC
emesis_NN
use_NN
patents_NN
in_PIN
District_NN
of_PIN
Pennsylvania_NN
._.
Zofran_NN
Lamictal_NN
In_PIN
August_NN
2001_CD
the_DT
Group_NN
commenced_VBD
an_DT
action_NOMZ
in_PIN
the_DT
US_FPP1
District_NN
In_PIN
August_NN
2002_CD
,_,
the_DT
Group_NN
commenced_VBD
an_DT
action_NOMZ
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
District_NN
of_PIN
New_NN
Jersey_NN
against_PIN
Reddy-Cheminor_NN
and_PHC
Court_NN
for_PIN
the_DT
District_NN
of_PIN
New_NN
Jersey_NN
against_PIN
Teva_NN
Pharmaceuticals_NN
Dr_NN
Reddys_NN
Laboratories_NN
._.
Dr_NN
Reddy_NN
had_VBD [PEAS]
certied_VBN
invalidity_NOMZ
of_PIN
three_CD
USA_NN
,_,
Inc._NN
alleging_VBG [PUBV] [WZPRES]
infringement_NOMZ
of_PIN
the_DT
Groups_NN
compound_VPRT
patent_NN
patents_NN
for_PIN
ondansetron_NN
,_,
the_DT
active_JJ
ingredient_NN
in_PIN
Zofran_NN
tablets_NN
,_,
for_PIN
lamotrigine_NN
,_,
the_DT
active_JJ
ingredient_NN
in_PIN
Lamictal_JJ
oral_JJ
tablets_NN
._.
That_DEMP
including_VBG
the_DT
compound_NN
patent_NN
that_TSUB
expires_VPRT
in_PIN
July_NN
2005_CD
and_CC
two_CD
patent_NN
affords_NN
protection_NOMZ
through_PIN
January_NN
2009_CD
after_IN
giving_VBG
effect_NN
method_NN
of_PIN
use_NN
patents_NN
,_,
the_DT
later_TIME
of_PIN
which_WDT [PIRE]
expires_VPRT
in_PIN
December_NN
to_PIN
an_DT
expected_VBN [PRIV]
grant_NN
of_PIN
paediatric_JJ
exclusivity_NOMZ
by_PIN
FDA_NN
._.
The_DT
2006_CD
,_,
in_PIN
both_DT
instances_NN
taking_VBG [WZPRES]
into_PIN
account_NN
the_DT
extension_NN
for_PIN
defendant_NN
had_VBD [PEAS]
led_VBN
an_DT
ANDA_NN
with_PIN
the_DT
FDA_NN
with_PIN
a_DT
certication_NOMZ
of_PIN
paediatric_JJ
exclusivity_NOMZ
._.
In_PIN
July_NN
2003_CD
the_DT
Group_NN
led_VBD
an_DT
action_NOMZ
against_PIN
invalidity_NOMZ
of_PIN
the_DT
Groups_NN
patent_NN
._.
The_DT
Hatch-Waxman_NN
stay_VB
on_PIN
the_DT
Dr_NN
Reddys_NN
Laboratories_NN
in_PIN
the_DT
same_JJ
district_NN
court_NN
for_PIN
infringement_NOMZ
FDA_NN
approval_NN
of_PIN
that_DEMO
ANDA_NN
has_VPRT [PEAS]
expired_VBN
._.
The_DT
trial_NN
in_PIN
the_DT
Teva_NN
case_NN
of_PIN
the_DT
Groups_NN
patents_NN
related_VBN [WZPAST]
to_PIN
the_DT
orally_RB
disintegrating_VBG
tablet_NN
concluded_VBD [PRIV]
in_PIN
January_NN
2005_CD
._.
Following_VBG [PRESP]
the_DT
trial_NN
the_DT
parties_NN
reached_VBD
presentation_NOMZ
of_PIN
Zofran_NN
._.
In_PIN
October_NN
2003_CD
the_DT
Group_NN
led_VBD
an_DT
action_NOMZ
a_DT
settlement_NOMZ
agreement_NOMZ
subject_NN
to_PIN
government_NOMZ
review_NN
,_,
pursuant_JJ
against_PIN
West-ward_JJ
Pharmaceuticals_NN
,_,
Inc._NN
in_PIN
the_DT
same_JJ
district_NN
court_NN
to_PIN
which_WDT [PIRE]
the_DT
Group_NN
has_VPRT [PEAS]
granted_VBN [SUAV]
Teva_NN
an_DT
exclusive_JJ
royalty-bearing_GER
for_PIN
infringement_NOMZ
of_PIN
the_DT
Groups_NN
patents_NN
related_VBN [WZPAST]
to_PIN
an_DT
injectable_JJ
licence_NN
to_TO
distribute_VB
in_PIN
the_DT
USA_NN
a_DT
generic_JJ
version_NN
of_PIN
lamotrigine_NN
presentation_NOMZ
of_PIN
Zofran_NN
._.
Both_DT
the_DT
Dr_NN
Reddy_NN
disintegrating_VBG [WZPRES]
tablet_NN
chewable_JJ
tablets_NN
on_PIN
a_DT
date_NN
not_XX0
later_TIME
than_PIN
June_NN
2005_CD
and_CC
the_DT
case_NN
and_CC
the_DT
West-ward_JJ
case_NN
were_VBD [PASS]
consolidated_VBN
with_PIN
the_DT
earlier_TIME
exclusive_JJ
right_NN
to_TO
manufacture_VB
and_PHC
sell_VB
Tevas_NN
own_JJ
generic_JJ
version_NN
Dr_NN
Reddy_NN
case_NN
._.
Prior_RB
to_PIN
trial_NN
both_DT
Reddy-Cheminor_NN
and_CC
West-ward_JJ
of_PIN
lamotrigine_NN
tablets_NN
in_PIN
the_DT
USA_NN
with_PIN
an_DT
expected_VBN [PRIV]
launch_NN
date_NN
in_PIN
withdrew_VBD
their_TPP3
challenges_NN
to_PIN
the_DT
compound_NN
patent_NN
._.
The_DT
trial_NN
2008_CD
._.
over_IN
infringement_NOMZ
of_PIN
the_DT
Groups_NN
method_NN
of_PIN
use_NN
and_PHC
process_NN
Imitrex_NN
patents_NN
was_VBD [PASS]
completed_VBN
in_PIN
June_NN
2004_CD
but_CC
as_IN
of_PIN
the_DT
date_NN
of_PIN
this_DEMO
In_PIN
December_NN
2003_CD
,_,
the_DT
Group_NN
commenced_VBD
an_DT
action_NOMZ
in_PIN
the_DT
US_FPP1
report_NN
closing_GER
arguments_NOMZ
have_VPRT [PEAS]
not_XX0
been_VBN [PASS]
held_VBN [PRIV]
and_CC
no_SYNE
decision_NN
District_NN
Court_NN
for_PIN
the_DT
Southern_NN
District_NN
of_PIN
New_NN
York_NN
against_PIN
has_VPRT [PEAS]
been_VBN [PASS]
announced_VBN [PUBV]
._.
Dr_NN
Reddys_NN
Laboratories_NN
,_,
alleging_VBG [PUBV]
infringement_NOMZ
of_PIN
one_CD
of_PIN
two_CD
In_PIN
March_NN
2002_CD
,_,
the_DT
Group_NN
led_VBD
a_DT
similar_JJ
action_NOMZ
against_PIN
Teva_NN
primary_JJ
compound_NN
patents_NN
for_PIN
sumatriptan_NN
,_,
the_DT
active_JJ
ingredient_NN
Pharmaceuticals_NN
USA_NN
Inc._NN
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
District_NN
of_PIN
in_PIN
Imitrex_NN
._.
The_DT
patent_NN
at_PIN
issue_NN
affords_NN
protection_NOMZ
through_PIN
February_NN
Delaware_NN
alleging_VBG [PUBV] [WZPRES]
infringement_NOMZ
of_PIN
the_DT
two_CD
method_NN
of_PIN
use_NN
patents_NN
2009_CD
after_IN
giving_VBG
effect_NN
to_PIN
a_DT
grant_NN
of_PIN
paediatric_JJ
exclusivity_NOMZ
by_PIN
the_DT
for_PIN
ondansetron_NN
._.
Teva_NN
had_VBD [PEAS]
certied_VBN
invalidity_NOMZ
or_CC
non-infringement_JJ
FDA_NN
._.
The_DT
defendant_NN
has_VPRT [PEAS]
led_VBN
an_DT
ANDA_NN
with_PIN
the_DT
FDA_NN
with_PIN
a_DT
of_PIN
the_DT
two_CD
method_NN
of_PIN
use_NN
patents_NN
._.
Teva_NN
did_VBD
not_XX0
challenge_VB
the_DT
certication_NOMZ
of_PIN
invalidity_NOMZ
of_PIN
that_DEMO
compound_NN
patent_NN
but_CC
did_VBD
not_XX0
compound_JJ
patent_NN
._.
The_DT
trial_NN
judge_NN
ruled_VBD [SUAV]
in_PIN
the_DT
Groups_NN
favor_VPRT
,_,
certify_VPRT [PUBV]
invalidity_NOMZ
or_CC
non-infringement_NOMZ
of_PIN
the_DT
second_JJ
compound_NN
upholding_VBG [WZPRES]
the_DT
validity_NOMZ
of_PIN
the_DT
method_NN
of_PIN
use_NN
patents_NN
._.
Teva_NN
appealed_VBD
patent_NN
that_TSUB
expires_VPRT
in_PIN
June_NN
2007_CD
after_IN
giving_VBG
effect_NN
to_TO
paediatric_VB
that_DEMO
decision_NN
to_PIN
the_DT
CAFC_NN
and_CC
oral_JJ
argument_NOMZ
is_VPRT [PASS]
expected_VBN [PRIV]
in_PIN
the_DT
exclusivity_NOMZ
._.
The_DT
case_NN
is_VPRT [BEMA]
in_PIN
its_PIT
early_TIME
stages_NN
._.
Six_CD
other_JJ
generic_JJ
third_JJ
quarter_NN
of_PIN
2005_CD
._.
In_PIN
September_NN
2003_CD
,_,
November_NN
2003_CD
and_CC
companies_NN
have_VPRT [PEAS]
led_VBN
ANDAs_NN
for_PIN
Imitrex_NN
but_CC
of_PIN
those_DEMO
only_DWNT
Cobalt_NN
January_NN
2004_CD
the_DT
Group_NN
led_VBD
actions_NOMZ
against_PIN
Teva_NN
in_PIN
the_DT
same_JJ
Pharmaceuticals_NN
has_VPRT [PEAS]
certied_VBN
invalidity_NOMZ
of_PIN
the_DT
same_JJ
compound_NN
court_NN
for_PIN
infringement_NOMZ
of_PIN
the_DT
Groups_NN
patents_NN
related_VBN [WZPAST]
to_PIN
the_DT
patent_NN
at_PIN
issue_NN
in_PIN
the_DT
Dr._NN
Reddys_NN
case_NN
._.
The_DT
Group_NN
has_VPRT [PEAS]
commenced_VBN
injectable_JJ
and_CC
orally_RB
disintegrating_VBG
tablet_JJ
presentations_NOMZ
of_PIN
Zofran_NN
._.
an_DT
infringement_NOMZ
action_NOMZ
against_PIN
Cobalt_NN
which_WDT [WHSUB]
has_VPRT [SPAU] [PEAS]
recently_TIME
been_VBN [BEMA]
These_DEMO
cases_NN
were_VBD [PASS]
consolidated_VBN
into_PIN
the_DT
case_NN
now_TIME
on_PIN
appeal_NN
._.
transferred_VBN [PASTP]
to_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
Southern_NN
District_NN
of_PIN
New_NN
York_NN
._.
In_PIN
February_NN
2005_CD
,_,
the_DT
Group_NN
commenced_VBD
an_DT
action_NOMZ
An_DT
earlier_TIME
ondansetron_NN
case_NN
,_,
involving_VBG [PRESP]
orally_RB
disintegrating_VBG
Zofran_NN
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
District_NN
of_PIN
Delaware_NN
against_PIN
tablets_NN
,_,
was_VBD [BYPA]
commenced_VBN
by_PIN
the_DT
Group_NN
in_PIN
January_NN
2003_CD
against_PIN
Spectrum_NN
Pharmaceuticals_NN
,_,
alleging_VBG [PUBV]
infringement_NOMZ
of_PIN
the_DT
same_JJ
Kali_NN
Laboratories_NN
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
District_NN
of_PIN
New_NN
compound_NN
patent_NN
at_PIN
issue_NN
in_PIN
the_DT
Dr._NN
Reddys_NN
case_NN
._.
Both_DT
Kali_NN
and_CC
the_DT
Group_NN
have_VPRT [SPAU] [PEAS]
subsequently_TIME
led_VBN
motions_NOMZ
its_PIT
certication_NOMZ
of_PIN
invalidity_NOMZ
or_CC
non-infringement_NOMZ
of_PIN
that_DEMO
patent_NN
as_IN
for_PIN
summary_NN
judgement_NOMZ
._.
part_NN
of_PIN
an_DT
ANDA_NN
ling_NN
for_PIN
approval_NN
for_PIN
sumatriptan_NN
injection_NOMZ
._.
118_CD
GlaxoSmithKline_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
30_CD
Legal_JJ
proceedings_GER
continued_VBD
Advair_NN
In_PIN
September_NN
2004_CD
,_,
the_DT
Group_NN
applied_VBD
to_PIN
the_DT
US_FPP1
Patent_NN
and_PHC
Valtrex_NN
Trademark_NN
Ofce_NN
USPTO_NN
for_PIN
re-issue_NN
of_PIN
its_PIT
combination_NOMZ
patent_NN
In_PIN
May_POMD
2003_CD
,_,
the_DT
Group_NN
commenced_VBD
an_DT
action_NOMZ
in_PIN
the_DT
US_FPP1
District_NN
for_PIN
Advair_NN
,_,
an_DT
inhaled_JJ
combination_NOMZ
of_PIN
salmeterol_NN
and_PHC
uticasone_NN
Court_NN
for_PIN
the_DT
District_NN
of_PIN
New_NN
Jersey_NN
against_PIN
Ranbaxy_NN
Laboratories_NN
,_,
propionate_NN
,_,
which_WDT [SERE]
expires_VPRT
in_PIN
September_NN
2010_CD
._.
This_DEMP
followed_VBD
alleging_VBG [PUBV]
infringement_NOMZ
of_PIN
the_DT
Groups_NN
compound_VPRT
patent_NN
for_PIN
an_DT
internal_JJ
review_NN
which_WDT [WHSUB]
concluded_VBD [PRIV]
that_THVC
the_DT
language_NN
in_PIN
the_DT
valaciclovir_NN
,_,
the_DT
active_JJ
ingredient_NN
in_PIN
Valtrex_NN
._.
That_DEMO
patent_NN
expires_VPRT
patent_NN
may_POMD
not_XX0
accurately_RB
describe_VB
all_QUAN
of_PIN
the_DT
circumstances_NN
of_PIN
in_PIN
2009_CD
._.
The_DT
defendant_NN
has_VPRT [PEAS]
led_VBN
an_DT
ANDA_NN
with_PIN
the_DT
FDA_NN
with_PIN
a_DT
the_DT
invention_NOMZ
and_CC
may_POMD
not_XX0
claim_VB [PUBV]
the_DT
invention_NOMZ
as_IN
precisely_RB
as_IN
it_PIT
certication_NOMZ
of_PIN
invalidity_NOMZ
of_PIN
the_DT
Groups_NN
compound_VPRT
patent_NN
and_CC
could_POMD
._.
The_DT
objective_NN
of_PIN
seeking_VBG
re-issuance_NN
is_VPRT
to_TO
strengthen_VB
the_DT
non-infringement_NOMZ
of_PIN
two_CD
other_JJ
patents_NN
expiring_VBG [WZPRES]
in_PIN
2016_CD
that_DEMP
are_VPRT [BYPA]
protection_NOMZ
afforded_VBN [WZPAST]
by_PIN
the_DT
patent_NN
._.
It_PIT
is_VPRT [PASS]
expected_VBN [PRIV]
that_THVC
the_DT
listed_VBN
in_PIN
the_DT
Orange_NN
Book_NN
._.
FDA_NN
approval_NN
of_PIN
that_DEMO
ANDA_NN
is_VPRT [PASS]
stayed_VBN
administrative_JJ
process_NN
with_PIN
the_DT
USPTO_NN
will_PRMD
take_VB
one_CD
to_PIN
two_CD
years_NN
._.
until_IN
the_DT
earlier_TIME
of_PIN
October_NN
2005_CD
or_CC
resolution_NOMZ
of_PIN
the_DT
patent_NN
While_OSUB
the_DT
application_NOMZ
for_PIN
re-issue_NN
is_VPRT
pending_VBG
,_,
the_DT
patent_NN
remains_VPRT
infringement_NOMZ
litigation_NOMZ
._.
Discovery_NN
is_VPRT
underway_NN
in_PIN
the_DT
case_NN
._.
in_PIN
force_NN
and_CC
is_VPRT [PASS]
listed_VBN
in_PIN
the_DT
Orange_NN
Book_NN
._.
Avandia_NN
and_PHC
Avandamet_NN
The_NN
Group_NN
holds_VPRT [PRIV] [THATD]
other_JJ
patents_NN
relating_VBG [WZPRES]
to_PIN
Advair_NN
which_WDT [WHSUB]
are_VPRT [BEMA]
not_XX0
In_PIN
August_NN
2003_CD
,_,
the_DT
Group_NN
led_VBD
an_DT
action_NOMZ
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
affected_VBN [WZPAST]
by_PIN
the_DT
re-issue_JJ
application_NOMZ
,_,
including_VBG [PRESP]
the_DT
compound_NN
for_PIN
the_DT
District_NN
of_PIN
New_NN
Jersey_NN
against_PIN
Teva_NN
Pharmaceuticals_NN
USA_NN
Inc._NN
patent_NN
related_VBN [WZPAST]
to_PIN
the_DT
active_JJ
ingredient_NN
salmeterol_NN
which_WDT [WHSUB]
affords_VPRT
for_PIN
infringement_NOMZ
of_PIN
the_DT
Groups_NN
patent_NN
relating_VBG [WZPRES]
to_PIN
the_DT
maleate_NN
salt_NN
protection_NOMZ
through_PIN
August_NN
2008_CD
after_IN
giving_VBG
effect_NN
to_PIN
an_DT
expected_VBN [PRIV]
form_NN
of_PIN
rosiglitazone_NN
,_,
the_DT
active_JJ
ingredient_NN
in_PIN
Avandia_NN
,_,
which_WDT [SERE]
grant_NN
of_PIN
paediatric_JJ
exclusivity_NOMZ
by_PIN
the_DT
FDA_NN
,_,
various_JJ
patents_NN
relating_VBG [WZPRES]
expires_VPRT
in_PIN
2015_CD
._.
In_PIN
September_NN
2003_CD
the_DT
Group_NN
led_VBD
a_DT
comparable_JJ
to_PIN
the_DT
Diskus_NN
device_NN
which_WDT [WHSUB]
expire_VPRT
over_IN
a_DT
period_NN
from_PIN
2011_CD
to_PIN
2016_CD
action_NOMZ
in_PIN
the_DT
same_JJ
court_NN
against_PIN
Dr_NN
Reddys_NN
Laboratories_NN
,_,
alleging_VBG [PUBV]
and_CC
patents_NN
relating_VBG [WZPRES]
to_PIN
the_DT
HFA_NN
formulation_NOMZ
and_CC
related_JJ
technology_NN
infringement_NOMZ
of_PIN
the_DT
same_JJ
patent_NN
for_PIN
the_DT
maleate_NN
salt_NN
form_NN
._.
Both_DT
which_WDT
expire_VPRT
over_IN
a_DT
period_NN
from_PIN
2015_CD
to_PIN
2021_CD
._.
Dr_NN
Reddys_NN
Laboratories_NN
and_PHC
Teva_NN
led_VBD
ANDAs_NN
with_PIN
the_DT
FDA_NN
with_PIN
certications_NOMZ
of_PIN
invalidity_NOMZ
of_PIN
the_DT
Groups_NN
maleate_VPRT
salt_NN
patent_NN
._.
FDA_NN
Levitra_NN
approval_NN
of_PIN
those_DEMO
ANDAs_NN
is_VPRT [PASS]
stayed_VBN
until_IN
the_DT
earlier_TIME
of_PIN
November_NN
In_PIN
October_NN
2002_CD
,_,
Pzer_NN
Inc._NN
led_VBD
an_DT
action_NOMZ
against_PIN
Bayer_NN
AG_NN
and_CC
2006_CD
or_CC
resolution_NOMZ
of_PIN
the_DT
respective_JJ
patent_NN
infringement_NOMZ
actions_NOMZ
._.
GlaxoSmithKline_NN
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
District_NN
of_PIN
Delaware_NN
,_,
alleging_VBG [PUBV]
that_THVC
the_DT
manufacture_NN
and_PHC
sale_NN
of_PIN
Levitra_NN
Teva_NN
subsequently_TIME
led_VBD
an_DT
additional_JJ
certication_NOMZ
challenging_VBG [WZPRES]
the_DT
vardenal_NN
would_PRMD
infringe_VB
a_DT
patent_NN
newly_RB
issued_VBN
to_PIN
Pzer_NN
and_PHC
validity_NOMZ
of_PIN
the_DT
Groups_NN
basic_JJ
compound_NN
patent_NN
for_PIN
rosiglitazone_NN
,_,
asking_VBG [SUAV]
that_THVC
Bayer_NN
and_PHC
GlaxoSmithKline_NN
be_VB [SPAU] [PASS]
permanently_RB
enjoined_VBN [SUAV]
._.
and_ANDC
in_PIN
January_NN
2004_CD
the_DT
Group_NN
commenced_VBD
an_DT
action_NOMZ
against_PIN
In_PIN
September_NN
2003_CD
the_DT
US_FPP1
Patent_NN
and_PHC
Trademark_NN
Ofce_NN
initiated_VBD
Teva_NN
in_PIN
the_DT
same_JJ
court_NN
for_PIN
infringement_NOMZ
of_PIN
that_DEMO
patent_NN
._.
The_DT
basic_JJ
a_DT
re-examination_NOMZ
of_PIN
the_DT
Pzer_NN
patent_NN
based_VBN [WZPAST]
on_PIN
questions_NOMZ
of_PIN
compound_NN
patent_NN
currently_RB
expires_VPRT
in_PIN
2008_CD
,_,
although_CONC
expiry_NN
is_VPRT
patentability_NOMZ
in_PIN
light_NN
of_PIN
prior_JJ
art_NN
._.
The_DT
Pzer_NN
action_NOMZ
,_,
including_VBG [PRESP]
an_DT
expected_VBN [PRIV]
to_TO
be_VB [PASS]
extended_VBN
to_PIN
2012_CD
after_IN
the_DT
US_FPP1
Patent_NN
and_CC
additional_JJ
suit_NN
led_VBD
in_PIN
the_DT
same_JJ
court_NN
following_VBG [WZPRES]
the_DT
launch_NN
of_PIN
Trademark_NN
Ofce_NN
has_VPRT [PEAS]
granted_VBN [SUAV]
patent_NN
term_NN
restoration_NOMZ
._.
Levitra_NN
in_PIN
the_DT
USA_NN
,_,
was_VBD [PASS]
predicated_VBN
on_PIN
the_DT
validity_NOMZ
of_PIN
that_DEMO
patent_NN
In_PIN
January_NN
2005_CD
,_,
the_DT
Group_NN
led_VBD
an_DT
action_NOMZ
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
and_CC
was_VBD [PASS]
stayed_VBN
pending_VBG
the_DT
outcome_NN
of_PIN
the_DT
re-examination_NOMZ
._.
In_PIN
for_PIN
the_DT
District_NN
of_PIN
New_NN
Jersey_NN
against_PIN
Teva_NN
for_PIN
infringement_NOMZ
of_PIN
the_DT
December_NN
2004_CD
the_DT
parties_NN
entered_VBD
into_PIN
an_DT
agreement_NOMZ
to_TO
settle_VB
same_JJ
two_CD
patents_NN
._.
Teva_NN
had_VBD [PEAS]
led_VBN
an_DT
ANDA_NN
with_PIN
the_DT
FDA_NN
for_PIN
a_DT
patent_NN
infringement_NOMZ
and_PHC
validity_NOMZ
proceedings_GER
on_PIN
a_DT
worldwide_JJ
generic_JJ
version_NN
of_PIN
Avandamet_NN
with_PIN
certications_NOMZ
of_PIN
invalidity_NOMZ
and_PHC
basis_NN
,_,
including_VBG [PRESP]
the_DT
US_FPP1
action_NOMZ
._.
FDA_NN
approval_NN
of_PIN
that_DEMO
ANDA_NN
is_VPRT [PASS]
Cervarix_NN
stayed_VBD
until_IN
the_DT
earlier_TIME
of_PIN
June_NN
2007_CD
or_CC
resolution_NOMZ
of_PIN
the_DT
patent_NN
In_PIN
February_NN
2005_CD
,_,
Merck_NN
&_CC
Co._NN
and_CC
the_DT
Group_NN
announced_VBD [PUBV]
a_DT
cross_NN
infringement_NOMZ
action_NOMZ
but_CC
since_OSUB
Avandamet_NN
is_VPRT [BYPA]
protected_VBN
by_PIN
the_DT
same_JJ
licence_NN
and_PHC
settlement_NOMZ
agreement_NOMZ
for_PIN
certain_JJ
patent_NN
rights_NN
related_VBN
patents_NN
as_IN
Avandia_NN
,_,
should_NEMD
the_DT
Avandia_NN
patents_NN
at_PIN
issue_NN
be_VB [PASS]
found_VBN [PRIV]
to_PIN
human_JJ
papillomavirus_NN
HPV_NN
vaccine_NN
._.
The_DT
Group_NN
will_PRMD
receive_VB
invalid_JJ
during_PIN
the_DT
litigation_NOMZ
with_PIN
Teva_NN
or_CC
Dr._NN
Reddys_NN
,_,
that_DEMP
ruling_VBG [SUAV]
an_DT
upfront_JJ
payment_NOMZ
and_PHC
royalties_NN
from_PIN
Merck_NN
based_VBN [WZPAST]
upon_PIN
sales_NN
would_PRMD
be_VB [BEMA]
dipositive_PRED
for_PIN
Avandamet_NN
as_RB
well_RB
._.
of_PIN
an_DT
HPV_NN
vaccine_NN
upon_PIN
development_NOMZ
and_PHC
launch_NN
._.
The_DT
agreement_NOMZ
Wellbutrin_NN
XL_NN
resolves_VPRT [SUAV]
competing_VBG
intellectual_JJ
property_NN
claims_NN
related_VBN [WZPAST]
to_PIN
the_DT
In_PIN
December_NN
2004_CD
,_,
Biovail_NN
commenced_VBD
actions_NOMZ
in_PIN
the_DT
US_FPP1
District_NN
Merck_NN
and_PHC
GlaxoSmithKline_NN
HPV_NN
vaccines_NN
,_,
respectively_RB
._.
Court_NN
for_PIN
the_DT
Central_NN
District_NN
of_PIN
California_NN
against_PIN
Anchen_NN
Pharmaceuticals_NN
and_CC
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
Southern_NN
UK_NN
and_PHC
Europe_NN
District_NN
of_PIN
Florida_NN
against_PIN
Abrika_NN
Pharmaceuticals_NN
,_,
in_PIN
each_QUAN
case_NN
Seroxat_NN
alleging_VBG [PUBV] [WZPRES]
infringement_NOMZ
of_PIN
Biovail_NN
formulation_NOMZ
patents_NN
for_PIN
Wellbutrin_NN
Following_VBG [WZPRES]
settlement_NOMZ
in_PIN
August_NN
2004_CD
of_PIN
most_EMPH
of_PIN
the_DT
Groups_NN
XL_NN
._.
Each_QUAN
of_PIN
Anchen_NN
and_PHC
Abrika_NN
patent_NN
litigation_NOMZ
with_PIN
Synthon_NN
BV_NN
,_,
Synthon_NN
is_VPRT [BEMA]
free_PRED
to_TO
market_VB
its_PIT
had_VBD [PEAS]
led_VBN
an_DT
ANDA_NN
with_PIN
the_DT
FDA_NN
with_PIN
a_DT
certication_NOMZ
of_PIN
invalidity_NOMZ
paroxetine_JJ
mesylate_JJ
product_NN
in_PIN
many_QUAN
markets_NN
globally_RB
where_RB
it_PIT
or_CC
non-infringement_NOMZ
of_PIN
the_DT
Biovail_NN
patents_NN
._.
FDA_NN
approval_NN
of_PIN
each_QUAN
has_VPRT [PEAS]
obtained_VBN
marketing_GER
authorisations_NOMZ
._.
Paroxetine_JJ
mesylate_NN
is_VPRT [BEMA]
a_DT
of_PIN
those_DEMO
ANDAs_NN
is_VPRT [PASS]
stayed_VBN
until_IN
the_DT
earlier_TIME
of_PIN
May_POMD
2007_CD
or_CC
different_JJ
salt_NN
form_NN
of_PIN
paroxetine_NN
than_PIN
that_DEMP
used_VBN
in_PIN
the_DT
marketed_VBN
resolution_NOMZ
of_PIN
the_DT
applicable_JJ
patent_NN
infringement_NOMZ
action_NOMZ
._.
The_DT
form_NN
of_PIN
Seroxat_NN
Paxil_NN
._.
In_PIN
certain_JJ
markets_NN
patent_NN
litigation_NOMZ
with_PIN
Group_NN
is_VPRT [BEMA]
a_DT
party_NN
to_PIN
the_DT
action_NOMZ
as_IN
a_DT
licensee_NN
under_IN
those_DEMO
patents_NN
Synthon_NN
is_VPRT [BEMA]
ongoing_PRED
and_CC
Synthon_NN
is_VPRT
asserting_VBG [PUBV]
counterclaims_NN
for_PIN
and_CC
owner_NN
of_PIN
the_DT
New_NN
Drug_NN
Application_NOMZ
for_PIN
Wellbutrin_NN
XL_NN
._.
Both_DT
unfair_JJ
competition_NOMZ
against_PIN
the_DT
Group_NN
._.
cases_NN
are_VPRT [BEMA]
in_PIN
their_TPP3
early_TIME
stages_NN
._.
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
GlaxoSmithKline_NN
119_CD
30_CD
Legal_NN
proceedings_GER
continued_VBD
Phenylpropanolamine_NN
Following_VBG [WZPRES]
a_DT
report_NN
from_PIN
the_DT
Yale_NN
Haemorrhagic_NN
Stroke_NN
Project_NN
Another_DT
generic_JJ
version_NN
of_PIN
Seroxat_NN
Paxils_NN
active_JJ
ingredient_NN
is_VPRT
that_DEMP
found_VBD [PRIV]
a_DT
suggestion_NOMZ
of_PIN
an_DT
association_NOMZ
between_PIN
first_JJ
use_NN
of_PIN
paroxetine_JJ
hydrochloride_NN
anhydrate_NN
._.
Generic_JJ
products_NN
containing_VBG [WZPRES]
phenylpropanolamine_NN
PPA_NN
decongestant_JJ
and_PHC
hemorrhagic_JJ
the_DT
anhydrate_NN
are_VPRT [BEMA]
now_TIME
on_PIN
the_DT
market_NN
in_PIN
most_EMPH
European_JJ
countries_NN
._.
stroke_NN
,_,
the_DT
Group_NN
and_CC
most_EMPH
other_JJ
manufacturers_NN
have_VPRT
voluntarily_RB
Whilst_OSUB
some_QUAN
of_PIN
these_DEMO
products_NN
are_VPRT [BEMA]
the_DT
subject_NN
of_PIN
continuing_VBG
withdrawn_VBN
consumer_NN
healthcare_NN
products_NN
in_PIN
which_WDT [PIRE]
PPA_NN
was_VBD [BEMA]
an_DT
litigation_NOMZ
,_,
most_EMPH
actions_NOMZ
have_VPRT [SPAU] [PEAS]
now_TIME
been_VBN [PASS]
settled_VBN
and_CC
it_PIT
is_VPRT [PASS]
expected_VBN [PRIV]
active_JJ
ingredient_NN
._.
Since_OSUB
the_DT
PPA_NN
product_NN
withdrawal_NN
the_DT
Group_NN
that_TSUB
more_EMPH
will_PRMD
be_VB [PASS]
settled_VBN
in_PIN
the_DT
future_NN
._.
In_PIN
the_DT
UK_NN
,_,
litigation_NOMZ
of_PIN
has_VPRT [PEAS]
been_VBN [PASS]
named_VBN
as_IN
a_DT
defendant_NN
in_PIN
numerous_JJ
personal_JJ
injury_NN
and_CC
several_QUAN
years_NN
standing_VBG [WZPRES]
between_PIN
the_DT
Group_NN
and_PHC
Apotex_NN
culminated_VBD
class_NN
action_NOMZ
lawsuits_NN
led_VBD
in_PIN
state_NN
and_CC
federal_JJ
courts_NN
alleging_VBG [PUBV] [WZPRES]
in_PIN
an_DT
Appeal_NN
Court_NN
decision_NN
that_TOBJ
the_DT
Groups_NN
anhydrate_JJ
process_NN
personal_JJ
injury_NN
or_CC
increased_VBN
risk_NN
of_PIN
injury_NN
from_PIN
use_NN
of_PIN
products_NN
patent_NN
was_VBD [BEMA]
valid_PRED
but_CC
not_XX0
infringed_VBN
._.
That_DEMO
decision_NN
is_VPRT [BEMA]
not_XX0
subject_PRED
to_TO
containing_VBG
PPA_NN
and_CC
unfair_JJ
and_PHC
deceptive_JJ
business_NOMZ
practices_NN
._.
As_CONJ
a_NULL
result_NULL
of_PIN
the_DT
litigation_NOMZ
,_,
Apotex_NN
was_VBD [PASS]
enjoined_VBN [SUAV] [THATD]
Plaintiffs_NN
seek_VPRT
remedies_NN
including_VBG [WZPRES]
compensatory_JJ
and_PHC
punitive_JJ
from_PIN
launching_VBG
its_PIT
product_NN
for_PIN
about_IN
one_CD
year_NN
but_CC
it_PIT
is_VPRT [BEMA]
now_TIME
on_PIN
damages_NN
and_PHC
refunds_NN
._.
The_DT
federal_JJ
cases_NN
have_VPRT [PEAS]
been_VBN [PASS]
consolidated_VBN
the_DT
market_NN
._.
A_DT
damages_NN
enquiry_VPRT
relating_VBG
to_PIN
the_DT
injunction_NOMZ
will_PRMD
in_PIN
a_DT
multidistrict_JJ
litigation_NOMZ
proceeding_GER
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
take_VB
place_NN
in_PIN
due_JJ
course_NN
._.
The_DT
judge_NN
responsible_JJ
for_PIN
those_DEMO
proceedings_GER
has_VPRT [PEAS]
denied_VBN [PUBV]
class_NN
certication_NOMZ
and_CC
struck_VBD
all_QUAN
class_NN
Product_NN
liability_NOMZ
allegations_NOMZ
in_PIN
the_DT
federal_JJ
personal_JJ
injury_NN
and_PHC
consumer_NN
refund_NN
Paxil_NN
class_NN
actions_NOMZ
._.
A_DT
limited_JJ
number_NN
of_PIN
cases_NN
in_PIN
which_WDT [PIRE]
the_DT
Group_NN
or_CC
The_NN
Group_NN
has_VPRT [PEAS]
received_VBN
lawsuits_NN
and_PHC
claims_NN
led_VBD
on_PIN
behalf_NN
other_JJ
manufacturers_NN
are_VPRT
defendants_NN
are_VPRT [SPAU]
now_TIME
reaching_VBG
trial_NN
in_PIN
of_PIN
patients_NN
alleging_VBG [PUBV] [WZPRES]
that_THVC
they_TPP3
have_VPRT [PEAS]
suffered_VBN
symptoms_NN
on_PIN
state_NN
courts_NN
._.
Class_NN
certication_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
denied_VBN [PUBV]
in_PIN
California_NN
discontinuing_VBG [WZPRES]
treatment_NOMZ
with_PIN
Paxil_NN
paroxetine_NN
._.
Separately_RB
,_,
the_DT
state_NN
court_NN
and_CC
a_DT
Pennsylvania_NN
state_NN
court_NN
putative_JJ
class_NN
action_NOMZ
Group_NN
has_VPRT [PEAS]
received_VBN
lawsuits_NN
and_PHC
claims_NN
that_TOBJ
patients_NN
who_WP [WHSUB]
had_VBD
has_VPRT [PEAS]
been_VBN [PASS]
dismissed_VBN
,_,
leaving_VBG [PRESP]
no_SYNE
putative_JJ
class_NN
actions_NOMZ
pending_VBG [WZPRES]
commenced_VBD
Paxil_NN
treatment_NOMZ
committed_VBN
or_CC
attempted_VBN
to_TO
commit_VB
against_PIN
the_DT
Group_NN
in_PIN
this_DEMO
litigation_NOMZ
._.
suicide_NN
and_CC
or_CC
acts_NN
of_PIN
violence_NN
._.
There_EX
are_VPRT
also_RB
private_JJ
consumer_NN
lawsuits_NN
alleging_VBG [PUBV] [WZPRES]
that_THVC
the_DT
Group_NN
concealed_VBD
and_PHC
misrepresented_VBD
Baycol_NN
data_NN
from_PIN
paediatric_JJ
clinical_JJ
trials_NN
of_PIN
Paxil_NN
._.
In_PIN
August_NN
2001_CD
,_,
Bayer_NN
AG_NN
withdrew_VBD
Baycol_NN
cerivastatin_NN
sodium_NN
worldwide_NN
in_PIN
light_NN
of_PIN
reports_NN
of_PIN
adverse_JJ
events_NN
,_,
including_VBG
deaths_NN
,_,
The_DT
Group_NN
has_VPRT [PEAS]
received_VBN
lawsuits_NN
led_VBD
in_PIN
state_NN
and_CC
federal_JJ
courts_NN
involving_VBG [WZPRES]
rhabdomyolosis_NN
._.
GlaxoSmithKline_NN
had_VBD [PEAS]
participated_VBN
in_PIN
in_PIN
the_DT
USA_NN
and_PHC
Canada_NN
on_PIN
behalf_NN
of_PIN
thousands_NN
of_PIN
plaintiffs_NN
,_,
the_DT
marketing_GER
of_PIN
Baycol_NN
in_PIN
the_DT
USA_NN
pursuant_JJ
to_PIN
a_DT
co-promotion_NOMZ
including_VBG [WZPRES]
14_CD
purported_JJ
class_NN
actions_NOMZ
,_,
alleging_VBG [PUBV]
that_THVC
paroxetine_JJ
agreement_NOMZ
with_PIN
Bayer_NN
which_WDT [WHSUB]
was_VBD [BEMA]
the_DT
licence_NN
holder_NN
and_CC
the_DT
active_JJ
ingredient_NN
in_PIN
Paxil_NN
is_VPRT [BEMA]
addictive_PRED
and_CC
causes_VPRT
dependency_NN
manufacturer_NN
of_PIN
the_DT
product_NN
._.
Plaintiffs_NN
seek_VPRT
remedies_NN
including_VBG [WZPRES]
compensatory_JJ
,_,
punitive_JJ
and_PHC
statutory_JJ
damages_NN
and_CC
the_DT
cost_NN
of_PIN
Following_VBG
the_DT
withdrawal_NN
,_,
Bayer_NN
and_PHC
GlaxoSmithKline_NN
have_VPRT [PEAS]
been_VBN [BEMA]
a_DT
fund_NN
for_PIN
medical_JJ
monitoring_GER
._.
In_PIN
2003_CD
a_DT
federal_JJ
judge_NN
in_PIN
the_DT
US_FPP1
named_VBD
as_IN
defendants_NN
in_PIN
thousands_NN
of_PIN
lawsuits_NN
led_VBN [WZPAST]
in_PIN
state_NN
and_PHC
District_NN
Court_NN
for_PIN
the_DT
Central_NN
District_NN
of_PIN
California_NN
denied_VBD [PUBV]
class_NN
federal_JJ
courts_NN
in_PIN
the_DT
USA_NN
on_PIN
behalf_NN
of_PIN
both_DT
individuals_NN
and_PHC
action_NOMZ
certications_NOMZ
for_PIN
a_DT
nationwide_JJ
class_NN
and_CC
a_DT
California_NN
putative_NN
classes_NN
of_PIN
former_JJ
Baycol_NN
users_NN
._.
A_DT
number_NN
of_PIN
the_DT
suits_NN
statewide_JJ
class_NN
as_IN
to_PIN
cases_NN
led_VBN [WZPAST]
in_PIN
federal_JJ
court_NN
in_PIN
that_DEMO
district_NN
._.
allege_VB [PUBV]
that_THVC
the_DT
plaintiffs_NN
have_VPRT [PEAS]
suffered_VBN
personal_JJ
injuries_NN
,_,
including_VBG
Subsequently_TIME
,_,
on_PIN
petition_NOMZ
from_PIN
plaintiffs_NN
counsel_NN
all_QUAN
federal_JJ
court_NN
rhabdomyolosis_NN
,_,
from_PIN
the_DT
use_NN
of_PIN
Baycol_NN
._.
Others_NN
claim_VPRT [PUBV]
that_THVC
persons_NN
cases_NN
have_VPRT [PEAS]
been_VBN [PASS]
transferred_VBN
to_PIN
that_DEMO
District_NN
Court_NN
for_PIN
consolidation_NOMZ
who_WP [WHSUB]
took_VBD
Baycol_NN
,_,
although_CONC
not_XX0
injured_VBN
,_,
may_POMD
be_VB [BEMA]
at_PIN
risk_NN
of_PIN
future_NN
in_PIN
Multidistrict_NN
Litigation_NOMZ
MDL_NN
._.
The_DT
first_JJ
five_CD
cases_NN
are_VPRT [PASS]
scheduled_VBN
injury_NN
or_CC
may_POMD
have_VB [PEAS]
suffered_VBN
economic_JJ
damages_NN
from_PIN
purchasing_VBG
to_TO
start_VB
trial_NN
in_PIN
the_DT
MDL_NN
court_NN
in_PIN
May_POMD
2005_CD
._.
There_EX
has_VPRT [PEAS]
been_VBN
no_DT
and_CC
using_VBG
Baycol_NN
._.
Plaintiffs_NN
seek_VPRT
remedies_NN
including_VBG [WZPRES]
compensatory_JJ
,_,
determination_NOMZ
as_IN
to_PIN
whether_IN
any_QUAN
of_PIN
the_DT
other_JJ
lawsuits_NN
pending_VBG [WZPRES]
punitive_JJ
and_PHC
statutory_JJ
damages_NN
and_PHC
creation_NOMZ
of_PIN
funds_NN
for_PIN
medical_JJ
in_PIN
the_DT
MDL_NN
or_CC
in_PIN
state_NN
courts_NN
will_PRMD
be_VB [PASS]
permitted_VBN
to_TO
proceed_VB
as_IN
monitoring_GER
._.
GlaxoSmithKline_NN
and_PHC
Bayer_NN
Corporation_NOMZ
,_,
the_DT
principal_JJ
class_NN
actions_NOMZ
._.
US_FPP1
subsidiary_NN
of_PIN
Bayer_NN
AG_NN
,_,
have_VPRT [PEAS]
signed_VBN
an_DT
allocation_NOMZ
agreement_NOMZ
under_IN
which_WDT
Bayer_NN
Corporation_NOMZ
has_VPRT [PEAS]
agreed_VBN [SUAV] [PUBV]
to_TO
pay_VB
95_CD
per_PIN
cent_NN
The_DT
Group_NN
has_VPRT [PEAS]
received_VBN
a_DT
number_NN
of_PIN
claims_NN
and_PHC
lawsuits_NN
alleging_VBG [PUBV] [WZPRES]
of_PIN
all_QUAN
settlements_NOMZ
and_CC
compensatory_JJ
damages_NN
judgements_NOMZ
with_PIN
that_DEMO
treatment_NOMZ
with_PIN
Paxil_NN
has_VPRT [PEAS]
caused_VBN
homicidal_JJ
or_CC
suicidal_JJ
each_QUAN
party_NN
retaining_VBG [WZPRES]
responsibility_NOMZ
for_PIN
its_PIT
own_JJ
attorneys_NN
fees_NN
and_PHC
behavior_NN
exhibited_VBN [WZPAST]
by_PIN
users_NN
of_PIN
the_DT
product_NN
._.
None_INPR
of_PIN
these_DEMP
are_VPRT [BEMA]
any_QUAN
punitive_JJ
damages_NN
._.
The_DT
federal_JJ
cases_NN
have_VPRT [PEAS]
been_VBN [BEMA]
consolidated_PRED
or_CC
purport_VB
to_TO
be_VB
class_NN
actions_NOMZ
._.
In_PIN
October_NN
2004_CD
the_DT
FDA_NN
in_PIN
a_DT
multidistrict_JJ
litigation_NOMZ
proceeding_GER
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
announced_VBN [PUBV]
that_THVC
it_PIT
would_PRMD
require_VB [SUAV] [THATD]
a_DT
black_JJ
box_NN
warning_VBG [PUBV] [WZPRES]
about_IN
the_DT
District_NN
of_PIN
Minnesota_NN
._.
Numerous_JJ
cases_NN
are_VPRT [PASS]
scheduled_VBN
for_PIN
trial_NN
suicidality_NOMZ
and_CC
other_JJ
strengthened_JJ
warnings_GER
for_PIN
selective_JJ
serotonin_NN
in_PIN
state_NN
and_CC
federal_JJ
courts_NN
during_PIN
2005_CD
._.
To_PIN
date_NN
,_,
a_DT
statewide_JJ
reuptake_NN
inhibitor_NN
SSRI_NN
products_NN
,_,
including_VBG
Paxil_NN
,_,
as_IN
a_DT
class_NN
._.
medical_JJ
monitoring_GER
class_NN
action_NOMZ
against_PIN
Bayer_NN
and_PHC
GlaxoSmithKline_NN
Avandia_NN
has_VPRT [PEAS]
been_VBN [PASS]
certied_VBN
in_PIN
Pennsylvania_NN
,_,
and_ANDC
another_DT
class_NN
action_NOMZ
,_,
in_PIN
The_DT
Group_NN
has_VPRT [PEAS]
received_VBN
lawsuits_NN
and_PHC
claims_NN
led_VBN [WZPAST]
in_PIN
state_NN
and_ANDC
which_WDT
GlaxoSmithKline_NN
was_VBD [PASS]
not_XX0
named_VBN
as_IN
a_DT
defendant_NN
,_,
has_VPRT [PEAS]
been_VBN [BEMA]
federal_JJ
courts_NN
in_PIN
the_DT
USA_NN
on_PIN
behalf_NN
of_PIN
numerous_JJ
patients_NN
alleging_VBG [PUBV] [WZPRES]
certied_VBN
in_PIN
Oklahoma_NN
._.
A_DT
substantial_JJ
number_NN
of_PIN
claims_NN
for_PIN
death_NN
that_DEMO
rosiglitazone_NN
the_DT
active_JJ
ingredient_NN
in_PIN
Avandia_NN
has_VPRT [PEAS]
caused_VBN
or_CC
serious_JJ
injury_NN
have_VPRT [PEAS]
been_VBN [PASS]
settled_VBN
._.
congestive_JJ
heart_NN
failure_NN
or_CC
liver_NN
damage_NN
._.
None_INPR
of_PIN
the_DT
cases_NN
purports_VPRT
to_TO
be_VB [BEMA]
a_DT
class_NN
action_NOMZ
._.
Most_EMPH
of_PIN
the_DT
cases_NN
are_VPRT [BEMA]
in_PIN
their_TPP3
early_TIME
stages_NN
although_CONC
certain_JJ
state_NN
court_NN
trials_NN
are_VPRT [PASS]
scheduled_VBN
to_TO
take_VB
place_NN
in_PIN
2005_CD
._.
120_CD
GlaxoSmithKline_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
30_CD
Legal_JJ
proceedings_GER
continued_VBD
In_CONJ
particular_NULL
the_DT
government_NOMZ
has_VPRT [PEAS]
inquired_VBN
about_IN
alleged_JJ
promotion_NOMZ
of_PIN
these_DEMO
drugs_NN
for_PIN
off-label_JJ
uses_NN
as_RB
well_RB
as_IN
Group_NN
sponsored_VBD
Fen-Phen_NN
continuing_VBG [WZPRES]
medical_JJ
education_NOMZ
programs_NN
,_,
other_JJ
speaker_NN
events_NN
,_,
In_PIN
1997_CD
,_,
the_DT
FDA_NN
became_VBD
aware_JJ
of_PIN
reports_NN
of_PIN
cardiac_JJ
valvular_JJ
special_JJ
issue_NN
boards_NN
,_,
advisory_JJ
boards_NN
,_,
speaker_NN
training_GER
programs_NN
,_,
problems_NN
in_PIN
individuals_NN
for_PIN
whom_WP [PIRE]
fenuramine_VPRT
or_CC
dexfenuramine_VPRT
clinical_JJ
studies_NN
,_,
and_ANDC
related_JJ
grants_NN
,_,
fees_NN
,_,
travel_NN
and_PHC
entertainment_NOMZ
._.
alone_RB
or_CC
in_PIN
combination_NOMZ
with_PIN
phentermine_NN
was_VBD [PASS]
prescribed_VBN
as_IN
part_NN
Although_CONC
the_DT
original_JJ
subpoena_NN
issued_VBN [WZPAST]
from_PIN
the_DT
US_FPP1
Attorneys_NN
of_PIN
a_DT
regimen_NN
of_PIN
weight_NN
reduction_NOMZ
and_CC
requested_VBD [SUAV]
the_DT
voluntary_JJ
ofce_NN
in_PIN
Colorado_NN
,_,
the_DT
scope_NN
of_PIN
the_DT
inquiry_NN
is_VPRT [BEMA]
nationwide_PRED
._.
The_DT
withdrawal_NN
of_PIN
fenuramine_NN
and_PHC
dexfenuramine_NN
from_PIN
the_DT
market_NN
._.
Group_NN
is_VPRT
co-operating_VBG
with_PIN
the_DT
investigation_NOMZ
which_WDT [WHSUB]
is_VPRT [BEMA]
in_PIN
its_PIT
early_TIME
The_DT
reports_NN
of_PIN
cardiac_JJ
valvular_JJ
problems_NN
and_CC
the_DT
subsequent_JJ
stages_NN
._.
The_DT
Group_NN
had_VBD [SPAU] [PEAS]
earlier_TIME
responded_VBD
to_PIN
an_DT
October_NN
2002_CD
letter_NN
withdrawal_NN
of_PIN
those_DEMO
products_NN
from_PIN
the_DT
market_NN
spawned_VBD
numerous_JJ
from_PIN
the_DT
FDAs_NN
Division_NN
of_PIN
Drug_NN
Marketing_GER
,_,
Advertising_GER
and_PHC
product_NN
liability_NOMZ
lawsuits_NN
led_VBD
against_PIN
the_DT
manufacturers_NN
and_PHC
Communication_NOMZ
requesting_VBG [SUAV] [WZPRES]
information_NOMZ
on_PIN
the_DT
Groups_NN
alleged_VBD [PUBV]
distributors_NN
of_PIN
fenuramine_NN
,_,
dexfenuramine_NN
and_PHC
phentermine_NN
._.
promotion_NOMZ
of_PIN
Wellbutrin_NN
SR_NN
for_PIN
off-label_JJ
use_NN
._.
As_IN
one_CD
of_PIN
a_DT
number_NN
of_PIN
manufacturers_NN
of_PIN
phentermine_NN
,_,
the_DT
Group_NN
is_VPRT [BEMA]
a_DT
defendant_NN
in_PIN
thousands_NN
of_PIN
lawsuits_NN
in_PIN
various_JJ
state_NN
and_CC
federal_JJ
Average_JJ
wholesale_JJ
price_NN
district_NN
courts_NN
in_PIN
the_DT
USA_NN
._.
Most_EMPH
of_PIN
the_DT
lawsuits_NN
seek_VPRT
relief_NN
including_VBG [WZPRES]
GlaxoSmithKline_NN
has_VPRT [PEAS]
responded_VBN
to_PIN
subpoenas_NN
from_PIN
the_DT
Ofce_NN
some_QUAN
combination_NOMZ
of_PIN
compensatory_JJ
and_PHC
punitive_JJ
damages_NN
,_,
of_PIN
the_DT
Inspector_NN
General_NN
of_PIN
the_DT
US_FPP1
Department_NOMZ
of_PIN
Health_NN
and_CC
medical_JJ
monitoring_GER
and_PHC
refunds_NN
for_PIN
purchases_NN
of_PIN
drugs_NN
._.
In_PIN
1997_CD
Human_NN
Services_NN
,_,
the_DT
US_FPP1
Department_NOMZ
of_PIN
Justice_NN
and_CC
the_DT
states_NN
of_PIN
the_DT
Judicial_NN
Panel_NN
on_PIN
Multidistrict_NN
Litigation_NOMZ
issued_VBD
an_DT
order_NN
Texas_NN
and_PHC
California_NN
in_PIN
connection_NOMZ
with_PIN
allegations_NOMZ
that_TSUB
consolidating_VBG
and_PHC
transferring_VBG
all_QUAN
federal_JJ
actions_NOMZ
to_PIN
the_DT
District_NN
pharmaceutical_JJ
companies_NN
,_,
including_VBG
GlaxoSmithKline_NN
,_,
have_VPRT
Court_NN
for_PIN
the_DT
Eastern_NN
District_NN
of_PIN
Pennsylvania_NN
._.
That_DEMO
court_NN
approved_VBD
violated_VBN
federal_JJ
fraud_NN
and_PHC
abuse_NN
laws_NN
such_JJ
as_IN
the_DT
Federal_NN
False_NN
a_DT
global_JJ
settlement_NOMZ
proposed_VBN [SUAV] [WZPAST]
by_PIN
defendant_NN
Wyeth_NN
,_,
which_WDT [SERE]
sold_VBD
Claims_NN
Act_NN
and_CC
,_,
with_PIN
respect_NN
to_PIN
Texas_NN
and_PHC
California_NN
,_,
comparable_JJ
fenuramine_NN
and_PHC
dexfenuramine_NN
._.
The_DT
settlement_NOMZ
,_,
subsequently_TIME
state_NN
laws_NN
as_CONJ
a_NULL
result_NULL
of_PIN
the_DT
way_NN
average_JJ
wholesale_JJ
price_NN
AWPSNNP
confirmed_VBD [PUBV]
by_PIN
the_DT
Third_NN
Circuit_NN
Court_NN
of_PIN
Appeals_NN
,_,
does_VPRT
not_XX0
include_VB
was_VBD [PASS]
determined_VBN [SUAV] [PRIV]
and_PHC
reported_VBN [PUBV]
for_PIN
certain_JJ
drugs_NN
and_CC
the_DT
way_NN
the_DT
any_QUAN
of_PIN
the_DT
phentermine_NN
defendants_NN
,_,
including_VBG [PRESP]
the_DT
Group_NN
._.
Medicare_NN
and_PHC
Medicaid_NN
programs_NN
reimburse_VPRT
for_PIN
those_DEMO
drugs_NN
._.
Individual_JJ
plaintiffs_NN
may_POMD
elect_VB
to_TO
opt_VB
out_PIN
of_PIN
the_DT
class_NN
settlement_NOMZ
Subsequently_TIME
,_,
several_QUAN
states_NN
through_PIN
their_TPP3
respective_JJ
attorneys_NN
and_CC
pursue_VB
their_TPP3
claims_NN
individually_RB
and_CC
tens_NN
of_PIN
thousands_NN
of_PIN
general_JJ
and_CC
several_QUAN
counties_NN
in_PIN
New_NN
York_NN
state_NN
led_VBD
civil_JJ
lawsuits_NN
plaintiffs_NN
have_VPRT [PEAS]
elected_VBN
to_TO
do_VB
so_RB
._.
Wyeth_NN
continues_VPRT
to_TO
settle_VB
in_PIN
state_NN
and_CC
federal_JJ
court_NN
against_PIN
GlaxoSmithKline_NN
and_CC
several_QUAN
individual_JJ
state_NN
court_NN
cases_NN
before_IN
trial_NN
and_CC
the_DT
Group_NN
continues_VPRT
other_JJ
drug_NN
companies_NN
._.
The_DT
actions_NOMZ
claim_VPRT [PUBV]
,_,
on_PIN
behalf_NN
of_PIN
the_DT
states_NN
to_TO
be_VB [PASS]
dismissed_VBN
from_PIN
lawsuits_NN
as_IN
they_TPP3
are_VPRT [BYPA]
settled_VBN
by_PIN
Wyeth_NN
._.
as_IN
payers_NN
and_CC
on_PIN
behalf_NN
of_PIN
in-state_JJ
patients_NN
as_IN
consumers_NN
,_,
Thimerosal_NN
damages_NN
and_PHC
restitution_NOMZ
due_JJ
to_TO
AWPSNNP
based_VBN
price_NN
reporting_VBG [PUBV] [WZPRES]
for_PIN
an_DT
GlaxoSmithKline_NN
,_,
along_IN
with_PIN
a_DT
number_NN
of_PIN
other_JJ
pharmaceutical_JJ
undefined_JJ
set_NN
of_PIN
pharmaceutical_JJ
products_NN
covered_VBN [WZPAST]
by_PIN
the_DT
states_NN
companies_NN
,_,
has_VPRT [PEAS]
been_VBN [PASS]
named_VBN
as_IN
a_DT
defendant_NN
in_PIN
numerous_JJ
individual_JJ
Medicaid_NN
programs_NN
._.
In_CONJ
addition_NULL
,_,
private_JJ
payer_NN
class_NN
action_NOMZ
personal_JJ
injury_NN
lawsuits_NN
in_PIN
state_NN
and_CC
federal_JJ
district_NN
courts_NN
in_PIN
lawsuits_NN
have_VPRT [PEAS]
been_VBN [PASS]
led_VBN
against_PIN
GlaxoSmithKline_NN
in_PIN
several_QUAN
the_DT
USA_NN
alleging_VBG [PUBV] [WZPRES]
that_THVC
thimerosal_JJ
,_,
a_DT
preservative_JJ
used_VBN
in_PIN
the_DT
federal_JJ
district_NN
and_PHC
state_NN
courts_NN
._.
All_QUAN
the_DT
federal_JJ
cases_NN
have_VPRT [PEAS]
been_VBN
manufacture_NN
of_PIN
vaccines_NN
,_,
causes_VPRT
neurodevelopmental_JJ
disorders_NN
consolidated_VBN [WZPAST]
in_PIN
a_DT
multidistrict_JJ
litigation_NOMZ
proceeding_GER
in_PIN
the_DT
US_FPP1
and_CC
other_JJ
injuries_NN
,_,
including_VBG
autism_NN
._.
Three_CD
of_PIN
the_DT
cases_NN
are_VPRT
District_NN
Court_NN
for_PIN
the_DT
District_NN
of_PIN
Massachusetts_NN
._.
The_DT
Group_NN
is_VPRT [BEMA]
purported_JJ
class_NN
actions_NOMZ
:_:
there_EX
has_VPRT [PEAS]
been_VBN
no_SYNE
determination_NOMZ
as_IN
to_PIN
one_CD
of_PIN
five_CD
companies_NN
designated_VBN [WZPAST]
for_PIN
fast_JJ
track_NN
discovery_NN
in_PIN
whether_IN
any_QUAN
of_PIN
those_DEMO
cases_NN
will_PRMD
be_VB [PASS]
permitted_VBN
to_TO
proceed_VB
as_IN
a_DT
that_DEMO
proceeding_GER
._.
A_DT
hearing_GER
on_PIN
the_DT
private-payer_JJ
plaintiffs_NN
motion_NOMZ
class_NN
action_NOMZ
._.
A_DT
number_NN
of_PIN
purported_JJ
class_NN
actions_NOMZ
in_PIN
other_JJ
for_PIN
class_NN
certication_NOMZ
took_VBD
place_NN
in_PIN
February_NN
2005_CD
but_CC
the_DT
judge_NN
jurisdictions_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
withdrawn_VBN
or_CC
dismissed_VBN
._.
Plaintiffs_NN
seek_VPRT
has_VPRT [PEAS]
not_XX0
yet_RB
ruled_VBN [SUAV]
on_PIN
that_DEMO
motion_NOMZ
._.
All_QUAN
of_PIN
the_DT
civil_JJ
suits_NN
led_VBN [WZPAST]
in_PIN
state_NN
remedies_NN
including_VBG [WZPRES]
compensatory_JJ
,_,
punitive_JJ
and_PHC
statutory_JJ
court_NN
by_PIN
state_NN
attorneys_NN
general_JJ
and_CC
a_DT
private_JJ
payer_NN
class_NN
action_NOMZ
damages_NN
and_CC
the_DT
cost_NN
of_PIN
a_DT
fund_NN
for_PIN
medical_JJ
monitoring_GER
and_PHC
case_NN
remanded_VBD
to_PIN
state_NN
court_NN
are_VPRT [BEMA]
in_PIN
their_TPP3
early_TIME
stages_NN
._.
Although_CONC
many_QUAN
of_PIN
the_DT
lawsuits_NN
are_VPRT [BEMA]
in_PIN
their_TPP3
early_TIME
stages_NN
,_,
Nominal_JJ
pricing_GER
a_DT
number_NN
of_PIN
cases_NN
are_VPRT [PASS]
scheduled_VBN
for_PIN
trial_NN
in_PIN
2005_CD
._.
The_DT
Group_NN
has_VPRT [PEAS]
been_VBN [BYPA]
advised_VBN
by_PIN
the_DT
US_FPP1
Department_NOMZ
of_PIN
Justice_NN
Lotronex_NN
that_TOBJ
they_TPP3
are_VPRT
investigating_VBG
certain_JJ
of_PIN
the_DT
Groups_NN
nominal_JJ
pricing_GER
Following_VBG [WZPRES]
the_DT
voluntary_JJ
withdrawal_NN
of_PIN
Lotronex_NN
in_PIN
the_DT
USA_NN
in_PIN
arrangements_NOMZ
to_TO
determine_VB [SUAV] [PRIV]
whether_IN [WHCL]
those_DEMO
arrangements_NOMZ
qualify_VPRT
November_NN
2000_CD
a_DT
number_NN
of_PIN
lawsuits_NN
have_VPRT [PEAS]
been_VBN [PASS]
led_VBN
against_PIN
under_IN
the_DT
nominal_JJ
price_NN
exception_NOMZ
to_PIN
best_JJ
price_NN
reporting_VBG [PUBV] [WZPRES]
the_DT
Group_NN
in_PIN
state_NN
and_CC
federal_JJ
district_NN
courts_NN
,_,
including_VBG
individual_JJ
requirements_NOMZ
under_IN
the_DT
Medicaid_NN
Drug_NN
Rebate_NN
Programme_NN
or_CC
personal_JJ
injury_NN
actions_NOMZ
and_CC
purported_JJ
class_NN
actions_NOMZ
asserting_VBG [PUBV] [WZPRES]
violate_VPRT
civil_JJ
statutes_NN
or_CC
laws_NN
._.
The_DT
Group_NN
is_VPRT
cooperating_VBG
in_PIN
that_DEMO
product_NN
liability_NOMZ
and_PHC
consumer_NN
fraud_NN
claims_NN
._.
Plaintiffs_NN
seek_VPRT
remedies_NN
investigation_NOMZ
which_WDT [WHSUB]
is_VPRT
being_VBG [BYPA]
conducted_VBN
by_PIN
the_DT
same_JJ
government_NOMZ
including_VBG [WZPRES]
compensatory_JJ
,_,
punitive_JJ
and_PHC
statutory_JJ
damages_NN
._.
The_DT
class_NN
attorneys_NN
involved_VBN [WZPAST]
in_PIN
the_DT
AWPSNNP
investigation_NOMZ
and_CC
has_VPRT [PEAS]
provided_VBN
previously_TIME
certied_VBN
in_PIN
West_NN
Virginia_NN
has_VPRT [PEAS]
been_VBN [PASS]
decertied_VBN
and_CC
the_DT
documents_NOMZ
and_PHC
information_NOMZ
regarding_VBG [WZPRES]
nominal_JJ
pricing_GER
action_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
dismissed_VBN
._.
A_DT
large_JJ
number_NN
of_PIN
claims_NN
brought_VBD
arrangements_NOMZ
for_PIN
a_DT
number_NN
of_PIN
the_DT
Groups_NN
products_NN
._.
following_VBG [PRESP]
the_DT
withdrawal_NN
have_VPRT [SPAU] [PEAS]
now_TIME
been_VBN [PASS]
settled_VBN
._.
Paxil_NN
Seroxat_NN
Following_VBG [WZPRES]
announcement_NOMZ
of_PIN
the_DT
New_NN
York_NN
State_NN
Attorney_NN
Generals_NN
Government_NOMZ
investigations_NOMZ
ofce_VPRT
over_IN
the_DT
states_NN
lawsuit_NN
,_,
subsequently_TIME
settled_VBN
in_PIN
August_NN
2004_CD
,_,
Marketing_GER
and_PHC
promotion_NOMZ
alleging_VBG [PUBV] [WZPRES]
failure_NN
to_TO
disclose_VB [PUBV]
data_NN
on_PIN
the_DT
use_NN
of_PIN
Paxil_NN
in_PIN
children_NN
In_PIN
February_NN
2004_CD
,_,
GlaxoSmithKline_NN
received_VBD
a_DT
subpoena_NN
from_PIN
and_CC
adolescents_NN
,_,
similar_JJ
cases_NN
,_,
some_QUAN
of_PIN
which_WDT [PIRE]
purport_VPRT
to_TO
be_VB [BEMA]
the_DT
US_FPP1
Attorneys_NN
ofce_NN
in_PIN
Colorado_NN
regarding_VBG [WZPRES]
the_DT
Groups_NN
sales_NN
class_NN
actions_NOMZ
,_,
have_VPRT [PEAS]
been_VBN [PASS]
led_VBN
in_PIN
state_NN
and_CC
federal_JJ
courts_NN
by_PIN
and_CC
promotional_JJ
practices_NN
relating_VBG [WZPRES]
to_PIN
nine_CD
of_PIN
its_PIT
largest_JJ
selling_GER
private_JJ
plaintiffs_NN
._.
All_QUAN
those_DEMO
cases_NN
are_VPRT [BEMA]
in_PIN
their_TPP3
early_TIME
stages_NN
._.
products_NN
for_PIN
the_DT
period_NN
from_PIN
January_NN
1997_CD
to_PIN
the_DT
present_NN
._.
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
GlaxoSmithKline_NN
121_CD
30_CD
Legal_NN
proceedings_GER
continued_VBD
Relafen_NN
In_PIN
August_NN
2001_CD
,_,
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
District_NN
of_PIN
In_PIN
the_DT
UK_NN
an_DT
investigation_NOMZ
remains_VPRT
pending_VBG
by_PIN
the_DT
UK_NN
Medicines_NN
Massachusetts_NN
ruled_VBD [SUAV]
the_DT
Groups_NN
patent_NN
for_PIN
nabumetone_NN
Relafen_NN
and_PHC
Healthcare_NN
products_NN
Regulatory_NN
Agency_NN
MHRA_NN
to_TO
determine_VB [SUAV] [PRIV]
invalid_JJ
for_PIN
anticipatory_JJ
art_NN
and_CC
unenforceable_JJ
on_PIN
the_DT
grounds_NN
of_PIN
whether_IN
the_DT
Group_NN
has_VPRT [PEAS]
complied_VBN
with_PIN
its_PIT
pharmacovigilance_NN
inequitable_JJ
conduct_NN
._.
In_PIN
August_NN
2002_CD
the_DT
CAFC_NN
issued_VBD
a_DT
decision_NN
obligations_NOMZ
in_PIN
reporting_GER
of_PIN
data_NN
from_PIN
clinical_JJ
trials_NN
for_PIN
Seroxat_NN
Paxil_NN
afrming_VBG [WZPRES]
the_DT
District_NN
Courts_NN
judgement_NOMZ
of_PIN
invalidity_NOMZ
but_CC
declining_VBG
in_PIN
children_NN
and_PHC
adolescents_NN
._.
to_TO
rule_VB [SUAV]
on_PIN
the_DT
judgement_NOMZ
of_PIN
inequitable_JJ
conduct_NN
._.
Cidra_NN
,_,
Puerto_NN
Rico_NN
manufacturing_VBG [WZPRES]
site_NN
Following_VBG [WZPRES]
the_DT
District_NN
Court_NN
decision_NN
,_,
anti-trust_JJ
claims_NN
alleging_VBG [PUBV] [WZPRES]
In_PIN
October_NN
2003_CD
,_,
the_DT
FDA_NN
inspected_VBD
the_DT
Groups_NN
manufacturing_VBG [WZPRES]
competitive_JJ
injury_NN
and_PHC
overcharges_NN
were_VBD [BYPA]
led_VBN
by_PIN
Teva_NN
and_PHC
Eon_NN
facility_NOMZ
in_PIN
Cidra_NN
,_,
Puerto_NN
Rico_NN
._.
The_DT
Cidra_NN
site_NN
is_VPRT [PASS]
engaged_VBN
in_PIN
tableting_VBG
Pharmaceuticals_NN
,_,
generic_JJ
manufacturers_NN
of_PIN
nabumetone_NN
,_,
by_PIN
and_CC
packaging_GER
for_PIN
a_DT
range_NN
of_PIN
GlaxoSmithKline_NN
products_NN
primarily_RB
purported_JJ
classes_NN
of_PIN
direct_JJ
and_PHC
indirect_JJ
purchasers_NN
and_PHC
payers_NN
for_PIN
the_DT
US_FPP1
market_NN
including_VBG [WZPRES]
Paxil_NN
,_,
Paxil_NN
CR_NN
,_,
Coreg_NN
,_,
Avandia_NN
and_CC
by_PIN
individual_JJ
retail_JJ
chains_NN
._.
Following_VBG [PRESP]
that_DEMO
inspection_NOMZ
the_DT
FDA_NN
has_VPRT [PEAS]
issued_VBN
two_CD
Forms_NN
483_CD
observations_NOMZ
of_PIN
possible_JJ
deficiencies_NN
in_PIN
The_DT
plaintiffs_NN
claims_NN
are_VPRT [PASS]
based_VBN
on_PIN
allegations_NOMZ
of_PIN
fraudulent_JJ
manufacturing_GER
practices_NN
to_PIN
the_DT
Group_NN
._.
The_DT
FDA_NN
carried_VBD
out_PIN
a_DT
procurement_NOMZ
of_PIN
a_DT
patent_NN
,_,
wrongful_JJ
listing_GER
of_PIN
the_DT
patent_NN
in_PIN
the_DT
further_JJ
inspection_NOMZ
in_PIN
November_NN
2004_CD
and_CC
subsequently_TIME
issued_VBN
FDA_NN
Orange_NN
Book_NN
and_PHC
prosecution_NOMZ
of_PIN
sham_NN
patent_NN
infringement_NOMZ
two_CD
further_JJ
Forms_NN
483_CD
._.
litigation_NOMZ
._.
Those_DEMO
cases_NN
,_,
which_WDT [SERE]
were_VBD [SPAU] [PASS]
originally_TIME
led_VBN
in_PIN
the_DT
US_FPP1
District_NN
Courts_NN
for_PIN
the_DT
District_NN
of_PIN
Massachusetts_NN
and_CC
the_DT
Eastern_NN
District_NN
of_PIN
The_DT
FDA_NN
observations_NOMZ
relate_VPRT
to_PIN
certain_JJ
aspects_NN
of_PIN
production_NOMZ
Pennsylvania_NN
,_,
were_VBD [BEMA]
all_QUAN
transferred_VBN
to_PIN
the_DT
District_NN
of_PIN
Massachusetts_NN
._.
controls_NN
,_,
process_NN
validation_NOMZ
and_PHC
laboratory_NN
investigations_NOMZ
._.
The_DT
The_NN
Group_NN
has_VPRT [PEAS]
settled_VBN
the_DT
cases_NN
led_VBN [WZPAST]
by_PIN
Teva_NN
,_,
Eon_NN
,_,
a_DT
group_NN
of_PIN
Group_NN
continues_VPRT
to_TO
cooperate_VB
with_PIN
the_DT
FDA_NN
in_PIN
responding_VBG
to_PIN
major_JJ
retail_JJ
pharmacy_NN
chains_NN
and_CC
the_DT
class_NN
of_PIN
direct_JJ
purchasers_NN
._.
the_DT
observations_NOMZ
contained_VBN [WZPAST]
in_PIN
the_DT
Forms_NN
483_CD
,_,
but_CC
there_RB
can_POMD
be_VB [BEMA]
The_DT
court_NN
has_VPRT [PEAS]
given_VBN
preliminary_JJ
approval_NN
to_PIN
the_DT
settlement_NOMZ
that_TOBJ
no_SYNE
assurance_NN
as_IN
to_PIN
any_QUAN
remedy_NN
the_DT
FDA_NN
may_POMD [SPAU]
ultimately_RB
seek_VB
._.
the_DT
Group_NN
has_VPRT [PEAS]
reached_VBN
with_PIN
a_DT
class_NN
of_PIN
indirect_JJ
purchasers_NN
._.
A_DT
hearing_GER
on_PIN
final_JJ
approval_NN
of_PIN
that_DEMO
settlement_NOMZ
is_VPRT [PASS]
scheduled_VBN
for_PIN
Anti-trust_JJ
4th_JJ
May_POMD
2005_CD
._.
Additionally_RB
,_,
a_DT
settlement_NOMZ
agreement_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
Paxil_NN
signed_VBD
with_PIN
the_DT
states_NN
regarding_VBG [WZPRES]
their_TPP3
global_JJ
claim_NN
for_PIN
alleged_JJ
In_PIN
November_NN
2000_CD
,_,
the_DT
US_FPP1
Federal_NN
Trade_NN
Commission_NN
FTC_NN
staff_NN
overcharges_NN
in_PIN
connection_NOMZ
with_PIN
state_NN
purchases_NN
of_PIN
the_DT
drug_NN
._.
advised_VBD
the_DT
Group_NN
that_TOBJ
they_TPP3
were_VBD
conducting_VBG
a_DT
non-public_JJ
investigation_NOMZ
to_TO
determine_VB [SUAV] [PRIV]
whether_IN [WHCL]
the_DT
Group_NN
was_VBD
violating_VBG
Augmentin_NN
Section_NOMZ
5_CD
of_PIN
the_DT
Federal_NN
Trade_NN
Commission_NN
Act_NN
by_PIN
monopolizing_VBG
In_PIN
2002_CD
,_,
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
Eastern_NN
District_NN
of_PIN
Virginia_NN
or_CC
attempting_VBG
to_TO
monopolize_VB
the_DT
market_NN
for_PIN
paroxetine_JJ
found_VBN [PRIV] [THATD]
various_JJ
patents_NN
covering_VBG [WZPRES]
Augmentin_NN
invalid_JJ
._.
That_DEMP
holding_VBG [PRIV]
hydrochloride_NN
by_PIN
preventing_VBG
generic_JJ
competition_NOMZ
to_PIN
Paxil_NN
and_CC
was_VBD [SPAU] [BYPA]
subsequently_TIME
afrmed_VBN
by_PIN
the_DT
CAFC_NN
._.
Following_VBG [PRESP]
the_DT
adverse_JJ
requested_VBD [SUAV]
the_DT
Group_NN
to_TO
submit_VB [PUBV]
certain_JJ
information_NOMZ
in_PIN
connection_NOMZ
trial_NN
court_NN
decision_NN
,_,
purported_JJ
anti-trust_JJ
class_NN
actions_NOMZ
were_VBD [PASS]
led_VBN
with_PIN
that_DEMO
investigation_NOMZ
._.
In_PIN
October_NN
2003_CD
the_DT
FTC_NN
closed_VBD
its_PIT
on_PIN
behalf_NN
of_PIN
classes_NN
of_PIN
direct_JJ
and_PHC
indirect_JJ
purchasers_NN
that_TSUB
were_VBD
investigation_NOMZ
on_PIN
the_DT
basis_NN
of_PIN
its_PIT
nding_NN
that_TOBJ
no_SYNE
further_JJ
action_NOMZ
is_VPRT [SPAU] [PASS]
ultimately_RB
consolidated_VBN
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
Eastern_NN
warranted_VBD
._.
Plaintiffs_NN
alleged_VBD [PUBV]
that_THVC
the_DT
Group_NN
knowingly_RB
obtained_VBD
invalid_JJ
patents_NN
and_CC
engaged_VBN
in_PIN
other_JJ
anticompetitive_JJ
Following_VBG
public_JJ
reference_NN
to_PIN
the_DT
FTC_NN
investigation_NOMZ
regarding_VBG [WZPRES]
Paxil_NN
,_,
conduct_NN
to_TO
prevent_VB
entry_NN
of_PIN
generic_JJ
products_NN
in_PIN
violation_NOMZ
of_PIN
the_DT
purported_JJ
class_NN
actions_NOMZ
were_VBD [PASS]
led_VBN
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
monopolization_NOMZ
section_NOMZ
of_PIN
the_DT
US_FPP1
anti-trust_JJ
laws_NN
._.
The_DT
court_NN
has_VPRT
Eastern_NN
District_NN
of_PIN
Pennsylvania_NN
on_PIN
behalf_NN
of_PIN
indirect_JJ
purchasers_NN
,_,
approved_VBD
the_DT
Groups_NN
settlement_NOMZ
of_PIN
those_DEMO
class_NN
action_NOMZ
claims_NN
._.
In_PIN
including_VBG
consumers_NN
and_CC
third_JJ
party_NN
payers_NN
,_,
and_ANDC
direct_JJ
purchasers_NN
._.
February_NN
2005_CD
the_DT
Group_NN
reached_VBD
an_DT
agreement_NOMZ
in_PIN
principle_NN
with_PIN
The_DT
plaintiffs_NN
claimed_VBD [PUBV]
that_THVC
the_DT
Group_NN
monopolized_VBD
a_DT
market_NN
for_PIN
Lek_NN
Pharmaceuticals_NN
,_,
a_DT
wholly-owned_JJ
subsidiary_NN
of_PIN
Novartis_NN
,_,
to_PIN
Paxil_NN
by_PIN
bringing_VBG
allegedly_RB
sham_JJ
patent_NN
litigation_NOMZ
and_CC
allegedly_RB
resolve_VB [SUAV] [THATD]
the_DT
anti-trust_JJ
lawsuit_NN
led_VBN [WZPAST]
by_PIN
Lek_NN
in_PIN
that_DEMO
same_JJ
District_NN
abusing_VBG [WZPRES]
the_DT
regulatory_JJ
procedures_NN
for_PIN
the_DT
listing_GER
of_PIN
patents_NN
in_PIN
the_DT
Court_NN
which_WDT [WHSUB]
sought_VBD
lost_VBN
profits_NN
,_,
treble_JJ
damages_NN
,_,
injunctive_JJ
relief_NN
FDA_NN
Orange_NN
Book_NN
._.
The_DT
court_NN
has_VPRT [PEAS]
granted_VBN [SUAV]
final_JJ
approval_NN
to_TO
and_CC
attorneys_NN
fees_NN
._.
settlement_NOMZ
with_PIN
the_DT
direct_JJ
purchaser_NN
class_NN
and_CC
preliminary_JJ
approval_NN
to_PIN
settlement_NOMZ
with_PIN
the_DT
purported_JJ
class_NN
of_PIN
indirect_JJ
purchasers_NN
._.
Canadian_JJ
importation_NOMZ
The_DT
hearing_GER
date_NN
for_PIN
final_JJ
approval_NN
for_PIN
the_DT
indirect_JJ
purchaser_NN
class_NN
The_DT
Group_NN
has_VPRT [PEAS]
been_VBN [PASS]
named_VBN
in_PIN
seven_CD
purported_JJ
class_NN
action_NOMZ
settlement_NOMZ
is_VPRT [BEMA]
9th_JJ
March_NN
2005_CD
._.
The_DT
Group_NN
has_VPRT [SPAU] [PEAS]
also_RB
reached_VBN
a_DT
final_JJ
lawsuits_NN
along_IN
with_PIN
eight_CD
other_JJ
pharmaceutical_JJ
companies_NN
._.
settlement_NOMZ
with_PIN
a_DT
group_NN
of_PIN
chain_NN
drugstores_NN
._.
In_PIN
state_NN
courts_NN
a_DT
Following_VBG
the_DT
Groups_NN
actions_NOMZ
in_PIN
2003_CD
to_TO
reduce_VB
illegal_JJ
importation_NOMZ
purported_JJ
consumer_NN
fraud_NN
class_NN
action_NOMZ
in_PIN
California_NN
remains_VPRT
at_PIN
of_PIN
prescription_NOMZ
drugs_NN
from_PIN
Canada_NN
,_,
the_DT
lawsuits_NN
an_DT
early_TIME
stage_NN
and_CC
,_,
separately_RB
,_,
both_DT
a_DT
state_NN
court_NN
class_NN
action_NOMZ
in_PIN
allege_VPRT [PUBV]
that_THVC
the_DT
companies_NN
entered_VBD
an_DT
unlawful_JJ
conspiracy_NN
to_PIN
California_NN
and_CC
a_DT
federal_JJ
class_NN
action_NOMZ
in_PIN
Florida_NN
,_,
each_QUAN
of_PIN
which_WDT [PIRE]
is_VPRT
prevent_VB
Canadian_JJ
pharmacies_NN
from_PIN
selling_VBG
their_TPP3
products_NN
to_PIN
a_DT
purported_JJ
indirect_JJ
purchaser_NN
class_NN
action_NOMZ
,_,
have_VPRT [PEAS]
been_VBN [PASS]
stayed_VBN
US_FPP1
customers_NN
._.
pending_VBG
disposition_NOMZ
of_PIN
the_DT
federal_JJ
court_NN
settlement_NOMZ
._.
A_DT
separate_JJ
The_DT
Group_NN
has_VPRT [SPAU] [PEAS]
also_RB
been_VBN [PASS]
named_VBN
as_IN
a_DT
defendant_NN
,_,
along_IN
with_PIN
action_NOMZ
by_PIN
the_DT
City_NOMZ
of_PIN
New_NN
York_NN
for_PIN
alleged_JJ
overcharges_NN
is_VPRT [BEMA]
also_RB
in_PIN
thirteen_CD
other_JJ
drug_NN
companies_NN
,_,
in_PIN
a_DT
state_NN
court_NN
action_NOMZ
in_PIN
California_NN
,_,
its_PIT
early_TIME
stages_NN
._.
in_PIN
which_WDT [PIRE]
the_DT
plaintiffs_NN
,_,
independent_JJ
pharmacies_NN
,_,
allege_VPRT [PUBV]
that_THVC
the_DT
Apotex_NN
,_,
Alphapharm_NN
,_,
BASF_NN
and_PHC
Sumika_NN
have_VPRT [PEAS]
led_VBN
anti-trust_JJ
and_CC
defendants_NN
unlawfully_RB
conspired_VBD
to_TO
keep_VB
prices_NN
artificially_RB
high_JJ
unfair_JJ
competition_NOMZ
counterclaims_NN
against_PIN
the_DT
Group_NN
based_VBN [WZPAST]
on_PIN
in_PIN
the_DT
USA_NN
to_PIN
the_DT
detriment_NOMZ
of_PIN
the_DT
plaintiffs_NN
._.
In_PIN
relation_NOMZ
to_PIN
the_DT
allegations_NOMZ
similar_JJ
to_PIN
those_DEMP
made_VBN
in_PIN
the_DT
purported_JJ
class_NN
actions_NOMZ
same_JJ
matter_NN
,_,
the_DT
Minnesota_NN
State_NN
Attorney_NN
General_NN
has_VPRT [PEAS]
led_VBN
a_DT
identied_VBN
in_PIN
the_DT
proceeding_GER
paragraph_NN
._.
While_OSUB
discovery_NN
in_PIN
the_DT
complaint_NN
alleging_VBG [PUBV] [WZPRES]
that_THVC
the_DT
Group_NN
has_VPRT [PEAS]
violated_VBN
state_NN
anti-trust_NN
Apotex_NN
matter_NN
is_VPRT [BEMA]
in_PIN
the_DT
early_TIME
stages_NN
,_,
the_DT
three_CD
other_JJ
actions_NOMZ
have_VPRT
and_CC
commercial_JJ
laws_NN
._.
All_QUAN
of_PIN
these_DEMO
actions_NOMZ
are_VPRT [BEMA]
in_PIN
their_TPP3
early_TIME
stages_NN
._.
122_CD
GlaxoSmithKline_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
30_CD
Legal_JJ
proceedings_GER
continued_VBD
31_CD
Post_NN
balance_NN
sheet_NN
event_NN
Wellbutrin_NN
SR_NN
On_PIN
10th_JJ
January_NN
2005_CD
,_,
GlaxoSmithKline_NN
announced_VBD [PUBV] [THATD]
it_PIT
had_VBD
In_PIN
December_NN
2004_CD
,_,
and_ANDC
January_NN
and_PHC
February_NN
2005_CD
,_,
lawsuits_NN
,_,
agreed_VBD [SUAV] [PUBV]
to_TO
transfer_VB
most_EMPH
of_PIN
its_PIT
European_JJ
and_PHC
International_JJ
several_QUAN
of_PIN
which_WDT [PIRE]
purported_JJ
to_TO
be_VB
class_NN
actions_NOMZ
,_,
were_VBD [PASS]
led_VBN
in_PIN
the_DT
co-promotion_NOMZ
rights_NN
for_PIN
Levitra_NN
to_PIN
Bayer_NN
for_PIN
a_DT
cash_NN
consideration_NOMZ
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
Eastern_NN
District_NN
of_PIN
Pennsylvania_NN
against_PIN
the_DT
of_PIN
148_CD
million_CD
and_CC
a_DT
reduction_NOMZ
in_PIN
the_DT
Groups_NN
commitment_NOMZ
to_PIN
Group_NN
on_PIN
behalf_NN
of_PIN
direct_JJ
and_PHC
indirect_JJ
purchasers_NN
of_PIN
Wellbutrin_NN
SR._NN
fund_NN
future_NN
research_NN
and_PHC
development_NOMZ
on_PIN
the_DT
product_NN
._.
The_DT
complaints_NN
allege_VPRT [PUBV]
violations_NOMZ
of_PIN
US_FPP1
anti-trust_JJ
laws_NN
through_PIN
sham_NN
GlaxoSmithKline_NN
retains_VPRT
co-promotion_NOMZ
or_CC
co-marketing_GER
rights_NN
litigation_NOMZ
and_PHC
fraud_NN
on_PIN
the_DT
patent_NN
ofce_NN
by_PIN
the_DT
Group_NN
in_PIN
obtaining_VBG
to_PIN
Levitra_NN
in_PIN
the_DT
USA_NN
and_CC
more_EMPH
than_PIN
20_CD
other_JJ
markets_NN
._.
and_ANDC
enforcing_VBG
patents_NN
covering_VBG [WZPRES]
Wellbutrin_NN
SR._NN
._.
The_DT
complaints_NN
follow_VPRT
the_DT
introduction_NOMZ
of_PIN
generic_JJ
competition_NOMZ
to_PIN
Wellbutrin_NN
SR_NN
in_PIN
32_CD
Related_VBN
party_NN
transactions_NOMZ
April_NN
2004_CD
after_IN
district_NN
and_CC
appellate_JJ
court_NN
rulings_GER
that_TOBJ
a_DT
generic_JJ
GlaxoSmithKline_NN
held_VBD [PRIV]
an_DT
18.6_CD
per_PIN
cent_NN
interest_NN
in_PIN
Quest_NN
manufacturer_NN
did_VBD
not_XX0
infringe_VB
the_DT
Groups_NN
patents_NN
._.
The_DT
cases_NN
are_VPRT
Diagnostics_NN
Inc._NN
at_PIN
31st_CD
December_NN
2004_CD
2003_CD
21_CD
per_PIN
cent_NN
._.
The_DT
Group_NN
and_PHC
Quest_NN
Diagnostics_NN
are_VPRT
parties_NN
to_PIN
a_DT
long-term_JJ
contractual_JJ
relationship_NN
under_IN
which_WDT
Quest_NN
Diagnostics_NN
is_VPRT [BEMA]
the_DT
Environmental_JJ
matters_NN
primary_JJ
provider_NN
of_PIN
clinical_JJ
laboratory_NN
testing_GER
to_TO
support_VB
the_DT
GlaxoSmithKline_NN
has_VPRT [PEAS]
been_VBN [PASS]
notied_VBN
of_PIN
its_PIT
potential_JJ
responsibility_NOMZ
Groups_NN
clinical_JJ
trials_NN
testing_GER
requirements_NOMZ
worldwide_VPRT
._.
During_PIN
relating_VBG
to_PIN
past_JJ
operations_NOMZ
and_CC
its_PIT
past_JJ
waste_NN
disposal_NN
practices_NN
2004_CD
,_,
Quest_NN
Diagnostics_NN
provided_VBD
services_NN
of_PIN
35_CD
million_CD
at_PIN
certain_JJ
sites_NN
,_,
primarily_RB
in_PIN
the_DT
USA_NN
._.
Some_QUAN
of_PIN
these_DEMO
matters_NN
are_VPRT [BEMA]
2003_CD
31_CD
million_CD
to_PIN
the_DT
Group_NN
._.
the_DT
subject_NN
of_PIN
litigation_NOMZ
,_,
including_VBG
proceedings_GER
initiated_VBN [WZPAST]
by_PIN
the_DT
US_FPP1
federal_JJ
or_CC
state_NN
governments_NOMZ
for_PIN
waste_NN
disposal_NN
site_NN
In_PIN
2004_CD
,_,
both_CC
the_DT
Group_NN
and_PHC
Shionogi_NN
&_CC
Co._NN
._.
Ltd._NN
entered_VBD
into_PIN
remediation_NOMZ
costs_NN
and_PHC
tort_NN
actions_NOMZ
brought_VBN [WZPAST]
by_PIN
private_JJ
parties_NN
._.
transactions_NOMZ
with_PIN
their_TPP3
50_CD
50_CD
US_FPP1
joint_JJ
venture_NN
company_NN
in_PIN
support_NN
of_PIN
the_DT
research_NN
and_PHC
development_NOMZ
activities_NOMZ
conducted_VBN [WZPAST]
by_PIN
that_DEMO
GlaxoSmithKline_NN
has_VPRT [PEAS]
been_VBN [PASS]
advised_VBN
that_DEMO
it_PIT
may_POMD
be_VB [BEMA]
a_DT
responsible_JJ
joint_JJ
venture_NN
company_NN
._.
During_PIN
2004_CD
,_,
GlaxoSmithKline_NN
provided_VBD
party_NN
at_PIN
approximately_RB
27_CD
sites_NN
,_,
of_PIN
which_WDT [PIRE]
14_CD
appear_VPRT [SMP]
on_PIN
the_DT
services_NN
to_PIN
the_DT
joint_JJ
venture_NN
of_PIN
1_CD
million_CD
2003_CD
1_CD
million_CD
._.
National_NN
Priority_NOMZ
List_NN
created_VBN [WZPAST]
by_PIN
the_DT
Comprehensive_NN
Environmental_NN
At_PIN
31st_CD
December_NN
2004_CD
the_DT
balance_NN
due_JJ
to_PIN
GlaxoSmithKline_NN
Response_NN
Compensation_NOMZ
and_PHC
Liability_NOMZ
Act_NN
Superfund_NN
._.
from_PIN
the_DT
joint_JJ
venture_NN
was_VBD [BEMA]
2_CD
million_CD
2003_CD
3_CD
million_CD
._.
These_DEMO
proceedings_GER
seek_VPRT
to_TO
require_VB [SUAV]
the_DT
operators_NN
of_PIN
hazardous_JJ
Dr_NN
Shapiro_NN
,_,
a_DT
Non-Executive_JJ
Director_NN
of_PIN
GlaxoSmithKline_NN
plc_NN
,_,
waste_NN
facilities_NOMZ
,_,
transporters_NN
of_PIN
waste_NN
to_PIN
the_DT
sites_NN
and_PHC
generators_NN
received_VBD
fees_NN
of_PIN
$_$
85,000_CD
2003_CD
$_$
85,000_CD
of_PIN
which_WDT [PIRE]
$_$
30,000_CD
of_PIN
hazardous_JJ
waste_NN
disposed_VBD
of_PIN
at_PIN
the_DT
sites_NN
to_TO
clean_VB
up_RP
the_DT
sites_NN
2003_CD
$_$
30,000_CD
was_VBD [BEMA]
in_PIN
the_DT
form_NN
of_PIN
ADSs_NN
,_,
from_PIN
a_DT
subsidiary_NN
of_PIN
or_CC
to_TO
reimburse_VB
the_DT
government_NOMZ
for_PIN
cleanup_NN
costs_NN
._.
In_PIN
most_EMPH
the_DT
company_NN
,_,
for_PIN
the_DT
membership_NN
on_PIN
the_DT
Groups_NN
scientific_JJ
instances_NN
,_,
GlaxoSmithKline_NN
is_VPRT [PASS]
involved_VBN
as_IN
an_DT
alleged_JJ
generator_NN
Advisory_NN
Board_NN
._.
These_DEMP
are_VPRT [PASS]
included_VBN
within_PIN
Annual_JJ
remuneration_NOMZ
of_PIN
hazardous_JJ
waste_NN
although_CONC
there_EX
are_VPRT
a_DT
few_QUAN
sites_NN
where_RB
in_PIN
the_DT
Remuneration_NOMZ
Report_NN
on_PIN
pages_NN
43_CD
to_PIN
58_CD
._.
GlaxoSmithKline_NN
is_VPRT [PASS]
involved_VBN
as_IN
a_DT
current_JJ
or_CC
former_JJ
operator_NN
of_PIN
the_DT
facility_NOMZ
._.
Although_CONC
Superfund_NN
provides_VPRT
that_DEMO
the_DT
defendants_NN
Dr_NN
Barzach_NN
,_,
a_DT
former_JJ
Non-Executive_NN
Director_NN
of_PIN
GlaxoSmithKline_NN
are_VPRT
jointly_RB
and_PHC
severally_RB
liable_JJ
for_PIN
cleanup_NN
costs_NN
,_,
these_DEMO
proceedings_GER
plc_NN
,_,
received_VBD
fees_NN
of_PIN
83,005_CD
2003_CD
72,268_CD
from_PIN
a_DT
subsidiary_NN
are_VPRT [SPAU] [PASS]
frequently_RB
resolved_VBN [SUAV]
on_PIN
the_DT
basis_NN
of_PIN
the_DT
nature_NN
and_PHC
quantity_NOMZ
of_PIN
of_PIN
the_DT
company_NN
for_PIN
healthcare_NN
consultancy_NN
provided_VBN
._.
These_DEMP
are_VPRT [PASS]
waste_NN
disposed_VBD
of_PIN
at_PIN
the_DT
site_NN
by_PIN
the_DT
generator_NN
._.
GlaxoSmithKlines_NN
included_VBD
within_PIN
Annual_JJ
remuneration_NOMZ
in_PIN
the_DT
Remuneration_NOMZ
proportionate_NN
liability_NOMZ
for_PIN
cleanup_NN
costs_NN
has_VPRT [PEAS]
been_VBN
substantially_RB
Report_NN
._.
determined_VBN [SUAV] [PRIV] [PASTP]
for_PIN
about_RB
20_CD
of_PIN
the_DT
sites_NN
referred_VBD
to_PIN
above_PLACE
._.
GlaxoSmithKlines_NN
potential_JJ
liability_NOMZ
varies_VPRT
greatly_AMP
from_PIN
site_NN
to_PIN
site_NN
._.
While_OSUB
the_DT
cost_NN
of_PIN
investigation_NOMZ
,_,
study_NN
and_PHC
remediation_NOMZ
at_PIN
such_JJ
sites_NN
could_POMD
,_,
over_IN
time_NN
,_,
be_VB [BEMA]
substantial_PRED
,_,
GlaxoSmithKline_NN
routinely_RB
accrues_VPRT
amounts_NN
related_VBN [WZPAST]
to_PIN
its_PIT
share_NN
of_PIN
liability_NOMZ
for_PIN
such_JJ
matters_NN
._.
Tax_NN
matters_VPRT
Pending_GER
tax_NN
matters_NN
are_VPRT [PASS]
described_VBN
in_PIN
Note_NN
12_CD
._.
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
GlaxoSmithKline_NN
123_CD
33_CD
Acquisitions_NOMZ
and_PHC
disposals_NN
Details_NN
of_PIN
the_DT
acquisition_NOMZ
and_PHC
disposal_NN
of_PIN
subsidiary_NN
and_CC
associated_VBN
undertakings_GER
,_,
joint_JJ
ventures_NN
and_CC
other_JJ
businesses_NOMZ
are_VPRT [PASS]
given_VBN
below_PLACE
:_:
2004_CD
Book_NN
Fair_NN
value_NN
Net_JJ
assets_NN
Goodwill_NN
Cost_NN
of_PIN
values_NN
adjustments_NOMZ
acquired_VBD
capitalized_JJ
acquisition_NOMZ
Acquisitions_NOMZ
m_VPRT
m_FW
m_FW
m_FW
m_FW
Fraxiparine_NN
,_,
Fraxodi_NN
and_PHC
Arixtra_NN
135 162 297 297_CD
Fraxiparine_NN
,_,
Fraxodi_NN
and_PHC
Arixtra_NN
In_PIN
September_NN
2004_CD
,_,
for_PIN
a_DT
cash_NN
consideration_NOMZ
of_PIN
297_CD
million_CD
the_DT
Group_NN
acquired_VBD
Fraxiparine_NN
,_,
Fraxodi_NN
and_PHC
Arixtra_NN
and_CC
related_JJ
assets_NN
including_VBG [WZPRES]
a_DT
manufacturing_GER
facility_NOMZ
._.
Euclid_NN
SR_NN
Partners_NN
,_,
LP_NN
During_PIN
the_DT
year_NN
an_DT
additional_JJ
2_CD
million_CD
was_VBD [PASS]
invested_VBN
in_PIN
Euclid_NN
SR_NN
Partners_NN
,_,
LP_NN
,_,
an_DT
associate_JJ
company_NN
in_PIN
which_WDT [PIRE]
the_DT
Group_NN
has_VPRT
a_DT
38.7_CD
per_PIN
cent_NN
interest_NN
._.
Disposals_NN
Quest_NN
Diagnostics_NN
Inc._NN
._.
During_PIN
2004_CD
,_,
the_DT
Group_NN
disposed_VBD
of_PIN
3.8_CD
million_CD
shares_NN
from_PIN
its_PIT
investment_NOMZ
in_PIN
Quest_NN
Diagnostics_NN
Inc._NN
for_PIN
cash_NN
proceeds_NN
of_PIN
188_CD
million_CD
,_,
reducing_VBG [PRESP]
the_DT
Groups_NN
shareholding_GER
at_PIN
31st_CD
December_NN
2004_CD
to_PIN
18.6_CD
per_PIN
cent_NN
._.
After_IN
recognizing_VBG [PRIV]
a_DT
charge_NN
for_PIN
goodwill_NN
previously_TIME
written_VBN [PUBV]
off_PIN
to_PIN
reserves_NN
of_PIN
17_CD
million_CD
a_DT
profit_NN
of_PIN
139_CD
million_CD
was_VBD [PASS]
recognized_VBN [PRIV]
._.
GlaxoSmithKline_NN
Vehicle_NN
Finance_NN
Ltd_NN
During_PIN
2004_CD
,_,
the_DT
Group_NN
disposed_VBD
of_PIN
its_PIT
employee_NN
vehicle_NN
nancing_VBG [WZPRES]
subsidiary_NN
resulting_VBG [WZPRES]
in_PIN
a_DT
loss_NN
of_PIN
3_CD
million_CD
._.
GlaxoSmithKline_NN
Pharmaceuticals_NN
Chongqing_GER
Ltd_NN
During_PIN
2004_CD
,_,
the_DT
Group_NN
disposed_VBD
of_PIN
GlaxoSmithKline_NN
Pharmaceuticals_NN
Chongqing_GER
Ltd_NN
,_,
a_DT
Group_NN
subsidiary_NN
located_VBN [WZPAST]
in_PIN
China_NN
,_,
for_PIN
7_CD
million_CD
._.
A_DT
profit_NN
on_PIN
disposal_NN
of_PIN
1_CD
million_CD
was_VBD [PASS]
realized_VBN [PRIV]
,_,
after_IN
recognizing_VBG [PRIV]
a_DT
charge_NN
for_PIN
goodwill_NN
previously_TIME
written_VBN [PUBV]
off_PIN
to_PIN
reserves_NN
of_PIN
3_CD
million_CD
._.
Beeyar_NN
Investments_NOMZ
Pty_NN
Ltd_NN
In_PIN
July_NN
2004_CD
,_,
the_DT
Group_NN
disposed_VBD
of_PIN
Beeyar_NN
Investments_NOMZ
Pty_NN
Ltd_NN
,_,
a_DT
subsidiary_NN
located_VBN [WZPAST]
in_PIN
South_NN
Africa_NN
,_,
for_PIN
cash_NN
proceeds_NN
of_PIN
1_CD
million_CD
,_,
realizing_VBG [PRIV] [PRESP]
a_DT
profit_NN
of_PIN
1_CD
million_CD
._.
OptiLead_NN
S._NN
r._NN
l._VBD
During_PIN
the_DT
year_NN
,_,
part_NN
of_PIN
the_DT
Groups_NN
holding_VBG [PRIV] [WZPRES]
in_PIN
an_DT
associated_VBN
undertaking_GER
,_,
OptiLead_NN
S._NN
r._NN
l._NN
was_VBD [PASS]
sold_VBN
,_,
resulting_VBG [PRESP]
in_PIN
a_DT
loss_NN
of_PIN
1_CD
million_CD
._.
Fraxiparine_NN
GSK_NN
GSK_NN
Fraxodi_NN
Quest_NN
Vehicle_NN
Pharmaceuticals_NN
Beeyar_NN
and_PHC
Arixtra_NN
Euclid_NN
SR_NN
Diagnostics_NN
Finance_NN
Chongqing_GER
Investments_NOMZ
Total_NN
Cash_NN
ows_VPRT
m_FW
m_FW
m_FW
m_FW
m_FW
m_FW
m_FW
Cash_NN
consideration_NOMZ
paid_VBD
297_CD
2_CD
299_CD
Net_JJ
cash_NN
proceeds_NN
from_PIN
disposals_NN
188_CD
34_CD
7_CD
1_CD
230_CD
2003_CD
Book_NN
Fair_NN
value_NN
Net_JJ
assets_NN
Goodwill_NN
Cost_NN
of_PIN
values_NN
adjustments_NOMZ
acquired_VBD
capitalized_JJ
acquisition_NOMZ
Acquisitions_NOMZ
m_VPRT
m_FW
m_FW
m_FW
m_FW
Europharm_FW
1_CD
123_CD
Europharm_NN
During_PIN
2003_CD
,_,
the_DT
Group_NN
completed_VBD
the_DT
buyout_NN
of_PIN
the_DT
minority_NOMZ
interests_NN
in_PIN
Europharm_NN
Holdings_GER
SA_NN
,_,
a_DT
Group_NN
subsidiary_NN
located_VBN [WZPAST]
in_PIN
Romania_NN
,_,
for_PIN
3_CD
million_CD
,_,
giving_VBG
rise_NN
to_PIN
goodwill_NN
of_PIN
a_DT
further_RB
2_CD
million_CD
,_,
which_WDT [SERE]
has_VPRT [PEAS]
been_VBN [PASS]
capitalized_VBN
._.
Iter_SYM
-_:
Sterilyo_NN
During_PIN
2003_CD
,_,
a_DT
further_JJ
payment_NOMZ
of_PIN
9_CD
million_CD
was_VBD [PASS]
made_VBN
pursuant_JJ
to_PIN
the_DT
2002_CD
acquisition_NOMZ
agreement_NOMZ
based_VBN [WZPAST]
on_PIN
the_DT
financial_JJ
performance_NN
of_PIN
the_DT
acquired_VBN
company_NN
._.
This_DEMO
amount_NN
has_VPRT [PEAS]
been_VBN [PASS]
included_VBN
as_IN
deferred_VBN
compensation_NOMZ
in_PIN
2002_CD
._.
124_CD
GlaxoSmithKline_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
33_CD
Acquisitions_NOMZ
and_PHC
disposals_NN
continued_VBD
Disposals_NN
SB_NN
Clinical_NN
Laboratories_NN
An_DT
additional_JJ
cash_NN
refund_NN
of_PIN
3_CD
million_CD
was_VBD [PASS]
received_VBN
during_PIN
2003_CD
in_PIN
respect_NN
of_PIN
indemnified_JJ
liabilities_NOMZ
arising_VBG [WZPRES]
from_PIN
the_DT
SB_NN
Clinical_NN
Laboratories_NN
disposal_NN
which_WDT [WHSUB]
occurred_VBD
in_PIN
1999_CD
._.
This_DEMO
refund_NN
follows_VPRT
the_DT
successful_JJ
outcome_NN
of_PIN
a_DT
case_NN
in_PIN
the_DT
US_FPP1
Court_NN
of_PIN
Appeal_NN
._.
IterSB_NN
Clinical_NN
Sterilyo_NN
Europharm_NN
Laboratories_NN
Other_JJ
Total_NN
Cash_NN
ows_VPRT
m_FW
m_FW
m_FW
m_FW
m_FW
Cash_NN
consideration_NOMZ
paid_VBD
9_CD
3_CD
3_CD
15_CD
Net_JJ
cash_NN
proceeds_NN
from_PIN
disposals_NN
3_CD
3_CD
2002_CD
Book_NN
Fair_NN
value_NN
Net_JJ
assets_NN
Goodwill_NN
Cost_NN
of_PIN
values_NN
adjustments_NOMZ
acquired_VBD
capitalized_JJ
acquisition_NOMZ
Acquisitions_NOMZ
m_VPRT
m_FW
m_FW
m_FW
m_FW
Iter_NN
Sterilyo_NN
7_CD
4_CD
3_CD
21_CD
18_CD
Human_NN
Kft_NN
10_CD
10_CD
1_CD
11_CD
Other_JJ
11_CD
3_CD
4_CD
7_CD
23_CD
30_CD
Iter_NN
Sterilyo_NN
During_PIN
2002_CD
,_,
the_DT
Group_NN
acquired_VBD
Iter-Sterilyo_NN
Group_NN
for_PIN
an_DT
initial_JJ
cash_NN
consideration_NOMZ
of_PIN
9_CD
million_CD
._.
A_DT
further_JJ
payment_NOMZ
was_VBD [PASS]
paid_VBN
during_PIN
2003_CD
,_,
of_PIN
9_CD
million_CD
,_,
which_WDT [SERE]
was_VBD [PASS]
based_VBN
on_PIN
the_DT
financial_JJ
performance_NN
of_PIN
the_DT
acquired_VBN
company_NN
during_PIN
2002_CD
._.
The_DT
net_JJ
assets_NN
of_PIN
Iter-Sterilyo_NN
have_VPRT [PEAS]
been_VBN [PASS]
incorporated_VBN
in_PIN
the_DT
financial_JJ
statements_NOMZ
at_PIN
their_TPP3
provisional_JJ
fair_JJ
values_NN
._.
No_SYNE
adjustments_NOMZ
were_VBD [PASS]
made_VBN
to_PIN
these_DEMO
values_NN
in_PIN
2003_CD
._.
Human_JJ
Kft_NN
During_PIN
2002_CD
,_,
the_DT
Group_NN
acquired_VBD
the_DT
vaccine_NN
related_VBN
assets_NN
of_PIN
Human_JJ
Kft_NN
,_,
a_DT
manufacturing_GER
business_NOMZ
located_VBN [WZPAST]
in_PIN
Hungary_NN
,_,
for_PIN
a_DT
cash_NN
consideration_NOMZ
of_PIN
11_CD
million_CD
._.
Disposals_NN
SB_NN
Clinical_NN
Laboratories_NN
A_DT
cash_NN
refund_NN
of_PIN
6_CD
million_CD
was_VBD [PASS]
received_VBN
during_PIN
2002_CD
in_PIN
respect_NN
of_PIN
indemnified_JJ
liabilities_NOMZ
arising_VBG [WZPRES]
from_PIN
the_DT
SB_NN
Clinical_NN
Laboratories_NN
disposal_NN
which_WDT [WHSUB]
occurred_VBD
in_PIN
1999_CD
._.
The_DT
refund_NN
follows_VPRT
the_DT
successful_JJ
outcome_NN
of_PIN
a_DT
case_NN
in_PIN
the_DT
US_FPP1
Court_NN
of_PIN
Appeal_NN
._.
SB_NN
Clinical_NN
Iter_NN
-_:
Human_JJ
Laboratories_NN
Sterilyo_NN
Kft_NN
Other_JJ
Total_NN
Cash_NN
ows_VPRT
m_FW
m_FW
m_FW
m_FW
m_FW
Cash_NN
consideration_NOMZ
paid_VBD
9_CD
11_CD
6_CD
26_CD
Net_JJ
cash_NN
proceeds_NN
from_PIN
disposals_NN
6_CD
6_CD
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
GlaxoSmithKline_NN
125_CD
34_CD
Financial_NN
instruments_NOMZ
and_CC
related_VBN
disclosures_NN
The_DT
Group_NN
applies_VPRT
Board-approved_JJ
limits_NN
to_PIN
the_DT
amount_NN
of_PIN
credit_NN
exposure_NN
to_PIN
any_QUAN
one_CD
counterparty_NN
and_CC
employs_VPRT
strict_JJ
minimum_NN
Policies_NN
credit_NN
worthiness_NOMZ
criteria_NN
as_IN
to_PIN
the_DT
choice_NN
of_PIN
counterparty_NN
._.
Discussion_NN
of_PIN
the_DT
Groups_NN
objectives_NN
and_PHC
policies_NN
for_PIN
the_DT
management_NOMZ
of_PIN
financial_JJ
instruments_NOMZ
and_CC
associated_VBN
risks_NN
is_VPRT
Fair_NN
value_NN
of_PIN
financial_JJ
assets_NN
and_PHC
liabilities_NOMZ
included_VBN
under_IN
Treasury_NN
Policies_NN
in_PIN
the_DT
Operating_GER
and_CC
financial_JJ
The_DT
table_NN
on_PIN
page_NN
126_CD
presents_VPRT
the_DT
carrying_VBG
amounts_NN
under_IN
review_NN
and_PHC
prospects_NN
on_PIN
pages_NN
74_CD
to_PIN
75_CD
._.
UK_NN
GAAP_NN
and_CC
the_DT
fair_JJ
values_NN
of_PIN
the_DT
Groups_NN
financial_JJ
assets_NN
and_PHC
liabilities_NOMZ
at_PIN
31st_CD
December_NN
2004_CD
and_CC
31st_CD
December_NN
2003_CD
._.
Investments_NOMZ
Debtors_NN
and_PHC
creditors_NN
due_JJ
within_PIN
one_CD
year_NN
have_VPRT [PEAS]
been_VBN [PASS]
excluded_VBN
._.
The_DT
Group_NN
holds_VPRT [PRIV]
a_DT
number_NN
of_PIN
equity_NOMZ
investments_NOMZ
,_,
frequently_RB
in_PIN
entities_NOMZ
where_RB
the_DT
Group_NN
has_VPRT [PEAS]
entered_VBN
into_PIN
research_NN
collaborations_NOMZ
._.
The_DT
fair_JJ
values_NN
of_PIN
the_DT
financial_JJ
assets_NN
and_PHC
liabilities_NOMZ
are_VPRT [PASS]
included_VBN
The_DT
Group_NN
seeks_VPRT
to_TO
realize_VB [PRIV]
the_DT
value_NN
in_PIN
these_DEMO
investments_NOMZ
,_,
which_WDT [SERE]
at_PIN
the_DT
amount_NN
at_PIN
which_WDT [PIRE]
the_DT
instrument_NOMZ
could_POMD
be_VB [PASS]
exchanged_VBN
in_PIN
a_DT
in_PIN
part_NN
the_DT
research_NN
collaboration_NOMZ
helps_VPRT
to_TO
create_VB
,_,
and_ANDC
therefore_CONJ
current_JJ
transaction_NOMZ
between_PIN
willing_JJ
parties_NN
,_,
other_JJ
than_PIN
in_PIN
a_DT
forced_JJ
certain_JJ
of_PIN
these_DEMO
investments_NOMZ
are_VPRT [PASS]
regarded_VBN
as_IN
available_JJ
for_PIN
sale_NN
and_CC
or_CC
liquidation_NOMZ
sale_NN
._.
The_DT
following_VBG
methods_NN
and_PHC
assumptions_NOMZ
were_VBD
are_VPRT [PASS]
accounted_VBN
for_PIN
as_IN
current_JJ
asset_NN
investments_NOMZ
._.
For_PIN
the_DT
purposes_NN
used_VBN
to_TO
estimate_VB [PRIV]
the_DT
fair_JJ
values_NN
:_:
of_PIN
US_FPP1
GAAP_NN
all_QUAN
the_DT
current_JJ
asset_NN
investments_NOMZ
are_VPRT [PASS]
classied_VBN
as_IN
Equity_NOMZ
investments_NOMZ
market_NN
value_NN
based_VBN [WZPAST]
on_PIN
quoted_VBN
market_NN
available_JJ
for_PIN
sale_NN
._.
prices_NN
in_PIN
the_DT
case_NN
of_PIN
listed_VBN
investments_NOMZ
:_:
market_NN
value_NN
by_PIN
In_PIN
2002_CD
,_,
GlaxoSmithKline_NN
hedged_VBD
part_NN
of_PIN
the_DT
equity_NOMZ
value_NN
of_PIN
its_PIT
reference_NN
to_TO
quoted_VBN
prices_NN
for_PIN
similar_JJ
companies_NN
or_CC
recent_JJ
holdings_GER
in_PIN
its_PIT
largest_JJ
equity_NOMZ
investment_NOMZ
,_,
Quest_NN
Diagnostics_NN
Inc._NN
nancing_VBG [WZPRES]
information_NOMZ
in_PIN
the_DT
case_NN
of_PIN
material_NN
unlisted_JJ
through_PIN
a_DT
series_NN
of_PIN
variable_JJ
sale_NN
forward_RB
contracts_NN
._.
These_DEMO
contracts_NN
investments_NOMZ
the_DT
equity_NOMZ
collar_NN
are_VPRT [PASS]
structured_VBN
in_PIN
five_CD
series_NN
,_,
each_QUAN
over_IN
one_CD
Cash_NN
at_PIN
bank_NN
approximates_VPRT
to_PIN
the_DT
carrying_VBG
amount_NN
million_CD
Quest_NN
shares_NN
,_,
and_ANDC
mature_VPRT
between_PIN
2006_CD
and_CC
2008_CD
._.
Liquid_NN
investments_NOMZ
based_VBN [WZPAST]
on_PIN
quoted_VBN
market_NN
prices_NN
for_PIN
similar_JJ
companies_NN
or_CC
recent_JJ
nancing_GER
information_NOMZ
in_PIN
the_DT
case_NN
of_PIN
The_DT
Group_NN
has_VPRT
liquid_JJ
investments_NOMZ
,_,
representing_VBG
funds_NN
surplus_NN
to_PIN
marketable_JJ
securities_NOMZ
:_:
approximates_VPRT
to_PIN
the_DT
carrying_VBG
amount_NN
immediate_JJ
operating_GER
requirements_NOMZ
,_,
which_WDT [SERE]
are_VPRT [PASS]
accounted_VBN
for_PIN
as_RB
in_PIN
the_DT
case_NN
of_PIN
time_NN
deposits_NN
because_CAUS
of_PIN
their_TPP3
short_JJ
maturity_NOMZ
current_JJ
asset_NN
investments_NOMZ
._.
For_PIN
the_DT
purposes_NN
of_PIN
US_FPP1
GAAP_NN
the_DT
Short-term_JJ
loans_NN
and_PHC
overdrafts_NN
approximates_VPRT
to_PIN
the_DT
carrying_VBG
investments_NOMZ
are_VPRT [PASS]
classied_VBN
as_IN
available_JJ
for_PIN
sale_NN
._.
The_DT
proceeds_NN
from_PIN
amount_NN
because_CAUS
of_PIN
the_DT
short_JJ
maturity_NOMZ
of_PIN
these_DEMO
instruments_NOMZ
sale_NN
of_PIN
investments_NOMZ
classied_VBD
as_IN
available_JJ
for_PIN
sale_NN
under_IN
US_FPP1
GAAP_NN
Medium-term_JJ
loans_NN
market_NN
value_NN
based_VBN [WZPAST]
on_PIN
quoted_VBN
market_NN
were_VBD [BEMA]
15,048_CD
million_CD
in_PIN
the_DT
year_NN
ended_VBD
31st_CD
December_NN
2004_CD
._.
prices_NN
in_PIN
the_DT
case_NN
of_PIN
the_DT
Eurobonds_NN
and_CC
other_JJ
xed_JJ
rate_NN
The_DT
proceeds_NN
include_VPRT
the_DT
roll-over_NN
of_PIN
liquid_JJ
funds_NN
on_PIN
short-term_JJ
borrowings_GER
:_:
approximates_VPRT
to_PIN
the_DT
carrying_VBG
amount_NN
in_PIN
the_DT
case_NN
deposit_NN
._.
Under_IN
US_FPP1
GAAP_NN
the_DT
gross_JJ
gains_NN
and_PHC
losses_NN
reected_VBD
in_PIN
of_PIN
oating_NN
rate_NN
bank_NN
loans_NN
and_CC
other_JJ
loans_NN
the_DT
consolidated_JJ
profit_NN
and_PHC
loss_NN
account_NN
in_PIN
respect_NN
of_PIN
investments_NOMZ
Forward_RB
exchange_NN
contracts_NN
based_VBN [WZPAST]
on_PIN
market_NN
prices_NN
and_CC
classied_VBD
as_IN
available_JJ
for_PIN
sale_NN
were_VBD [BEMA]
34_CD
million_CD
and_CC
2_CD
million_CD
,_,
exchange_NN
rates_NN
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
respectively_RB
._.
Currency_NN
swaps_NN
based_VBN [WZPAST]
on_PIN
market_NN
valuations_NOMZ
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
Foreign_JJ
exchange_NN
risk_NN
management_NOMZ
Equity_NOMZ
collar_NN
fair_JJ
value_NN
is_VPRT [PASS]
determined_VBN [SUAV] [PRIV]
based_VBN
on_PIN
an_DT
option_NOMZ
The_DT
Group_NN
has_VPRT [PEAS]
entered_VBN
into_PIN
forward_RB
foreign_JJ
exchange_NN
contracts_NN
pricing_VBG [WZPRES]
model_NN
in_PIN
order_NN
to_TO
swap_VB
liquid_JJ
assets_NN
and_PHC
borrowings_GER
into_PIN
the_DT
currencies_NN
Interest_NN
rate_NN
instruments_NOMZ
fair_JJ
value_NN
is_VPRT [PASS]
determined_VBN [SUAV] [PRIV]
using_VBG
the_DT
net_NN
required_VBN [SUAV] [WZPAST]
for_PIN
Group_NN
purposes_NN
._.
At_PIN
31st_CD
December_NN
2004_CD
the_DT
Group_NN
present_JJ
value_NN
of_PIN
discounted_JJ
cash_NN
ows_NN
had_VBD
outstanding_JJ
contracts_NN
to_TO
sell_VB
or_CC
purchase_VB
foreign_JJ
currency_NN
Debtors_NN
and_PHC
creditors_NN
approximates_VPRT
to_PIN
the_DT
carrying_VBG
amount_NN
having_VBG [WZPRES]
a_DT
total_JJ
notional_JJ
principal_NN
amount_NN
of_PIN
11,137_CD
million_CD
Provisions_NN
approximates_VPRT
to_PIN
the_DT
carrying_VBG
amount_NN
2003_CD
8,544_CD
million_CD
._.
The_DT
majority_NOMZ
of_PIN
contracts_NN
are_VPRT [BEMA]
for_PIN
periods_NN
Auction_NOMZ
rate_NN
preference_NN
stock_NN
approximates_VPRT
to_PIN
the_DT
carrying_GER
of_PIN
12_CD
months_NN
or_CC
less_JJ
._.
amount_NN
in_PIN
the_DT
case_NN
of_PIN
oating_NN
rate_NN
instruments_NOMZ
At_PIN
the_DT
end_NN
of_PIN
2004_CD
,_,
the_DT
Group_NN
had_VBD
a_DT
number_NN
of_PIN
currency_NN
swaps_NN
Flexible_JJ
auction_NOMZ
market_NN
preferred_VBN [SUAV] [THATD]
stock_NN
based_VBN [WZPAST]
on_PIN
market_NN
in_PIN
place_NN
in_PIN
respect_NN
of_PIN
medium-term_JJ
debt_NN
instruments_NOMZ
._.
Borrowings_GER
valuations_NOMZ
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
._.
denominated_VBN [PASTP]
in_PIN [STPR]
,_,
or_CC
swapped_VBD
into_PIN [STPR]
,_,
foreign_JJ
currencies_NN
which_WDT [WHSUB]
match_VPRT
investments_NOMZ
in_PIN
overseas_PLACE
Group_NN
assets_NN
are_VPRT [PASS]
treated_VBN
as_IN
a_DT
hedge_NN
Fair_NN
value_NN
of_PIN
investments_NOMZ
in_PIN
own_JJ
shares_NN
against_PIN
the_DT
relevant_JJ
net_JJ
assets_NN
and_PHC
exchange_NN
gains_NN
or_CC
losses_NN
are_VPRT [BEMA]
The_DT
Group_NN
had_VBD
at_PIN
31st_CD
December_NN
2004_CD
investments_NOMZ
in_PIN
own_JJ
recorded_VBN
in_PIN
reserves_NN
._.
shares_NN
of_PIN
2,574_CD
million_CD
2003_CD
2,729_CD
million_CD
with_PIN
a_DT
fair_JJ
value_NN
of_PIN
2,123_CD
million_CD
2003_CD
2,276_CD
million_CD
based_VBN
on_PIN
quoted_VBN
Interest_NN
rate_NN
risk_NN
management_NOMZ
market_NN
price_NN
._.
The_DT
shares_NN
represent_VPRT
purchases_NN
by_PIN
the_DT
ESOP_NN
Trusts_NN
To_TO
manage_VB
the_DT
xed_VBN
oating_NN
interest_NN
rate_NN
prole_NN
of_PIN
debt_NN
,_,
the_DT
to_TO
satisfy_VB
future_JJ
exercises_NN
of_PIN
options_NOMZ
and_PHC
awards_NN
under_IN
employee_NN
Group_NN
had_VBD
several_QUAN
interest_NN
rate_NN
swaps_NN
outstanding_JJ
with_PIN
incentive_NN
schemes_NN
._.
They_TPP3
are_VPRT [PASS]
excluded_VBN
from_PIN
financial_JJ
instrument_NOMZ
commercial_JJ
banks_NN
at_PIN
31st_CD
December_NN
2004_CD
._.
disclosure_NN
._.
Concentrations_NOMZ
of_PIN
credit_NN
risk_NN
and_PHC
credit_NN
exposures_NN
of_PIN
financial_JJ
instruments_NOMZ
The_DT
Group_NN
does_VPRT
not_XX0
believe_VB [PRIV] [THATD]
it_PIT
is_VPRT [PASS]
exposed_VBN
to_PIN
major_JJ
concentrations_NOMZ
of_PIN
credit_NN
risk_NN
on_PIN
its_PIT
financial_JJ
instruments_NOMZ
._.
The_DT
Group_NN
is_VPRT [PASS]
exposed_VBN
to_PIN
credit-related_JJ
losses_NN
in_PIN
the_DT
event_NN
of_PIN
non-performance_JJ
by_PIN
counterparties_NN
to_PIN
financial_JJ
instruments_NOMZ
,_,
but_CC
does_VPRT
not_XX0
expect_VB [PRIV]
any_QUAN
counterparties_NN
to_TO
fail_VB
to_TO
meet_VB
their_TPP3
obligations_NOMZ
._.
126_CD
GlaxoSmithKline_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
34_CD
Financial_NN
instruments_NOMZ
and_CC
related_VBN
disclosures_NN
continued_VBD
Classication_NOMZ
and_CC
fair_JJ
values_NN
of_PIN
financial_JJ
assets_NN
and_PHC
liabilities_NOMZ
The_DT
following_JJ
table_NN
sets_VPRT
out_PIN
the_DT
classication_NOMZ
of_PIN
financial_JJ
assets_NN
and_PHC
liabilities_NOMZ
and_CC
provides_VPRT
a_DT
reconciliation_NOMZ
to_PIN
Group_NN
net_JJ
debt_NN
in_PIN
Note_NN
25_CD
._.
Short-term_JJ
debtors_NN
and_PHC
creditors_NN
have_VPRT [PEAS]
been_VBN [PASS]
excluded_VBN
from_PIN
financial_JJ
assets_NN
and_PHC
liabilities_NOMZ
._.
Provisions_NN
have_VPRT [PEAS]
been_VBN [PASS]
included_VBN
where_RB
there_EX
is_VPRT
a_DT
contractual_JJ
obligation_NOMZ
to_TO
settle_VB
in_PIN
cash_NN
._.
2004_CD
2003_CD
Carrying_VBG
Fair_NN
Carrying_VBG [WZPRES]
Fair_NN
amount_NN
value_NN
amount_NN
value_NN
mm_NN
mm_NN
Net_JJ
debt_NN
Liquid_NN
investments_NOMZ
2,818_CD
2,820_CD
2,493_CD
2,509_CD
Cash_NN
at_PIN
bank_NN
1,161_CD
1,161_CD
962_CD
962_CD
Current_JJ
asset_NN
financial_JJ
instruments_NOMZ
3,979_CD
3,981_CD
3,455_CD
3,471_CD
Sterling_GER
notes_NN
and_PHC
bonds_NN
1,475_CD
1,533_CD
1,474_CD
1,552_CD
1,475_CD
1,533_CD
1,474_CD
1,552_CD
US_FPP1
dollar_NN
notes_NN
,_,
bonds_NN
and_CC
private_JJ
nancing_GER
1,828_CD
1,817_CD
866_CD
893_CD
Notes_NN
and_PHC
bonds_NN
swapped_VBD
into_PIN
US_FPP1
dollars_NN
498 497 498 499_CD
Currency_NN
swaps_NN
92_CD
59_CD
Interest_NN
rate_NN
swaps_NN
28_CD
2_CD
2,326_CD
2,250_CD
1,364_CD
1,335_CD
Notes_NN
and_PHC
bonds_NN
swapped_VBD
into_PIN
Yen_NN
348 338 463 457_CD
Currency_NN
swaps_NN
10_CD
3_CD
348 328 463 454_CD
Euro_NN
notes_NN
and_PHC
bonds_NN
705 717 699 700_CD
Interest_NN
rate_NN
swap_NN
12_CD
4_CD
705 705 699 704_CD
Other_JJ
medium-term_JJ
borrowings_GER
79_CD
79_CD
34_CD
34_CD
Other_JJ
short-term_JJ
loans_NN
and_PHC
overdrafts_NN
1,030_CD
1,030_CD
1,069_CD
1,069_CD
Total_JJ
borrowings_GER
5,963_CD
5,925_CD
5,103_CD
5,148_CD
Total_JJ
net_JJ
debt_NN
1,984_CD
1,944_CD
1,648_CD
1,677_CD
Fixed_VBN
asset_NN
equity_NOMZ
investments_NOMZ
145_CD
151_CD
98_CD
100_CD
Current_JJ
asset_NN
equity_NOMZ
investments_NOMZ
153 199 164 237_CD
Other_JJ
debtors_NN
due_JJ
after_IN
1_CD
year_NN
597 499 522 522_CD
Other_JJ
creditors_NN
due_JJ
after_IN
1_CD
year_NN
244 244 232 232_CD
Provisions_NN
256 256 245 245_CD
Other_JJ
foreign_JJ
exchange_NN
derivatives_NN
67_CD
79_CD
52_CD
71_CD
Non-hedging_JJ
derivatives_NN
59_CD
36_CD
Auction_NOMZ
rate_NN
preference_NN
stock_NN
224_CD
224_CD
Flexible_JJ
auction_NOMZ
market_NN
preferred_VBN [SUAV]
stock_NN
279_CD
279_CD
Total_JJ
non-equity_JJ
minority_NOMZ
interests_NN
503_CD
503_CD
Total_JJ
financial_JJ
assets_NN
and_PHC
liabilities_NOMZ
1,656_CD
1,733_CD
1,792_CD
1,691_CD
Total_JJ
financial_JJ
assets_NN
4,874_CD
4,830_CD
4,291_CD
4,437_CD
Total_JJ
financial_JJ
liabilities_NOMZ
6,530_CD
6,563_CD
6,083_CD
6,128_CD
Where_RB
appropriate_JJ
,_,
currency_NN
and_PHC
interest_NN
rate_NN
swaps_NN
have_VPRT [PEAS]
been_VBN [PASS]
presented_VBN
alongside_PLACE
the_DT
underlying_VBG
principal_NN
instrument_NOMZ
._.
The_DT
carrying_VBG
amounts_NN
of_PIN
these_DEMO
instruments_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
adjusted_VBN
for_PIN
the_DT
effect_NN
of_PIN
the_DT
currency_NN
and_PHC
interest_NN
rate_NN
swaps_NN
acting_VBG [WZPRES]
as_IN
hedges_NN
._.
The_DT
difference_NN
between_PIN
the_DT
carrying_VBG
amount_NN
and_CC
the_DT
fair_JJ
value_NN
of_PIN
equity_NOMZ
xed_VBD
and_CC
current_JJ
assets_NN
and_CC
liquid_JJ
investments_NOMZ
represents_VPRT
gross_JJ
unrealised_JJ
gains_NN
of_PIN
52_CD
million_CD
and_CC
2_CD
million_CD
,_,
respectively_RB
._.
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
GlaxoSmithKline_NN
127_CD
34_CD
Financial_NN
instruments_NOMZ
and_CC
related_VBN
disclosures_NN
continued_VBD
Currency_NN
and_PHC
interest_NN
rate_NN
risk_NN
prole_NN
of_PIN
financial_JJ
liabilities_NOMZ
Financial_JJ
liabilities_NOMZ
,_,
after_IN
taking_VBG
account_NN
of_PIN
currency_NN
and_PHC
interest_NN
rate_NN
swaps_NN
,_,
are_VPRT [PASS]
analyzed_VBN
below_PLACE
._.
Total_JJ
financial_JJ
liabilities_NOMZ
comprise_VPRT
total_JJ
borrowings_GER
of_PIN
5,963_CD
million_CD
2003_CD
5,103_CD
million_CD
,_,
other_JJ
creditors_NN
due_RB
after_IN
one_CD
year_NN
of_PIN
244_CD
million_CD
2003_CD
232_CD
million_CD
,_,
provisions_NN
of_PIN
256_CD
million_CD
2003_CD
245_CD
million_CD
and_CC
non-equity_JJ
minority_NOMZ
interest_NN
preference_NN
shares_NN
of_PIN
nil_NN
2003_CD
503_CD
million_CD
but_CC
exclude_VB
creditors_NN
due_JJ
within_PIN
one_CD
year_NN
and_CC
foreign_JJ
exchange_NN
derivatives_NN
of_PIN
67_CD
million_CD
2003_CD
nil_NN
._.
The_DT
benchmark_JJ
rate_NN
for_PIN
determining_VBG [SUAV] [PRIV]
interest_NN
payments_NOMZ
for_PIN
all_QUAN
oating_NN
rate_NN
financial_JJ
liabilities_NOMZ
in_PIN
the_DT
tables_NN
below_PLACE
is_VPRT
LIBOR_NN
._.
Fixed_JJ
rate_NN
Floating_VBG [WZPRES]
rate_NN
Non-interest_JJ
bearing_GER
Weighted_NN
Weighted_NN
average_JJ
average_JJ
Weighted_JJ
interest_NN
years_NN
for_PIN
average_JJ
At_PIN
31st_CD
December_NN
2004_CD
rate_NN
which_WDT [WHOBJ]
rate_NN
years_NN
to_PIN
Total_JJ
Currency_NN
m_CD
%_NN
is_VPRT [PASS]
xed_VBN
m_FW
m_FW
maturity_NOMZ
m_NN
US_FPP1
dollars_NN
571_CD
5.9_CD
13.8_CD
1,764_CD
411_CD
8.9_CD
2,746_CD
Sterling_GER
1,489_CD
6.4_CD
19.3_CD
842_CD
123_CD
2.1_CD
2,454_CD
Euro_NN
747_CD
44_CD
5.3_CD
791_CD
Japanese_JJ
Yen_NN
348_CD
0.4_CD
4.6_CD
348_CD
Other_JJ
currencies_NN
89_CD
35_CD
6.1_CD
124_CD
2,408_CD
5.4_CD
15.9_CD
3,442_CD
613_CD
4.6_CD
6,463_CD
Fixed_VBN
rate_NN
Floating_VBG [WZPRES]
rate_NN
Non-interest_JJ
bearing_GER
Weighted_NN
Weighted_NN
average_JJ
average_JJ
Weighted_JJ
interest_NN
years_NN
for_PIN
average_JJ
At_PIN
31st_CD
December_NN
2003_CD
rate_NN
which_WDT [WHOBJ]
rate_NN
years_NN
to_PIN
Total_JJ
Currency_NN
m_CD
%_NN
is_VPRT [PASS]
xed_VBN
m_FW
m_FW
maturity_NOMZ
m_NN
US_FPP1
dollars_NN
279_CD
6.1_CD
2.1_CD
1,676_CD
311_CD
10.5_CD
2,266_CD
Sterling_GER
1,478_CD
6.4_CD
20.4_CD
852_CD
100_CD
4.1_CD
2,430_CD
Euro_NN
3_CD
750_CD
34_CD
5.6_CD
787_CD
Japanese_JJ
Yen_NN
463_CD
0.5_CD
4.3_CD
52_CD
515_CD
Other_JJ
currencies_NN
14_CD
39_CD
32_CD
4.8_CD
85_CD
2,237_CD
5.1_CD
14.7_CD
3,369_CD
477_CD
8.4_CD
6,083_CD
Currency_NN
and_PHC
interest_NN
rate_NN
risk_NN
prole_NN
of_PIN
financial_JJ
assets_NN
Total_JJ
financial_JJ
assets_NN
comprise_VPRT
xed_JJ
asset_NN
equity_NOMZ
investments_NOMZ
of_PIN
145_CD
million_CD
2003_CD
98_CD
million_CD
,_,
current_JJ
asset_NN
equity_NOMZ
investments_NOMZ
of_PIN
153_CD
million_CD
2003_CD
164_CD
million_CD
,_,
liquid_JJ
investments_NOMZ
of_PIN
2,818_CD
million_CD
2003_CD
2,493_CD
million_CD
,_,
cash_NN
at_PIN
bank_NN
of_PIN
1,161_CD
million_CD
2003_CD
962_CD
million_CD
and_CC
debtors_NN
due_RB
after_IN
one_CD
year_NN
of_PIN
597_CD
million_CD
2003_CD
522_CD
million_CD
,_,
but_CC
exclude_VPRT
foreign_JJ
exchange_NN
derivatives_NN
of_PIN
nil_NN
2003_CD
52_CD
million_CD
._.
The_DT
benchmark_JJ
rate_NN
for_PIN
determining_VBG [SUAV] [PRIV]
interest_NN
receipts_NN
for_PIN
all_QUAN
oating_NN
rate_NN
assets_NN
in_PIN
the_DT
tables_NN
below_PLACE
is_VPRT
LIBOR_NN
._.
Fixed_JJ
rate_NN
Floating_VBG [WZPRES]
rate_NN
Non-interest_JJ
bearing_GER
Weighted_NN
Weighted_NN
Fixed_VBN
average_JJ
average_JJ
years_NN
At_PIN
31st_CD
December_NN
2004_CD
rate_NN
interest_NN
rate_NN
for_PIN
which_WDT [PIRE]
Total_JJ
Currency_NN
m_CD
%_NN
rate_NN
is_VPRT [PASS]
xed_VBN
m_FW
m_FW
m_FW [BEMA]
US_FPP1
dollars_NN
164_CD
6.2_CD
11.9_CD
1,429_CD
757_CD
2,350_CD
Sterling_GER
1,088_CD
89_CD
1,177_CD
Euro_NN
629_CD
57_CD
686_CD
Japanese_JJ
Yen_NN
1_CD
28_CD
29_CD
Other_JJ
currencies_NN
155_CD
3.0_CD
0.2_CD
353 124 632 319_CD
4.7_CD
6.2_CD
3,500_CD
1,055_CD
4,874_CD
Fixed_VBN
rate_NN
Floating_VBG [WZPRES]
rate_NN
Non-interest_JJ
bearing_GER
Weighted_NN
Weighted_NN
Fixed_VBN
average_JJ
average_JJ
years_NN
At_PIN
31st_CD
December_NN
2003_CD
rate_NN
interest_NN
rate_NN
for_PIN
which_WDT [PIRE]
Total_JJ
Currency_NN
m_CD
%_NN
rate_NN
is_VPRT [PASS]
xed_VBN
m_FW
m_FW
m_FW [BEMA]
US_FPP1
dollars_NN
300_CD
6.6_CD
5_CD
1,248_CD
479_CD
2,027_CD
Sterling_GER
20_CD
7.8_CD
2.6_CD
1,209_CD
60_CD
1,289_CD
Euro_NN
1_CD
3.0_CD
0.6_CD
328_CD
77_CD
406_CD
Japanese_JJ
Yen_NN
1_CD
33_CD
34_CD
Other_JJ
currencies_NN
103_CD
2.7_CD
0.1_CD
293 87 483 424_CD
5.0_CD
3.6_CD
3,079_CD
736_CD
4,239_CD
128_CD
GlaxoSmithKline_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
34_CD
Financial_NN
instruments_NOMZ
and_CC
related_VBN
disclosures_NN
continued_VBD
Currency_NN
exposure_NN
of_PIN
net_JJ
monetary_JJ
assets_NN
liabilities_NOMZ
The_DT
Groups_NN
currency_NN
exposures_NN
that_TSUB
give_VPRT
rise_VB
to_PIN
net_JJ
currency_NN
gains_NN
and_PHC
losses_NN
that_TSUB
are_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
arise_VB
principally_RB
in_PIN
companies_NN
with_PIN
sterling_GER
functional_JJ
currency_NN
._.
Monetary_NN
assets_NN
and_PHC
liabilities_NOMZ
denominated_VBN [WZPAST]
in_PIN
overseas_PLACE
functional_JJ
currency_NN
and_PHC
borrowings_GER
designated_VBN
as_IN
a_DT
hedge_NN
against_PIN
overseas_PLACE
net_JJ
assets_NN
are_VPRT [PASS]
excluded_VBN
from_PIN
the_DT
table_NN
below_PLACE
._.
At_PIN
31st_CD
December_NN
2004_CD
Functional_JJ
currency_NN
of_PIN
Group_NN
operation_NOMZ
Net_JJ
monetary_JJ
assets_NN
liabilities_NOMZ
Sterling_GER
US$_$
Euro_NN
Yen_NN
Other_JJ
Total_NN
held_VBD [PRIV]
in_PIN
non-functional_JJ
currency_NN
m_NN
m_FW
m_FW
m_FW
m_FW
m_FW
Sterling_GER
5_CD
53 130 178_CD
US_FPP1
dollars_NN
234_CD
18_CD
1_CD
23_CD
228_CD
Euro_NN
97_CD
15_CD
46_CD
158_CD
Japanese_JJ
Yen_NN
29_CD
1_CD
1_CD
31_CD
Other_JJ
39_CD
8_CD
4_CD
27_CD
205_CD
18_CD
38_CD
1_CD
198_CD
50_CD
At_PIN
31st_CD
December_NN
2003_CD
Functional_JJ
currency_NN
of_PIN
Group_NN
operation_NOMZ
Net_JJ
monetary_JJ
assets_NN
liabilities_NOMZ
Sterling_GER
US$_$
Euro_NN
Yen_NN
Other_JJ
Total_NN
held_VBD [PRIV]
in_PIN
non-functional_JJ
currency_NN
m_NN
m_FW
m_FW
m_FW
m_FW
m_FW
Sterling_GER
157 30 242 369_CD
US_FPP1
dollars_NN
41_CD
12_CD
45_CD
98_CD
Euro_NN
55_CD
111_CD
6_CD
62_CD
Japanese_JJ
Yen_NN
7_CD
1_CD
6_CD
Other_JJ
145_CD
55 12 212 152_CD
212 30 293 323_CD
Finance_NN
Total_NN
Total_NN
Debt_NN
leases_VPRT
Other_JJ
2004_CD
2003_CD
Maturity_NOMZ
of_PIN
financial_JJ
liabilities_NOMZ
m_VPRT
m_FW
m_FW
m_FW
m_FW [BEMA]
Within_PIN
one_CD
year_NN
or_CC
on_PIN
demand_NN
1,547_CD
35_CD
53_CD
1,635_CD
2,032_CD
Between_PIN
one_CD
and_CC
two_CD
years_NN
262_CD
27 88 377 630_CD
Between_PIN
two_CD
and_CC
five_CD
years_NN
1,817_CD
24_CD
132_CD
1,973_CD
1,597_CD
After_IN
five_CD
years_NN
2,244_CD
7_CD
227_CD
2,478_CD
1,824_CD
5,870_CD
93_CD
500_CD
6,463_CD
6,083_CD
2004_CD
Gains_NN
Losses_NN
Net_JJ
Hedges_NN
m_FW
m_FW
m_FW [BEMA]
Unrecognised_JJ
gains_NN
and_PHC
losses_NN
at_PIN
the_DT
beginning_GER
of_PIN
the_DT
year_NN
171_CD
60_CD
111_CD
Unrecognised_JJ
gains_NN
and_PHC
losses_NN
arising_VBG [WZPRES]
in_PIN
previous_JJ
years_NN
and_CC
recognized_VBN [PRIV]
in_PIN
the_DT
year_NN
27_CD
27_CD
Unrecognised_JJ
gains_NN
and_PHC
losses_NN
arising_VBG [WZPRES]
in_PIN
the_DT
year_NN
8_CD
77_CD
69_CD
Total_JJ
unrecognised_JJ
gains_NN
and_PHC
losses_NN
at_PIN
the_DT
end_NN
of_PIN
the_DT
year_NN
152_CD
137_CD
15_CD
Expected_VBN [PRIV]
to_TO
be_VB [PASS]
recognized_VBN [PRIV]
within_PIN
one_CD
year_NN
9_CD
9_CD
Expected_VBN [PRIV]
to_TO
be_VB [PASS]
recognized_VBN [PRIV]
after_IN
one_CD
year_NN
152_CD
128_CD
24_CD
Total_JJ
unrecognised_JJ
gains_NN
and_PHC
losses_NN
at_PIN
the_DT
end_NN
of_PIN
the_DT
year_NN
152_CD
137_CD
15_CD
The_DT
unrecognised_JJ
gains_NN
and_PHC
losses_NN
above_PLACE
represent_VPRT
the_DT
difference_NN
between_PIN
the_DT
carrying_VBG
amount_NN
and_CC
the_DT
fair_JJ
value_NN
of_PIN
the_DT
currency_NN
swaps_NN
,_,
interest_NN
rate_NN
swaps_NN
,_,
equity_NOMZ
collar_NN
and_CC
other_JJ
foreign_JJ
exchange_NN
derivatives_NN
._.
Committed_VBN
facilities_NOMZ
The_DT
Group_NN
has_VPRT [PEAS]
committed_VBN
facilities_NOMZ
to_TO
back_VB
up_RP
the_DT
commercial_JJ
paper_NN
program_NN
of_PIN
$_$
900_CD
million_CD
469_CD
million_CD
2003_CD
$_$
1,404_CD
million_CD
784_CD
million_CD
of_PIN
364_CD
days_NN
duration_NOMZ
,_,
renewable_JJ
annually_RB
._.
At_PIN
31st_CD
December_NN
2004_CD
,_,
undrawn_JJ
committed_JJ
facilities_NOMZ
totalled_VBD
$_$
900_CD
million_CD
469_CD
million_CD
2003_CD
$_$
1,404_CD
million_CD
784_CD
million_CD
._.
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
GlaxoSmithKline_NN
129_CD
35_CD
Employee_NN
costs_NN
2003 2002 2004_CD
restated_VBN
restated_VBN
m_NN
mm_NN
Wages_NN
and_PHC
salaries_NN
3,864_CD
3,999_CD
3,876_CD
Social_NN
security_NOMZ
costs_NN
430 444 385_CD
Pension_NN
and_CC
other_JJ
post-retirement_JJ
costs_NN
295 386 257_CD
Cost_NN
of_PIN
share-based_JJ
incentive_NN
plans_NN
24_CD
20_CD
117_CD
Severance_NN
costs_NN
arising_VBG [WZPRES]
from_PIN
integration_NOMZ
and_PHC
restructuring_GER
activities_NOMZ
80 222 228_CD
Pension_NN
and_CC
other_JJ
post-retirement_JJ
costs_NN
arising_VBG [WZPRES]
from_PIN
integration_NOMZ
and_PHC
restructuring_GER
activities_NOMZ
6_CD
43_CD
59_CD
4,699_CD
5,074_CD
4,922_CD
The_DT
Group_NN
provides_VPRT
benets_NN
to_PIN
employees_NN
,_,
commensurate_JJ
with_PIN
local_JJ
practice_NN
in_PIN
individual_JJ
countries_NN
,_,
including_VBG
,_,
in_PIN
some_QUAN
markets_NN
,_,
healthcare_NN
insurance_NN
,_,
subsidised_VBN
car_NN
schemes_NN
and_CC
personal_JJ
life_NN
assurance_NN
._.
Information_NOMZ
on_PIN
Directors_NN
remuneration_NOMZ
is_VPRT [PASS]
given_VBN
in_PIN
the_DT
Remuneration_NOMZ
Report_NN
on_PIN
pages_NN
43_CD
to_PIN
58_CD
._.
2004 2003 2002_CD
The_DT
average_JJ
number_NN
of_PIN
persons_NN
employed_VBN [WZPAST]
by_PIN
the_DT
Group_NN
including_VBG [WZPRES]
Directors_NN
during_PIN
the_DT
year_NN
Number_NN
Number_NN
Number_NN
Manufacturing_GER
31,427_CD
34,265_CD
36,548_CD
Selling_GER
,_,
general_JJ
and_CC
administration_NOMZ
53,513_CD
54,128_CD
54,810_CD
Research_NN
and_PHC
development_NOMZ
14,897_CD
14,773_CD
14,808_CD
99,837_CD
103,166_CD
106,166_CD
The_DT
average_JJ
number_NN
of_PIN
Group_NN
employees_NN
excludes_VPRT
temporary_JJ
and_CC
contract_NN
staff_NN
._.
The_DT
numbers_NN
of_PIN
Group_NN
employees_NN
at_PIN
the_DT
end_NN
of_PIN
each_QUAN
financial_JJ
year_NN
are_VPRT [PASS]
given_VBN
in_PIN
the_DT
Financial_NN
record_NN
page_NN
162_CD
._.
2004 2003 2002_CD
Pension_NN
and_CC
other_JJ
post-retirement_JJ
costs_NN
m_VPRT
m_FW
m_FW
UK_NN
pension_NN
schemes_NN
96_CD
113_CD
18_CD
US_FPP1
pension_NN
schemes_NN
28_CD
75_CD
86_CD
Other_JJ
overseas_PLACE
pensions_NN
schemes_NN
69_CD
74_CD
52_CD
Unfunded_JJ
post-retirement_NOMZ
healthcare_NN
schemes_NN
84_CD
100_CD
61_CD
Post-employment_NOMZ
costs_NN
18_CD
24 40 295 386_CD
257_CD
Analysed_VBN
as_IN
:_:
Funded_VBN
dened_VBN
benefit_NN
hybrid_NN
schemes_NN
148_CD
213_CD
92_CD
Unfunded_JJ
dened_VBN
benefit_NN
schemes_NN
22_CD
24_CD
34_CD
Dened_VBN
contribution_NOMZ
schemes_NN
23_CD
25_CD
30_CD
Unfunded_JJ
post-retirement_NOMZ
healthcare_NN
schemes_NN
84_CD
100_CD
61_CD
Post-employment_NOMZ
costs_NN
18_CD
24 40 295 386_CD
257_CD
Pension_NN
and_CC
other_JJ
post-retirement_JJ
costs_NN
arising_VBG [WZPRES]
from_PIN
integration_NOMZ
and_PHC
restructuring_GER
6_CD
43_CD
59_CD
Pensions_NN
Group_NN
undertakings_GER
operate_VPRT
pension_NN
arrangements_NOMZ
which_WDT [WHSUB]
cover_VPRT
the_DT
Groups_NN
material_NN
obligations_NOMZ
to_TO
provide_VB
pensions_NN
to_PIN
retired_JJ
employees_NN
._.
These_DEMO
arrangements_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
developed_VBN
in_PIN
accordance_NN
with_PIN
local_JJ
practices_NN
in_PIN
the_DT
countries_NN
concerned_VBN
._.
Pension_NN
benets_NN
can_POMD
be_VB [BYPA]
provided_VBN
by_PIN
state_NN
schemes_NN
:_:
by_PIN
dened_VBN
contribution_NOMZ
schemes_NN
,_,
whereby_OSUB
retirement_NOMZ
benets_NN
are_VPRT [BYPA]
determined_VBN [SUAV] [PRIV]
by_PIN
the_DT
value_NN
of_PIN
funds_NN
arising_VBG [WZPRES]
from_PIN
contributions_NOMZ
paid_VBN [WZPAST]
in_PIN
respect_NN
of_PIN
each_QUAN
employee_NN
,_,
or_CC
by_PIN
dened_JJ
benefit_NN
schemes_NN
,_,
whereby_OSUB
retirement_NOMZ
benets_NN
are_VPRT [PASS]
based_VBN
on_PIN
employee_NN
pensionable_JJ
remuneration_NOMZ
and_PHC
length_NN
of_PIN
service_NN
._.
Some_QUAN
dened_VBD
benefit_NN
schemes_NN
now_TIME
also_RB
include_VPRT
dened_VBN
contribution_NOMZ
sections_NOMZ
and_CC
are_VPRT [PASS]
described_VBN
as_IN
hybrid_JJ
schemes_NN
in_PIN
the_DT
table_NN
._.
In_PIN
the_DT
majority_NOMZ
of_PIN
cases_NN
the_DT
contributions_NOMZ
to_PIN
dened_JJ
benefit_NN
schemes_NN
are_VPRT [PASS]
determined_VBN [SUAV] [PRIV]
in_PIN
accordance_NN
with_PIN
the_DT
advice_NN
of_PIN
independent_JJ
,_,
professionally_RB
qualied_VBD
actuaries_NN
._.
Formal_JJ
,_,
independent_JJ
,_,
actuarial_JJ
valuations_NOMZ
of_PIN
the_DT
Groups_NN
main_JJ
plans_NN
are_VPRT [PASS]
undertaken_VBN
regularly_RB
,_,
normally_RB
at_PIN
least_JJ
every_QUAN
three_CD
years_NN
._.
The_DT
assets_NN
of_PIN
funded_JJ
schemes_NN
are_VPRT [SPAU] [PASS]
generally_RB
held_VBN [PRIV]
in_PIN
separately_RB
administered_VBN
trusts_NN
or_CC
are_VPRT [PASS]
insured_VBN [PRIV]
._.
Assets_NN
are_VPRT [PASS]
invested_VBN
in_PIN
different_JJ
classes_NN
in_PIN
order_NN
to_TO
maintain_VB [PUBV]
a_DT
balance_NN
between_PIN
risk_NN
and_PHC
return_NN
._.
Investments_NOMZ
are_VPRT [PASS]
diversied_VBN
to_TO
limit_VB
the_DT
financial_JJ
effect_NN
of_PIN
the_DT
failure_NN
of_PIN
any_QUAN
individual_JJ
investment_NOMZ
._.
130_CD
GlaxoSmithKline_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
35_CD
Employee_NN
costs_NN
continued_VBD
Pension_NN
costs_NN
of_PIN
dened_VBN
benefit_NN
schemes_NN
for_PIN
accounting_GER
purposes_NN
have_VPRT [PEAS]
been_VBN [PASS]
assessed_VBN
in_PIN
accordance_NN
with_PIN
independent_JJ
actuarial_JJ
advice_NN
,_,
generally_RB
using_VBG
the_DT
projected_VBN
unit_NN
method_NN
and_CC
by_PIN
spreading_VBG
surpluses_NN
or_CC
deficits_NN
over_IN
the_DT
average_NN
expected_VBN [PRIV]
remaining_VBG
service_NN
lives_NN
of_PIN
the_DT
respective_JJ
memberships_NN
._.
In_PIN
certain_JJ
countries_NN
pension_NN
benets_NN
are_VPRT [PASS]
provided_VBN
on_PIN
an_DT
unfunded_JJ
basis_NN
,_,
some_QUAN
administered_VBN
by_PIN
trustee_NN
companies_NN
._.
Where_RB
assets_NN
are_VPRT [PASS]
not_XX0
held_VBN [PRIV]
with_PIN
the_DT
specic_JJ
purpose_NN
of_PIN
matching_VBG
the_DT
liabilities_NOMZ
of_PIN
unfunded_JJ
schemes_NN
,_,
a_DT
provision_NN
is_VPRT [PASS]
included_VBN
within_PIN
provisions_NN
for_PIN
pensions_NN
and_CC
other_JJ
post-retirement_JJ
benets_NN
._.
Liabilities_NOMZ
are_VPRT [SPAU] [PASS]
generally_RB
assessed_VBN
annually_RB
in_PIN
accordance_NN
with_PIN
the_DT
advice_NN
of_PIN
independent_JJ
actuaries_NN
._.
The_DT
market_NN
value_NN
of_PIN
the_DT
assets_NN
of_PIN
the_DT
Groups_NN
funded_VBN
dened_VBD
benefit_NN
pension_NN
funds_NN
at_PIN
the_DT
dates_NN
of_PIN
the_DT
latest_JJ
actuarial_JJ
valuations_NOMZ
,_,
some_QUAN
of_PIN
which_WDT [PIRE]
date_NN
back_RB
to_PIN
2001_CD
,_,
was_VBD [BEMA]
5.1_CD
billion_CD
and_CC
the_DT
actuarial_JJ
value_NN
of_PIN
assets_NN
was_VBD [BEMA]
sufficient_PRED
to_TO
cover_VB
approximately_RB
97_CD
per_PIN
cent_NN
of_PIN
the_DT
benets_NN
that_TSUB
had_VBD [PEAS]
accrued_VBN
to_PIN
members_NN
after_IN
allowing_VBG [SUAV]
for_PIN
future_JJ
salary_NN
and_PHC
pension_NN
increases_NN
._.
The_DT
UK_NN
dened_VBD
benefit_NN
pension_NN
schemes_NN
account_VPRT
for_PIN
approximately_RB
60_CD
per_PIN
cent_NN
of_PIN
the_DT
Groups_NN
plans_NN
in_PIN
asset_NN
valuation_NOMZ
and_CC
projected_VBD
benefit_NN
terms_NN
and_CC
the_DT
US_FPP1
dened_VBD
benefit_NN
pension_NN
schemes_NN
account_VPRT
for_PIN
approximately_RB
30_CD
per_PIN
cent_NN
of_PIN
the_DT
Groups_NN
plans_NN
in_PIN
asset_NN
valuation_NOMZ
and_CC
projected_VBD
benefit_NN
terms_NN
._.
During_PIN
2004_CD
,_,
the_DT
Group_NN
made_VBD
special_JJ
funding_GER
contributions_NOMZ
to_PIN
the_DT
UK_NN
and_PHC
US_FPP1
pension_NN
schemes_NN
totalling_VBG [WZPRES]
256_CD
million_CD
._.
The_DT
Group_NN
has_VPRT [PEAS]
agreed_VBN [SUAV] [PUBV]
with_PIN
the_DT
trustees_NN
of_PIN
certain_JJ
of_PIN
the_DT
pension_NN
schemes_NN
to_TO
make_VB
additional_JJ
contributions_NOMZ
dependent_JJ
on_PIN
the_DT
funding_GER
status_NN
of_PIN
those_DEMO
schemes_NN
._.
In_PIN
2005_CD
,_,
following_VBG [PRESP]
the_DT
move_NN
to_PIN
IFRS_NN
,_,
pension_NN
costs_NN
for_PIN
the_DT
Group_NN
are_VPRT [PASS]
expected_VBN [PRIV]
to_TO
be_VB [BEMA]
approximately_RB
35_CD
million_CD
higher_JJ
than_PIN
they_TPP3
were_VBD [BEMA]
in_PIN
2004_CD
._.
UK_NN
In_PIN
the_DT
UK_NN
the_DT
dened_VBN
benefit_NN
pension_NN
schemes_NN
operated_VBD
for_PIN
the_DT
benefit_NN
of_PIN
former_JJ
Glaxo_NN
Wellcome_NN
employees_NN
and_CC
former_JJ
SmithKline_NN
Beecham_NN
employees_NN
remain_VPRT
separate_JJ
._.
These_DEMO
schemes_NN
were_VBD [PASS]
closed_VBN
to_PIN
new_JJ
entrants_NN
in_PIN
2001_CD
and_CC
subsequent_JJ
UK_NN
employees_NN
are_VPRT [PASS]
entitled_VBN
to_TO
join_VB
a_DT
dened_VBN
contribution_NOMZ
scheme_NN
._.
The_DT
relevant_JJ
assumptions_NOMZ
used_VBN [WZPAST]
in_PIN
calculating_VBG [PRIV]
the_DT
pension_NN
costs_NN
of_PIN
all_QUAN
of_PIN
the_DT
UK_NN
dened_VBD
benefit_NN
schemes_NN
for_PIN
accounting_GER
purposes_NN
are_VPRT
as_IN
follows_VPRT
:_:
2004_CD
2003_CD
%_NN
pa_CD
%_NN
pa_NN
Rate_NN
of_PIN
increase_NN
of_PIN
future_JJ
earnings_GER
3.75_CD
3.75_CD
Discount_NN
rate_NN
7.75_CD
7.75_CD
Expected_VBN [PRIV]
long-term_JJ
rate_NN
of_PIN
return_NN
on_PIN
investments_NOMZ
7.75_CD
7.75_CD
Expected_VBN [PRIV]
pension_NN
increases_NN
2.25_CD
2.25_CD
The_DT
regular_JJ
cost_NN
for_PIN
the_DT
Glaxo_NN
Wellcome_NN
pension_NN
arrangements_NOMZ
in_PIN
2004_CD
was_VBD [BEMA]
57_CD
million_CD
,_,
which_WDT [SERE]
reduced_VBD
to_PIN
an_DT
accounting_GER
cost_NN
of_PIN
47_CD
million_CD
,_,
after_IN
allowance_NN
was_VBD [PASS]
made_VBN
for_PIN
spreading_VBG
the_DT
surplus_NN
disclosed_VBD [PUBV]
as_IN
a_DT
level_NN
percentage_NN
of_PIN
salary_NN
over_IN
the_DT
expected_JJ
future_NN
working_VBG [WZPRES]
lifetime_NN
of_PIN
the_DT
existing_VBG
members_NN
some_QUAN
9_CD
years_NN
._.
The_DT
most_EMPH
recent_JJ
triennial_JJ
actuarial_JJ
valuations_NOMZ
for_PIN
funding_VBG
purposes_NN
were_VBD [PASS]
carried_VBN
out_PIN
as_IN
at_PIN
31st_CD
December_NN
2002_CD
._.
At_PIN
that_DEMO
date_NN
the_DT
assets_NN
of_PIN
the_DT
schemes_NN
represented_VBD
92_CD
per_PIN
cent_NN
of_PIN
the_DT
actuarial_JJ
value_NN
of_PIN
all_QUAN
benets_NN
accrued_VBN [WZPAST]
to_PIN
members_NN
after_IN
allowing_VBG [SUAV]
for_PIN
future_JJ
salary_NN
and_PHC
pension_NN
increases_NN
._.
The_DT
market_NN
value_NN
of_PIN
the_DT
assets_NN
held_VBN [PRIV] [WZPAST]
by_PIN
the_DT
schemes_NN
at_PIN
31st_CD
December_NN
2002_CD
was_VBD [BEMA]
2,103_CD
million_CD
._.
The_DT
regular_JJ
cost_NN
for_PIN
the_DT
SmithKline_NN
Beecham_NN
schemes_NN
in_PIN
2004_CD
was_VBD [BEMA]
15_CD
million_CD
,_,
which_WDT [SERE]
increased_VBD
to_PIN
an_DT
accounting_GER
cost_NN
of_PIN
49_CD
million_CD
after_IN
allowance_NN
was_VBD [PASS]
made_VBN
for_PIN
the_DT
spreading_VBG
of_PIN
the_DT
deficit_NN
over_IN
the_DT
expected_JJ
future_NN
working_VBG [WZPRES]
lifetime_NN
of_PIN
current_JJ
employees_NN
in_PIN
the_DT
scheme_NN
some_QUAN
10_CD
years_NN
._.
The_DT
latest_JJ
valuation_NOMZ
was_VBD [PASS]
carried_VBN
out_PIN
at_PIN
31st_CD
December_NN
2002_CD
and_CC
at_PIN
that_DEMO
date_NN
the_DT
scheme_NN
assets_NN
represented_VBD
56_CD
per_PIN
cent_NN
of_PIN
the_DT
actuarial_JJ
value_NN
of_PIN
the_DT
accrued_JJ
service_NN
liabilities_NOMZ
based_VBN [WZPAST]
on_PIN
the_DT
2003_CD
assumptions_NOMZ
._.
The_DT
market_NN
value_NN
of_PIN
assets_NN
held_VBN [PRIV] [WZPAST]
by_PIN
the_DT
scheme_NN
at_PIN
31st_CD
December_NN
2002_CD
was_VBD [BEMA]
856_CD
million_CD
._.
USA_NN
In_PIN
the_DT
USA_NN
the_DT
former_JJ
Glaxo_NN
Wellcome_NN
and_PHC
SmithKline_NN
Beecham_NN
dened_VBD
benefit_NN
and_CC
hybrid_JJ
schemes_NN
were_VBD [PASS]
merged_VBN
during_PIN
2001_CD
._.
The_DT
relevant_JJ
assumptions_NOMZ
used_VBN [WZPAST]
in_PIN
calculating_VBG [PRIV]
the_DT
pension_NN
costs_NN
for_PIN
accounting_GER
purposes_NN
are_VPRT
as_IN
follows_VPRT
:_:
2004_CD
2003_CD
%_NN
pa_CD
%_NN
pa_NN
Rate_NN
of_PIN
increase_NN
of_PIN
future_JJ
earnings_GER
5.50_CD
5.50_CD
Discount_NN
rate_NN
7.75_CD
8.50_CD
Expected_VBN [PRIV]
long-term_JJ
rate_NN
of_PIN
return_NN
on_PIN
investments_NOMZ
7.75_CD
8.50_CD
Cash_NN
balance_NN
credit_NN
conversion_NN
rate_NN
5.25_CD
5.75_CD
The_DT
regular_JJ
cost_NN
for_PIN
the_DT
main_JJ
US_FPP1
schemes_NN
in_PIN
2004_CD
was_VBD [BEMA]
51_CD
million_CD
,_,
which_WDT [SERE]
decreased_VBD
to_PIN
an_DT
accounting_GER
cost_NN
of_PIN
28_CD
million_CD
after_IN
allowance_NN
was_VBD [PASS]
made_VBN
for_PIN
the_DT
spreading_VBG
of_PIN
the_DT
surplus_NN
over_IN
the_DT
expected_JJ
future_NN
working_VBG [WZPRES]
lifetime_NN
of_PIN
current_JJ
employees_NN
in_PIN
the_DT
schemes_NN
._.
The_DT
latest_JJ
valuation_NOMZ
was_VBD [PASS]
carried_VBN
out_PIN
at_PIN
1st_CD
January_NN
2004_CD
and_CC
at_PIN
that_DEMO
date_NN
the_DT
actuarial_JJ
value_NN
of_PIN
scheme_NN
assets_NN
represented_VBD
110_CD
per_PIN
cent_NN
of_PIN
the_DT
actuarial_JJ
value_NN
of_PIN
the_DT
accrued_JJ
service_NN
liabilities_NOMZ
._.
The_DT
market_NN
value_NN
of_PIN
assets_NN
held_VBN [PRIV] [WZPAST]
by_PIN
the_DT
scheme_NN
at_PIN
1st_CD
January_NN
2004_CD
was_VBD [BEMA]
1,593_CD
million_CD
._.
Post-retirement_NOMZ
healthcare_NN
The_DT
Group_NN
operates_VPRT
a_DT
number_NN
of_PIN
post-retirement_JJ
healthcare_NN
schemes_NN
,_,
the_DT
principal_NN
one_CD
of_PIN
which_WDT [PIRE]
is_VPRT [BEMA]
in_PIN
the_DT
USA_NN
._.
The_DT
cost_NN
of_PIN
the_DT
US_FPP1
scheme_NN
has_VPRT [PEAS]
been_VBN [PASS]
assessed_VBN
using_VBG
the_DT
same_JJ
assumptions_NOMZ
as_IN
for_PIN
the_DT
US_FPP1
pension_NN
scheme_NN
,_,
together_RB
with_PIN
the_DT
assumption_NOMZ
for_PIN
future_JJ
medical_JJ
ination_NOMZ
of_PIN
10_CD
per_PIN
cent_NN
reducing_VBG [WZPRES]
by_PIN
one_CD
per_PIN
cent_NN
per_PIN
year_NN
to_PIN
five_CD
per_PIN
cent_NN
._.
The_DT
total_JJ
provision_NN
for_PIN
post-retirement_JJ
benets_NN
at_PIN
31st_CD
December_NN
2004_CD
amounted_VBD
to_PIN
594_CD
million_CD
2003_CD
569_CD
million_CD
._.
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
GlaxoSmithKline_NN
131_CD
35_CD
Employee_NN
costs_NN
continued_VBD
FRS_NN
17_CD
disclosures_NN
The_DT
Group_NN
continues_VPRT
to_TO
account_VB
for_PIN
pension_NN
arrangements_NOMZ
in_PIN
accordance_NN
with_PIN
SSAP_NN
24_CD
Accounting_GER
for_PIN
Pension_NN
Costs_NN
._.
Under_IN
the_DT
transitional_JJ
provisions_NN
of_PIN
FRS_NN
17_CD
Retirement_NOMZ
Benets_NN
certain_JJ
disclosures_NN
are_VPRT [PASS]
required_VBN [SUAV]
on_PIN
the_DT
basis_NN
of_PIN
the_DT
valuation_NOMZ
methodology_NN
adopted_VBN [WZPAST]
by_PIN
FRS_NN
17_CD
._.
For_PIN
dened_VBN
benefit_NN
schemes_NN
the_DT
fair_JJ
values_NN
of_PIN
pension_NN
scheme_NN
assets_NN
at_PIN
31st_CD
December_NN
2004_CD
are_VPRT [PASS]
compared_VBN
with_PIN
the_DT
future_JJ
pension_NN
liabilities_NOMZ
calculated_VBN [PRIV]
under_IN
the_DT
projected_VBN
unit_NN
method_NN
applying_VBG [WZPRES]
the_DT
following_VBG
assumptions_NOMZ
:_:
UK_NN
USA_NN
Rest_VPRT
of_PIN
World_NN
2004 2003 2002 2004_CD
2003 2002 2004 2003_CD
2002_CD
%_NN
pa_CD
%_NN
pa_CD
%_NN
pa_CD
%_NN
pa_CD
%_NN
pa_CD
%_NN
pa_CD
%_NN
pa_CD
%_NN
pa_CD
%_NN
pa_NN
Rate_NN
of_PIN
increase_NN
of_PIN
future_JJ
earnings_GER
4.00_CD
4.00_CD
3.75_CD
5.00_CD
5.50_CD
5.50_CD
3.25_CD
3.00_CD
3.00_CD
Discount_NN
rate_NN
5.25_CD
5.25_CD
5.75_CD
5.75_CD
6.25_CD
6.75_CD
4.25_CD
4.75_CD
4.75_CD
Expected_VBN [PRIV]
pension_NN
increases_NN
2.50_CD
2.50_CD
2.25_CD
n_VBD
a_DT
n_NN
a_DT
n_NN
a_DT
2.00_CD
2.00_CD
1.50_CD
Cash_NN
balance_NN
credit_NN
conversion_NN
rate_NN
n_VBD
a_DT
n_NN
a_DT
n_NN
a_DT
4.75_CD
5.25_CD
5.75_CD
1.75_CD
1.50_CD
n_NN
a_DT
Ination_NOMZ
rate_NN
2.50_CD
2.50_CD
2.25_CD
2.50_CD
2.50_CD
2.25_CD
1.75_CD
1.50_CD
1.50_CD
The_DT
expected_VBN [PRIV]
long-term_JJ
rates_NN
of_PIN
return_NN
on_PIN
the_DT
assets_NN
determined_VBD [SUAV] [PRIV]
based_VBN
on_PIN
actuarial_JJ
advice_NN
and_CC
the_DT
fair_JJ
values_NN
of_PIN
the_DT
assets_NN
and_PHC
liabilities_NOMZ
of_PIN
the_DT
UK_NN
and_PHC
US_FPP1
dened_VBD
benefit_NN
schemes_NN
,_,
together_RB
with_PIN
aggregated_JJ
data_NN
for_PIN
other_JJ
dened_VBN
benefit_NN
schemes_NN
in_PIN
the_DT
Group_NN
are_VPRT
as_IN
follows_VPRT
:_:
UK_NN
USA_NN
Rest_VPRT
of_PIN
World_NN
Group_NN
Average_JJ
At_PIN
31st_CD
December_NN
2004_CD
Expected_VBN [PRIV]
rate_NN
Fair_NN
Expected_VBN [PRIV]
rate_NN
Fair_NN
expected_VBN [PRIV]
rate_NN
Fair_NN
Fair_NN
of_PIN
return_NN
value_NN
of_PIN
return_NN
value_NN
of_PIN
return_NN
value_NN
value_NN
%_NN
m_CD
%_NN
m_CD
%_NN
m_NN
m_NN
Equities_NOMZ
8.25_CD
2,716_CD
8.50_CD
1,229_CD
7.50_CD
205_CD
4,150_CD
Property_NN
6.50_CD
58_CD
6.25_CD
7_CD
65_CD
Bonds_NN
4.50_CD
1,404_CD
5.75_CD
307_CD
3.75_CD
270_CD
1,981_CD
Other_JJ
assets_NN
4.00_CD
44_CD
2.50_CD
50_CD
2.25_CD
62_CD
156_CD
Fair_NN
value_NN
of_PIN
assets_NN
4,164_CD
1,644_CD
544_CD
6,352_CD
Present_JJ
value_NN
of_PIN
scheme_NN
liabilities_NOMZ
5,326_CD
1,750_CD
760_CD
7,836_CD
1,162_CD
106_CD
216_CD
1,484_CD
Value_NN
of_PIN
schemes_NN
in_PIN
surplus_NN
18_CD
7_CD
25_CD
Deferred_JJ
tax_NN
liability_NOMZ
7_CD
2_CD
9_CD
11_CD
5_CD
16_CD
Value_NN
of_PIN
schemes_NN
in_PIN
deficit_NN
1,162_CD
124_CD
223_CD
1,509_CD
Deferred_JJ
tax_NN
asset_NN
349_CD
46 78 473 813_CD
78_CD
145_CD
1,036_CD
Group_NN
total_JJ
1,020_CD
UK_NN
USA_NN
Rest_VPRT
of_PIN
World_NN
Group_NN
Average_JJ
At_PIN
31st_CD
December_NN
2003_CD
Expected_VBN [PRIV]
rate_NN
Fair_NN
Expected_VBN [PRIV]
rate_NN
Fair_NN
expected_VBN [PRIV]
rate_NN
Fair_NN
Fair_NN
of_PIN
return_NN
value_NN
of_PIN
return_NN
value_NN
of_PIN
return_NN
value_NN
value_NN
%_NN
m_CD
%_NN
m_CD
%_NN
m_NN
m_NN
Equities_NOMZ
8.25_CD
2,927_CD
8.50_CD
1,201_CD
7.75_CD
174_CD
4,302_CD
Property_NN
6.50_CD
52_CD
6.50_CD
6_CD
58_CD
Bonds_NN
4.50_CD
574_CD
5.75_CD
314_CD
4.00_CD
226_CD
1,114_CD
Other_JJ
assets_NN
4.00_CD
185_CD
1.00_CD
26_CD
2.00_CD
18_CD
229_CD
Fair_NN
value_NN
of_PIN
assets_NN
3,686_CD
1,593_CD
424_CD
5,703_CD
Present_JJ
value_NN
of_PIN
scheme_NN
liabilities_NOMZ
5,181_CD
1,743_CD
674_CD
7,598_CD
1,495_CD
150_CD
250_CD
1,895_CD
Value_NN
of_PIN
schemes_NN
in_PIN
surplus_NN
7_CD
7_CD
Deferred_JJ
tax_NN
liability_NOMZ
2_CD
2_CD
5_CD
5_CD
Value_NN
of_PIN
schemes_NN
in_PIN
deficit_NN
1,495_CD
150_CD
257_CD
1,902_CD
Deferred_JJ
tax_NN
asset_NN
449_CD
53_CD
95_CD
597_CD
1,046_CD
97_CD
162_CD
1,305_CD
Group_NN
total_JJ
1,300_CD
132_CD
GlaxoSmithKline_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
35_CD
Employee_NN
costs_NN
continued_VBD
UK_NN
USA_NN
Rest_VPRT
of_PIN
World_NN
Group_NN
Average_JJ
At_PIN
31st_CD
December_NN
2002_CD
Expected_VBN [PRIV]
rate_NN
Fair_NN
Expected_VBN [PRIV]
rate_NN
Fair_NN
expected_VBN [PRIV]
rate_NN
Fair_NN
Fair_NN
of_PIN
return_NN
value_NN
of_PIN
return_NN
value_NN
of_PIN
return_NN
value_NN
value_NN
%_NN
m_CD
%_NN
m_CD
%_NN
m_NN
m_NN
Equities_NOMZ
8.25_CD
2,523_CD
9.25_CD
804_CD
6.75_CD
172_CD
3,499_CD
Property_NN
7.00_CD
53_CD
7.00_CD
5_CD
58_CD
Bonds_NN
4.50_CD
299_CD
6.25_CD
265_CD
4.50_CD
145_CD
709_CD
Other_JJ
assets_NN
4.00_CD
137_CD
1.50_CD
240_CD
1.75_CD
9_CD
386_CD
Fair_NN
value_NN
of_PIN
assets_NN
2,959_CD
1,362_CD
331_CD
4,652_CD
Present_JJ
value_NN
of_PIN
scheme_NN
liabilities_NOMZ
4,153_CD
1,782_CD
578_CD
6,513_CD
1,194_CD
420_CD
247_CD
1,861_CD
Value_NN
of_PIN
schemes_NN
in_PIN
surplus_NN
11_CD
11_CD
Deferred_JJ
tax_NN
liability_NOMZ
3_CD
3_CD
88_CD
Value_NN
of_PIN
schemes_NN
in_PIN
deficit_NN
1,194_CD
420_CD
258_CD
1,872_CD
Deferred_JJ
tax_NN
asset_NN
358_CD
147 97 602 836_CD
273_CD
161_CD
1,270_CD
Group_NN
total_JJ
1,262_CD
The_DT
UK_NN
dened_VBD
benefit_NN
schemes_NN
also_RB
have_VPRT [PEAS]
dened_VBN
contribution_NOMZ
sections_NOMZ
with_PIN
account_NN
balances_NN
totalling_VBG [WZPRES]
404_CD
million_CD
at_PIN
31st_CD
December_NN
2004 2003 327_CD
million_CD
,_,
2002_CD
281_CD
million_CD
._.
The_DT
dened_VBN
benefit_NN
sections_NOMZ
of_PIN
the_DT
UK_NN
schemes_NN
have_VPRT [PEAS]
been_VBN [PASS]
closed_VBN
to_PIN
new_JJ
members_NN
and_CC
,_,
under_IN
the_DT
projected_VBN
unit_NN
method_NN
of_PIN
valuing_VBG
the_DT
pension_NN
scheme_NN
liabilities_NOMZ
,_,
the_DT
current_JJ
service_NN
cost_NN
will_PRMD
increase_VB
as_IN
a_DT
percentage_NN
of_PIN
payroll_NN
as_IN
the_DT
members_NN
of_PIN
the_DT
schemes_NN
approach_VPRT
retirement_NOMZ
._.
The_DT
deficits_NN
under_IN
FRS_NN
17_CD
reect_NN
the_DT
different_JJ
basis_NN
for_PIN
valuing_VBG
liabilities_NOMZ
compared_VBN [WZPAST]
with_PIN
SSAP_NN
24_CD
._.
The_DT
liability_NOMZ
under_IN
FRS_NN
17_CD
for_PIN
the_DT
US_FPP1
post-retirement_NOMZ
healthcare_NN
scheme_NN
has_VPRT [PEAS]
been_VBN [PASS]
assessed_VBN
using_VBG
the_DT
same_JJ
assumptions_NOMZ
as_IN
for_PIN
the_DT
US_FPP1
pension_NN
scheme_NN
,_,
together_RB
with_PIN
the_DT
assumption_NOMZ
for_PIN
future_JJ
medical_JJ
ination_NOMZ
of_PIN
9_CD
per_PIN
cent_NN
,_,
reducing_VBG [PRESP]
by_PIN
one_CD
per_PIN
cent_NN
per_PIN
year_NN
to_PIN
five_CD
per_PIN
cent_NN
._.
On_PIN
this_DEMO
basis_NN
the_DT
liability_NOMZ
for_PIN
the_DT
US_FPP1
scheme_NN
has_VPRT [PEAS]
been_VBN [PASS]
assessed_VBN
at_PIN
895_CD
million_CD
2003_CD
908_CD
million_CD
:_:
2002_CD
766_CD
million_CD
,_,
which_WDT [SERE]
reduced_VBD
to_PIN
564_CD
million_CD
2003_CD
590_CD
million_CD
:_:
2002_CD
475_CD
million_CD
after_IN
taking_VBG
account_NN
of_PIN
deferred_JJ
tax_NN
._.
If_COND
the_DT
dened_VBN
benefit_NN
pension_NN
and_PHC
post-retirement_NOMZ
benefit_NN
schemes_NN
had_VBD [PEAS]
been_VBN [PASS]
accounted_VBN
for_PIN
under_IN
FRS_NN
17_CD
,_,
the_DT
following_JJ
amounts_NN
would_PRMD
have_VB [PEAS]
been_VBN [PASS]
recorded_VBN
in_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
and_PHC
statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
for_PIN
the_DT
three_CD
years_NN
ended_VBN
31st_CD
December_NN
2004_CD
._.
Post-retirement_NOMZ
Pensions_NN
benets_VPRT
2004_CD
UK_NN
USA_NN
Rest_VPRT
of_PIN
World_NN
Group_NN
Group_NN
m_FW
m_FW
m_FW
m_FW
m_FW [PASS]
Amounts_NN
charged_VBD
to_TO
operating_VBG
profit_NN
Current_JJ
service_NN
cost_NN
117_CD
58_CD
42_CD
217_CD
37_CD
Past_JJ
service_NN
cost_NN
3_CD
2_CD
5_CD
Curtailments_NOMZ
settlements_NOMZ
5_CD
5_CD
125_CD
58_CD
44_CD
227_CD
37_CD
Amounts_NN
credited_VBD
charged_VBN
to_PIN
net_JJ
interest_NN
Expected_VBN [PRIV]
return_NN
on_PIN
pension_NN
scheme_NN
assets_NN
274_CD
118_CD
20_CD
412_CD
Interest_NN
on_PIN
scheme_NN
liabilities_NOMZ
269_CD
104_CD
27_CD
400_CD
55_CD
5_CD
14_CD
7_CD
12_CD
55_CD
Amounts_NN
recorded_VBN [WZPAST]
in_PIN
statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
Actual_JJ
return_NN
less_RB
expected_JJ
return_NN
on_PIN
pension_NN
scheme_NN
assets_NN
106_CD
82_CD
1_CD
189_CD
Experience_NN
gains_NN
losses_NN
arising_VBG [WZPRES]
on_PIN
scheme_NN
liabilities_NOMZ
11_CD
6_CD
43_CD
48_CD
47_CD
Changes_NN
in_PIN
assumptions_NOMZ
relating_VBG [WZPRES]
to_PIN
present_JJ
value_NN
of_PIN
scheme_NN
liabilities_NOMZ
62_CD
31_CD
93_CD
82_CD
117_CD
14_CD
13_CD
144_CD
35_CD
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
GlaxoSmithKline_NN
133_CD
35_CD
Employee_NN
costs_NN
continued_VBD
Post-retirement_JJ
Pensions_NN
benets_VPRT
2003_CD
UK_NN
USA_NN
Rest_VPRT
of_PIN
World_NN
Group_NN
Group_NN
m_FW
m_FW
m_FW
m_FW
m_FW [PASS]
Amounts_NN
charged_VBD
to_TO
operating_VBG
profit_NN
Current_JJ
service_NN
cost_NN
108_CD
67_CD
44_CD
219_CD
29_CD
Past_JJ
service_NN
cost_NN
7_CD
16_CD
23_CD
3_CD
Curtailments_NOMZ
settlements_NOMZ
78_CD
15_CD
93_CD
186_CD
75_CD
28_CD
289_CD
26_CD
Amounts_NN
credited_VBD
charged_VBN
to_PIN
net_JJ
interest_NN
Expected_VBN [PRIV]
return_NN
on_PIN
pension_NN
scheme_NN
assets_NN
231_CD
111_CD
17_CD
359_CD
Interest_NN
on_PIN
scheme_NN
liabilities_NOMZ
246_CD
119_CD
25_CD
390_CD
64_CD
15_CD
8_CD
8_CD
31_CD
64_CD
Amounts_NN
recorded_VBN [WZPAST]
in_PIN
statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
Actual_JJ
return_NN
less_RB
expected_JJ
return_NN
on_PIN
pension_NN
scheme_NN
assets_NN
368_CD
230_CD
10_CD
608_CD
Experience_NN
losses_NN
gains_NN
arising_VBG [WZPRES]
on_PIN
scheme_NN
liabilities_NOMZ
193_CD
5_CD
28 216 123_CD
Changes_NN
in_PIN
assumptions_NOMZ
relating_VBG [WZPRES]
to_PIN
present_JJ
value_NN
of_PIN
scheme_NN
liabilities_NOMZ
616_CD
61_CD
32_CD
709 67 441 174_CD
50 317 190_CD
Post-retirement_NOMZ
Pensions_NN
benets_VPRT
2002_CD
UK_NN
USA_NN
Rest_VPRT
of_PIN
World_NN
Group_NN
Group_NN
m_FW
m_FW
m_FW
m_FW
m_FW [PASS]
Amounts_NN
charged_VBD
to_TO
operating_VBG
profit_NN
Current_JJ
service_NN
cost_NN
118_CD
74_CD
32_CD
224_CD
24_CD
Past_JJ
service_NN
cost_NN
28_CD
34_CD
62_CD
Curtailments_NOMZ
settlements_NOMZ
1_CD
1_CD
146_CD
108_CD
33_CD
287_CD
24_CD
Amounts_NN
credited_VBD
charged_VBN
to_PIN
net_JJ
interest_NN
Expected_VBN [PRIV]
return_NN
on_PIN
pension_NN
scheme_NN
assets_NN
293_CD
129_CD
14_CD
436_CD
Interest_NN
on_PIN
scheme_NN
liabilities_NOMZ
235_CD
129_CD
22_CD
386_CD
53_CD
58_CD
8_CD
50_CD
53_CD
Amounts_NN
recorded_VBN [WZPAST]
in_PIN
statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
Actual_JJ
return_NN
less_RB
expected_JJ
return_NN
on_PIN
pension_NN
scheme_NN
assets_NN
1,024_CD
293_CD
56_CD
1,373_CD
Experience_NN
gains_NN
losses_NN
arising_VBG [WZPRES]
on_PIN
scheme_NN
liabilities_NOMZ
34_CD
3_CD
2_CD
33_CD
95_CD
Changes_NN
in_PIN
assumptions_NOMZ
relating_VBG [WZPRES]
to_PIN
present_JJ
value_NN
of_PIN
scheme_NN
liabilities_NOMZ
15_CD
57_CD
10_CD
62_CD
124_CD
1,005_CD
353_CD
44_CD
1,402_CD
29_CD
134_CD
GlaxoSmithKline_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
35_CD
Employee_NN
costs_NN
continued_VBD
Post-retirement_JJ
Pensions_NN
benets_VPRT
Movements_NOMZ
in_PIN
deficits_NN
UK_NN
USA_NN
Rest_VPRT
of_PIN
World_NN
Group_NN
Group_NN
m_FW
m_FW
m_FW
m_FW
m_FW
deficits_NN
in_PIN
schemes_NN
at_PIN
1st_CD
January_NN
2002 255 245 214_CD
714_CD
854_CD
Exchange_NN
adjustments_NOMZ
37_CD
9_CD
28_CD
85_CD
Charged_VBN
to_TO
operating_VBG
profit_NN
146_CD
108_CD
33_CD
287_CD
24_CD
Employer_NN
contributions_NOMZ
154_CD
249_CD
61_CD
464_CD
41_CD
Other_JJ
finance_NN
income_NN
expense_NN
58_CD
8_CD
50_CD
53_CD
Actuarial_JJ
losses_NN
recognized_VBN [PRIV] [WZPAST]
in_PIN
statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
1,005_CD
353_CD
44_CD
1,402_CD
29_CD
deficits_NN
in_PIN
schemes_NN
at_PIN
31st_CD
December_NN
2002_CD
1,194_CD
420_CD
247_CD
1,861_CD
834_CD
Exchange_NN
adjustments_NOMZ
20_CD
15_CD
5_CD
96_CD
Charged_VBN
to_TO
operating_VBG
profit_NN
186_CD
75_CD
28_CD
289_CD
26_CD
Employer_NN
contributions_NOMZ
341_CD
159_CD
98_CD
598_CD
41_CD
Other_JJ
finance_NN
income_NN
expense_NN
15_CD
8_CD
8_CD
31_CD
64_CD
Actuarial_JJ
losses_NN
gains_NN
recognized_VBN [PRIV] [WZPAST]
in_PIN
statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
441_CD
174 50 317 190_CD
deficits_NN
in_PIN
schemes_NN
at_PIN
31st_CD
December_NN
2003_CD
1,495_CD
150_CD
250_CD
1,895_CD
977_CD
Exchange_NN
adjustments_NOMZ
9_CD
4_CD
13_CD
59_CD
Charged_VBN
to_TO
operating_VBG
profit_NN
125_CD
58_CD
44_CD
227_CD
37_CD
Employer_NN
contributions_NOMZ
336_CD
65_CD
68_CD
469_CD
40_CD
Other_JJ
finance_NN
income_NN
expense_NN
5_CD
14_CD
7_CD
12_CD
55_CD
Actuarial_JJ
losses_NN
gains_NN
recognized_VBN [PRIV] [WZPAST]
in_PIN
statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
117_CD
14_CD
13_CD
144_CD
35_CD
deficits_NN
in_PIN
schemes_NN
at_PIN
31st_CD
December_NN
2004_CD
1,162_CD
106_CD
216_CD
1,484_CD
1,005_CD
Post-retirement_NOMZ
Pensions_NN
benets_VPRT
History_NN
of_PIN
experience_NN
gains_NN
and_PHC
losses_NN
UK_NN
USA_NN
Rest_VPRT
of_PIN
World_NN
Group_NN
Group_NN
m_FW
m_FW
m_FW
m_FW
m_FW [BEMA]
2004_CD
Difference_NN
between_PIN
the_DT
expected_VBN [PRIV]
and_CC
actual_JJ
return_NN
on_PIN
scheme_NN
assets_NN
m_VPRT [BEMA]
106_CD
82_CD
1_CD
189_CD
Percentage_NN
of_PIN
scheme_NN
assets_NN
at_PIN
31st_CD
December_NN
2004_CD
3_CD
%_NN
5_CD
%_NN
3_CD
%_NN
Experience_NN
gains_NN
losses_NN
of_PIN
scheme_NN
liabilities_NOMZ
m_VPRT [BEMA]
11_CD
6_CD
43_CD
48_CD
47_CD
Percentage_NN
of_PIN
present_JJ
value_NN
of_PIN
scheme_NN
liabilities_NOMZ
at_PIN
31st_CD
December_NN
2004_CD
6_CD
%_NN
1_CD
%_NN
5_CD
%_NN
Total_JJ
amount_NN
recognized_VBN [PRIV] [WZPAST]
in_PIN
statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
m_VPRT [BEMA]
117_CD
14_CD
13_CD
144_CD
35_CD
Percentage_NN
of_PIN
present_JJ
value_NN
of_PIN
scheme_NN
liabilities_NOMZ
at_PIN
31st_CD
December_NN
2004_CD
2_CD
%_NN
1_CD
%_NN
2_CD
%_NN
2_CD
%_NN
3_CD
%_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
GlaxoSmithKline_NN
135_CD
35_CD
Employee_NN
costs_NN
continued_VBD
Post-retirement_JJ
Pensions_NN
benets_VPRT
History_NN
of_PIN
experience_NN
gains_NN
and_PHC
losses_NN
UK_NN
USA_NN
Rest_VPRT
of_PIN
World_NN
Group_NN
Group_NN
m_FW
m_FW
m_FW
m_FW
m_FW [BEMA]
2003_CD
Difference_NN
between_PIN
the_DT
expected_VBN [PRIV]
and_CC
actual_JJ
return_NN
on_PIN
scheme_NN
assets_NN
m_VPRT [BEMA]
368_CD
230_CD
10_CD
608_CD
Percentage_NN
of_PIN
scheme_NN
assets_NN
at_PIN
31st_CD
December_NN
2003_CD
10_CD
%_NN
14_CD
%_NN
2_CD
%_NN
11_CD
%_NN
Experience_NN
losses_NN
gains_NN
of_PIN
scheme_NN
liabilities_NOMZ
m_VPRT [BEMA]
193_CD
5_CD
28 216 123_CD
Percentage_NN
of_PIN
present_JJ
value_NN
of_PIN
scheme_NN
liabilities_NOMZ
at_PIN
31st_CD
December_NN
2003_CD
4_CD
%_NN
4_CD
%_NN
3_CD
%_NN
13_CD
%_NN
Total_JJ
amount_NN
recognized_VBN [PRIV] [WZPAST]
in_PIN
statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
m_VPRT [BEMA]
441_CD
174 50 317 190_CD
Percentage_NN
of_PIN
present_JJ
value_NN
of_PIN
scheme_NN
liabilities_NOMZ
at_PIN
31st_CD
December_NN
2003_CD
9_CD
%_NN
10_CD
%_NN
7_CD
%_NN
4_CD
%_NN
19_CD
%_NN
2002_CD
Difference_NN
between_PIN
the_DT
expected_VBN [PRIV]
and_CC
actual_JJ
return_NN
on_PIN
scheme_NN
assets_NN
m_VPRT [BEMA]
1,024_CD
293_CD
56_CD
1,373_CD
Percentage_NN
of_PIN
scheme_NN
assets_NN
at_PIN
31st_CD
December_NN
2002_CD
35_CD
%_NN
22_CD
%_NN
17_CD
%_NN
30_CD
%_NN
Experience_NN
gains_NN
losses_NN
of_PIN
scheme_NN
liabilities_NOMZ
m_VPRT [BEMA]
34_CD
3_CD
2_CD
33_CD
95_CD
Percentage_NN
of_PIN
present_JJ
value_NN
of_PIN
scheme_NN
liabilities_NOMZ
at_PIN
31st_CD
December_NN
2002_CD
1_CD
%_NN
1_CD
%_NN
11_CD
%_NN
Total_JJ
amount_NN
recognized_VBN [PRIV] [WZPAST]
in_PIN
statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
m_VPRT [BEMA]
1,005_CD
353_CD
44_CD
1,402_CD
29_CD
Percentage_NN
of_PIN
present_JJ
value_NN
of_PIN
scheme_NN
liabilities_NOMZ
at_PIN
31st_CD
December_NN
2002_CD
24_CD
%_NN
20_CD
%_NN
8_CD
%_NN
22_CD
%_NN
3_CD
%_NN
If_COND
the_DT
FRS_NN
17_CD
valuation_NOMZ
basis_NN
had_VBD [PEAS]
been_VBN [PASS]
applied_VBN
in_PIN
the_DT
financial_JJ
statements_NOMZ
instead_CONJ
of_NULL
the_DT
SSAP_NN
24_CD
valuation_NOMZ
basis_NN
,_,
the_DT
effect_NN
on_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
reserve_NN
after_IN
taking_VBG
account_NN
of_PIN
deferred_JJ
tax_NN
would_PRMD
have_VB [PEAS]
been_VBN
as_IN
follows_VPRT
:_:
2003_CD
2004_CD
restated_VBN
m_FW
m_FW
m_FW
m_FW
profit_NN
and_PHC
loss_NN
account_NN
reserve_NN
per_PIN
balance_NN
sheet_NN
4,781_CD
4,112_CD
Pension_NN
liability_NOMZ
under_IN
FRS_NN
17_CD
1,020_CD
1,300_CD
Net_JJ
pension_NN
asset_NN
under_IN
SSAP_NN
24_CD
per_PIN
balance_NN
sheet_NN
387_CD
152_CD
1,407_CD
1,452_CD
Post-retirement_NOMZ
healthcare_NN
schemes_NN
under_IN
FRS_NN
17 640 638_CD
Net_JJ
post-retirement_JJ
healthcare_NN
schemes_NN
provision_NN
per_PIN
balance_NN
sheet_NN
379 372 261 266_CD
profit_NN
and_PHC
loss_NN
account_NN
reserve_NN
including_VBG [WZPRES]
FRS_NN
17_CD
pension_NN
and_CC
post-retirement_JJ
healthcare_NN
liability_NOMZ
3,113_CD
2,394_CD
136_CD
GlaxoSmithKline_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
36_CD
Employee_NN
share_NN
schemes_NN
The_DT
Group_NN
operates_VPRT
share_NN
option_NOMZ
schemes_NN
,_,
whereby_OSUB
options_NOMZ
are_VPRT [PASS]
granted_VBN [SUAV]
to_PIN
employees_NN
to_TO
acquire_VB
shares_NN
or_CC
ADSs_NN
in_PIN
GlaxoSmithKline_NN
plc_NN
at_PIN
the_DT
grant_NN
price_NN
,_,
and_ANDC
share_NN
award_NN
schemes_NN
,_,
whereby_OSUB
awards_NN
are_VPRT [PASS]
granted_VBN [SUAV]
to_PIN
employees_NN
to_TO
acquire_VB
shares_NN
or_CC
ADSs_NN
in_PIN
GlaxoSmithKline_NN
plc_NN
at_PIN
no_SYNE
cost_NN
,_,
subject_JJ
to_PIN
the_DT
achievement_NOMZ
of_PIN
performance_NN
targets_NN
._.
In_PIN
2004_CD
,_,
the_DT
Group_NN
introduced_VBD
a_DT
new_JJ
share_NN
award_NN
scheme_NN
,_,
the_DT
Restricted_NN
Share_NN
Plan_NN
,_,
whereby_OSUB
awards_NN
are_VPRT [PASS]
granted_VBN [SUAV]
to_PIN
employees_NN
to_TO
acquire_VB
shares_NN
or_CC
ADSs_NN
in_PIN
GlaxoSmithKline_NN
plc_NN
at_PIN
no_SYNE
cost_NN
after_IN
a_DT
three_CD
year_NN
period_NN
._.
The_DT
granting_VBG [SUAV]
of_PIN
restricted_JJ
share_NN
awards_NN
has_VPRT [PEAS]
replaced_VBN
the_DT
granting_VBG [SUAV]
of_PIN
options_NOMZ
to_PIN
certain_JJ
employees_NN
as_IN
the_DT
cost_NN
of_PIN
the_DT
scheme_NN
more_EMPH
readily_RB
equates_VPRT
to_PIN
the_DT
potential_JJ
gain_NN
to_TO
be_VB [BYPA]
made_VBN
by_PIN
the_DT
employee_NN
._.
The_DT
Group_NN
operates_VPRT
share_NN
option_NOMZ
schemes_NN
and_CC
savings-related_JJ
share_NN
option_NOMZ
schemes_NN
._.
Grants_NN
under_IN
share_NN
option_NOMZ
schemes_NN
are_VPRT [BEMA]
normally_RB
exercisable_PRED
between_PIN
three_CD
and_CC
ten_CD
years_NN
from_PIN
the_DT
date_NN
of_PIN
grant_NN
._.
Grants_NN
under_IN
savings-related_JJ
share_NN
option_NOMZ
schemes_NN
are_VPRT [BEMA]
normally_RB
exercisable_PRED
after_IN
three_CD
years_NN
saving_VBG [WZPRES]
._.
Options_NOMZ
under_IN
the_DT
share_NN
option_NOMZ
schemes_NN
are_VPRT [SPAU] [PASS]
normally_RB
granted_VBN [SUAV]
at_PIN
the_DT
market_NN
price_NN
ruling_NN
at_PIN
the_DT
date_NN
of_PIN
grant_NN
._.
In_PIN
accordance_NN
with_PIN
UK_NN
practice_NN
,_,
the_DT
majority_NOMZ
of_PIN
options_NOMZ
under_IN
the_DT
savings-related_JJ
share_NN
option_NOMZ
schemes_NN
are_VPRT [PASS]
granted_VBN [SUAV]
at_PIN
a_DT
price_NN
20_CD
per_PIN
cent_NN
below_PLACE
the_DT
market_NN
price_NN
ruling_NN
at_PIN
the_DT
date_NN
of_PIN
grant_NN
._.
In_PIN
accordance_NN
with_PIN
the_DT
exemption_NOMZ
granted_VBN [SUAV] [WZPAST]
in_PIN
UITF_NN
17_CD
revised_VBN
no_SYNE
charge_NN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
is_VPRT [PASS]
made_VBN
in_PIN
relation_NOMZ
to_PIN
these_DEMO
savings-related_JJ
share_NN
option_NOMZ
schemes_NN
._.
Share_NN
option_NOMZ
Share_NN
option_NOMZ
Savings-related_JJ
Options_NOMZ
outstanding_JJ
schemes_NN
shares_NN
schemes_NN
ADSs_NN
share_NN
option_NOMZ
schemes_NN
Weighted_NN
Weighted_NN
Weighted_NN
Number_NN
exercise_NN
Number_NN
exercise_NN
Number_NN
exercise_NN
000_CD
price_NN
000_CD
price_NN
000_CD
price_NN
At_PIN
31st_CD
December_NN
2001_CD
179,936_CD
15.67_CD
73,825_CD
$_$
50.31_CD
8,200_CD
14.13_CD
Options_NOMZ
granted_VBN [SUAV]
33,454_CD
11.91_CD
22,991_CD
$_$
37.57_CD
9,793_CD
9.16_CD
Options_NOMZ
exercised_VBN
8,857_CD
10.55_CD
1,504_CD
$_$
21.75_CD
398_CD
14.04_CD
Options_NOMZ
canceled_VBN
7,061_CD
17.53_CD
4,435_CD
$_$
54.69_CD
4,607_CD
14.41_CD
At_PIN
31st_CD
December_NN
2002_CD
197,472_CD
15.20_CD
90,877_CD
$_$
47.34_CD
12,988_CD
10.29_CD
Options_NOMZ
granted_VBN [SUAV]
32,750_CD
12.84_CD
23,630_CD
$_$
43.34_CD
1,416_CD
10.20_CD
Options_NOMZ
exercised_VBN
4,728_CD
4.75_CD
1,828_CD
$_$
22.22_CD
112_CD
10.23_CD
Options_NOMZ
canceled_VBN
19,789_CD
7.45_CD
6,150_CD
$_$
32.73_CD
3,709_CD
12.23_CD
At_PIN
31st_CD
December_NN
2003_CD
205,705_CD
14.89_CD
106,529_CD
$_$
46.58_CD
10,583_CD
9.59_CD
Options_NOMZ
granted_VBN [SUAV]
9,837_CD
11.23_CD
9,222_CD
$_$
42.99_CD
1,580_CD
9.52_CD
Options_NOMZ
exercised_VBN
5,764_CD
6.54_CD
1,845_CD
$_$
25.65_CD
232_CD
9.18_CD
Options_NOMZ
canceled_VBN
11,997_CD
15.33_CD
3,427_CD
$_$
48.28_CD
1,790_CD
10.46_CD
At_PIN
31st_CD
December_NN
2004_CD
197,781_CD
14.92_CD
110,479_CD
$_$
46.57_CD
10,141_CD
9.44_CD
Range_NN
of_PIN
exercise_NN
prices_NN
3.98_CD
19.77_CD
$_$
12.83_CD
$_$
61.35_CD
9.16_CD
14.12_CD
In_PIN
order_NN
to_TO
encourage_VB
employees_NN
to_TO
convert_VB
options_NOMZ
,_,
excluding_VBG
savings-related_JJ
share_NN
options_NOMZ
,_,
held_VBN [PRIV]
over_IN
Glaxo_NN
Wellcome_NN
or_CC
SmithKline_NN
Beecham_NN
shares_NN
or_CC
ADSs_NN
,_,
into_PIN
those_DEMO
over_IN
GlaxoSmithKline_NN
shares_NN
or_CC
ADSs_NN
,_,
a_DT
program_NN
was_VBD [PASS]
established_VBN [PRIV]
to_TO
give_VB
an_DT
additional_JJ
cash_NN
benefit_NN
of_PIN
10_CD
per_PIN
cent_NN
of_PIN
the_DT
exercise_NN
price_NN
of_PIN
the_DT
original_JJ
option_NOMZ
provided_VBD
that_DEMO
the_DT
employee_NN
did_VBD
not_XX0
voluntarily_RB
leave_VB
the_DT
Group_NN
for_PIN
two_CD
years_NN
from_PIN
the_DT
date_NN
of_PIN
the_DT
merger_NN
and_CC
did_VBD
not_XX0
exercise_VB
the_DT
option_NOMZ
before_IN
the_DT
earlier_TIME
of_PIN
six_CD
months_NN
from_PIN
the_DT
expiry_NN
date_NN
of_PIN
the_DT
original_JJ
option_NOMZ
and_CC
two_CD
years_NN
from_PIN
the_DT
date_NN
of_PIN
the_DT
merger_NN
._.
The_DT
cash_NN
benefit_NN
will_PRMD [SPAU]
also_RB
be_VB [PASS]
paid_VBN
if_COND
the_DT
options_NOMZ
expire_VPRT
unexercised_JJ
if_COND
the_DT
market_NN
price_NN
is_VPRT
below_PLACE
the_DT
exercise_NN
price_NN
on_PIN
the_DT
date_NN
of_PIN
expiry_NN
._.
There_EX
has_VPRT [PEAS]
been_VBN
no_SYNE
change_NN
in_PIN
the_DT
effective_JJ
exercise_NN
price_NN
of_PIN
any_QUAN
outstanding_JJ
options_NOMZ
during_PIN
the_DT
year_NN
._.
No_DT
further_RB
options_NOMZ
were_VBD [PASS]
granted_VBN [SUAV]
between_PIN
31st_CD
December_NN
2004_CD
and_CC
25th_JJ
February_NN
2005_CD
._.
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
GlaxoSmithKline_NN
137_CD
36_CD
Employee_NN
share_NN
schemes_NN
continued_VBD
Share_NN
option_NOMZ
Share_NN
option_NOMZ
Savings-related_JJ
Options_NOMZ
exercisable_JJ
schemes_NN
shares_NN
schemes_NN
ADSs_NN
share_NN
option_NOMZ
schemes_NN
Weighted_NN
Weighted_NN
Weighted_NN
Number_NN
exercise_NN
Number_NN
exercise_NN
Number_NN
exercise_NN
000_CD
price_NN
000_CD
price_NN
000_CD
price_NN
At_PIN
31st_CD
December_NN
2002_CD
72,611_CD
14.33_CD
27,129_CD
$_$
48.89_CD
2,227_CD
13.27_CD
At_PIN
31st_CD
December_NN
2003_CD
79,693_CD
14.56_CD
22,364_CD
$_$
49.82_CD
192_CD
16.48_CD
At_PIN
31st_CD
December_NN
2004_CD
126,917_CD
16.49_CD
57,421_CD
$_$
51.75_CD
270_CD
14.12_CD
GlaxoSmithKline_NN
share_NN
award_NN
schemes_NN
Performance_NN
Share_NN
Plan_NN
The_NN
Group_NN
operates_VPRT
a_DT
Performance_NN
Share_NN
Plan_NN
whereby_OSUB
awards_NN
are_VPRT [PASS]
granted_VBN [SUAV]
to_PIN
Directors_NN
and_CC
senior_JJ
executives_NN
at_PIN
no_SYNE
cost_NN
._.
The_DT
percentage_NN
of_PIN
each_QUAN
award_NN
that_TOBJ
vests_NN
is_VPRT [PASS]
based_VBN
upon_PIN
the_DT
performance_NN
of_PIN
the_DT
Group_NN
over_IN
a_DT
three_CD
year_NN
measurement_NOMZ
period_NN
._.
The_DT
performance_NN
conditions_NOMZ
consist_VPRT
of_PIN
two_CD
parts_NN
,_,
each_QUAN
of_PIN
which_WDT [PIRE]
applies_VPRT
to_PIN
50_CD
per_PIN
cent_NN
of_PIN
the_DT
award_NN
._.
For_PIN
awards_NN
granted_VBN [SUAV] [WZPAST]
in_PIN
2002_CD
and_CC
2003_CD
,_,
the_DT
first_JJ
part_NN
of_PIN
the_DT
condition_NOMZ
compares_VPRT
GlaxoSmithKlines_NN
Total_NN
Shareholder_NN
Return_NN
TSR_NN
over_IN
the_DT
period_NN
with_PIN
the_DT
TSR_NN
of_PIN
companies_NN
in_PIN
the_DT
UK_NN
FTSE_NN
100_CD
Index_NN
over_IN
the_DT
same_JJ
period_NN
._.
For_PIN
awards_NN
granted_VBN [SUAV] [WZPAST]
in_PIN
2004_CD
the_DT
first_JJ
part_NN
of_PIN
the_DT
condition_NOMZ
compares_VPRT
GlaxoSmithKlines_NN
TSR_NN
over_IN
the_DT
period_NN
with_PIN
TSR_NN
of_PIN
13_CD
pharmaceutical_JJ
companies_NN
in_PIN
the_DT
comparator_NN
group_NN
over_IN
the_DT
same_JJ
period_NN
._.
The_DT
second_JJ
part_NN
of_PIN
the_DT
performance_NN
condition_NOMZ
compares_VPRT
GlaxoSmithKlines_NN
earnings_GER
per_PIN
share_NN
growth_NN
to_PIN
the_DT
increase_NN
in_PIN
the_DT
UK_NN
Retail_NN
Prices_NN
Index_NN
over_IN
the_DT
three_CD
year_NN
performance_NN
period_NN
._.
Awards_RB
granted_VBN [SUAV]
to_PIN
Directors_NN
and_PHC
members_NN
of_PIN
the_DT
CET_NN
from_PIN
15th_JJ
December_NN
2003_CD
are_VPRT [BEMA]
subject_PRED
to_PIN
a_DT
single_JJ
performance_NN
condition_NOMZ
which_WDT [WHSUB]
compares_VPRT
GlaxoSmithKlines_NN
TSR_NN
over_IN
the_DT
period_NN
with_PIN
the_DT
TSR_NN
of_PIN
companies_NN
in_PIN
the_DT
comparator_NN
group_NN
over_IN
the_DT
same_JJ
period_NN
._.
Other_JJ
awards_NN
Shares_NN
ADSs_NN
Number_NN
of_PIN
shares_NN
and_PHC
ADSs_NN
issuable_JJ
Number_NN
000_CD
Number_NN
000_CD
At_PIN
31st_CD
December_NN
2001_CD
3,181_CD
1,760_CD
Awards_NN
granted_VBD [SUAV]
863_CD
477_CD
Awards_NN
exercised_VBN
728_CD
197_CD
Awards_NN
canceled_VBD
152_CD
97_CD
At_PIN
31st_CD
December_NN
2002_CD
3,164_CD
1,943_CD
Awards_NN
granted_VBD [SUAV]
1,070_CD
832_CD
Awards_NN
exercised_VBN
625_CD
189_CD
Awards_NN
canceled_VBD
109_CD
107_CD
At_PIN
31st_CD
December_NN
2003_CD
3,500_CD
2,479_CD
Awards_NN
granted_VBD [SUAV]
1,778_CD
1,339_CD
Awards_NN
exercised_VBN
409_CD
187_CD
Awards_NN
canceled_VBD
520_CD
276_CD
At_PIN
31st_CD
December_NN
2004_CD
4,349_CD
3,355_CD
Restricted_NN
Share_NN
Plan_NN
The_NN
Group_NN
operates_VPRT
a_DT
Restricted_NN
Share_NN
Plan_NN
whereby_OSUB
awards_NN
are_VPRT [PASS]
granted_VBN [SUAV]
to_PIN
employees_NN
at_PIN
no_SYNE
cost_NN
._.
The_DT
award_NN
vests_NN
after_IN
three_CD
years_NN
with_PIN
no_SYNE
performance_NN
criteria_NN
attached_VBN
._.
Shares_NN
ADSs_NN
Number_NN
of_PIN
shares_NN
and_PHC
ADSs_NN
issuable_JJ
Number_NN
000_CD
Number_NN
000_CD
At_PIN
31st_CD
December_NN
2003_CD
Awards_NN
granted_VBD [SUAV]
4,419_CD
3,562_CD
At_PIN
31st_CD
December_NN
2004_CD
4,419_CD
3,562_CD
138_CD
GlaxoSmithKline_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
36_CD
Employee_NN
share_NN
schemes_NN
continued_VBD
Employee_NN
Share_NN
Ownership_NN
Plan_NN
Trusts_NN
The_NN
Group_NN
sponsors_VPRT
Employee_NN
Share_NN
Ownership_NN
Plan_NN
ESOP_NN
Trusts_NN
to_TO
acquire_VB
and_PHC
hold_VB [PRIV]
shares_NN
in_PIN
GlaxoSmithKline_NN
plc_NN
to_TO
satisfy_VB
awards_NN
made_VBN
under_IN
employee_NN
incentive_NN
plans_NN
and_PHC
options_NOMZ
granted_VBN [SUAV]
under_IN
employee_NN
share_NN
option_NOMZ
schemes_NN
._.
The_DT
trustees_NN
of_PIN
the_DT
ESOP_NN
Trusts_NN
purchase_NN
shares_NN
on_PIN
the_DT
open_JJ
market_NN
with_PIN
finance_NN
provided_VBN [WZPAST]
by_PIN
the_DT
Group_NN
by_PIN
way_NN
of_PIN
loans_NN
or_CC
contributions_NOMZ
._.
The_DT
expected_VBN [PRIV]
cost_NN
of_PIN
the_DT
obligations_NOMZ
to_TO
deliver_VB
shares_NN
under_IN
the_DT
schemes_NN
are_VPRT [SPAU] [PASS]
normally_RB
spread_VBN
over_IN
the_DT
periods_NN
of_PIN
service_NN
in_PIN
respect_NN
of_PIN
which_WDT [PIRE]
the_DT
awards_NN
and_PHC
options_NOMZ
are_VPRT [PASS]
granted_VBN [SUAV]
._.
An_DT
accelerated_JJ
charge_NN
was_VBD [PASS]
made_VBN
in_PIN
2000_CD
in_PIN
respect_NN
of_PIN
the_DT
outstanding_JJ
cost_NN
of_PIN
providing_VBG
shares_NN
for_PIN
awards_NN
and_PHC
options_NOMZ
which_WDT [WHSUB]
became_VBD
exercisable_JJ
solely_RB
as_CONJ
a_NULL
result_NULL
of_PIN
the_DT
merger_NN
._.
Shares_NN
held_VBD [PRIV]
for_PIN
share_NN
award_NN
schemes_NN
2003_CD
2004_CD
restated_VBN
Number_NN
of_PIN
shares_NN
000_CD
22,992_CD
7,748_CD
m_NN
m_NN [BEMA]
Nominal_JJ
value_NN
6_CD
2_CD
Carrying_VBG
value_NN
213_CD
84_CD
Market_NN
value_NN
281_CD
99_CD
Shares_NN
held_VBN [PRIV] [WZPAST]
for_PIN
share_NN
option_NOMZ
schemes_NN
2004_CD
2003_CD
Number_NN
of_PIN
shares_NN
000_CD
151,535_CD
170,066_CD
m_NN
m_NN [BEMA]
Nominal_JJ
value_NN
38_CD
43_CD
Carrying_VBG
value_NN
2,361_CD
2,645_CD
Market_NN
value_NN
1,852_CD
2,177_CD
Results_NN
in_PIN
2003_CD
have_VPRT [PEAS]
been_VBN [PASS]
restated_VBN
following_VBG
the_DT
implementation_NOMZ
of_PIN
UITF17_NN
revised_VBD
._.
UITF17_CD
revised_VBN
requires_VPRT [SUAV]
that_THVC
the_DT
minimum_JJ
expense_NN
should_NEMD
be_VB [BEMA]
the_DT
difference_NN
between_PIN
the_DT
fair_JJ
value_NN
of_PIN
the_DT
shares_NN
at_PIN
the_DT
date_NN
of_PIN
award_NN
and_CC
the_DT
amount_NN
that_TOBJ
an_DT
employee_NN
may_POMD
be_VB [PASS]
required_VBN [SUAV]
to_TO
pay_VB
for_PIN
the_DT
shares_NN
i._VPRT
e._VB
the_DT
intrinsic_JJ
value_NN
of_PIN
the_DT
award_NN
._.
The_DT
Trusts_NN
also_RB
acquire_VB
and_PHC
hold_VB [PRIV]
shares_NN
to_TO
meet_VB
notional_JJ
dividends_NN
re-invested_VBD
on_PIN
deferred_VBN
awards_NN
under_IN
the_DT
SmithKline_NN
Beecham_NN
Mid-Term_NN
Incentive_NN
Plan_NN
._.
The_DT
trustees_NN
have_VPRT [PEAS]
waived_VBN
their_TPP3
rights_NN
to_PIN
dividends_NN
on_PIN
the_DT
shares_NN
held_VBN [PRIV] [WZPAST]
by_PIN
the_DT
Employee_NN
Share_NN
Ownership_NN
Trusts_NN
._.
Option_NOMZ
pricing_GER
For_PIN
the_DT
purposes_NN
of_PIN
valuing_VBG
options_NOMZ
to_TO
arrive_VB
at_PIN
the_DT
stock-based_JJ
compensation_NOMZ
adjustment_NOMZ
in_PIN
the_DT
Reconciliation_NOMZ
to_PIN
US_FPP1
accounting_GER
principles_NN
in_PIN
Note_NN
37_CD
,_,
the_DT
Black-Scholes_NN
option_NOMZ
pricing_GER
model_NN
has_VPRT [PEAS]
been_VBN [PASS]
used_VBN
._.
The_DT
assumptions_NOMZ
used_VBN [WZPAST]
in_PIN
the_DT
model_NN
for_PIN
2004_CD
and_CC
2003_CD
are_VPRT
as_IN
follows_VPRT
:_:
2004_CD
2003_CD
Risk-free_JJ
interest_NN
rate_NN
3.3_CD
%_NN
4.6_CD
%_NN
4.2_CD
%_NN
4.9_CD
%_NN
Dividend_NN
yield_NN
3.1_CD
%_NN
2.9_CD
%_NN
Volatility_NOMZ
26_CD
%_NN
29_CD
%_NN
34_CD
%_NN
Expected_VBN [PRIV]
lives_NN
of_PIN
options_NOMZ
granted_VBN [SUAV]
under_IN
:_:
Share_NN
option_NOMZ
schemes_NN
5_CD
years_NN
5_CD
years_NN
Savings-related_JJ
share_NN
option_NOMZ
schemes_NN
3_CD
years_NN
3_CD
years_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
GlaxoSmithKline_NN
139_CD
37_CD
Reconciliation_NOMZ
to_PIN
US_FPP1
accounting_GER
principles_NN
Additionally_RB
,_,
the_DT
Group_NN
reassesses_VPRT
the_DT
useful_JJ
lives_NN
of_PIN
existing_VBG
recognized_VBN [PRIV]
intangible_JJ
assets_NN
._.
Intangible_JJ
assets_NN
deemed_VBD [PRIV]
to_TO
have_VB
The_DT
analyses_NN
and_PHC
reconciliations_NOMZ
presented_VBN [WZPAST]
in_PIN
this_DEMO
Note_NN
represent_VPRT
indefinite_JJ
lives_NN
are_VPRT [SPAU] [PASS]
no_RB
longer_RB
amortised_VBN
,_,
instead_CONJ
they_TPP3
are_VPRT [PASS]
tested_VBN
the_DT
financial_JJ
information_NOMZ
prepared_VBN [WZPAST]
on_PIN
the_DT
basis_NN
of_PIN
US_FPP1
Generally_RB
annually_RB
for_PIN
potential_JJ
impairment_NOMZ
._.
Separable_JJ
intangible_JJ
assets_NN
Accepted_JJ
Accounting_GER
Principles_NN
US_FPP1
GAAP_NN
rather_RB
than_PIN
UK_NN
GAAP_NN
._.
with_PIN
nite_JJ
lives_NN
continue_VPRT
to_TO
be_VB [PASS]
amortised_VBN
over_IN
their_TPP3
useful_JJ
lives_NN
._.
Summary_NN
of_PIN
material_NN
differences_NN
between_PIN
UK_NN
and_PHC
US_FPP1
GAAP_NN
The_NN
Group_NN
adopted_VBD
SFAS_NN
142_CD
as_IN
of_PIN
1st_CD
January_NN
2002_CD
._.
The_DT
Acquisition_NOMZ
of_PIN
SmithKline_NN
Beecham_NN
implementation_NOMZ
of_PIN
SFAS_NN
142_CD
resulted_VBD
in_PIN
no_SYNE
impairment_NOMZ
of_PIN
the_DT
The_DT
combination_NOMZ
of_PIN
Glaxo_NN
Wellcome_NN
plc_NN
and_PHC
SmithKline_NN
Beecham_NN
Groups_NN
goodwill_NN
and_CC
an_DT
initial_JJ
impairment_NOMZ
of_PIN
173_CD
million_CD
plc_NN
was_VBD [PASS]
accounted_VBN
for_PIN
as_IN
a_DT
merger_NN
pooling_VBG [WZPRES]
of_PIN
interests_NN
in_PIN
127_CD
million_CD
net_NN
of_PIN
tax_NN
on_PIN
indefinite-lived_JJ
assets_NN
._.
This_DEMP
is_VPRT [PASS]
shown_VBN [PRIV]
accordance_NN
with_PIN
UK_NN
GAAP_NN
._.
Under_IN
US_FPP1
GAAP_NN
,_,
this_DEMO
business_NOMZ
as_IN
a_DT
cumulative_JJ
effect_NN
of_PIN
an_DT
accounting_GER
change_NN
._.
combination_NOMZ
did_VBD
not_XX0
qualify_VB
for_PIN
pooling_VBG
of_PIN
interests_NN
accounting_VBG [WZPRES]
Under_IN
UK_NN
GAAP_NN
,_,
costs_VPRT
to_TO
be_VB [PASS]
incurred_VBN
in_PIN
integrating_VBG
and_CC
and_CC
Glaxo_NN
Wellcome_NN
was_VBD [PASS]
determined_VBN [SUAV] [PRIV]
to_TO
be_VB [BEMA]
the_DT
accounting_GER
restructuring_VBG [WZPRES]
the_DT
Wellcome_NN
,_,
SmithKline_NN
Beecham_NN
and_PHC
Block_NN
Drug_NN
acquirer_NN
in_PIN
a_DT
purchase_NN
business_NOMZ
combination_NOMZ
._.
businesses_NOMZ
following_VBG [WZPRES]
the_DT
acquisitions_NOMZ
in_PIN
1995_CD
,_,
2000_CD
and_CC
2001_CD
Accordingly_RB
the_DT
net_JJ
assets_NN
of_PIN
SmithKline_NN
Beecham_NN
were_VBD [BEMA]
fair_PRED
valued_VBN
respectively_RB
were_VBD [PASS]
charged_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
post_NN
as_IN
at_PIN
the_DT
date_NN
of_PIN
acquisition_NOMZ
._.
As_CONJ
a_NULL
result_NULL
of_PIN
the_DT
fair_JJ
value_NN
exercise_NN
,_,
acquisition_NOMZ
._.
Under_IN
US_FPP1
GAAP_NN
,_,
certain_JJ
of_PIN
such_JJ
costs_NN
were_VBD [PASS]
considered_VBN [PRIV]
increases_NN
in_PIN
the_DT
values_NN
of_PIN
SmithKline_NN
Beechams_NN
inventory_NN
,_,
tangible_JJ
in_PIN
the_DT
allocation_NOMZ
of_PIN
purchase_NN
consideration_NOMZ
thereby_RB
affecting_VBG
xed_JJ
assets_NN
,_,
investments_NOMZ
and_PHC
pension_NN
obligations_NOMZ
were_VBD [PASS]
recognized_VBN [PRIV] [THATD]
the_DT
goodwill_NN
arising_VBG [WZPRES]
on_PIN
acquisition_NOMZ
._.
and_ANDC
fair_JJ
market_NN
values_NN
attributed_VBD
to_PIN
its_PIT
intangible_JJ
assets_NN
,_,
mainly_RB
Under_IN
UK_NN
GAAP_NN
,_,
certain_JJ
intangible_JJ
assets_NN
related_VBN [WZPAST]
to_PIN
specic_JJ
product_NN
rights_NN
inclusive_NN
of_PIN
patents_NN
and_PHC
trade_NN
marks_NN
and_CC
in-process_JJ
compounds_NN
or_CC
products_NN
which_WDT [WHSUB]
are_VPRT [PASS]
purchased_VBN
from_PIN
a_DT
third_JJ
party_NN
research_NN
and_PHC
development_NOMZ
,_,
together_RB
with_PIN
appropriate_JJ
deferred_VBN
and_PHC
are_VPRT [PASS]
developed_VBN
for_PIN
commercial_JJ
applications_NOMZ
are_VPRT [PASS]
capitalized_VBN
._.
The_DT
difference_NN
between_PIN
the_DT
cost_NN
of_PIN
acquisition_NOMZ
Under_IN
US_FPP1
GAAP_NN
,_,
payments_NOMZ
made_VBD
for_PIN
these_DEMO
compounds_NN
or_CC
products_NN
and_CC
the_DT
fair_JJ
value_NN
of_PIN
the_DT
assets_NN
and_PHC
liabilities_NOMZ
of_PIN
SmithKline_NN
which_WDT [WHSUB]
are_VPRT [BEMA]
still_RB
in_PIN
development_NOMZ
and_CC
have_VPRT [PEAS]
not_XX0
yet_RB
received_VBN
regulatory_JJ
Beecham_NN
has_VPRT [PEAS]
been_VBN [PASS]
recorded_VBN
as_IN
goodwill_NN
._.
approval_NN
are_VPRT [PASS]
charged_VBN
directly_RB
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
Capitalised_VBN
interest_NN
until_IN
such_JJ
time_NN
that_TOBJ
they_TPP3
receive_VPRT
regulatory_JJ
approval_NN
._.
Under_IN
UK_NN
GAAP_NN
,_,
the_DT
Group_NN
does_VPRT
not_XX0
capitalize_VB
interest_NN
._.
US_FPP1
GAAP_NN
requires_VPRT [SUAV] [THATD]
interest_NN
incurred_VBN
as_IN
part_NN
of_PIN
the_DT
cost_NN
of_PIN
constructing_VBG
xed_VBD
Restructuring_GER
costs_NN
assets_NN
to_TO
be_VB [PASS]
capitalized_VBN
and_PHC
amortised_VBN
over_IN
the_DT
life_NN
of_PIN
the_DT
asset_NN
._.
Under_IN
UK_NN
GAAP_NN
,_,
restructuring_VBG
costs_NN
incurred_VBN
following_VBG
acquisitions_NOMZ
were_VBD [PASS]
charged_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
post_NN
acquisition_NOMZ
._.
Computer_NN
software_NN
For_PIN
US_FPP1
GAAP_NN
purposes_NN
,_,
certain_JJ
of_PIN
these_DEMO
costs_NN
were_VBD [PASS]
recognized_VBN [PRIV]
Under_IN
UK_NN
GAAP_NN
,_,
the_DT
Group_NN
capitalises_VPRT
costs_NN
incurred_VBN [WZPAST]
in_PIN
acquiring_VBG
as_IN
liabilities_NOMZ
upon_PIN
acquisition_NOMZ
in_PIN
the_DT
opening_GER
balance_NN
sheet_NN
._.
and_ANDC
developing_VBG
computer_NN
software_NN
for_PIN
internal_JJ
use_NN
where_RB
the_DT
software_NN
supports_VPRT
a_DT
significant_JJ
business_NOMZ
system_NN
and_CC
the_DT
Other_JJ
restructuring_GER
costs_NN
are_VPRT [PASS]
recorded_VBN
as_IN
a_DT
provision_NN
under_IN
UK_NN
expenditure_NN
leads_VPRT
to_PIN
the_DT
creation_NOMZ
of_PIN
a_DT
durable_JJ
asset_NN
._.
For_PIN
US_FPP1
GAAP_NN
when_RB
a_DT
restructuring_GER
plan_NN
has_VPRT [PEAS]
been_VBN [PASS]
announced_VBN [PUBV]
._.
Under_IN
US_FPP1
GAAP_NN
,_,
the_DT
Group_NN
applies_VPRT
SOP_NN
98-1_CD
,_,
Accounting_GER
for_PIN
the_DT
Costs_NN
of_PIN
GAAP_NN
,_,
a_DT
provision_NN
may_POMD [SPAU]
only_DWNT
be_VB [PASS]
recognized_VBN [PRIV]
when_RB [WHCL]
further_JJ
criteria_NN
Computer_NN
Software_NN
Developed_VBD
or_CC
Obtained_VBN
for_PIN
Internal_NN
Use_NN
,_,
are_VPRT [PASS]
met_VBN
or_CC
the_DT
liability_NOMZ
is_VPRT [PASS]
incurred_VBN
._.
Accordingly_RB
,_,
adjustments_NOMZ
have_VPRT
which_WDT
restricts_VPRT
the_DT
categories_NN
of_PIN
costs_NN
which_WDT [WHSUB]
can_POMD
be_VB [PASS]
capitalized_VBN
._.
been_VBN [PASS]
made_VBN
to_TO
eliminate_VB
the_DT
UK_NN
GAAP_NN
provisions_NN
for_PIN
restructuring_VBG
costs_NN
that_TSUB
do_VPRT
not_XX0
meet_VB
US_FPP1
GAAP_NN
requirements_NOMZ
._.
Goodwill_NN
and_CC
intangible_JJ
xed_JJ
assets_NN
Under_IN
UK_NN
GAAP_NN
,_,
goodwill_NN
arising_VBG [WZPRES]
on_PIN
acquisitions_NOMZ
before_IN
1998_CD
Marketable_JJ
securities_NOMZ
accounted_VBD
for_PIN
under_IN
the_DT
purchase_NN
method_NN
has_VPRT [PEAS]
been_VBN [PASS]
eliminated_VBN
Marketable_JJ
securities_NOMZ
consist_VPRT
primarily_RB
of_PIN
equity_NOMZ
securities_NOMZ
and_CC
against_PIN
shareholders_NN
funds_NN
._.
Additionally_RB
,_,
UK_NN
GAAP_NN
requires_VPRT [SUAV]
that_THVC
certain_JJ
other_JJ
liquid_JJ
investments_NOMZ
._.
Under_IN
UK_NN
GAAP_NN
,_,
these_DEMO
securities_NOMZ
on_PIN
subsequent_JJ
disposal_NN
or_CC
closure_NN
of_PIN
a_DT
business_NOMZ
,_,
any_QUAN
goodwill_NN
are_VPRT [PASS]
stated_VBN [PUBV]
at_PIN
the_DT
lower_JJ
of_PIN
cost_NN
and_CC
net_JJ
realisable_JJ
value_NN
._.
Under_IN
previously_TIME
taken_VBN
directly_RB
to_PIN
shareholders_NN
funds_NN
is_VPRT [SPAU] [PASS]
then_RB
charged_VBN
US_FPP1
GAAP_NN
these_DEMO
securities_NOMZ
are_VPRT [PASS]
considered_VBN [PRIV]
available_JJ
for_PIN
sale_NN
under_IN
against_PIN
income_NN
._.
Under_IN
UK_NN
GAAP_NN
,_,
goodwill_NN
arising_VBG [WZPRES]
on_PIN
acquisitions_NOMZ
SFAS_NN
115_CD
Accounting_GER
for_PIN
certain_JJ
investments_NOMZ
in_PIN
debt_NN
and_PHC
equity_NOMZ
from_PIN
1998_CD
is_VPRT [PASS]
capitalized_VBN
and_PHC
amortised_VBN
over_IN
a_DT
period_NN
not_XX0
exceeding_VBG
securities_NOMZ
and_CC
are_VPRT [PASS]
carried_VBN
at_PIN
fair_JJ
value_NN
,_,
with_PIN
the_DT
unrealised_JJ
gains_NN
20_CD
years_NN
._.
Intangible_JJ
assets_NN
are_VPRT [PASS]
amortised_VBN
over_IN
their_TPP3
estimated_VBN [PRIV]
and_CC
losses_NN
,_,
net_NN
of_PIN
tax_NN
,_,
recorded_VBN
as_IN
a_DT
separate_JJ
component_NN
of_PIN
useful_JJ
economic_JJ
life_NN
except_PIN
in_PIN
the_DT
case_NN
of_PIN
certain_JJ
acquired_VBN
brands_NN
shareholders_NN
equity_NOMZ
._.
where_RB
the_DT
end_NN
of_PIN
the_DT
useful_JJ
economic_JJ
life_NN
of_PIN
the_DT
brand_NN
can_POMD
not_XX0
be_VB [PASS]
foreseen_VBN
._.
Equity_NOMZ
securities_NOMZ
are_VPRT [PASS]
reviewed_VBN
at_PIN
least_JJ
annually_RB
for_PIN
other_JJ
than_PIN
temporary_JJ
impairment_NOMZ
._.
The_DT
factors_NN
considered_VBN [PRIV] [WZPAST]
are_VPRT
:_:
Under_IN
US_FPP1
GAAP_NN
,_,
goodwill_NN
arising_VBG [WZPRES]
on_PIN
acquisitions_NOMZ
prior_RB
to_PIN
30th_JJ
June_NN
2001_CD
was_VBD [PASS]
capitalized_VBN
and_PHC
amortised_VBN
over_IN
a_DT
period_NN
not_XX0
the_DT
investees_NN
current_JJ
financial_JJ
performance_NN
and_CC
future_JJ
exceeding_VBG
40_CD
years_NN
._.
All_QUAN
intangible_JJ
assets_NN
,_,
including_VBG
brands_NN
,_,
were_VBD [PASS]
prospects_NN
amortised_VBN
over_IN
a_DT
nite_JJ
life_NN
._.
In_PIN
July_NN
2001_CD
,_,
the_DT
Financial_NN
Accounting_GER
the_DT
general_JJ
market_NN
condition_NOMZ
of_PIN
the_DT
geographic_JJ
or_CC
Standards_NN
Board_NN
FASB_NN
issued_VBD
Statement_NOMZ
of_PIN
Financial_NN
Accounting_GER
industry_NN
area_NN
in_PIN
which_WDT [PIRE]
the_DT
investee_NN
operates_VPRT
Standard_NN
SFAS_NN
142_CD
,_,
Goodwill_NN
and_CC
Other_JJ
Intangible_NN
Assets_NN
._.
the_DT
duration_NOMZ
and_PHC
extent_NN
to_PIN
which_WDT [PIRE]
the_DT
market_NN
value_NN
SFAS_NN
142_CD
requires_VPRT [SUAV]
that_THVC
goodwill_NN
no_RB
longer_RB
be_VB [PASS]
amortised_VBN
over_IN
its_PIT
if_COND
available_JJ
has_VPRT [PEAS]
been_VBN
below_PLACE
cost_NN
._.
The_DT
Group_NN
must_NEMD [SPAU]
instead_CONJ
identify_VB
and_PHC
value_VB
Gross_NN
unrealised_JJ
gains_NN
and_PHC
losses_NN
on_PIN
marketable_JJ
securities_NOMZ
were_VBD [BEMA]
its_PIT
reporting_VBG [PUBV]
units_NN
for_PIN
the_DT
purpose_NN
of_PIN
assessing_VBG
,_,
at_PIN
least_JJ
annually_RB
,_,
60_CD
million_CD
and_CC
3_CD
million_CD
respectively_RB
at_PIN
31st_CD
December_NN
2004_CD
potential_JJ
impairment_NOMZ
of_PIN
goodwill_NN
allocated_VBN [WZPAST]
to_PIN
each_QUAN
reporting_VBG [PUBV]
unit_NN
._.
68_CD
million_CD
and_CC
5_CD
million_CD
respectively_RB
at_PIN
31st_CD
December_NN
2003_CD
._.
140_CD
GlaxoSmithKline_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
37_CD
Reconciliation_NOMZ
to_PIN
US_FPP1
accounting_GER
principles_NN
continued_VBD
These_DEMO
changes_NN
have_VPRT [PEAS]
been_VBN [PASS]
accounted_VBN
for_PIN
as_IN
prior_JJ
year_NN
adjustments_NOMZ
under_IN
UK_NN
GAAP_NN
and_CC
the_DT
reconciliations_NOMZ
of_PIN
profit_NN
attributable_JJ
to_PIN
Pensions_NN
and_CC
other_JJ
post-retirement_JJ
benets_NN
shareholders_NN
and_PHC
Equity_NOMZ
shareholders_NN
funds_NN
from_PIN
UK_NN
GAAP_NN
to_PIN
The_DT
key_JJ
differences_NN
between_PIN
UK_NN
SSAP_NN
24_CD
and_CC
US_FPP1
GAAP_NN
US_FPP1
GAAP_NN
have_VPRT [PEAS]
been_VBN [PASS]
restated_VBN
accordingly_RB
to_TO
reconcile_VB
from_PIN
the_DT
in_PIN
relation_NOMZ
to_TO
dened_VBN
benefit_NN
pension_NN
plans_NN
are_VPRT
:_:
restated_VBN
UK_NN
GAAP_NN
gures_VPRT
._.
under_IN
UK_NN
GAAP_NN
,_,
the_DT
effect_NN
of_PIN
variations_NOMZ
in_PIN
cost_NN
can_POMD
be_VB [BEMA]
A_DT
reconciling_VBG
difference_NN
between_PIN
UK_NN
GAAP_NN
and_PHC
US_FPP1
GAAP_NN
remains_VPRT
accumulated_VBN
at_PIN
successive_JJ
valuations_NOMZ
and_CC
amortised_VBN
on_PIN
an_DT
in_PIN
respect_NN
of_PIN
the_DT
charge_NN
recognized_VBN [PRIV] [WZPAST]
against_PIN
profit_NN
._.
Under_IN
US_FPP1
GAAP_NN
,_,
aggregate_JJ
basis_NN
._.
Under_IN
US_FPP1
GAAP_NN
the_DT
amortisation_NOMZ
of_PIN
the_DT
shares_NN
purchased_VBN [WZPAST]
by_PIN
the_DT
ESOP_NN
Trusts_NN
are_VPRT [PASS]
accounted_VBN
for_PIN
within_PIN
transition_NOMZ
asset_NN
and_CC
the_DT
costs_NN
of_PIN
past_JJ
service_NN
benefit_NN
shareholders_NN
equity_NOMZ
with_PIN
gains_NN
and_PHC
losses_NN
on_PIN
issuance_NN
of_PIN
shares_NN
to_PIN
improvements_NOMZ
are_VPRT [SPAU] [PASS]
separately_RB
tracked_VBN
:_:
experience_NN
gains_NN
losses_NN
employees_NN
being_VBG [WZPRES] [PASS]
recorded_VBN
as_IN
adjustments_NOMZ
to_PIN
shareholders_NN
equity_NOMZ
._.
are_VPRT [PASS]
dealt_VBN
with_PIN
on_PIN
an_DT
aggregate_JJ
basis_NN
but_CC
amortised_VBD
only_DWNT
if_COND
outside_PLACE
a_DT
10_CD
per_PIN
cent_NN
corridor_NN
Guarantor_NN
obligations_NOMZ
The_DT
Group_NN
adopted_VBD
the_DT
FASBs_NN
Financial_NN
Interpretation_NOMZ
No._NN
._.
45_CD
UK_NN
GAAP_NN
allows_VPRT [SUAV]
measurements_NOMZ
of_PIN
plan_NN
assets_NN
and_PHC
liabilities_NOMZ
FIN_NN
45_CD
,_,
Guarantors_NN
Accounting_GER
and_PHC
Disclosure_NN
Requirements_NOMZ
to_TO
be_VB [PASS]
based_VBN
on_PIN
the_DT
result_NN
of_PIN
the_DT
latest_JJ
actuarial_JJ
valuation_NOMZ
._.
for_PIN
Guarantees_NN
,_,
Including_VBG
Indirect_NN
Guarantees_NN
of_PIN
Indebtedness_NOMZ
US_FPP1
GAAP_NN
requires_VPRT [SUAV]
measurement_NOMZ
of_PIN
plan_NN
assets_NN
and_PHC
liabilities_NOMZ
of_PIN
Others_NN
with_PIN
effect_NN
from_PIN
1st_CD
January_NN
2003_CD
._.
to_TO
be_VB [PASS]
made_VBN
at_PIN
the_DT
date_NN
of_PIN
the_DT
Financial_NN
statements_NOMZ
or_CC
up_RB
to_PIN
three_CD
months_NN
prior_RB
to_PIN
that_DEMO
date_NN
This_DEMP
requires_VPRT [SUAV]
that_THVC
the_DT
Group_NN
recognize_VB [PRIV]
and_PHC
measure_VB
,_,
at_PIN
fair_JJ
value_NN
,_,
the_DT
pension_NN
adjustment_NOMZ
also_RB
includes_VPRT
the_DT
impact_NN
of_PIN
changes_NN
on_PIN
a_DT
prospective_JJ
basis_NN
,_,
certain_JJ
guarantees_NN
issued_VBN
or_CC
modied_VBN
after_IN
in_PIN
minimum_JJ
pension_NN
liabilities_NOMZ
included_VBD
within_PIN
accumulated_VBN
31st_CD
December_NN
2002_CD
._.
Under_IN
UK_NN
GAAP_NN
,_,
such_JJ
guarantor_NN
obligations_NOMZ
other_JJ
comprehensive_JJ
income_NN
._.
are_VPRT [PASS]
recognized_VBN [PRIV]
when_RB [WHCL]
further_JJ
additional_JJ
criteria_NN
are_VPRT [PASS]
met_VBN
or_CC
the_DT
liability_NOMZ
is_VPRT [PASS]
incurred_VBN
._.
During_PIN
2002_CD
,_,
the_DT
Group_NN
decided_VBD [SUAV] [PRIV]
to_TO
align_VB
the_DT
measurement_NOMZ
date_NN
for_PIN
all_QUAN
of_PIN
its_PIT
pension_NN
and_PHC
post-retirement_NOMZ
benefit_NN
plans_VPRT
to_PIN
Derivative_JJ
instruments_NOMZ
31st_VPRT
December_NN
as_IN
certain_JJ
of_PIN
the_DT
Groups_NN
plans_NN
had_VBD
a_DT
measurement_NOMZ
SFAS_NN
133_CD
,_,
Accounting_GER
for_PIN
Derivative_NN
Instruments_NOMZ
and_PHC
Hedging_GER
date_NN
for_PIN
assets_NN
and_PHC
liabilities_NOMZ
of_PIN
30th_JJ
September_NN
._.
Activities_NOMZ
,_,
as_IN
amended_VBN
by_PIN
SFAS_NN
137_CD
and_CC
SFAS_NN
138_CD
and_CC
as_IN
The_DT
impact_NN
,_,
reected_VBD
as_IN
a_DT
cumulative_JJ
effect_NN
of_PIN
an_DT
accounting_GER
interpreted_VBN [WZPAST]
by_PIN
the_DT
Derivatives_NN
Implementation_NOMZ
Group_NN
,_,
was_VBD [PASS]
adopted_VBN
change_NN
,_,
was_VBD [BEMA]
a_DT
37_CD
million_CD
credit_NN
,_,
net_NN
of_PIN
tax_NN
,_,
to_PIN
income_NN
._.
by_PIN
the_DT
Group_NN
with_PIN
effect_NN
from_PIN
1st_CD
January_NN
2001_CD
._.
SFAS_NN
133_CD
establishes_VPRT [PRIV]
accounting_GER
and_PHC
reporting_GER
standards_NN
for_PIN
derivative_JJ
Stock-based_JJ
compensation_NOMZ
instruments_NOMZ
,_,
including_VBG
certain_JJ
derivative_JJ
instruments_NOMZ
embedded_VBD
Under_IN
UK_NN
GAAP_NN
,_,
share_NN
options_NOMZ
are_VPRT [PASS]
accounted_VBN
for_PIN
as_IN
equity_NOMZ
when_RB
in_PIN
other_JJ
contracts_NN
collectively_RB
,_,
referred_VBD
to_PIN
as_IN
derivatives_NN
and_CC
for_PIN
exercised_VBN
,_,
valued_VBN [PASTP]
at_PIN
the_DT
issuance_NN
price_NN
._.
Under_IN
US_FPP1
GAAP_NN
,_,
the_DT
Group_NN
hedging_GER
activities_NOMZ
._.
Under_IN
UK_NN
GAAP_NN
,_,
some_QUAN
derivative_JJ
instruments_NOMZ
applies_VPRT
SFAS_NN
123_CD
,_,
Accounting_GER
for_PIN
stock-based_JJ
compensation_NOMZ
,_,
and_ANDC
used_VBN
for_PIN
hedging_VBG
are_VPRT [PASS]
not_XX0
recognized_VBN [PRIV]
on_PIN
the_DT
balance_NN
sheet_NN
and_CC
related_JJ
accounting_GER
interpretations_NOMZ
in_PIN
accounting_GER
for_PIN
its_PIT
option_NOMZ
plans_VPRT
the_DT
matching_VBG
principle_NN
is_VPRT [PASS]
used_VBN
to_TO
match_VB
the_DT
gain_NN
or_CC
loss_NN
under_IN
which_WDT
require_VPRT [SUAV]
options_NOMZ
to_TO
be_VB [BEMA]
fair_PRED
valued_VBN
at_PIN
their_TPP3
grant_NN
date_NN
and_CC
these_DEMP
hedging_VBG
contracts_NN
to_PIN
the_DT
foreign_JJ
currency_NN
transaction_NOMZ
or_CC
included_VBN
in_PIN
profit_NN
and_PHC
loss_NN
over_IN
the_DT
vesting_JJ
period_NN
of_PIN
the_DT
options_NOMZ
._.
profits_NN
to_PIN
which_WDT [PIRE]
they_TPP3
relate_VPRT
._.
SFAS_NN
133_CD
requires_VPRT [SUAV]
that_THVC
an_DT
entity_NOMZ
recognize_VB [PRIV]
all_QUAN
derivatives_NN
as_IN
either_DT
assets_NN
or_CC
liabilities_NOMZ
in_PIN
the_DT
The_NN
Group_NN
is_VPRT [PASS]
entitled_VBN
to_TO
receive_VB
a_DT
tax_NN
deduction_NOMZ
for_PIN
the_DT
amount_NN
consolidated_JJ
balance_NN
sheet_NN
and_CC
measure_VB
those_DEMO
instruments_NOMZ
at_PIN
treated_VBN
as_IN
compensation_NOMZ
under_IN
US_FPP1
tax_NN
rules_NN
for_PIN
employee_NN
fair_JJ
value_NN
._.
Changes_NN
in_PIN
fair_JJ
value_NN
over_IN
the_DT
period_NN
are_VPRT [PASS]
recorded_VBN
in_PIN
stock_NN
options_NOMZ
which_WDT [WHSUB]
have_VPRT [PEAS]
been_VBN [BYPA]
exercised_VBN
by_PIN
US_FPP1
employees_NN
during_PIN
current_JJ
earnings_GER
unless_COND
hedge_JJ
accounting_GER
is_VPRT [PASS]
obtained_VBN
._.
Under_IN
UK_NN
GAAP_NN
,_,
this_DEMP
is_VPRT [PASS]
treated_VBN
as_IN
a_DT
reduction_NOMZ
of_PIN
tax_NN
does_VPRT
not_XX0
designate_VB
any_QUAN
of_PIN
its_PIT
derivatives_NN
as_IN
qualifying_VBG
hedge_JJ
expense_NN
whereas_OSUB
,_,
under_IN
US_FPP1
GAAP_NN
,_,
a_DT
portion_NOMZ
of_PIN
this_DEMO
amount_NN
instruments_NOMZ
under_IN
SFAS_NN
133_CD
._.
SFAS_NN
133_CD
prescribes_VPRT
requirements_NOMZ
is_VPRT [PASS]
credited_VBN
to_PIN
equity_NOMZ
._.
for_PIN
designation_NOMZ
and_PHC
documentation_NOMZ
of_PIN
hedging_VBG
relationships_NN
and_CC
ongoing_JJ
assessments_NOMZ
of_PIN
effectiveness_NOMZ
in_PIN
order_NN
to_TO
qualify_VB
for_PIN
hedge_NN
Employee_NN
Share_NN
Ownership_NN
Plan_NN
Trusts_NN
accounting_GER
._.
Prior_RB
to_PIN
2004_CD
,_,
under_IN
UK_NN
GAAP_NN
shares_NN
of_PIN
the_DT
Groups_NN
stock_NN
held_VBN [PRIV] [WZPAST]
by_PIN
The_DT
Group_NN
also_RB
evaluates_VPRT
contracts_NN
for_PIN
embedded_VBN
derivatives_NN
,_,
the_DT
ESOP_NN
Trusts_NN
were_VBD [PASS]
recorded_VBN
at_PIN
cost_NN
,_,
less_JJ
a_DT
provision_NN
representing_VBG [WZPRES]
and_PHC
considers_VPRT [PRIV]
whether_IN [WHCL]
any_QUAN
embedded_VBN
derivatives_NN
have_VPRT
to_TO
be_VB [BEMA]
the_DT
difference_NN
between_PIN
the_DT
cost_NN
and_CC
the_DT
option_NOMZ
exercise_NN
price_NN
,_,
and_ANDC
bifurcated_VBN
,_,
or_CC
separated_VBD
,_,
from_PIN
the_DT
host_NN
contracts_NN
in_PIN
accordance_NN
accounted_VBD
for_PIN
as_IN
xed_JJ
asset_NN
investments_NOMZ
._.
Projected_JJ
losses_NN
on_PIN
the_DT
with_PIN
SFAS_NN
133_CD
requirements_NOMZ
._.
If_COND
embedded_VBN
derivatives_NN
exist_VPRT
and_PHC
exercise_VPRT
of_PIN
the_DT
options_NOMZ
covered_VBN [WZPAST]
by_PIN
the_DT
shares_NN
were_VBD [PASS]
recorded_VBN
are_VPRT
not_XX0
clearly_RB
and_PHC
closely_RB
related_VBN
to_PIN
the_DT
host_NN
contract_NN
,_,
they_TPP3
are_VPRT [BEMA]
through_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
over_IN
the_DT
life_NN
of_PIN
the_DT
options_NOMZ
._.
In_PIN
accounted_VBN
for_PIN
separately_RB
from_PIN
the_DT
host_NN
contract_NN
as_IN
derivatives_NN
._.
2004_CD
,_,
UITF_NN
Abstract_NN
38_CD
,_,
Accounting_GER
for_PIN
ESOP_NN
Trusts_NN
,_,
and_ANDC
related_JJ
amendments_NOMZ
to_PIN
UITF_NN
Abstract_NN
17_CD
,_,
Employee_NN
share_NN
schemes_NN
,_,
were_VBD
Gains_NN
and_PHC
losses_NN
related_VBN [WZPAST]
to_PIN
the_DT
fair_JJ
value_NN
adjustments_NOMZ
of_PIN
all_QUAN
implemented_VBN
in_PIN
the_DT
Groups_NN
UK_NN
GAAP_NN
financial_JJ
statements_NOMZ
._.
UITF_NN
38_CD
derivative_JJ
instruments_NOMZ
are_VPRT [PASS]
classied_VBN
in_PIN
the_DT
consolidated_JJ
statement_NOMZ
changes_VPRT
the_DT
presentation_NOMZ
of_PIN
an_DT
entitys_JJ
own_JJ
shares_NN
held_VBN [PRIV] [WZPAST]
in_PIN
an_DT
ESOP_NN
of_PIN
income_NN
and_PHC
cash_NN
ows_NN
in_PIN
accordance_NN
with_PIN
the_DT
nature_NN
of_PIN
Trust_NN
from_PIN
requiring_VBG [SUAV]
them_TPP3
to_TO
be_VB [PASS]
recognized_VBN [PRIV]
as_IN
assets_NN
to_TO
requiring_VBG [SUAV]
the_DT
derivative_NN
._.
them_TPP3
to_TO
be_VB [PASS]
deducted_VBN
in_PIN
arriving_VBG
at_PIN
shareholders_NN
funds_NN
,_,
as_IN
under_IN
The_DT
fair_JJ
value_NN
and_PHC
book_NN
value_NN
of_PIN
derivative_JJ
instruments_NOMZ
in_PIN
respect_NN
US_FPP1
GAAP_NN
._.
UITF_NN
17_CD
revised_VBN
requires_VPRT [SUAV]
that_THVC
the_DT
minimum_JJ
expense_NN
of_PIN
financial_JJ
assets_NN
and_PHC
liabilities_NOMZ
as_IN
at_PIN
31st_CD
December_NN
2004_CD
is_VPRT
should_NEMD
be_VB [BEMA]
the_DT
difference_NN
between_PIN
the_DT
fair_JJ
value_NN
of_PIN
the_DT
shares_NN
at_PIN
disclosed_VBN [PUBV]
in_PIN
the_DT
Classication_NOMZ
and_CC
fair_JJ
value_NN
of_PIN
financial_JJ
assets_NN
the_DT
date_NN
of_PIN
award_NN
and_CC
the_DT
amount_NN
that_TOBJ
an_DT
employee_NN
may_POMD
be_VB
and_CC
liabilities_NOMZ
table_NN
in_PIN
Note_NN
34_CD
._.
required_VBN [SUAV]
to_TO
pay_VB
for_PIN
the_DT
shares_NN
i._VPRT
e._VB
the_DT
intrinsic_JJ
value_NN
of_PIN
the_DT
award_NN
._.
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
GlaxoSmithKline_NN
141_CD
37_CD
Reconciliation_NOMZ
to_PIN
US_FPP1
accounting_GER
principles_NN
continued_VBD
Sales_NN
incentives_NN
In_PIN
accordance_NN
with_PIN
UK_NN
GAAP_NN
,_,
certain_JJ
amounts_NN
paid_VBN [WZPAST]
by_PIN
the_DT
Group_NN
Valuation_NOMZ
of_PIN
derivative_JJ
instruments_NOMZ
to_PIN
its_PIT
customers_NN
are_VPRT [PASS]
recorded_VBN
as_IN
promotional_JJ
expense_NN
included_VBD
in_PIN
The_DT
fair_JJ
value_NN
of_PIN
derivative_JJ
instruments_NOMZ
is_VPRT [BEMA]
sensitive_PRED
to_PIN
movements_NOMZ
operating_VBG [WZPRES]
income_NN
._.
Under_IN
US_FPP1
GAAP_NN
,_,
these_DEMO
items_NN
are_VPRT [PASS]
recorded_VBN
as_IN
a_DT
in_PIN
the_DT
underlying_VBG
market_NN
rates_NN
and_PHC
variables_NN
._.
The_DT
Group_NN
monitors_VPRT
reduction_NOMZ
in_PIN
revenue_NN
._.
While_OSUB
these_DEMO
items_NN
do_VPRT
not_XX0
result_VB
in_PIN
a_DT
net_NN
the_DT
fair_JJ
value_NN
of_PIN
derivative_JJ
instruments_NOMZ
on_PIN
at_PIN
least_JJ
a_DT
quarterly_JJ
basis_NN
,_,
impact_NN
to_PIN
the_DT
income_NN
statement_NOMZ
under_IN
US_FPP1
GAAP_NN
,_,
the_DT
amount_NN
that_DEMO
with_PIN
a_DT
formal_JJ
review_NN
every_QUAN
six_CD
months_NN
._.
Derivatives_NN
including_VBG [WZPRES]
would_PRMD
be_VB [PASS]
classied_VBN
as_IN
a_DT
reduction_NOMZ
in_PIN
revenue_NN
in_PIN
2004_CD
would_PRMD
interest_VB
rate_NN
swaps_NN
and_PHC
cross-currency_NN
swaps_NN
are_VPRT [PASS]
valued_VBN
using_VBG
be_VB [BEMA]
373_CD
million_CD
2003_CD
324_CD
million_CD
._.
standard_JJ
valuation_NOMZ
models_NN
,_,
counterparty_NN
valuations_NOMZ
,_,
or_CC
third_JJ
party_NN
valuations_NOMZ
._.
Standard_NN
valuation_NOMZ
models_NN
used_VBN [WZPAST]
by_PIN
the_DT
Group_NN
consider_VB [PRIV]
Variable_JJ
interest_NN
entities_NOMZ
relevant_JJ
discount_NN
rates_NN
,_,
the_DT
market_NN
yield_NN
curve_NN
on_PIN
the_DT
valuation_NOMZ
In_PIN
January_NN
2003_CD
,_,
the_DT
FASB_NN
issued_VBD
Interpretation_NOMZ
No._NN
._.
46_CD
FIN_NN
46_CD
,_,
date_NN
,_,
forward_RB
currency_NN
exchange_NN
rates_NN
and_PHC
counterparty_NN
risk_NN
._.
All_QUAN
Consolidation_NOMZ
of_PIN
Variable_JJ
Interest_NN
Entities_NOMZ
,_,
and_ANDC
in_PIN
December_NN
significant_JJ
rates_NN
and_PHC
variables_NN
are_VPRT [PASS]
obtained_VBN
from_PIN
market_NN
sources_NN
._.
2003_CD
issued_VBN
FIN_NN
46R_NN
,_,
a_DT
revision_NN
of_PIN
this_DEMO
Interpretation_NOMZ
._.
Under_IN
the_DT
All_QUAN
valuations_NOMZ
are_VPRT [PASS]
based_VBN
on_PIN
the_DT
remaining_VBG
term_NN
to_PIN
maturity_NOMZ
of_PIN
the_DT
revised_VBN
Interpretation_NOMZ
,_,
certain_JJ
entities_NOMZ
,_,
known_VBN [PRIV]
as_IN
Variable_JJ
Interest_NN
instrument_NOMZ
._.
Foreign_JJ
exchange_NN
contracts_NN
are_VPRT [PASS]
valued_VBN
using_VBG
forward_RB
Entities_NOMZ
VIEs_NN
,_,
must_NEMD
be_VB [BYPA]
consolidated_VBN
by_PIN
the_DT
primary_JJ
beneciary_JJ
rates_NN
observed_VBD [PRIV]
from_PIN
quoted_VBN
prices_NN
in_PIN
the_DT
relevant_JJ
markets_NN
when_RB
of_PIN
the_DT
entity_NOMZ
._.
The_DT
primary_JJ
beneciary_NN
is_VPRT [SPAU] [PASS]
generally_RB
dened_VBN
as_IN
possible_JJ
._.
The_DT
Group_NN
assumes_VPRT [PRIV]
parties_NN
to_PIN
long-term_JJ
contracts_NN
are_VPRT
having_VBG
the_DT
majority_NOMZ
of_PIN
the_DT
risks_NN
and_PHC
rewards_NN
arising_VBG [WZPRES]
from_PIN
the_DT
VIE_NN
._.
economically_RB
viable_JJ
but_CC
reserves_NN
the_DT
right_NN
to_TO
exercise_VB
early_TIME
Additionally_RB
,_,
for_PIN
VIEs_NN
in_PIN
which_WDT [PIRE]
a_DT
significant_JJ
,_,
but_CC
not_XX0
majority_NOMZ
,_,
termination_NOMZ
rights_NN
if_COND
economically_RB
beneficial_JJ
when_RB
such_JJ
rights_NN
variable_JJ
interest_NN
is_VPRT [PASS]
held_VBN [PRIV]
,_,
certain_JJ
disclosures_NN
are_VPRT [PASS]
required_VBN [SUAV]
._.
The_DT
Group_NN
has_VPRT [PEAS]
completed_VBN
a_DT
review_NN
of_PIN
potential_JJ
VIEs_NN
and_CC
,_,
as_IN
a_DT
Dividends_NN
consequence_NN
,_,
has_VPRT [PEAS]
consolidated_VBN
Theravance_NN
Inc._NN
from_PIN
May_POMD
2004_CD
Under_IN
UK_NN
GAAP_NN
,_,
dividends_NN
proposed_VBN [SUAV] [WZPAST]
are_VPRT [PASS]
provided_VBN
for_PIN
in_PIN
the_DT
year_NN
see_VPRT [PRIV]
Note_NN
c_NN
on_PIN
page_NN
145_CD
._.
No_SYNE
other_JJ
VIEs_NN
of_PIN
which_WDT [PIRE]
the_DT
Group_NN
is_VPRT [BEMA]
in_PIN
respect_NN
of_PIN
which_WDT [PIRE]
they_TPP3
are_VPRT [BYPA]
recommended_VBN [SUAV]
by_PIN
the_DT
Board_NN
the_DT
primary_JJ
beneciary_JJ
were_VBD [PASS]
identied_VBN
._.
of_PIN
Directors_NN
for_PIN
approval_NN
by_PIN
the_DT
shareholders_NN
._.
Under_IN
US_FPP1
GAAP_NN
,_,
such_JJ
dividends_NN
are_VPRT [PASS]
not_XX0
provided_VBN
for_PIN
until_IN
declared_VBN [PUBV]
by_PIN
the_DT
Board_NN
Recent_JJ
Financial_NN
Accounting_GER
Standards_NN
Board_NN
FASB_NN
of_PIN
Directors_NN
._.
pronouncements_NOMZ
In_PIN
May_POMD
2004_CD
,_,
the_DT
FASB_NN
issued_VBD
FASB_NN
Staff_NN
Position_NOMZ
FSP_NN
Consolidated_NN
summary_NN
statement_NOMZ
of_PIN
cash_NN
ows_VPRT
FAS_NN
106-2_CD
,_,
Accounting_GER
and_PHC
Disclosure_NN
Requirements_NOMZ
Related_NN
to_PIN
The_DT
US_FPP1
GAAP_NN
cash_NN
ow_NN
statement_NOMZ
reports_NN
changes_NN
in_PIN
cash_NN
and_CC
the_DT
Medicare_NN
Prescription_NOMZ
Drug_NN
,_,
Improvement_NOMZ
and_PHC
Modernization_NOMZ
cash_NN
equivalents_NN
,_,
which_WDT [SERE]
includes_VPRT
short-term_JJ
highly_AMP
liquid_JJ
Act_NN
of_PIN
2003_CD
,_,
superseding_VBG
FSP_NN
106-1_CD
._.
FSP_NN
106-2_CD
addresses_NN
the_DT
investments_NOMZ
with_PIN
original_JJ
maturities_NOMZ
of_PIN
three_CD
months_NN
or_CC
less_JJ
._.
accounting_VBG
implications_NOMZ
of_PIN
the_DT
Act_NN
for_PIN
an_DT
entity_NOMZ
that_TSUB
sponsors_VPRT
a_DT
Only_DWNT
three_CD
categories_NN
of_PIN
cash_NN
ows_NN
are_VPRT [PASS]
reported_VBN [PUBV]
:_:
operating_VBG
post-retirement_JJ
health_NN
care_NN
plan_NN
providing_VBG [WZPRES]
prescription_NOMZ
drug_NN
activities_NOMZ
including_VBG [WZPRES]
tax_NN
and_PHC
interest_NN
:_:
investing_VBG
activities_NOMZ
benets_NN
._.
The_DT
Act_NN
introduces_VPRT
in_PIN
the_DT
USA_NN
a_DT
prescription_NOMZ
drug_NN
including_VBG [WZPRES]
capital_NN
expenditure_NN
,_,
acquisitions_NOMZ
and_PHC
disposals_NN
together_RB
benefit_VPRT
under_IN
Medicare_NN
,_,
as_RB
well_RB
as_IN
a_DT
federal_JJ
subsidy_NN
to_PIN
sponsors_NN
with_PIN
cash_NN
ows_NN
from_PIN
available_JJ
for_PIN
sale_NN
current_JJ
asset_NN
investments_NOMZ
:_:
of_PIN
certain_JJ
post-retirement_JJ
health_NN
care_NN
plans_NN
._.
For_PIN
companies_NN
that_DEMP
and_CC
nancing_VBG
activities_NOMZ
including_VBG [WZPRES]
dividends_NN
paid_VBN
._.
A_DT
summary_NN
elected_VBN [WZPAST]
for_PIN
deferral_JJ
under_IN
FSP_NN
106-1_CD
,_,
FSP_NN
106-2_CD
is_VPRT [BEMA]
effective_PRED
for_PIN
statement_NOMZ
of_PIN
cash_NN
ows_NN
is_VPRT [PASS]
presented_VBN
on_PIN
page_NN
143_CD
._.
reporting_VBG [PUBV] [THATD]
periods_NN
commencing_VBG [WZPRES]
after_IN
15th_JJ
June_NN
2004_CD
._.
The_DT
estimated_VBN [PRIV]
amount_NN
of_PIN
the_DT
federal_JJ
subsidy_NN
is_VPRT [PASS]
treated_VBN
as_IN
a_DT
prior_JJ
Cash_NN
and_PHC
cash_NN
equivalents_NN
service_NN
gain_NN
and_CC
credited_VBD
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
over_IN
the_DT
Under_IN
UK_NN
GAAP_NN
,_,
the_DT
cash_NN
balance_NN
includes_VPRT
only_DWNT
cash_NN
at_PIN
bank_NN
and_CC
average_JJ
service_NN
lives_NN
of_PIN
the_DT
employees_NN
._.
Under_IN
US_FPP1
GAAP_NN
,_,
this_DEMO
other_JJ
cash_NN
balances_NN
._.
Under_IN
US_FPP1
GAAP_NN
,_,
cash_NN
and_PHC
cash_NN
equivalents_NN
change_VPRT
resulted_VBN
in_PIN
a_DT
decrease_NN
of_PIN
71_CD
million_CD
in_PIN
the_DT
accumulated_VBN
include_VPRT
cash_NN
at_PIN
bank_NN
and_CC
certain_JJ
liquid_JJ
investments_NOMZ
with_PIN
original_JJ
benefit_NN
obligation_NOMZ
and_CC
a_DT
reduction_NOMZ
of_PIN
2_CD
million_CD
in_PIN
net_JJ
periodic_JJ
maturities_NOMZ
of_PIN
three_CD
months_NN
or_CC
less_JJ
._.
post-retirement_JJ
benefit_NN
cost_NN
for_PIN
the_DT
year_NN
ended_VBD
31st_CD
December_NN
2004_CD
._.
Comprehensive_JJ
income_NN
statement_NOMZ
The_DT
requirement_NOMZ
of_PIN
SFAS_NN
130_CD
,_,
Reporting_GER
comprehensive_JJ
income_NN
,_,
to_TO
provide_VB
a_DT
comprehensive_JJ
income_NN
statement_NOMZ
is_VPRT [PASS]
met_VBN
under_IN
UK_NN
GAAP_NN
by_PIN
the_DT
Statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
pages_NN
90_CD
and_CC
91_CD
._.
Reclassications_NOMZ
Certain_NN
prior_JJ
year_NN
balances_NN
have_VPRT [PEAS]
been_VBN [PASS]
reclassied_VBN
for_PIN
comparative_JJ
purposes_NN
._.
Certain_JJ
amounts_NN
previously_TIME
presented_VBN
in_PIN
aggregate_NN
in_PIN
the_DT
reconciliation_NOMZ
of_PIN
profit_NN
under_IN
US_FPP1
GAAP_NN
to_PIN
UK_NN
GAAP_NN
have_VPRT [PEAS]
been_VBN [PASS]
presented_VBN
separately_RB
in_PIN
the_DT
current_JJ
year_NN
presentation_NOMZ
to_TO
provide_VB
more_EMPH
information_NOMZ
related_VBN [WZPAST]
to_PIN
these_DEMO
adjustments_NOMZ
._.
142_CD
GlaxoSmithKline_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
37_CD
Reconciliation_NOMZ
to_PIN
US_FPP1
accounting_GER
principles_NN
continued_VBD
The_DT
following_GER
is_VPRT [BEMA]
a_DT
summary_NN
of_PIN
the_DT
material_NN
adjustments_NOMZ
to_TO
profit_VB
and_CC
shareholders_NN
funds_NN
which_WDT [WHSUB]
would_PRMD
be_VB [PASS]
required_VBN [SUAV]
if_COND
US_FPP1
GAAP_NN
had_VBD [PEAS]
been_VBN [PASS]
applied_VBN
instead_CONJ
of_NULL
UK_NN
GAAP_NN
._.
2003 2002 2004_CD
restated_VBN
restated_JJ
profit_NN
Notes_NN
m_VPRT
m_FW
m_FW
profit_NN
attributable_JJ
to_PIN
shareholders_NN
under_IN
UK_NN
GAAP_NN
4,302_CD
4,478_CD
3,930_CD
Goodwill_NN
amortisation_NOMZ
reversal_NN
including_VBG [WZPRES]
goodwill_NN
in_PIN
associated_VBN
undertakings_GER
a_DT
17_CD
1918_CD
Amortisation_NOMZ
and_PHC
impairment_NOMZ
of_PIN
intangible_JJ
assets_NN
b_NN
1,426_CD
2,292_CD
4,089_CD
Acquisition_NOMZ
and_PHC
disposal_NN
of_PIN
product_NN
rights_NN
b_NN
210 105 181_CD
Capitalised_VBN
interest_NN
17_CD
23_CD
20_CD
Tangible_JJ
xed_JJ
assets_NN
2_CD
525_CD
Disposal_NN
of_PIN
interest_NN
in_PIN
associate_JJ
81_CD
Disposal_NN
of_PIN
goodwill_NN
in_PIN
subsidiaries_NN
3_CD
Product_NN
divestments_NOMZ
1_CD
77_CD
Equity_NOMZ
investments_NOMZ
30_CD
31_CD
8_CD
Recognition_NOMZ
of_PIN
cost_NN
of_PIN
sales_NN
on_PIN
fair_JJ
value_NN
step-up_NN
of_PIN
inventory_NN
13_CD
Pensions_NN
and_CC
post-retirement_JJ
benets_NN
f_LS
162 122 138_CD
Stock-based_JJ
compensation_NOMZ
296 372 320_CD
Derivative_JJ
instruments_NOMZ
and_CC
hedging_VBG
33_CD
41_CD
37_CD
Fair_NN
value_NN
of_PIN
put_NN
option_NOMZ
granted_VBN [SUAV] [WZPAST]
to_PIN
minority_NOMZ
shareholders_NN
c_NN
17_CD
Guarantor_NN
obligations_NOMZ
19_CD
21_CD
Restructuring_GER
12_CD
98_CD
37_CD
Tax_NN
benets_NN
on_PIN
exercise_NN
of_PIN
US_FPP1
stock_NN
options_NOMZ
d_LS
10_CD
13_CD
13_CD
Deferred_JJ
taxation_NOMZ
d_SYM
661_CD
787_CD
1,178_CD
Variable_JJ
interest_NN
entities_NOMZ
c_NN
60_CD
Net_JJ
income_NN
under_IN
US_FPP1
GAAP_NN
before_IN
cumulative_JJ
effect_NN
of_PIN
changes_NN
in_PIN
accounting_GER
principles_NN
2,732_CD
2,420_CD
503_CD
Cumulative_JJ
effect_NN
of_PIN
changes_NN
in_PIN
accounting_GER
principles_NN
90_CD
Net_JJ
income_NN
after_IN
cumulative_JJ
effect_NN
of_PIN
changes_NN
in_PIN
accounting_GER
principles_NN
2,732_CD
2,420_CD
413_CD
Certain_NN
items_NN
for_PIN
the_DT
year_NN
ended_VBD
31st_CD
December_NN
2002_CD
have_VPRT [PEAS]
been_VBN [PASS]
reclassied_VBN
for_PIN
comparative_JJ
purposes_NN
._.
2004 2003 2002_CD
Earnings_GER
per_PIN
share_NN
under_IN
US_FPP1
GAAP_NN
pence_NN
pence_NN
pence_NN
Basic_JJ
net_JJ
income_NN
per_PIN
share_NN
before_IN
cumulative_JJ
effect_NN
of_PIN
changes_NN
in_PIN
accounting_GER
principles_NN
under_IN
US_FPP1
GAAP_NN
47.6_CD
41.7_CD
8.5_CD
Cumulative_JJ
effect_NN
of_PIN
changes_NN
in_PIN
accounting_GER
principles_NN
per_PIN
share_NN
under_IN
US_FPP1
GAAP_NN
1.5_CD
Basic_JJ
net_JJ
income_NN
per_PIN
share_NN
after_IN
cumulative_JJ
effect_NN
of_PIN
changes_NN
in_PIN
accounting_GER
principles_NN
under_IN
US_FPP1
GAAP_NN
47.6_CD
41.7_CD
7.0_CD
Diluted_NN
net_JJ
income_NN
per_PIN
share_NN
before_IN
cumulative_JJ
effect_NN
of_PIN
changes_NN
in_PIN
accounting_GER
principles_NN
under_IN
US_FPP1
GAAP_NN
47.5_CD
41.6_CD
8.5_CD
Cumulative_JJ
effect_NN
of_PIN
changes_NN
in_PIN
accounting_GER
principles_NN
per_PIN
share_NN
under_IN
US_FPP1
GAAP_NN
1.5_CD
Diluted_NN
net_JJ
income_NN
per_PIN
share_NN
after_IN
cumulative_JJ
effect_NN
of_PIN
changes_NN
in_PIN
accounting_GER
principles_NN
under_IN
US_FPP1
GAAP_NN
47.5_CD
41.6_CD
7.0_CD
2004 2003 2002_CD
Earnings_GER
per_PIN
ADS_NN
under_IN
US_FPP1
GAAP_NN
$_$
$_$
$_$
Basic_JJ
net_JJ
income_NN
per_PIN
ADS_NN
before_IN
cumulative_JJ
effect_NN
of_PIN
changes_NN
in_PIN
accounting_GER
principles_NN
under_IN
US_FPP1
GAAP_NN
1.74_CD
1.37_CD
0.26_CD
Cumulative_JJ
effect_NN
of_PIN
changes_NN
in_PIN
accounting_GER
principles_NN
per_PIN
ADS_NN
under_IN
US_FPP1
GAAP_NN
0.05_CD
Basic_JJ
net_JJ
income_NN
per_PIN
ADS_NN
after_IN
cumulative_JJ
effect_NN
of_PIN
changes_NN
in_PIN
accounting_GER
principles_NN
under_IN
US_FPP1
GAAP_NN
1.74_CD
1.37_CD
0.21_CD
Diluted_NN
net_JJ
income_NN
per_PIN
ADS_NN
before_IN
cumulative_JJ
effect_NN
of_PIN
changes_NN
in_PIN
accounting_GER
principles_NN
under_IN
US_FPP1
GAAP_NN
1.74_CD
1.36_CD
0.26_CD
Cumulative_JJ
effect_NN
of_PIN
changes_NN
in_PIN
accounting_GER
principles_NN
per_PIN
ADS_NN
under_IN
US_FPP1
GAAP_NN
0.05_CD
Diluted_NN
net_JJ
income_NN
per_PIN
ADS_NN
after_IN
cumulative_JJ
effect_NN
of_PIN
changes_NN
in_PIN
accounting_GER
principles_NN
under_IN
US_FPP1
GAAP_NN
1.74_CD
1.36_CD
0.21_CD
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
GlaxoSmithKline_NN
143_CD
37_CD
Reconciliation_NOMZ
to_PIN
US_FPP1
accounting_GER
principles_NN
continued_VBD
2003_CD
2004_CD
restated_VBN
Equity_NOMZ
shareholders_NN
funds_NN
Notes_NN
m_VPRT
m_NN
Equity_NOMZ
shareholders_NN
funds_NN
under_IN
UK_NN
GAAP_NN
5,925_CD
5,059_CD
US_FPP1
GAAP_NN
adjustments_NOMZ
:_:
Goodwill_NN
a_DT
17,982_CD
17,986_CD
Product_NN
rights_NN
b_NN
13,994_CD
15,652_CD
Pension_NN
intangible_JJ
asset_NN
b_NN
102_CD
128_CD
Tangible_JJ
xed_JJ
assets_NN
43_CD
45_CD
Capitalised_VBN
interest_NN
180_CD
198_CD
Marketable_JJ
securities_NOMZ
49_CD
84_CD
Other_JJ
investments_NOMZ
554_CD
832_CD
Fair_NN
value_NN
step-up_NN
of_PIN
inventory_NN
1_CD
Pensions_NN
and_CC
other_JJ
post-retirement_JJ
benets_NN
f_LS
1,287_CD
1,702_CD
Restructuring_GER
costs_NN
80_CD
92_CD
Derivative_JJ
instruments_NOMZ
and_CC
hedging_VBG
15_CD
26_CD
Fair_NN
value_NN
of_PIN
put_NN
option_NOMZ
granted_VBN [SUAV] [WZPAST]
to_PIN
minority_NOMZ
shareholders_NN
c_NN
17_CD
Guarantor_NN
obligations_NOMZ
2_CD
21_CD
Dividends_NN
683_CD
808_CD
Deferred_JJ
taxation_NOMZ
e_SYM
4,204_CD
5,071_CD
Variable_JJ
interest_NN
entities_NOMZ
c_NN
60_CD
Shareholders_NN
equity_NOMZ
under_IN
US_FPP1
GAAP_NN
34,042_CD
34,116_CD
2004 2003 2002_CD
Consolidated_NN
statement_NOMZ
of_PIN
cash_NN
ows_NN
under_IN
US_FPP1
GAAP_NN
m_NN
mm_NN
Net_JJ
cash_NN
provided_VBN [WZPAST]
by_PIN
operating_VBG
activities_NOMZ
4,618_CD
4,895_CD
5,345_CD
Net_JJ
cash_NN
used_VBN [WZPAST]
in_PIN
investing_VBG
activities_NOMZ
988_CD
904_CD
1,051_CD
Net_JJ
cash_NN
used_VBN [WZPAST]
in_PIN
nancing_VBG
activities_NOMZ
3,038_CD
3,051_CD
4,002_CD
Net_JJ
increase_NN
in_PIN
cash_NN
and_PHC
cash_NN
equivalents_NN
592 940 292_CD
Exchange_NN
rate_NN
movements_NOMZ
93_CD
36_CD
42_CD
Cash_NN
and_PHC
cash_NN
equivalents_NN
at_PIN
beginning_GER
of_PIN
year_NN
1,986_CD
1,082_CD
832_CD
Cash_NN
and_PHC
cash_NN
equivalents_NN
at_PIN
end_NN
of_PIN
year_NN
2,485_CD
1,986_CD
1,082_CD
Notes_NN
to_PIN
the_DT
profit_NN
and_PHC
Equity_NOMZ
shareholders_NN
funds_NN
reconciliations_VPRT
a_DT
Goodwill_NN
The_NN
following_VBG [WZPRES]
tables_NN
set_VBN [WZPAST]
out_PIN
the_DT
UK_NN
to_PIN
US_FPP1
GAAP_NN
adjustments_NOMZ
required_VBN [SUAV] [WZPAST]
to_PIN
the_DT
UK_NN
GAAP_NN
statement_NOMZ
of_PIN
profit_NN
and_PHC
loss_NN
and_PHC
balance_NN
sheet_NN
in_PIN
respect_NN
of_PIN
goodwill_NN
including_VBG [WZPRES]
goodwill_NN
in_PIN
respect_NN
of_PIN
associated_VBN
undertakings_GER
:_:
2004 2003 2002_CD
Income_NN
statement_NOMZ
m_NN
m_FW
m_FW
Amortisation_NOMZ
under_IN
UK_NN
GAAP_NN
17_CD
19_CD
18_CD
Amortisation_NOMZ
under_IN
US_FPP1
GAAP_NN
UK_NN
to_PIN
US_FPP1
GAAP_NN
adjustment_NOMZ
for_PIN
amortisation_NOMZ
including_VBG [WZPRES]
goodwill_NN
in_PIN
respect_NN
of_PIN
associated_VBN
undertakings_GER
17_CD
19 18 2004 2003_CD
Balance_NN
sheet_NN
m_NN
m_NN
Goodwill_NN
under_IN
UK_NN
GAAP_NN
139_CD
143_CD
Goodwill_NN
under_IN
US_FPP1
GAAP_NN
18,121_CD
18,129_CD
UK_NN
to_PIN
US_FPP1
GAAP_NN
adjustments_NOMZ
17,982_CD
17,986_CD
Of_PIN
the_DT
18,121_CD
million_CD
2003_CD
-_:
18,129_CD
million_CD
US_FPP1
GAAP_NN
goodwill_NN
balance_NN
at_PIN
31st_CD
December_NN
2004_CD
,_,
15,875_CD
million_CD
2003_CD
-_:
15,875_CD
million_CD
is_VPRT [BEMA]
in_PIN
respect_NN
of_PIN
the_DT
goodwill_NN
arising_VBG [WZPRES]
on_PIN
the_DT
acquisition_NOMZ
of_PIN
SmithKline_NN
Beecham_NN
by_PIN
Glaxo_NN
Wellcome_NN
in_PIN
2000_CD
._.
144_CD
GlaxoSmithKline_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
37_CD
Reconciliation_NOMZ
to_PIN
US_FPP1
accounting_GER
principles_NN
continued_VBD
The_DT
following_JJ
tables_NN
present_VPRT
the_DT
changes_NN
in_PIN
goodwill_NN
allocated_VBN [WZPAST]
to_PIN
the_DT
Groups_NN
reportable_JJ
segments_NOMZ
:_:
Consumer_NN
Pharmaceuticals_NN
Healthcare_NN
Total_NN
m_FW
m_FW
m_FW [BEMA]
At_PIN
31st_CD
December_NN
2002_CD
15,679_CD
2,481_CD
18,160_CD
Additions_NOMZ
2_CD
2_CD
Exchange_NN
adjustments_NOMZ
13_CD
20_CD
33_CD
At_PIN
31st_CD
December_NN
2003_CD
15,668_CD
2,461_CD
18,129_CD
Asset_NN
written_VBN [PUBV] [WZPAST]
off_PIN
1_CD
1_CD
Exchange_NN
adjustments_NOMZ
5_CD
12_CD
7_CD
At_PIN
31st_CD
December_NN
2004_CD
15,672_CD
2,449_CD
18,121_CD
b_NN
Intangible_JJ
assets_NN
The_DT
following_JJ
tables_NN
set_VBN [WZPAST]
out_PIN
the_DT
UK_NN
to_PIN
US_FPP1
GAAP_NN
adjustments_NOMZ
required_VBN [SUAV] [WZPAST]
to_PIN
the_DT
UK_NN
GAAP_NN
statement_NOMZ
of_PIN
profit_NN
and_PHC
loss_NN
and_PHC
balance_NN
sheet_NN
in_PIN
respect_NN
of_PIN
intangible_JJ
assets_NN
:_:
2004 2003 2002_CD
Income_NN
statement_NOMZ
m_NN
m_FW
m_FW
Amortisation_NOMZ
charge_NN
under_IN
UK_NN
GAAP_NN
94_CD
74_CD
60_CD
Amortisation_NOMZ
charge_NN
under_IN
US_FPP1
GAAP_NN
1,516_CD
1,641_CD
1,787_CD
UK_NN
to_PIN
US_FPP1
GAAP_NN
adjustment_NOMZ
for_PIN
amortisation_NOMZ
1,422_CD
1,567_CD
1,727_CD
Impairment_NOMZ
charge_NN
under_IN
UK_NN
GAAP_NN
22_CD
41_CD
46_CD
Impairment_NOMZ
charge_NN
under_IN
US_FPP1
GAAP_NN
26_CD
766_CD
2,581_CD
UK_NN
to_PIN
US_FPP1
GAAP_NN
adjustment_NOMZ
for_PIN
impairments_NOMZ
4_CD
725_CD
2,535_CD
Cumulative_JJ
effect_NN
of_PIN
change_NN
in_PIN
accounting_GER
principle_NN
173_CD
UK_NN
to_PIN
US_FPP1
GAAP_NN
adjustment_NOMZ
for_PIN
impairments_NOMZ
for_PIN
the_DT
period_NN
4_CD
725_CD
2,362_CD
Following_VBG
the_DT
initial_JJ
implementation_NOMZ
of_PIN
SFAS_NN
142_CD
in_PIN
2002_CD
,_,
the_DT
carrying_VBG
value_NN
of_PIN
the_DT
brands_NN
determined_VBD [SUAV] [PRIV]
to_TO
have_VB
indefinite_JJ
lives_NN
were_VBD [PASS]
reviewed_VBN
and_CC
an_DT
impairment_NOMZ
of_PIN
173_CD
million_CD
127_CD
million_CD
net_NN
of_PIN
tax_NN
was_VBD [PASS]
recognized_VBN [PRIV]
._.
This_DEMP
was_VBD [PASS]
recorded_VBN
as_IN
a_DT
cumulative_JJ
effect_NN
of_PIN
a_DT
change_NN
in_PIN
accounting_GER
principle_NN
._.
In_CONJ
addition_NULL
to_PIN
the_DT
above_PLACE
adjustments_NOMZ
for_PIN
amortisation_NOMZ
and_PHC
impairments_NOMZ
,_,
further_JJ
UK_NN
to_PIN
US_FPP1
GAAP_NN
adjustments_NOMZ
arose_VBD
during_PIN
the_DT
year_NN
of_PIN
173_CD
million_CD
2003_CD
-_:
105_CD
million_CD
:_:
2002_CD
-_:
181_CD
million_CD
in_PIN
respect_NN
of_PIN
the_DT
acquisition_NOMZ
of_PIN
licences_NN
,_,
patents_NN
etc._FW
._.
which_WDT [SERE]
are_VPRT [PASS]
capitalized_VBN
under_IN
UK_NN
GAAP_NN
but_CC
charged_VBD
directly_RB
to_PIN
research_NN
and_PHC
development_NOMZ
expense_NN
under_IN
US_FPP1
GAAP_NN
,_,
and_ANDC
37_CD
million_CD
2003_CD
and_CC
2002_CD
nil_NN
in_PIN
respect_NN
of_PIN
disposals_NN
of_PIN
product_NN
rights_NN
which_WDT [WHSUB]
have_VPRT
a_DT
higher_JJ
carrying_VBG
value_NN
under_IN
US_FPP1
GAAP_NN
than_PIN
under_IN
UK_NN
GAAP_NN
._.
2004_CD
2003_CD
Balance_NN
sheet_NN
m_NN
m_NN [BEMA]
Intangible_JJ
assets_NN
under_IN
UK_NN
GAAP_NN
2,003_CD
1,697_CD
Intangible_JJ
assets_NN
under_IN
US_FPP1
GAAP_NN
16,099_CD
17,477_CD
UK_NN
to_PIN
US_FPP1
GAAP_NN
adjustments_NOMZ
14,096_CD
15,780_CD
Less_RB
pensions_NN
intangible_JJ
asset_NN
102_CD
128_CD
Net_JJ
UK_NN
to_PIN
US_FPP1
GAAP_NN
product_NN
rights_NN
adjustments_NOMZ
13,994_CD
15,652_CD
Intangible_JJ
assets_NN
under_IN
US_FPP1
GAAP_NN
are_VPRT [PASS]
analyzed_VBN
as_IN
follows_VPRT
:_:
2004_CD
2003_CD
m_NN [PASS]
m_NN [PASS]
Acquired_VBN
products_NN
10,589_CD
12,054_CD
Licences_NN
,_,
patents_NN
etc._FW
._.
371_CD
126_CD
Brands_NN
5,037_CD
5,169_CD
Pensions_NN
102_CD
128_CD
Intangible_JJ
assets_NN
under_IN
US_FPP1
GAAP_NN
16,099_CD
17,477_CD
The_DT
following_VBG
tables_NN
present_JJ
details_NN
of_PIN
the_DT
Groups_NN
intangible_JJ
assets_NN
,_,
differentiating_VBG [PRESP]
between_PIN
those_DEMO
subject_JJ
to_PIN
amortisation_NOMZ
and_CC
those_DEMP
which_WDT
are_VPRT [BEMA]
not_XX0
subject_PRED
to_PIN
amortisation_NOMZ
:_:
2004_CD
2003_CD
m_NN
m_NN [BEMA]
Intangible_JJ
assets_NN
subject_JJ
to_PIN
amortisation_NOMZ
11,922_CD
13,234_CD
Intangible_JJ
assets_NN
not_XX0
subject_JJ
to_PIN
amortisation_NOMZ
4,177_CD
4,243_CD
Intangible_JJ
assets_NN
under_IN
US_FPP1
GAAP_NN
16,099_CD
17,477_CD
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
GlaxoSmithKline_NN
145_CD
37_CD
Reconciliation_NOMZ
to_PIN
US_FPP1
accounting_GER
principles_NN
continued_VBD
The_DT
following_JJ
intangible_JJ
assets_NN
are_VPRT [BEMA]
subject_PRED
to_PIN
amortisation_NOMZ
:_:
2004_CD
2003_CD
Product_NN
Product_NN
rights_NN
rights_NN
m_NN
m_NN
Cost_NN
21,555_CD
21,329_CD
Accumulated_VBN
amortisation_NOMZ
6,872_CD
5,360_CD
Impairment_NOMZ
2,761_CD
2,735_CD
Net_JJ
11,922_CD
13,234_CD
The_DT
carrying_GER
values_NN
of_PIN
certain_JJ
product_NN
rights_NN
were_VBD [PASS]
reviewed_VBN
and_CC
an_DT
impairment_NOMZ
of_PIN
26_CD
million_CD
has_VPRT [PEAS]
been_VBN [PASS]
recorded_VBN
._.
In_PIN
2003_CD
,_,
impairments_NOMZ
of_PIN
658_CD
million_CD
were_VBD [PASS]
recorded_VBN
,_,
of_PIN
which_WDT [PIRE]
633_CD
million_CD
related_VBN
to_PIN
Paxil_NN
which_WDT [WHSUB]
was_VBD [PASS]
impaired_VBN
following_VBG
the_DT
launch_NN
in_PIN
the_DT
USA_NN
of_PIN
a_DT
generic_JJ
Paxil_NN
product_NN
._.
Fair_NN
values_NN
are_VPRT [PASS]
determined_VBN [SUAV] [PRIV]
using_VBG
a_DT
discounted_JJ
cash_NN
ow_NN
model_NN
._.
As_IN
discussed_VBN
in_PIN
Note_NN
30_CD
Legal_NN
proceedings_GER
,_,
a_DT
number_NN
of_PIN
distributors_NN
of_PIN
generic_JJ
drugs_NN
have_VPRT [PEAS]
led_VBN
applications_NOMZ
to_PIN
market_NN
generic_JJ
versions_NN
of_PIN
a_DT
number_NN
of_PIN
the_DT
Groups_NN
products_NN
prior_RB
to_PIN
the_DT
expiration_NOMZ
of_PIN
the_DT
Groups_NN
patents_NN
._.
If_COND
generic_JJ
versions_NN
of_PIN
products_NN
are_VPRT [PASS]
launched_VBN
in_PIN
future_NN
periods_NN
at_PIN
earlier_TIME
dates_NN
than_PIN
the_DT
Group_NN
currently_RB
expects_VPRT [PRIV]
,_,
impairments_NOMZ
of_PIN
the_DT
carrying_VBG
value_NN
of_PIN
the_DT
products_NN
may_POMD
arise_VB
._.
The_DT
estimated_JJ
future_JJ
amortisation_NOMZ
expense_NN
for_PIN
the_DT
next_JJ
five_CD
years_NN
for_PIN
intangible_JJ
assets_NN
subject_JJ
to_PIN
amortisation_NOMZ
as_IN
of_PIN
31st_CD
December_NN
2004_CD
is_VPRT
as_IN
follows_VPRT
:_:
Year_NN
m_NN [BEMA]
2005_CD
1,528_CD
2006_CD
1,487_CD
2007_CD
1,473_CD
2008_CD
1,472_CD
2009_CD
756_CD
Total_JJ
6,716_CD
Intangible_JJ
assets_NN
which_WDT [WHSUB]
are_VPRT [BEMA]
not_XX0
subject_PRED
to_PIN
amortisation_NOMZ
include_VPRT
a_DT
pension_NN
asset_NN
of_PIN
102_CD
million_CD
at_PIN
31st_CD
December_NN
2004_CD
128_CD
million_CD
at_PIN
31st_CD
December_NN
2003_CD
and_CC
certain_JJ
product_NN
rights_NN
._.
The_DT
intangible_JJ
assets_NN
relating_VBG [WZPRES]
to_PIN
product_NN
rights_NN
are_VPRT [PASS]
analyzed_VBN
as_IN
follows_VPRT
:_:
2004_CD
2003_CD
m_NN
m_NN
Cost_NN
4,652_CD
4,693_CD
Impairment_NOMZ
577_CD
578_CD
Net_JJ
4,075_CD
4,115_CD
An_DT
impairment_NOMZ
charge_NN
of_PIN
nil_NN
was_VBD [PASS]
recognized_VBN [PRIV]
during_PIN
2004 2003 108_CD
million_CD
._.
c_NN
Theravance_NN
In_PIN
May_POMD
2004_CD
,_,
the_DT
Group_NN
formed_VBD
a_DT
strategic_JJ
alliance_NN
with_PIN
Theravance_NN
Inc._NN
to_TO
develop_VB
and_PHC
commercialise_VB
novel_JJ
medicines_NN
across_PLACE
a_DT
variety_NN
of_PIN
important_JJ
therapeutic_JJ
areas_NN
._.
Under_IN
the_DT
terms_NN
of_PIN
the_DT
alliance_NN
,_,
Theravance_NN
received_VBD
$_$
129_CD
million_CD
,_,
a_DT
significant_JJ
part_NN
of_PIN
which_WDT [PIRE]
related_VBN
to_PIN
the_DT
Groups_NN
purchase_NN
of_PIN
Theravance_NN
shares_NN
._.
The_DT
Group_NN
has_VPRT
a_DT
call_NN
option_NOMZ
in_PIN
2007_CD
to_PIN
further_JJ
increase_NN
its_PIT
ownership_NN
to_PIN
over_IN
50_CD
per_PIN
cent_NN
at_PIN
a_DT
significant_JJ
premium_NN
to_PIN
the_DT
price_NN
paid_VBN [WZPAST]
in_PIN
the_DT
2004_CD
transaction_NOMZ
._.
Theravances_NN
shareholders_NN
have_VPRT
a_DT
put_NN
option_NOMZ
at_PIN
a_DT
lower_JJ
exercise_NN
price_NN
to_TO
cause_VB
GlaxoSmithKline_NN
to_TO
acquire_VB
up_RP
to_PIN
half_DT
of_PIN
their_TPP3
outstanding_JJ
stock_NN
in_PIN
2007_CD
._.
Given_VBN
the_DT
maximum_JJ
number_NN
of_PIN
shares_NN
subject_JJ
to_PIN
the_DT
put_NN
option_NOMZ
,_,
the_DT
Groups_NN
obligation_NOMZ
is_VPRT [PASS]
capped_VBN
at_PIN
$_$
525_CD
million_CD
._.
The_DT
Group_NN
has_VPRT
an_DT
exclusive_JJ
option_NOMZ
to_TO
license_VB
potential_JJ
new_JJ
medicines_NN
from_PIN
all_QUAN
of_PIN
Theravances_NN
programs_NN
until_IN
August_NN
2007_CD
._.
Upon_PIN
exercising_VBG
its_PIT
option_NOMZ
over_IN
a_DT
Theravance_NN
program_NN
,_,
the_DT
Group_NN
will_PRMD
be_VB [BEMA]
responsible_PRED
for_PIN
the_DT
relevant_JJ
development_NOMZ
,_,
manufacturing_GER
and_PHC
commercialisation_NOMZ
activities_NOMZ
._.
Depending_VBG [PRESP]
on_PIN
the_DT
success_NN
of_PIN
such_JJ
programs_NN
,_,
Theravance_NN
will_PRMD
receive_VB
clinical_JJ
,_,
regulatory_JJ
and_PHC
commercial_JJ
milestone_NN
payments_NOMZ
and_PHC
royalties_NN
on_PIN
the_DT
subsequent_JJ
sales_NN
of_PIN
medicines_NN
._.
Based_VBN [PASTP]
on_PIN
the_DT
assessment_NOMZ
performed_VBN
,_,
the_DT
Group_NN
is_VPRT [BEMA]
the_DT
primary_JJ
beneciary_NN
of_PIN
Theravance_NN
,_,
as_IN
dened_VBN
by_PIN
FIN_NN
46R_NN
,_,
and_ANDC
as_CONJ
a_NULL
result_NULL
Theravance_NN
has_VPRT [PEAS]
been_VBN [PASS]
consolidated_VBN
into_PIN
the_DT
Groups_NN
US_FPP1
GAAP_NN
financial_JJ
statements_NOMZ
from_PIN
May_POMD
2004_CD
._.
The_DT
net_JJ
assets_NN
acquired_VBN [WZPAST]
were_VBD [PASS]
measured_VBN
at_PIN
fair_JJ
value_NN
._.
The_DT
principal_JJ
adjustment_NOMZ
to_PIN
the_DT
carrying_VBG
value_NN
of_PIN
the_DT
net_JJ
assets_NN
in_PIN
Theravances_NN
balance_NN
sheet_NN
prior_RB
to_PIN
the_DT
acquisition_NOMZ
was_VBD
recognition_NOMZ
of_PIN
in-process_JJ
research_NN
and_PHC
development_NOMZ
IPR&D_NN
at_PIN
a_DT
valuation_NOMZ
of_PIN
273_CD
million_CD
._.
The_DT
IPR&D_NN
was_VBD [BEMA]
written-off_PIN
immediately_TIME
after_IN
the_DT
acquisition_NOMZ
in_PIN
accordance_NN
with_PIN
US_FPP1
GAAP_NN
purchase_NN
accounting_GER
._.
The_DT
effect_NN
of_PIN
consolidating_VBG
Theravance_NN
has_VPRT [PEAS]
been_VBN
to_TO
decrease_VB
shareholders_NN
equity_NOMZ
and_CC
net_JJ
income_NN
by_PIN
60_CD
million_CD
._.
Additionally_RB
,_,
the_DT
Group_NN
has_VPRT [PEAS]
accounted_VBN
for_PIN
the_DT
Theravance_NN
put_VBD
option_NOMZ
discussed_VBN
above_PLACE
in_PIN
accordance_NN
with_PIN
SFAS_NN
150_CD
,_,
Accounting_GER
for_PIN
Certain_NN
Financial_NN
Instruments_NOMZ
with_PIN
Characteristics_NN
of_PIN
both_DT
Liabilities_NOMZ
and_PHC
Equity_NOMZ
,_,
which_WDT [SERE]
requires_VPRT [SUAV]
the_DT
Group_NN
to_TO
record_VB
the_DT
fair_JJ
value_NN
of_PIN
the_DT
put_NN
option_NOMZ
as_IN
a_DT
liability_NOMZ
._.
The_DT
fair_JJ
value_NN
of_PIN
the_DT
Theravance_NN
put_VBD
option_NOMZ
at_PIN
31st_CD
December_NN
2004_CD
is_VPRT [BEMA]
69_CD
million_CD
:_:
as_RB
at_PIN
the_DT
initial_JJ
consolidation_NOMZ
of_PIN
Theravance_NN
,_,
the_DT
value_NN
of_PIN
the_DT
put_NN
option_NOMZ
was_VBD [BEMA]
86_CD
million_CD
._.
In_PIN
accordance_NN
with_PIN
SFAS_NN
133_CD
,_,
Accounting_GER
for_PIN
Derivative_NN
Instruments_NOMZ
and_PHC
Hedging_GER
Activities_NOMZ
the_DT
call_NN
option_NOMZ
is_VPRT [PASS]
not_XX0
recognized_VBN [PRIV]
in_PIN
the_DT
financial_JJ
statements_NOMZ
as_IN
it_PIT
is_VPRT
not_XX0
readily_RB
convertible_PRED
into_PIN
cash_NN
._.
146_CD
GlaxoSmithKline_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
37_CD
Reconciliation_NOMZ
to_PIN
US_FPP1
accounting_GER
principles_NN
continued_VBD
d_SYM
Taxation_NOMZ
2003 2002 2004_CD
restated_VBN
restated_VBN
Total_JJ
tax_NN
expense_NN
m_NN
m_FW
m_FW
UK_NN
GAAP_NN
:_:
Current_JJ
tax_NN
expense_NN
1,707_CD
2,001_CD
1,432_CD
Deferred_JJ
tax_NN
credit_NN
expense_NN
6_CD
272_CD
32_CD
Total_JJ
tax_NN
expense_NN
1,701_CD
1,729_CD
1,464_CD
US_FPP1
GAAP_NN
:_:
Current_JJ
tax_NN
expense_NN
1,717_CD
2,014_CD
1,445_CD
Deferred_JJ
tax_NN
credit_NN
667_CD
1,059_CD
1,146_CD
Total_JJ
tax_NN
expense_NN
1,050_CD
955_CD
299_CD
Cumulative_JJ
effect_NN
of_PIN
changes_NN
in_PIN
accounting_GER
principles_NN
34_CD
Total_JJ
tax_NN
expense_NN
1,050_CD
955_CD
265_CD
UK_NN
to_PIN
US_FPP1
GAAP_NN
adjustments_NOMZ
:_:
Current_JJ
tax_NN
expense_NN
10_CD
13_CD
13_CD
Deferred_JJ
tax_NN
credit_NN
661_CD
787_CD
1,178_CD
Total_JJ
tax_NN
expense_NN
651_CD
774_CD
1,165_CD
Cumulative_JJ
effect_NN
of_PIN
changes_NN
in_PIN
accounting_GER
principles_NN
34_CD
Total_JJ
tax_NN
expense_NN
651_CD
774_CD
1,199_CD
e_SYM
Deferred_VBN
taxation_NOMZ
under_IN
US_FPP1
GAAP_NN
Classication_NOMZ
of_PIN
GlaxoSmithKlines_NN
deferred_VBD
taxation_NOMZ
liabilities_NOMZ
and_PHC
assets_NN
under_IN
US_FPP1
GAAP_NN
is_VPRT
as_IN
follows_VPRT
:_:
2003_CD
2004_CD
restated_VBN
m_FW
m_FW
Liabilities_NOMZ
Stock_NN
valuation_NOMZ
adjustment_NOMZ
51_CD
52_CD
Current_JJ
deferred_VBN
taxation_NOMZ
liabilities_NOMZ
51_CD
52_CD
Accelerated_VBN
capital_NN
allowances_NN
664_CD
689_CD
Product_NN
rights_NN
4,454_CD
4,917_CD
Other_JJ
timing_NN
differences_NN
66_CD
229_CD
Total_JJ
deferred_VBN
taxation_NOMZ
liabilities_NOMZ
5,103_CD
5,887_CD
Assets_NN
Intra-Group_JJ
profit_NN
594_CD
485_CD
Other_JJ
timing_NN
differences_NN
675_CD
607_CD
Current_JJ
deferred_VBN
taxation_NOMZ
assets_NN
1,269_CD
1,092_CD
Asset_NN
disposal_NN
31_CD
59_CD
Pensions_NN
and_CC
other_JJ
post-retirement_JJ
benets_NN
57_CD
86_CD
Tax_NN
losses_NN
20_CD
94_CD
Manufacturing_GER
restructuring_GER
66_CD
132_CD
Legal_NN
and_CC
other_JJ
disputes_NN
157_CD
167_CD
Other_JJ
timing_NN
differences_NN
188_CD
127_CD
Total_JJ
deferred_VBN
taxation_NOMZ
assets_NN
1,726_CD
1,639_CD
Net_JJ
deferred_VBN
taxation_NOMZ
under_IN
US_FPP1
GAAP_NN
3,377_CD
4,248_CD
Net_JJ
deferred_VBN
taxation_NOMZ
under_IN
UK_NN
GAAP_NN
827_CD
823_CD
UK_NN
to_PIN
US_FPP1
GAAP_NN
adjustment_NOMZ
4,204_CD
5,071_CD
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
GlaxoSmithKline_NN
147_CD
37_CD
Reconciliation_NOMZ
to_PIN
US_FPP1
accounting_GER
principles_NN
continued_VBD
f_SYM
Pensions_NN
and_PHC
post-retirement_NOMZ
costs_NN
under_IN
US_FPP1
GAAP_NN
2004 2003 2002_CD
m_FW
m_FW
m_FW
UK_NN
pension_NN
schemes_NN
225 278 103_CD
US_FPP1
pension_NN
schemes_NN
54_CD
79_CD
67_CD
Other_JJ
overseas_PLACE
pension_NN
schemes_NN
77_CD
83_CD
51_CD
Unfunded_JJ
post-retirement_NOMZ
healthcare_NN
schemes_NN
96_CD
118_CD
78_CD
Post-employment_NOMZ
costs_NN
18_CD
24 40 470 582_CD
339_CD
Analysed_VBN
as_IN
:_:
Funded_VBN
dened_VBN
benefit_NN
hybrid_NN
schemes_NN
298 389 149_CD
Unfunded_JJ
dened_VBN
benefit_NN
schemes_NN
37_CD
26_CD
48_CD
Dened_VBN
contribution_NOMZ
schemes_NN
21_CD
25_CD
24_CD
Unfunded_JJ
post-retirement_NOMZ
healthcare_NN
schemes_NN
96_CD
118_CD
78_CD
Post-employment_NOMZ
costs_NN
18_CD
24 40 470 582_CD
339_CD
The_DT
disclosures_NN
below_PLACE
include_VPRT
the_DT
additional_JJ
information_NOMZ
required_VBN [SUAV] [WZPAST]
by_PIN
SFAS_NN
132R_NN
._.
The_DT
pension_NN
costs_NN
of_PIN
the_DT
UK_NN
,_,
US_FPP1
and_CC
major_JJ
overseas_PLACE
dened_VBN
benefit_NN
pension_NN
plans_NN
have_VPRT [PEAS]
been_VBN [PASS]
restated_VBN
in_PIN
the_DT
following_VBG
tables_NN
in_PIN
accordance_NN
with_PIN
US_FPP1
GAAP_NN
._.
Pension_NN
costs_NN
in_PIN
2004_CD
of_PIN
5_CD
million_CD
2003_CD
9_CD
million_CD
:_:
2002_CD
12_CD
million_CD
,_,
in_PIN
respect_NN
of_PIN
minor_JJ
retirement_NOMZ
plans_NN
,_,
which_WDT [SERE]
have_VPRT [PEAS]
not_XX0
been_VBN [PASS]
recalculated_VBN
in_PIN
accordance_NN
with_PIN
the_DT
requirements_NOMZ
of_PIN
SFAS_NN
87_CD
,_,
have_VPRT [PEAS]
been_VBN [PASS]
excluded_VBN
._.
2004 2003 2002_CD
Net_JJ
periodic_JJ
pension_NN
cost_NN
for_PIN
the_DT
major_JJ
retirement_NOMZ
plans_NN
m_VPRT
m_FW
m_FW
Service_NN
cost_NN
213 211 219_CD
Interest_NN
cost_NN
400 392 388_CD
Expected_VBN [PRIV]
return_NN
on_PIN
plan_NN
assets_NN
431 408 470_CD
Amortisation_NOMZ
of_PIN
prior_JJ
service_NN
cost_NN
14_CD
17_CD
20_CD
Amortisation_NOMZ
of_PIN
transition_NOMZ
obligation_NOMZ
2_CD
3_CD
6_CD
Amortisation_NOMZ
of_PIN
net_JJ
actuarial_JJ
loss_NN
115_CD
79_CD
3_CD
Net_JJ
periodic_JJ
pension_NN
cost_NN
under_IN
US_FPP1
GAAP_NN
313 294 154_CD
Termination_NOMZ
benets_NN
and_PHC
curtailment_NOMZ
costs_NN
13_CD
112_CD
56_CD
Adjustment_NOMZ
for_PIN
change_NN
in_PIN
accounting_GER
principle_NN
62_CD
During_PIN
2002_CD
,_,
the_DT
Group_NN
decided_VBD [SUAV] [PRIV]
to_TO
align_VB
the_DT
measurement_NOMZ
date_NN
for_PIN
all_QUAN
of_PIN
its_PIT
pension_NN
plans_NN
._.
As_IN
certain_JJ
of_PIN
the_DT
Groups_NN
pension_NN
plans_NN
had_VBD
a_DT
measurement_NOMZ
date_NN
for_PIN
pension_NN
assets_NN
and_PHC
liabilities_NOMZ
of_PIN
30th_JJ
September_NN
,_,
the_DT
Group_NN
elected_VBD
to_TO
change_VB
the_DT
measurement_NOMZ
date_NN
for_PIN
these_DEMO
plans_NN
from_PIN
30th_JJ
September_NN
to_TO
31st_VB
December_NN
._.
2004 2003 2002_CD
Major_JJ
assumptions_NOMZ
used_VBN [WZPAST]
in_PIN
computing_VBG
pension_NN
costs_NN
%_NN
pa_CD
%_NN
pa_CD
%_NN
pa_NN
Rates_NN
of_PIN
future_JJ
pay_NN
increases_VPRT
4.25_CD
4.25_CD
4.25_CD
Discount_NN
rate_NN
5.25_CD
5.50_CD
6.00_CD
Expected_VBN [PRIV]
long-term_JJ
rates_NN
of_PIN
return_NN
on_PIN
plan_NN
assets_NN
7.00_CD
7.50_CD
7.75_CD
In_PIN
aggregate_JJ
,_,
average_JJ
international_JJ
plan_NN
assumptions_NOMZ
did_VBD
not_XX0
vary_VB
signicantly_RB
from_PIN
US_FPP1
assumptions_NOMZ
._.
Estimated_JJ
future_NN
benefit_NN
payments_NOMZ
m_VPRT [BEMA]
2005 297 2006 306_CD
2007 317 2008 330_CD
2009 346 20102014_CD
2,011_CD
148_CD
GlaxoSmithKline_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
37_CD
Reconciliation_NOMZ
to_PIN
US_FPP1
accounting_GER
principles_NN
continued_VBD
2004_CD
2003_CD
Change_NN
in_PIN
benefit_NN
obligation_NOMZ
m_NN
m_NN
benefit_NN
obligation_NOMZ
at_PIN
beginning_GER
of_PIN
year_NN
7,866_CD
6,760_CD
Amendments_NOMZ
2_CD
20_CD
Service_NN
cost_NN
213_CD
211_CD
Interest_NN
cost_NN
400_CD
392_CD
Plan_NN
participants_NN
contributions_NOMZ
15_CD
16_CD
Actuarial_JJ
loss_NN
137_CD
899_CD
Benets_NN
paid_VBD
345_CD
328_CD
Termination_NOMZ
benets_NN
and_PHC
curtailment_NOMZ
costs_NN
5_CD
92_CD
Exchange_NN
122_CD
156_CD
benefit_NN
obligation_NOMZ
at_PIN
end_NN
of_PIN
year_NN
8,171_CD
7,866_CD
benefit_NN
obligation_NOMZ
at_PIN
end_NN
of_PIN
year_NN
for_PIN
pension_NN
plans_NN
with_PIN
accumulated_VBN
benefit_NN
obligations_NOMZ
in_PIN
excess_NN
of_PIN
plan_NN
assets_NN
5,554_CD
6,960_CD
The_DT
accumulated_VBN
benefit_NN
obligation_NOMZ
at_PIN
31st_CD
December_NN
2004_CD
was_VBD [BEMA]
7,691_CD
million_CD
31st_JJ
December_NN
2003_CD
7,391_CD
million_CD
._.
2004_CD
2003_CD
Change_NN
in_PIN
plan_NN
assets_NN
m_VPRT
m_NN
Fair_NN
value_NN
of_PIN
plan_NN
assets_NN
at_PIN
beginning_GER
of_PIN
year_NN
5,968_CD
4,855_CD
Actual_JJ
return_NN
on_PIN
plan_NN
assets_NN
651_CD
979_CD
Employer_NN
contributions_NOMZ
465_CD
596_CD
Plan_NN
participants_NN
contributions_NOMZ
15_CD
16_CD
Benets_NN
paid_VBD
345_CD
328_CD
Exchange_NN
64_CD
150_CD
Fair_NN
value_NN
of_PIN
plan_NN
assets_NN
at_PIN
end_NN
of_PIN
year_NN
6,690_CD
5,968_CD
Fair_NN
value_NN
of_PIN
plan_NN
assets_NN
at_PIN
end_NN
of_PIN
year_NN
for_PIN
pension_NN
plans_NN
with_PIN
accumulated_VBN
benefit_NN
obligations_NOMZ
in_PIN
excess_NN
of_PIN
plan_NN
assets_NN
4,519_CD
5,525_CD
Plan_NN
assets_NN
consist_VPRT
primarily_RB
of_PIN
investments_NOMZ
in_PIN
UK_NN
and_CC
overseas_PLACE
equities_NOMZ
,_,
xed_VBN
interest_NN
securities_NOMZ
,_,
securities_NOMZ
linked_VBN [WZPAST]
to_PIN
the_DT
UK_NN
Retail_NN
Prices_NN
Index_NN
and_PHC
property_NN
._.
At_PIN
31st_CD
December_NN
2004_CD
UK_NN
equities_NOMZ
included_VBD
0.3_CD
million_CD
GlaxoSmithKline_NN
shares_NN
2003_CD
0.5_CD
million_CD
shares_NN
with_PIN
a_DT
market_NN
value_NN
of_PIN
4_CD
million_CD
2003_CD
7_CD
million_CD
._.
Normal_JJ
employer_NN
contributions_NOMZ
are_VPRT [PASS]
expected_VBN [PRIV]
to_TO
be_VB [BEMA]
approximately_RB
360_CD
million_CD
in_PIN
2005_CD
._.
2004_CD
2003_CD
Funded_VBN
status_NN
m_NN [PASS]
m_NN [PASS]
Funded_VBN
status_NN
1,481_CD
1,898_CD
Unrecognised_JJ
net_JJ
actuarial_JJ
loss_NN
1,900_CD
2,123_CD
Unrecognised_JJ
prior_JJ
service_NN
cost_NN
75_CD
96_CD
Unrecognised_JJ
transition_NOMZ
obligation_NOMZ
24_CD
26_CD
Net_JJ
amount_NN
recognized_VBN [PRIV] [THATD]
518 347 2004 2003_CD
Amounts_NN
recognized_VBN [PRIV] [WZPAST]
in_PIN
the_DT
statement_NOMZ
of_PIN
financial_JJ
position_NOMZ
m_NN
m_FW
Prepaid_FW
benefit_NN
cost_NN
365_CD
18_CD
Accrued_VBN
pension_NN
liability_NOMZ
1,065_CD
1,471_CD
Intangible_JJ
asset_NN
102_CD
128_CD
Accumulated_VBN
other_JJ
comprehensive_JJ
income_NN
1,116_CD
1,672_CD
Net_JJ
amount_NN
recognized_VBN [PRIV]
518_CD
347_CD
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
GlaxoSmithKline_NN
149_CD
37_CD
Reconciliation_NOMZ
to_PIN
US_FPP1
accounting_GER
principles_NN
continued_VBD
Post-retirement_JJ
healthcare_NN
under_IN
US_FPP1
GAAP_NN
The_NN
post-retirement_JJ
healthcare_NN
costs_NN
of_PIN
the_DT
UK_NN
,_,
US_FPP1
and_CC
major_JJ
overseas_PLACE
post-retirement_NOMZ
healthcare_NN
schemes_NN
have_VPRT [PEAS]
been_VBN [PASS]
restated_VBN
in_PIN
the_DT
following_VBG
tables_NN
in_PIN
accordance_NN
with_PIN
US_FPP1
GAAP_NN
._.
Costs_NN
in_PIN
2004_CD
of_PIN
nil_NN
2003_CD
13_CD
million_CD
,_,
2002_CD
nil_NN
,_,
which_WDT [SERE]
have_VPRT [PEAS]
not_XX0
been_VBN [PASS]
recalculated_VBN
,_,
have_VPRT [PEAS]
been_VBN [PASS]
excluded_VBN
._.
2004 2003 2002_CD
Net_JJ
healthcare_NN
cost_NN
m_NN
mm_NN
Service_NN
cost_NN
32_CD
29_CD
23_CD
Interest_NN
cost_NN
55_CD
64_CD
53_CD
Amortisation_NOMZ
of_PIN
prior_JJ
service_NN
cost_NN
1_CD
2_CD
1_CD
Amortisation_NOMZ
of_PIN
net_JJ
actuarial_JJ
loss_NN
11_CD
14_CD
3_CD
Net_JJ
healthcare_NN
cost_NN
97_CD
105_CD
78_CD
The_DT
major_JJ
assumptions_NOMZ
used_VBN [WZPAST]
in_PIN
calculating_VBG [PRIV]
the_DT
net_JJ
healthcare_NN
cost_NN
were_VBD
:_:
%_NN
pa_CD
%_NN
pa_CD
%_NN
pa_NN
Rate_NN
of_PIN
future_JJ
healthcare_NN
ination_NOMZ
9.0_CD
to_PIN
5.0_CD
10.0_CD
to_PIN
5.0_CD
11.0_CD
to_PIN
5.0_CD
Discount_NN
rate_NN
5.75_CD
6.25_CD
6.75_CD
The_DT
rate_NN
of_PIN
future_JJ
healthcare_NN
ination_NOMZ
reects_VPRT
the_DT
fact_NN
that_TOBJ
the_DT
benets_NN
of_PIN
certain_JJ
groups_NN
of_PIN
participants_NN
are_VPRT [PASS]
capped_VBN
._.
2004_CD
2003_CD
Change_NN
in_PIN
benefit_NN
obligation_NOMZ
m_NN
m_NN
benefit_NN
obligation_NOMZ
at_PIN
beginning_GER
of_PIN
year_NN
975_CD
830_CD
Amendments_NOMZ
3_CD
Service_NN
cost_NN
32_CD
29_CD
Interest_NN
cost_NN
55_CD
64_CD
Plan_NN
participants_NN
contributions_NOMZ
8_CD
8_CD
Actuarial_JJ
loss_NN
6_CD
192_CD
Benets_NN
paid_VBD
47_CD
49_CD
Exchange_NN
64_CD
96_CD
benefit_NN
obligation_NOMZ
at_PIN
end_NN
of_PIN
year_NN
965_CD
975_CD
Change_NN
in_PIN
plan_NN
assets_NN
Fair_NN
value_NN
of_PIN
plan_NN
assets_NN
at_PIN
beginning_GER
of_PIN
year_NN
Employer_NN
and_PHC
plan_NN
participants_NN
contributions_NOMZ
47_CD
49_CD
Benets_NN
paid_VBD
47_CD
49_CD
Fair_NN
value_NN
of_PIN
plan_NN
assets_NN
at_PIN
end_NN
of_PIN
year_NN
Funded_VBN
status_NN
Funded_VBN
status_NN
965_CD
975_CD
Unrecognised_JJ
net_JJ
actuarial_JJ
loss_NN
340_CD
371_CD
Unrecognised_JJ
prior_JJ
service_NN
cost_NN
14_CD
17_CD
Accrued_VBN
post-retirement_JJ
healthcare_NN
cost_NN
639_CD
621_CD
1_CD
%_NN
decrease_NN
1_CD
%_NN
increase_NN
Impact_NN
of_PIN
a_DT
one_CD
per_PIN
cent_NN
variation_NOMZ
in_PIN
the_DT
rate_NN
of_PIN
future_JJ
healthcare_NN
ination_NOMZ
m_FW
m_FW
Effect_NN
on_PIN
total_JJ
service_NN
and_PHC
interest_NN
cost_NN
7_CD
8_CD
Effect_NN
on_PIN
provision_NN
for_PIN
post-retirement_JJ
benets_NN
75_CD
82_CD
150_CD
GlaxoSmithKline_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
38_CD
Principal_NN
Group_NN
companies_NN
The_DT
following_JJ
represent_VPRT
the_DT
principal_JJ
subsidiary_NN
and_CC
associated_VBN
undertakings_GER
of_PIN
the_DT
GlaxoSmithKline_NN
Group_NN
at_PIN
31st_CD
December_NN
2004_CD
._.
Details_NN
are_VPRT [PASS]
given_VBN
of_PIN
the_DT
principal_JJ
country_NN
of_PIN
operation_NOMZ
,_,
the_DT
location_NOMZ
of_PIN
the_DT
headquarters_NN
,_,
the_DT
business_NOMZ
segment_NOMZ
and_CC
the_DT
business_NOMZ
activities_NOMZ
._.
The_DT
equity_NOMZ
share_NN
capital_NN
of_PIN
these_DEMO
undertakings_GER
is_VPRT [SPAU] [BYPA]
wholly_RB
owned_VBN
by_PIN
the_DT
Group_NN
except_PIN
where_RB
its_PIT
percentage_NN
interest_NN
is_VPRT [PASS]
shown_VBN [PRIV]
otherwise_CONJ
._.
All_QUAN
companies_NN
are_VPRT [PASS]
incorporated_VBN
in_PIN
their_TPP3
principal_JJ
country_NN
of_PIN
operation_NOMZ
except_PIN
where_RB
stated_VBN [PUBV]
._.
Europe_NN
Location_NOMZ
Subsidiary_NN
undertaking_VBG [WZPRES]
Segment_NOMZ
Activity_NOMZ
%_NN
England_NN
Brentford_NN
GlaxoSmithKline_NN
Holdings_GER
One_CD
Limited_NN
Ph_NN
,_,
CH_NN
h_NN
Brentford_NN
GlaxoSmithKline_NN
Services_NN
Unlimited_NN
Ph_NN
,_,
CH_NN
s_VPRT
Brentford_NN
GlaxoSmithKline_NN
Finance_NN
plc_NN
Ph_NN
,_,
CH_NN
f_LS
Brentford_NN
GlaxosmithKline_NN
Capital_NN
plc_NN
Ph_NN
f_SYM
Brentford_NN
SmithKline_NN
Beecham_NN
p._FW
l._FW
c._FW
Ph_FW
,_,
CH_NN
d_LS
e_SYM
h_FW
m_FW
p_FW
r_NN
Brentford_NN
Wellcome_NN
Limited_NN
Ph_NN
,_,
CH_NN
h_NN
Greenford_NN
Glaxo_NN
Group_NN
Limited_NN
Ph_NN
h_VPRT
Greenford_NN
Glaxo_NN
Operations_NOMZ
UK_NN
Limited_NN
Ph_NN
p_VPRT
Brentford_NN
Glaxo_NN
Wellcome_NN
International_NN
B._NN
V._NN
Footnote_NN
i_FPP1
Ph_NN
,_,
CH_NN
h_NN
Brentford_NN
Glaxo_NN
Wellcome_NN
Investments_NOMZ
B._NN
V._NN
Footnote_NN
i_FPP1
Ph_NN
,_,
CH_NN
h_NN
Stockley_NN
Park_NN
Glaxo_NN
Wellcome_NN
UK_NN
Limited_NN
Ph_NN
h_VPRT
m_FW
p_FW
Brentford_NN
GlaxoSmithKline_NN
Export_NN
Limited_NN
Ph_NN
e_SYM
Brentford_NN
GlaxoSmithKline_NN
Research_NN
&_CC
Development_NOMZ
Limited_NN
Ph_NN
d_SYM
r_SYM
Brentford_NN
GlaxoSmithKline_NN
UK_NN
Limited_NN
Ph_NN
m_FW
p_FW
Brentford_NN
SmithKline_NN
Beecham_NN
Investments_NOMZ
Limited_NN
Ph_NN
,_,
CH_NN
f_LS
Brentford_NN
SmithKline_NN
Beecham_NN
SWG_NN
Limited_NN
CH_NN
e_LS
m_FW
Brentford_NN
SmithKline_NN
Beecham_NN
Research_NN
Limited_NN
Ph_NN
m_NN
Brentford_NN
Stafford-Miller_NN
Limited_NN
CH_NN
m_FW
p_FW
Greenford_NN
The_DT
Wellcome_NN
Foundation_NOMZ
Limited_NN
Ph_NN
p_VPRT
Brentford_NN
Setrst_NN
No._NN
._.
2_CD
Limited_JJ
Ph_NN
,_,
CH_NN
f_LS
h_FW
formerly_TIME
GlaxoSmithKline_NN
Luxembourg_NN
S._NN
A._NN
Footnote_NN
ii_FW
Austria_NN
Vienna_NN
GlaxoSmithKline_NN
Pharma_NN
G._NN
m._FW
b._FW
H_NN
Ph_NN
m_NN
Belgium_NN
Genval_NN
GlaxoSmithKline_NN
S._NN
A._NN
Ph_NN
m_NN
Rixensart_NN
GlaxoSmithKline_NN
Biologicals_NN
S._NN
A._NN
Ph_NN
d_SYM
e_SYM
m_FW
p_FW
r_NN
Rixensart_NN
GlaxoSmithKline_NN
Biologicals_NN
Manufacturing_GER
S._NN
A._NN
Phh_NN
Guernsey_NN
St._NN
Peter_NN
Port_NN
SmithKline_NN
Beecham_NN
Limited_NN
Ph_NN
,_,
CH_NN
i_FPP1
Denmark_NN
Ballerup_NN
GlaxoSmithKline_NN
Consumer_NN
Healthcare_NN
A_NN
S_NN
CH_NN
m_FW
Brndby_NN
GlaxoSmithKline_NN
Pharma_NN
A_NN
S_NN
Ph_NN
m_VBD
Finland_NN
Espoo_NN
GlaxoSmithKline_NN
Oy_NN
Ph_NN
m_NN
France_NN
Marly_NN
le_FW
Roi_NN
Groupe_NN
GlaxoSmithKline_NN
S._NN
A._NN
S_NN
Ph_NN
h_VPRT
Marly_NN
le_FW
Roi_NN
Laboratoire_NN
GlaxoSmithKline_NN
S._NN
A._NN
S_NN
Ph_NN
m_NN
Marly_NN
le_FW
Roi_NN
Glaxo_NN
Wellcome_NN
Production_NOMZ
S._NN
A._NN
S_NN
Ph_NN
m_FW
p_FW
Marly_NN
le_FW
Roi_NN
GlaxoSmithKline_NN
Sante_NN
Grand_NN
Public_NN
S._NN
A._NN
S._NN
CH_NN
m_NN
Germany_NN
Buehl_NN
GlaxoSmithKline_NN
Consumer_NN
Healthcare_NN
GmbH_NN
&_CC
Co_NN
KG_NN
CH_NN
d_LS
h_FW
m_FW
p_FW
r_NN
s_VPRT
Buehl_NN
GlaxoSmithKline_NN
Healthcare_NN
GmbH_NN
CH_NN
h_NN
Greece_NN
Athens_NN
GlaxoSmithKline_NN
A._NN
E._NN
B._NN
E_NN
Ph_NN
,_,
CH_NN
h_FW
m_FW
Hungary_NN
Budapest_NN
GlaxoSmithKline_NN
Kft_NN
Ph_NN
,_,
CH_NN
e_LS
m_FW
Italy_NN
Verona_NN
GlaxoSmithKline_NN
S._NN
p._NN
A._NN
Ph_NN
d_SYM
h_FW
m_FW
r_NN
Milan_NN
GlaxoSmithKline_NN
Consumer_NN
Healthcare_NN
S._NN
p_NN
A._NN
CH_NN
h_FW
m_FW
Luxembourg_NN
Mamer_NN
GlaxoSmithKline_NN
International_NN
Luxembourg_NN
S._NN
A._NN
Ph_NN
,_,
CH_NN
f_LS
h_VPRT
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
GlaxoSmithKline_NN
151_CD
38_CD
Principal_NN
Group_NN
companies_NN
continued_VBD
Europe_NN
Location_NOMZ
Subsidiary_NN
undertaking_VBG [WZPRES]
Segment_NOMZ
Activity_NOMZ
%_NN
Netherlands_NN
Zeist_NN
GlaxoSmithKline_NN
B._NN
V._NN
Ph_NN
m_NN
Zeist_NN
GlaxoSmithKline_NN
Consumer_NN
Healthcare_NN
B._NN
V._NN
CH_NN
m_FW
Norway_NN
Oslo_NN
GlaxoSmithKline_NN
AS_NN
Ph_NN
m_NN
Poland_NN
Poznan_NN
GlaxoSmithKline_NN
Pharmaceuticals_NN
S._NN
A._NN
Ph_NN
m_NN
p_NN
97_CD
Warsaw_NN
GlaxoSmithKline_NN
Consumer_NN
Healthcare_NN
Sp_NN
._.
o._FW
CH_FW
m_FW
e_SYM
Portugal_NN
Lisbon_NN
Farmaceuticos_NN
Lda_NN
Ph_NN
m_NN
Republic_NN
of_PIN
Dublin_NN
GlaxoSmithKline_NN
Consumer_NN
Healthcare_NN
Ireland_NN
Limited_NN
Footnote_NN
iii_FW
CH_NN
m_FW
Ireland_NN
Carrigaline_NN
SmithKline_NN
Beecham_NN
Cork_NN
Limited_NN
Footnote_NN
iii_FW
Ph_NN
p_FW
Carrigaline_NN
SmithKline_NN
Beecham_NN
Manufacturing_GER
Limited_NN
Footnote_NN
iii_FW
Ph_NN
p_NN
Spain_NN
Tres_NN
Cantos_NN
GlaxoSmithKline_NN
,_,
S._NN
A._NN
Ph_NN
m_NN
Aranda_NN
fide_NN
Duero_NN
GlaxoSmithKline_NN
,_,
S._NN
A._NN
Ph_NN
p_NN
Alcala_NN
fide_NN
Henares_NN
SmithKline_NN
Beecham_NN
S._NN
A._NN
Ph_NN
p_VPRT
Sweden_NN
Mlndal_NN
GlaxoSmithKline_NN
AB_NN
Ph_NN
m_NN
Switzerland_NN
Muenchenbuchsee_NN
GlaxoSmithKline_NN
Investments_NOMZ
Switzerland_NN
GmbH_NN
Ph_NN
,_,
CH_NN
h_NN
Muenchenbuchsee_NN
GlaxoSmithKline_NN
AG_NN
Ph_NN
m_NN
Zug_NN
Adechsa_NN
GmbH_NN
Ph_NN
e_SYM
USA_NN
USA_NN
Philadelphia_NN
SmithKline_NN
Beecham_NN
Corporation_NOMZ
Ph_NN
,_,
CH_NN
d_LS
e_SYM
h_FW
m_FW
p_FW
r_NN
s_VPRT
Pittsburgh_NN
GlaxoSmithKline_NN
Consumer_NN
Healthcare_NN
,_,
L._NN
P._NN
CH_NN
m_FW
p_FW
88_CD
Pittsburgh_NN
Block_NN
Drug_NN
Company_NN
,_,
Inc_NN
CH_NN
h_VPRT
m_FW
p_FW
Wilmington_NN
GlaxoSmithKline_NN
Financial_NN
Inc_NN
Ph_NN
f_SYM
Wilmington_NN
GlaxoSmithKline_NN
Holdings_GER
Americas_NN
Inc_NN
Ph_NN
,_,
CH_NN
h_NN
Americas_NN
Bermuda_NN
Hamilton_NN
GlaxoSmithKline_NN
Insurance_NN
Ltd_NN
Ph_NN
,_,
CH_NN
i_FPP1
Canada_NN
Mississauga_NN
GlaxoSmithKline_NN
Inc_NN
Ph_NN
,_,
CH_NN
m_FW
p_FW
r_NN
Asia_NN
Pacic_NN
Australia_NN
Boronia_NN
Glaxo_NN
Wellcome_NN
Australia_NN
Pty_NN
Ltd_NN
Ph_NN
,_,
CH_NN
d_LS
e_SYM
m_FW
p_FW
r_NN
China_NN
Hong_NN
Kong_NN
GlaxoSmithKline_NN
Limited_NN
Ph_NN
,_,
CH_NN
m_NN
Tianjin_NN
Sino-American_NN
Tianjin_NN
Smith_NN
Kline_NN
&_CC
French_NN
Laboratories_NN
Ltd_NN
Ph_NN
d_SYM
m_FW
p_FW
r_NN
55_CD
India_NN
Mumbai_NN
GlaxoSmithKline_NN
Pharmaceuticals_NN
Limited_NN
Ph_NN
m_FW
p_FW
59_CD
Nabha_NN
GlaxoSmithKline_NN
Consumer_NN
Healthcare_NN
Limited_NN
Footnote_NN
iv_NN
CH_NN
m_FW
p_FW
40_CD
Malaysia_NN
Petaling_GER
Jaya_NN
Selangor_NN
GlaxoSmithKline_NN
Pharmaceutical_NN
Sdn_NN
Bhd_NN
Ph_NN
m_NN
Darul_NN
Ehsan_NN
New_NN
Zealand_NN
Auckland_NN
GlaxoSmithKline_NN
NZ_NN
Limited_NN
Ph_NN
,_,
CH_NN
m_NN
Pakistan_NN
Karachi_NN
GlaxoSmithKline_NN
Pakistan_NN
Limited_NN
Ph_NN
,_,
CH_NN
m_FW
pe79_FW
Philippines_NN
Makati_NN
GlaxoSmithKline_NN
Philippines_NN
Inc._NN
._.
Ph_NN
,_,
CH_NN
m_NN
Singapore_NN
Singapore_NN
Glaxo_NN
Wellcome_NN
Manufacturing_GER
Pte_NN
Ltd_NN
Ph_NN
p_VPRT
Singapore_NN
GlaxoSmithKline_NN
Pte_NN
Ltd_NN
Ph_NN
m_NN
South_NN
Korea_NN
Seoul_NN
GlaxoSmithKline_NN
Korea_NN
Ph_NN
m_FW
p_FW
Taiwan_NN
Taipei_NN
Glaxo_NN
Wellcome_NN
Taiwan_NN
Limited_NN
Ph_NN
m_NN
p_NN
152_CD
GlaxoSmithKline_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
38_CD
Principal_NN
Group_NN
companies_NN
continued_VBD
Japan_NN
Location_NOMZ
Subsidiary_NN
undertaking_VBG [WZPRES]
Segment_NOMZ
Activity_NOMZ
%_NN
Japan_NN
Tokyo_NN
GlaxoSmithKline_NN
K._NN
K._NN
Ph_NN
,_,
CH_NN
d_LS
m_FW
p_FW
r_NN
85_CD
Latin_NN
America_NN
Argentina_NN
Buenos_NN
Aires_NN
GlaxoSmithKline_NN
Argentina_NN
S._NN
A._NN
Ph_NN
,_,
CH_NN
m_FW
p_FW
Brazil_NN
Rio_NN
fide_VBD
Janeiro_NN
GlaxoSmithKline_NN
Brasil_NN
Ltda_NN
Ph_NN
,_,
CH_NN
m_FW
p_FW
Colombia_NN
Bogota_NN
GlaxoSmithKline_NN
Colombia_NN
S._NN
A._NN
Ph_NN
,_,
CH_NN
m_NN
Mexico_NN
Mexico_NN
City_NOMZ
GlaxoSmithKline_NN
Mexico_NN
,_,
S._NN
A._NN
fide_NN
C._NN
V._NN
Ph_NN
,_,
CH_NN
e_LS
m_FW
p_FW
s_PRP
Puerto_NN
Rico_NN
Guaynabo_NN
GlaxoSmithKline_NN
Puerto_NN
Rico_NN
Inc._NN
._.
Ph_NN
m_FW
San_NN
Juan_NN
SB_NN
Pharmco_NN
Puerto_NN
Rico_NN
Inc._NN
._.
Ph_NN
p_NN
Venezuela_NN
Caracas_NN
GlaxoSmithKline_NN
Venezuela_NN
C._NN
A._NN
Ph_NN
,_,
CH_NN
m_NN
Middle_NN
East_NN
&_CC
Africa_NN
Egypt_NN
Cairo_NN
GlaxoSmithKlineS_NN
._.
A._NN
E_NN
Ph_NN
m_FW
p_FW
90_CD
South_NN
Africa_NN
Bryanston_NN
GlaxoSmithKline_NN
South_NN
Africa_NN
Pty_NN
Ltd_NN
Ph_NN
,_,
CH_NN
m_FW
p_FW
Turkey_NN
Istanbul_NN
GlaxoSmithKline_NN
Ilaclari_NN
Sanayi_NN
five_CD
Ticaret_NN
A._NN
S._NN
Ph_NN
m_NN
p_NN
USA_NN
Location_NOMZ
Associated_NN
undertaking_VBG [WZPRES]
Business_NOMZ
%_NN
USA_NN
Teterboro_NN
Quest_NN
Diagnostics_NN
Incorporated_NN
Footnote_NN
v._CC
Clinical_JJ
testing_GER
19_CD
Footnotes_NN
i_FPP1
Incorporated_NN
in_PIN
the_DT
Netherlands_NN
ii_FW
Originally_TIME
incorporated_VBN
in_PIN
Luxembourg_NN
,_,
now_DPAR
registered_VBN
in_PIN
Guernsey_NN
._.
iii_FW
Exempt_FW
from_PIN
the_DT
provisions_NN
of_PIN
Section_NOMZ
7_CD
of_PIN
the_DT
Companies_NN
Amendment_NOMZ
Act_NN
1986_CD
Ireland_NN
iv_NN
Consolidated_NN
as_IN
a_DT
subsidiary_NN
undertaking_GER
in_PIN
accordance_NN
with_PIN
Section_NOMZ
258_CD
4_CD
a_DT
of_PIN
the_DT
Companies_NN
Act_NN
on_PIN
the_DT
grounds_NN
of_PIN
dominant_JJ
inuence_NN
v_NN
Equity_NOMZ
accounted_VBD
on_PIN
the_DT
grounds_NN
of_PIN
significant_JJ
inuence_NN
Directly_RB
held_VBD [PRIV]
wholly_RB
owned_VBN
subsidiary_NN
of_PIN
GlaxoSmithKline_NN
plc_NN
Business_NOMZ
segment_NOMZ
:_:
Ph_NN
Pharmaceuticals_NN
,_,
CH_NN
Consumer_NN
Healthcare_NN
Business_NOMZ
activity_NOMZ
:_:
d_LS
development_NOMZ
,_,
e_SYM
exporting_VBG
,_,
f_SYM
finance_NN
,_,
h_VPRT
holding_VBG [PRIV]
company_NN
,_,
i_FPP1
insurance_NN
,_,
m_NN
marketing_GER
,_,
p_NN
production_NOMZ
,_,
r_NN
research_NN
,_,
s_VPRT
service_NN
Full_NN
details_NN
of_PIN
all_QUAN
Group_NN
subsidiary_NN
and_CC
associated_VBN
undertakings_GER
will_PRMD
be_VB [PASS]
attached_VBN
to_PIN
the_DT
companys_NN
Annual_JJ
Return_NN
to_TO
be_VB [PASS]
led_VBN
with_PIN
the_DT
Registrar_NN
of_PIN
Companies_NN
._.
GlaxoSmithKline_NN
153_CD
Investor_NN
information_NOMZ
This_DEMO
section_NOMZ
includes_VPRT
the_DT
financial_JJ
record_NN
presenting_VBG [WZPRES]
historical_JJ
information_NOMZ
prepared_VBN
under_IN
UK_NN
GAAP_NN
._.
In_CONJ
addition_NULL
,_,
historical_JJ
information_NOMZ
restated_VBN [WZPAST]
in_PIN
accordance_NN
with_PIN
International_NN
Financial_NN
Reporting_GER
Standards_NN
is_VPRT [PASS]
presented_VBN
._.
This_DEMO
section_NOMZ
also_RB
discusses_VPRT
shareholder_NN
return_NN
the_DT
return_NN
to_PIN
shareholders_NN
in_PIN
the_DT
form_NN
of_PIN
dividends_NN
and_PHC
share_NN
price_NN
movements_NOMZ
and_CC
provides_VPRT
other_JJ
information_NOMZ
for_PIN
shareholders_NN
._.
Financial_NN
record_NN
Information_NOMZ
prepared_VBN
under_IN
UK_NN
GAAP_NN
154_CD
Quarterly_JJ
trend_NN
160_CD
Five_CD
year_NN
record_NN
Financial_NN
information_NOMZ
under_IN
International_NN
Financial_NN
Reporting_GER
Standards_NN
IFRS_NN
163_CD
Background_NN
164_CD
IFRS_NN
accounting_GER
policies_NN
167_CD
IFRS_NN
adjustments_NOMZ
169_CD
IFRS_NN
pharmaceutical_JJ
turnover_NN
-_:
total_JJ
Group_NN
170_CD
IFRS_NN
Consolidated_NN
income_NN
statement_NOMZ
172_CD
IFRS_NN
Consolidated_NN
balance_NN
sheet_NN
172_CD
IFRS_NN
Consolidated_NN
statement_NOMZ
of_PIN
recognized_VBN [PRIV]
income_NN
and_PHC
expense_NN
173_CD
IFRS_NN
Consolidated_NN
cash_NN
ow_NN
statement_NOMZ
174_CD
Shareholder_NN
return_NN
175_CD
Shareholder_NN
information_NOMZ
176_CD
Share_NN
capital_NN
178_CD
Taxation_NOMZ
information_NOMZ
for_PIN
shareholders_NN
